<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>WS-1790 OPDIVO - EN PI annotated</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRomanPSMT\,Times New Rom";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Times New Roman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"CG Times";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Minion;}
@font-face
	{font-family:CourierNew;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Noto Sans Symbols";}
@font-face
	{font-family:LZLLQG+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPS;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:HelveticaNeueLTStd-Cn;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HelveticaNeueLTStd-Cn";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Wingdings-Regular";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Geneva;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,BoldItalic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:ArialMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
h5
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:normal;}
h6
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-indent:0in;
	font-size:9.0pt;
	font-family:"Arial",sans-serif;
	font-style:italic;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char1";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.MsoEndnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	text-align:justify;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#954F72;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	font-size:10.5pt;
	font-family:Consolas;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.EMEATableCentered, li.EMEATableCentered, div.EMEATableCentered
	{mso-style-name:"EMEA Table Centered";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEATableLeft, li.EMEATableLeft, div.EMEATableLeft
	{mso-style-name:"EMEA Table Left";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEABodyTextIndent, li.EMEABodyTextIndent, div.EMEABodyTextIndent
	{mso-style-name:"EMEA Body Text Indent";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEABodyText, li.EMEABodyText, div.EMEABodyText
	{mso-style-name:"EMEA Body Text";
	mso-style-link:"EMEA Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEATitle, li.EMEATitle, div.EMEATitle
	{mso-style-name:"EMEA Title";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAHeading1NoIndent, li.EMEAHeading1NoIndent, div.EMEAHeading1NoIndent
	{mso-style-name:"EMEA Heading 1 No Indent";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeading3, li.EMEAHeading3, div.EMEAHeading3
	{mso-style-name:"EMEA Heading 3";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAHeading1, li.EMEAHeading1, div.EMEAHeading1
	{mso-style-name:"EMEA Heading 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeading2, li.EMEAHeading2, div.EMEAHeading2
	{mso-style-name:"EMEA Heading 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAAddress, li.EMEAAddress, div.EMEAAddress
	{mso-style-name:"EMEA Address";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAComment, li.EMEAComment, div.EMEAComment
	{mso-style-name:"EMEA Comment";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.EMEAHiddenTitlePIL, li.EMEAHiddenTitlePIL, div.EMEAHiddenTitlePIL
	{mso-style-name:"EMEA Hidden Title PIL";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.EMEATitlePAC, li.EMEATitlePAC, div.EMEATitlePAC
	{mso-style-name:"EMEA Title PAC";
	margin:0in;
	page-break-after:avoid;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.BMSInstructionText
	{mso-style-name:"BMS Instruction Text";
	font-family:"Times New Roman",serif;
	color:red;
	display:none;
	font-style:italic;
	text-decoration:none none;
	vertical-align:baseline;}
span.EMEASubscript
	{mso-style-name:"EMEA Subscript";
	vertical-align:sub;}
span.EMEASuperscript
	{mso-style-name:"EMEA Superscript";
	vertical-align:super;}
p.EMEATableHeader, li.EMEATableHeader, div.EMEATableHeader
	{mso-style-name:"EMEA Table Header";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.EMEABodyTextChar
	{mso-style-name:"EMEA Body Text Char";
	mso-style-link:"EMEA Body Text";}
span.CommentTextChar1
	{mso-style-name:"Comment Text Char1";
	mso-style-link:"Comment Text";}
p.BMSHeading1, li.BMSHeading1, div.BMSHeading1
	{mso-style-name:"BMS Heading 1";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	text-transform:uppercase;
	font-weight:bold;}
p.BMSHeading2, li.BMSHeading2, div.BMSHeading2
	{mso-style-name:"BMS Heading 2";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;}
p.BMSHeading3, li.BMSHeading3, div.BMSHeading3
	{mso-style-name:"BMS Heading 3";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;
	font-style:italic;}
p.BMSHeading4, li.BMSHeading4, div.BMSHeading4
	{mso-style-name:"BMS Heading 4";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	font-weight:bold;
	font-style:italic;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma",sans-serif;}
p.BMSBodyText, li.BMSBodyText, div.BMSBodyText
	{mso-style-name:"BMS Body Text";
	mso-style-link:"BMS Body Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	line-height:110%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.BMSBodyTextChar
	{mso-style-name:"BMS Body Text Char";
	mso-style-link:"BMS Body Text";
	color:black;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-weight:bold;}
p.BMSTableTitle, li.BMSTableTitle, div.BMSTableTitle
	{mso-style-name:"BMS Table Title";
	mso-style-link:"BMS Table Title Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.5in;
	text-indent:-1.5in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.BMSTableHeader, li.BMSTableHeader, div.BMSTableHeader
	{mso-style-name:"BMS Table Header";
	mso-style-link:"BMS Table Header Char";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.BMSTableText, li.BMSTableText, div.BMSTableText
	{mso-style-name:"BMS Table Text";
	mso-style-link:"BMS Table Text Char";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.BMSTableTextChar
	{mso-style-name:"BMS Table Text Char";
	mso-style-link:"BMS Table Text";}
span.BMSTableHeaderChar
	{mso-style-name:"BMS Table Header Char";
	mso-style-link:"BMS Table Header";
	font-weight:bold;}
span.BMSTableTitleChar
	{mso-style-name:"BMS Table Title Char";
	mso-style-link:"BMS Table Title";
	font-weight:bold;}
span.BMSSuperscript
	{mso-style-name:"BMS Superscript";
	vertical-align:super;}
p.BMSTableNoteInfo, li.BMSTableNoteInfo, div.BMSTableNoteInfo
	{mso-style-name:"BMS Table Note Info";
	mso-style-link:"BMS Table Note Info Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.15in;
	text-align:justify;
	text-indent:-.15in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:Consolas;}
p.BMSHeadingAppendix, li.BMSHeadingAppendix, div.BMSHeadingAppendix
	{mso-style-name:"BMS Heading Appendix";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.5in;
	text-indent:-1.5in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	text-transform:uppercase;
	font-weight:bold;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";}
p.BMSFigureCaption, li.BMSFigureCaption, div.BMSFigureCaption
	{mso-style-name:"BMS Figure Caption";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.5in;
	text-indent:-1.5in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";
	color:black;}
p.BMSBullets, li.BMSBullets, div.BMSBullets
	{mso-style-name:"BMS Bullets";
	mso-style-link:"BMS Bullets Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:.25in;
	text-align:justify;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.BMSBulletsChar
	{mso-style-name:"BMS Bullets Char";
	mso-style-link:"BMS Bullets";
	color:black;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-weight:bold;
	font-style:italic;}
p.6, li.6, div.6
	{mso-style-name:6;
	mso-style-link:"Texto comentario Car";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.TextocomentarioCar
	{mso-style-name:"Texto comentario Car";
	mso-style-link:6;}
span.KommentartextZchn
	{mso-style-name:"Kommentartext Zchn";}
p.5, li.5, div.5
	{mso-style-name:5;
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.4, li.4, div.4
	{mso-style-name:4;
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.3, li.3, div.3
	{mso-style-name:3;
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.2, li.2, div.2
	{mso-style-name:2;
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.1, li.1, div.1
	{mso-style-name:1;
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.BMSTableNoteInfoChar
	{mso-style-name:"BMS Table Note Info Char";
	mso-style-link:"BMS Table Note Info";}
span.BMSTableNote
	{mso-style-name:"BMS Table Note";
	font-family:"Times New Roman",serif;
	color:windowtext;
	text-decoration:none none;
	vertical-align:super;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 841.95pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink="#954F72" style='word-wrap:break-word'>

<div class=WordSection1>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>ANNEX I</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeading1><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO&nbsp;10&nbsp;mg/mL concentrate
for solution for infusion.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each mL of concentrate for solution for
infusion contains&nbsp;10&nbsp;mg of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>One vial of&nbsp;4&nbsp;mL contains&nbsp;40&nbsp;mg
of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>One vial of&nbsp;10&nbsp;mL contains&nbsp;100&nbsp;mg
of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>One vial of&nbsp;24&nbsp;mL
contains&nbsp;240&nbsp;mg of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab is produced in Chinese hamster
ovary cells by recombinant DNA technology.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Excipient
with known effect</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Each mL of concentrate contains&nbsp;0.1&nbsp;mmol
(or&nbsp;2.5&nbsp;mg) sodium.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For the full list of excipients, see
section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>3. PHARMACEUTICAL FORM</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Concentrate for solution for infusion
(sterile concentrate).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Clear to opalescent, colourless to pale
yellow liquid that may contain few light particles. The solution has a pH of
approximately&nbsp;6.0 and an osmolality of
approximately&nbsp;340&nbsp;mOsm/kg.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>4. CLINICAL PARTICULARS</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.1 Therapeutic indications</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Melanoma</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO as monotherapy or in combination
with ipilimumab is indicated for the treatment of advanced (unresectable or
metastatic) melanoma in adults.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Relative to nivolumab monotherapy, an
increase in progression&#8209;free survival (PFS) and overall survival (OS) for
the combination of nivolumab with ipilimumab is established only in patients
with low tumour PD&#8209;L1 expression (see sections&nbsp;4.4 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Adjuvant
treatment of melanoma</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO as monotherapy is indicated for
the adjuvant treatment of adults with melanoma with involvement of lymph nodes
or metastatic disease who have undergone complete resection (see
section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Non&#8209;small
cell lung cancer (NSCLC)</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO in combination with ipilimumab
and 2&nbsp;cycles of platinum-based chemotherapy is indicated for the
first-line treatment of metastatic non-small cell lung cancer in adults whose
tumours have no sensitising EGFR mutation or ALK translocation.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO as monotherapy is indicated for
the treatment of locally advanced or metastatic non&#8209;small cell lung
cancer after prior chemotherapy</span><span lang=EN-GB style='color:black;
background:white'> in adults</span><span lang=EN-GB>.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u>Renal cell carcinoma
(RCC)</u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO as monotherapy is indicated for
the treatment of advanced renal cell carcinoma after prior therapy in adults.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO in combination with ipilimumab is
indicated for the first&#8209;line treatment of adult patients with
intermediate/poor&#8209;risk advanced renal cell carcinoma (see section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Classical
Hodgkin lymphoma (cHL)</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO as monotherapy is indicated for
the treatment of adult patients with relapsed or refractory classical Hodgkin
lymphoma after autologous stem cell transplant (ASCT) and treatment with brentuximab
vedotin. </span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Squamous
cell cancer of the head and neck (SCCHN)</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO as monotherapy is indicated for
the treatment of recurrent or metastatic squamous cell cancer of the head and
neck in adults progressing on or after platinum&#8209;based therapy (see
section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Urothelial
carcinoma</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO as monotherapy is indicated for
the treatment of locally advanced unresectable or metastatic urothelial
carcinoma in adults after failure of prior platinum&#8209;containing therapy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Oesophageal
squamous cell carcinoma (OSCC)</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO as monotherapy is indicated for
the treatment of</span><span lang=EN-GB> adult patients with unresectable
advanced, recurrent or metastatic oesophageal squamous cell carcinoma after
prior fluoropyrimidine- and platinum-based combination chemotherapy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.2 Posology and method of
administration</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Treatment must be initiated and supervised
by physicians experienced in the treatment of cancer.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Posology</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>OPDIVO
as monotherapy</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>The recommended dose of OPDIVO is either
nivolumab 240&nbsp;mg every 2&nbsp;weeks <b>or</b> 480&nbsp;mg
every&nbsp;4&nbsp;weeks (see section&nbsp;5.1) depending on the indication, as
presented in Table&nbsp;1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid;height:24.25pt'>
  <td width=546 colspan=2 style='width:409.4pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.25pt'>
  <p class=EMEABodyText style='margin-left:56.7pt;text-indent:-56.7pt;
  page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;1:</span></b> <b><span
  lang=EN-GB>Recommended dose </span><span lang=EN-GB>and infusion time for intravenous
  administration of nivolumab monotherapy</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:29.95pt'>
  <td width=206 style='width:154.25pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:29.95pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Indication*</span></b></p>
  </td>
  <td width=340 style='width:255.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:29.95pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Recommended dose </span></b><b><span lang=EN-GB>and
  infusion time</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:29.95pt'>
  <td width=206 style='width:154.25pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:29.95pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Melanoma
  (advanced or adjuvant treatment)</span><span lang=EN-GB> </span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Renal
  cell carcinoma</span></p>
  </td>
  <td width=340 style='width:255.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:29.95pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>240&nbsp;mg
  every 2&nbsp;weeks over&nbsp;30&nbsp;minutes or</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>480&nbsp;mg
  every </span><span lang=EN-GB>4&nbsp;weeks over&nbsp;60&nbsp;minutes</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:29.95pt'>
  <td width=206 style='width:154.25pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:29.95pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Non&#8209;small
  cell lung cancer</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Classical
  Hodgkin lymphoma</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Squamous
  cell cancer of the head and neck</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Urothelial
  carcinoma</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Oesophageal
  squamous cell carcinoma</span></p>
  </td>
  <td width=340 style='width:255.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:29.95pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>240&nbsp;mg
  every 2&nbsp;weeks over&nbsp;30&nbsp;minutes</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB style='font-size:10.0pt'>*As per
monotherapy indication in section&nbsp;4.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>If melanoma or RCC patients need to be
switched from the 240&nbsp;mg every&nbsp;2&nbsp;weeks schedule to the
480&nbsp;mg every&nbsp;4&nbsp;weeks schedule, the first 480&nbsp;mg dose should
be administered two weeks after the last 240&nbsp;mg dose. Conversely, if
patients need to be switched from the 480&nbsp;mg every&nbsp;4&nbsp;weeks schedule
to the 240&nbsp;mg every&nbsp;2&nbsp;weeks schedule, the first 240&nbsp;mg dose
should be administered four weeks after the last 480&nbsp;mg dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>OPDIVO
in combination with ipilimumab</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Melanoma</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The recommended dose is 1&nbsp;mg/kg
nivolumab in combination with 3&nbsp;mg/kg ipilimumab administered
intravenously every 3&nbsp;weeks for the first 4&nbsp;doses. This is then
followed by a second phase in which nivolumab monotherapy is administered intravenously
at either 240&nbsp;mg every 2&nbsp;weeks <b>or</b> at 480&nbsp;mg every
4&nbsp;weeks, as presented in Table&nbsp;2. For the monotherapy phase, the
first dose of nivolumab should be administered;</span></p>

<p class=EMEABodyTextIndent style='margin-left:17.0pt;text-indent:-17.0pt;
text-autospace:none'><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>3&nbsp;weeks
after the last dose of the combination of nivolumab and ipilimumab if using
240&nbsp;mg every 2&nbsp;weeks; or</span></p>

<p class=EMEABodyTextIndent style='margin-left:17.0pt;text-indent:-17.0pt;
text-autospace:none'><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>6&nbsp;weeks
after the last dose of the combination of nivolumab and ipilimumab if using
480&nbsp;mg every 4&nbsp;weeks.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=603
 style='width:451.95pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid;height:19.55pt'>
  <td width=603 colspan=3 style='width:451.95pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.55pt'>
  <p class=EMEABodyText style='margin-left:63.8pt;text-indent:-63.8pt;
  page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;2:</span></b> <b><span
  lang=EN-GB>Recommended doses </span><span lang=EN-GB>and infusion times for intravenous
  administration of nivolumab in combination with ipilimumab </span></b><b><span
  lang=EN-GB>for melanoma</span><span lang=EN-GB> </span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:34.5pt'>
  <td width=92 style='width:69.2pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=170 style='width:127.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Combination phase, every 3&nbsp;weeks for
  4&nbsp;dosing cycles</span></b></p>
  </td>
  <td width=340 style='width:255.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Monotherapy phase</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:34.5pt'>
  <td width=92 style='width:69.2pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Nivolumab</span></b></p>
  </td>
  <td width=170 style='width:127.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>1&nbsp;mg/kg
  over 30&nbsp;minutes</span></p>
  </td>
  <td width=340 style='width:255.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>240&nbsp;mg
  every 2&nbsp;weeks over 30&nbsp;minutes or</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>480&nbsp;mg
  every 4&nbsp;weeks over 60&nbsp;minutes</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:34.5pt'>
  <td width=92 style='width:69.2pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Ipilimumab</span></b></p>
  </td>
  <td width=170 style='width:127.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>3&nbsp;mg/kg
  over 90&nbsp;minutes</span></p>
  </td>
  <td width=340 style='width:255.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&#8209;</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Renal
cell carcinoma</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The recommended dose is 3&nbsp;mg/kg
nivolumab in combination with 1&nbsp;mg/kg ipilimumab administered
intravenously every 3&nbsp;weeks for the first 4&nbsp;doses. This is then
followed by a second phase in which nivolumab monotherapy is administered intravenously
at either 240&nbsp;mg every 2&nbsp;weeks <b>or</b> at 480&nbsp;mg every
4&nbsp;weeks, as presented in Table&nbsp;3. For the monotherapy phase, the
first dose of nivolumab should be administered;</span></p>

<p class=EMEABodyTextIndent style='margin-left:17.0pt;text-indent:-17.0pt;
text-autospace:none'><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>3&nbsp;weeks
after the last dose of the combination of nivolumab and ipilimumab if using
240&nbsp;mg every 2&nbsp;weeks; or</span></p>

<p class=EMEABodyTextIndent style='margin-left:17.0pt;text-indent:-17.0pt;
text-autospace:none'><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>6&nbsp;weeks
after the last dose of the combination of nivolumab and ipilimumab if using
480&nbsp;mg every 4&nbsp;weeks.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=603
 style='width:451.95pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid;height:19.55pt'>
  <td width=603 colspan=3 style='width:451.95pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.55pt'>
  <p class=EMEABodyText style='margin-left:63.8pt;text-indent:-63.8pt;
  page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;3:</span></b> <b><span
  lang=EN-GB>Recommended doses </span><span lang=EN-GB>and infusion times for intravenous
  administration of nivolumab in combination with ipilimumab for RCC</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:34.5pt'>
  <td width=92 style='width:69.2pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=170 style='width:127.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Combination phase, every 3&nbsp;weeks for
  4&nbsp;dosing cycles</span></b></p>
  </td>
  <td width=340 style='width:255.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Monotherapy phase</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:34.5pt'>
  <td width=92 style='width:69.2pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Nivolumab</span></b></p>
  </td>
  <td width=170 style='width:127.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>3&nbsp;mg/kg
  over 30&nbsp;minutes</span></p>
  </td>
  <td width=340 style='width:255.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>240&nbsp;mg
  every 2&nbsp;weeks over 30&nbsp;minutes or</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>480&nbsp;mg
  every 4&nbsp;weeks over 60&nbsp;minutes</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:34.5pt'>
  <td width=92 style='width:69.2pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Ipilimumab</span></b></p>
  </td>
  <td width=170 style='width:127.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>1&nbsp;mg/kg
  over 30&nbsp;minutes</span></p>
  </td>
  <td width=340 style='width:255.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:34.5pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&#8209;</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>OPDIVO
in combination with ipilimumab and chemotherapy</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Non&#8209;small
cell lung cancer</span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'>The recommended dose is
360&nbsp;mg nivolumab <span lang=EN-GB>administered intravenously over
30&nbsp;minutes </span>every 3&nbsp;weeks in combination with 1&nbsp;mg/kg
ipilimumab <span lang=EN-GB>administered intravenously over 30&nbsp;minutes </span>every
6&nbsp;weeks, and platinum-based chemotherapy administered every 3&nbsp;weeks.
After completion of 2&nbsp;cycles of chemotherapy, treatment is continued with
360&nbsp;mg nivolumab <span lang=EN-GB>administered intravenously </span>every
3&nbsp;weeks in combination with 1&nbsp;mg/kg ipilimumab every 6&nbsp;weeks.
Treatment is recommended until disease progression, unacceptable toxicity, or
up to 24&nbsp;months in patients without disease progression. </p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Duration
of treatment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Treatment with OPDIVO, either as a
monotherapy or in combination with ipilimumab, should be continued as long as
clinical benefit is observed or until treatment is no longer tolerated by the
patient (and up to maximum duration of therapy if specified for an indication).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For adjuvant therapy, the maximum
treatment duration with OPDIVO is 12&nbsp;months.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Atypical responses (i.e., an initial
transient increase in tumour size or small new lesions within the first few
months followed by tumour shrinkage) have been observed. It is recommended to
continue treatment with nivolumab or nivolumab in combination with ipilimumab for
clinically stable patients with initial evidence of disease progression until
disease progression is confirmed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Dose escalation or reduction is not
recommended. Dosing delay or discontinuation may be required based on individual
safety and tolerability. </span><span lang=EN-GB>Guidelines for permanent
discontinuation or withholding of doses are described in Table&nbsp;4. Detailed
guidelines for the management of immune&#8209;related adverse reactions are
described in section&nbsp;4.4.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=605 colspan=3 valign=top style='width:453.55pt;border:none;
   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableTitle style='margin-top:0in;margin-right:0in;margin-bottom:
   0in;margin-left:64.75pt;text-indent:-64.75pt;page-break-after:auto'><span
   style='font-size:11.0pt'>Table&nbsp;4:</span> <span style='font-size:
   11.0pt'>Recommended treatment modifications for OPDIVO </span><span
   style='font-size:11.0pt'>or OPDIVO in combination with ipilimumab</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=145 valign=top style='width:109.0pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader align=left style='margin:0in;text-align:left'><span
   lang=EN-GB>Immune&#8209;related adverse reaction </span></p>
   </td>
   <td width=231 valign=top style='width:173.6pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader align=left style='margin:0in;text-align:left'><span
   lang=EN-GB>Severity</span></p>
   </td>
   <td width=228 valign=top style='width:170.95pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader align=left style='margin:0in;text-align:left'><span
   lang=EN-GB>Treatment modification</span></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=145 rowspan=2 style='width:109.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Immune&#8209;related pneumonitis</span></p>
  </td>
  <td width=231 valign=top style='width:173.6pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;2&nbsp;pneumonitis</span></p>
  </td>
  <td width=228 valign=top style='width:170.95pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Withhold dose(s) until symptoms resolve, radiographic
  abnormalities improve, and management with corticosteroids is complete</span></p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=top style='width:173.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;3&nbsp;or&nbsp;4&nbsp;pneumonitis</span></p>
  </td>
  <td width=228 valign=top style='width:170.95pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Permanently discontinue treatment</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=145 rowspan=4 style='width:109.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Immune&#8209;related colitis</span></p>
  </td>
  <td width=231 valign=top style='width:173.6pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;2&nbsp;diarrhoea or colitis</span></p>
  </td>
  <td width=228 valign=top style='width:170.95pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Withhold dose(s) until symptoms resolve and management with
  corticosteroids, if needed, is complete</span></p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=top style='width:173.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;3&nbsp;diarrhoea or colitis <br>
 &#8209; OPDIVO monotherapy</span></p>
  </td>
  <td width=228 valign=top style='width:170.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Withhold dose(s) until symptoms resolve and management with
  corticosteroids is complete</span></p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=top style='width:173.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB> &#8209; OPDIVO+ipilimumab<sup>a</sup></span></p>
  </td>
  <td width=228 valign=top style='width:170.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Permanently discontinue treatment</span></p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=top style='width:173.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;4&nbsp;diarrhoea or colitis</span></p>
  </td>
  <td width=228 valign=top style='width:170.95pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Permanently discontinue treatment</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=145 rowspan=2 style='width:109.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Immune&#8209;related hepatitis</span></p>
  </td>
  <td width=231 valign=top style='width:173.6pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;2&nbsp;elevation in aspartate aminotransferase (AST),
  alanine aminotransferase (ALT), or total bilirubin </span></p>
  </td>
  <td width=228 valign=top style='width:170.95pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Withhold dose(s) until laboratory values return to baseline and
  management with corticosteroids, if needed, is complete</span></p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=top style='width:173.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;3&nbsp;or&nbsp;4&nbsp;elevation in AST, ALT, or total
  bilirubin </span></p>
  </td>
  <td width=228 valign=top style='width:170.95pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Permanently discontinue treatment</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=145 rowspan=2 style='width:109.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Immune&#8209;related nephritis and renal dysfunction</span></p>
  </td>
  <td width=231 valign=top style='width:173.6pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;2&nbsp;or&nbsp;3&nbsp;creatinine elevation </span></p>
  </td>
  <td width=228 valign=top style='width:170.95pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Withhold dose(s) until creatinine returns to baseline and
  management with corticosteroids is complete</span></p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=top style='width:173.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;4&nbsp;creatinine elevation</span></p>
  </td>
  <td width=228 valign=top style='width:170.95pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Permanently discontinue treatment</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=145 rowspan=2 style='width:109.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Immune&#8209;related endocrinopathies</span></p>
  </td>
  <td width=231 valign=top style='width:173.6pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Symptomatic Grade&nbsp;2&nbsp;or&nbsp;3 hypothyroidism,
  hyperthyroidism, hypophysitis,</span></p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;2&nbsp;adrenal insufficiency</span></p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;3&nbsp;diabetes</span></p>
  </td>
  <td width=228 valign=top style='width:170.95pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Withhold dose(s) until symptoms resolve and management with
  corticosteroids (if needed for symptoms of acute inflammation) is complete.
  Treatment should be continued in the presence of hormone replacement therapy</span><span
  class=EMEASuperscript><span lang=EN-GB style='font-size:11.0pt'>b</span></span><span
  lang=EN-GB> as long as no symptoms are present</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=top style='width:173.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;4&nbsp;hypothyroidism </span></p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;4&nbsp;hyperthyroidism </span></p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;4&nbsp;hypophysitis</span></p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;3&nbsp;or&nbsp;4&nbsp;adrenal insufficiency</span></p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;4&nbsp;diabetes</span></p>
  </td>
  <td width=228 style='width:170.95pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Permanently discontinue treatment</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=145 rowspan=3 style='width:109.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Immune&#8209;related skin adverse reactions</span></p>
  </td>
  <td width=231 valign=top style='width:173.6pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;3&nbsp;rash</span></p>
  </td>
  <td width=228 valign=top style='width:170.95pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Withhold dose(s) until symptoms resolve and management with
  corticosteroids is complete</span></p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=top style='width:173.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;4&nbsp;rash</span></p>
  </td>
  <td width=228 valign=top style='width:170.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Permanently discontinue treatment</span></p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=top style='width:173.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Stevens&#8209;Johnson syndrome (SJS) or toxic epidermal necrolysis
  (TEN)</span></p>
  </td>
  <td width=228 valign=top style='width:170.95pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Permanently discontinue treatment (see section&nbsp;4.4)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=145 rowspan=2 style='width:109.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'>Immune-related</p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'>myocarditis</p>
  </td>
  <td width=231 valign=top style='width:173.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'>Grade&nbsp;2&nbsp;myocarditis</p>
  </td>
  <td width=228 valign=top style='width:170.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'>Withhold
  dose(s) until symptoms resolve and management with corticosteroids is
  complete<sup>c</sup></p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=top style='width:173.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'>Grade&nbsp;3&nbsp;or&nbsp;4&nbsp;myocarditis</p>
  </td>
  <td width=228 valign=top style='width:170.95pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'>Permanently
  discontinue treatment</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=145 rowspan=2 style='width:109.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Other immune&#8209;related adverse reactions</span></p>
  </td>
  <td width=231 valign=top style='width:173.6pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;3&nbsp;(first occurrence)</span></p>
  </td>
  <td width=228 valign=top style='width:170.95pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Withhold dose(s)</span></p>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=231 valign=top style='width:173.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Grade&nbsp;4 or recurrent Grade&nbsp;3&nbsp;; persistent
  Grade&nbsp;2 or&nbsp;3 despite treatment modification; inability to reduce
  corticosteroid dose to&nbsp;10&nbsp;mg prednisone or equivalent per day</span></p>
  </td>
  <td width=228 style='width:170.95pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>Permanently discontinue treatment</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB style='font-size:10.0pt'>Note: Toxicity
grades are in accordance with National Cancer Institute Common Terminology
Criteria for Adverse Events Version&nbsp;4.0&nbsp;(NCI&#8209;CTCAE&nbsp;v4).</span></p>

<p class=EMEABodyText style='margin-left:27.0pt;text-indent:-27.0pt'><span
class=EMEASuperscript><span lang=EN-GB>a</span></span><span lang=EN-GB
style='font-size:10.0pt'> </span><span lang=EN-GB style='font-size:
10.0pt'>During administration of the second phase of treatment (nivolumab
monotherapy) following combination treatment, permanently discontinue treatment
if Grade&nbsp;3 diarrhoea or colitis occurs.</span></p>

<p class=EMEABodyText><span class=EMEASuperscript><span lang=EN-GB>b</span></span><span
lang=EN-GB style='font-size:10.0pt'> Recommendation for the use of
hormone replacement therapy is provided in section&nbsp;4.4.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
class=EMEASuperscript><span lang=EN-GB>c</span></span><span lang=EN-GB
style='font-size:10.0pt'> The safety of re-initiating nivolumab or
nivolumab in combination with ipilimumab therapy in patients previously
experiencing immune-related myocarditis is not known.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO or OPDIVO in combination with
ipilimumab should be permanently discontinued for:</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Grade&nbsp;4&nbsp;or&nbsp;recurrent&nbsp;Grade&nbsp;3&nbsp;adverse
reactions;</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Persistent
Grade&nbsp;2&nbsp;or&nbsp;3&nbsp;adverse reactions despite management.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Patients treated with OPDIVO must be
given the patient alert card and be informed about the risks of OPDIVO (see
also package leaflet).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>When OPDIVO is administered in
combination with ipilimumab, if either agent is withheld, the other agent
should also be withheld. If dosing is resumed after a delay, either the
combination treatment or OPDIVO monotherapy could be resumed based on the evaluation
of the individual patient.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Special
populations</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Paediatric
population</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of OPDIVO in
children below&nbsp;18&nbsp;years of age have not been established. No data are
available.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Elderly</span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>No dose
adjustment is required for elderly patients (&#8805;&nbsp;65&nbsp;years) (see
section&nbsp;5.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>Data from SCCHN, adjuvant melanoma and
first&#8209;line RCC patients 75&nbsp;years of age or older are too limited to
draw conclusions on this population (see sections&nbsp;4.8 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Renal
impairment</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Based on the population pharmacokinetic (PK)
results, no dose adjustment is required in patients with </span><span
lang=EN-GB>mild or moderate renal impairment (see section&nbsp;5.2). Data from
patients with severe renal impairment are too limited to draw conclusions on
this population.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Hepatic
impairment</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Based on the population PK results, no
dose adjustment is required in patients with mild hepatic impairment (see
section&nbsp;5.2). Data from patients with moderate or severe hepatic
impairment are too limited to draw conclusions on these populations. OPDIVO</span><span
lang=EN-GB> must be administered with caution in patients with moderate (total
bilirubin&nbsp;&gt;&nbsp;1.5&nbsp;&nbsp;to&nbsp;3&nbsp;&nbsp;the upper limit
of normal [ULN] and any AST) or severe (total bilirubin&nbsp;&gt;&nbsp;3&nbsp;&nbsp;ULN
and any AST) hepatic impairment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:11.5pt'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Method
of administration</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO is for intravenous use only. It
is to be administered as an intravenous infusion over a period of&nbsp;30 or 60&nbsp;minutes</span><span
lang=EN-GB> depending on the dose (see Tables&nbsp;1, 2&nbsp;and&nbsp;3). The
infusion must be administered through a sterile, non&#8209;pyrogenic, low
protein binding in&#8209;line filter with a pore size of&nbsp;0.2&#8209;1.2&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>m.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO must not be administered as an
intravenous push or bolus injection.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The total dose of OPDIVO required can be
infused directly as a&nbsp;10&nbsp;mg/mL solution or can be diluted with sodium
chloride&nbsp;9&nbsp;mg/mL&nbsp;(0.9%) solution for injection or glucose&nbsp;50&nbsp;mg/mL&nbsp;(5%)
solution for injection (see section&nbsp;6.6).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>When administered in combination with
ipilimumab or in combination with ipilimumab and chemotherapy<i>, </i>OPDIVO should
be given first followed by ipilimumab and then by chemotherapy on the same day.
Use separate infusion bags and filters for each infusion.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For instructions on the preparation and handling
of the medicinal product before administration, see section&nbsp;6.6.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.3 Contraindications</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Hypersensitivity to the active substance
or to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.4 Special warnings and precautions
for use</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Traceability
</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In order to improve the traceability of
biological medicinal products, the name and the batch number of the
administered product should be clearly recorded.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Immune-related
adverse reactions</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>When nivolumab is administered in
combination, refer to the Summary of Product Characteristics of the other
combination therapy components prior to initiation of treatment. Immune&#8209;related
adverse reactions have occurred at higher frequencies when nivolumab was
administered in combination with ipilimumab compared with nivolumab as
monotherapy. Most immune&#8209;related adverse reactions improved or resolved
with appropriate management, including initiation of corticosteroids and
treatment modifications (see section&nbsp;4.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cardiac and pulmonary adverse reactions including
pulmonary embolism have also been reported with combination therapy. Patients
should be monitored for cardiac and pulmonary adverse reactions continuously,
as well as for clinical signs, symptoms, and laboratory abnormalities
indicative of electrolyte disturbances and dehydration prior to and
periodically during treatment. Nivolumab in combination with ipilimumab should
be discontinued for life&#8209;threatening or recurrent severe cardiac and
pulmonary adverse reactions (see section&nbsp;4.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Patients should be monitored
continuously (at least up to 5&nbsp;months after the last dose) as an adverse
reaction with nivolumab or nivolumab in combination with ipilimumab may occur
at any time during or after discontinuation of therapy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For suspected immune&#8209;related
adverse reactions, adequate evaluation should be performed to confirm aetiology
or exclude other causes. Based on the severity of the adverse reaction,
nivolumab or nivolumab in combination with ipilimumab should be withheld and
corticosteroids administered. If immunosuppression with corticosteroids is used
to treat an adverse reaction, a taper of at least&nbsp;1&nbsp;month duration
should be initiated upon improvement. Rapid tapering may lead to worsening or
recurrence of the adverse reaction. Non&#8209;corticosteroid immunosuppressive therapy
should be added if there is worsening or no improvement despite corticosteroid
use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab or nivolumab in combination
with ipilimumab should not be resumed while the patient is receiving
immunosuppressive doses of corticosteroids or other immunosuppressive therapy.
Prophylactic antibiotics should be used to prevent opportunistic infections in
patients receiving immunosuppressive therapy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab </span><span lang=EN-GB>or
nivolumab in combination with ipilimumab must be permanently discontinued for
any severe immune&#8209;related adverse reaction that recurs and for any life&#8209;threatening
immune&#8209;related adverse reaction.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Immune&#8209;related
pneumonitis</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Severe pneumonitis or interstitial lung
disease, including fatal cases, has been observed with nivolumab monotherapy or
nivolumab in combination with ipilimumab (see section&nbsp;4.8). Patients should
be monitored for signs and symptoms of pneumonitis such as radiographic changes
(e.g., focal ground glass opacities, patchy filtrates), dyspnoea, and hypoxia. Infectious
and disease&#8209;related aetiologies should be ruled out.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For
Grade&nbsp;3&nbsp;or&nbsp;4&nbsp;pneumonitis, nivolumab or nivolumab in
combination with ipilimumab must be permanently discontinued, and
corticosteroids should be initiated at a dose of&nbsp;2&nbsp;to&nbsp;4&nbsp;mg/kg/day
methylprednisolone equivalents.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For Grade&nbsp;2&nbsp;(symptomatic)
pneumonitis, nivolumab or nivolumab in combination with ipilimumab should be
withheld and corticosteroids initiated at a dose of&nbsp;1&nbsp;mg/kg/day
methylprednisolone equivalents. Upon improvement, nivolumab or nivolumab in
combination with ipilimumab may be resumed after corticosteroid taper. If
worsening or no improvement occurs despite initiation of corticosteroids, corticosteroid
dose should be increased to&nbsp;2&nbsp;to&nbsp;4&nbsp;mg/kg/day
methylprednisolone equivalents and nivolumab or nivolumab in combination with
ipilimumab must be permanently discontinued.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=BMSHeading3 style='margin:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'>Immune&#8209;related
colitis</span></p>

<p class=MsoNormal><span lang=EN-GB>Severe diarrhoea or colitis has been
observed with nivolumab monotherapy or nivolumab in combination with ipilimumab
(see section&nbsp;4.8). Patients should be monitored for diarrhoea and
additional symptoms of colitis, such as abdominal pain and mucus or blood in
stool. Cytomegalovirus (CMV) infection/reactivation has been reported in
patients with corticosteroid&#8209;refractory immune&#8209;related colitis. Infectious
and other aetiologies of diarrhoea should be ruled out, therefore appropriate
laboratory tests and additional examinations must be performed. If diagnosis of
corticosteroid&#8209;refractory immune&#8209;related colitis is confirmed
addition of an alternative immunosuppressive agent to the corticosteroid
therapy, or replacement of the corticosteroid therapy, should be considered.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For Grade&nbsp;4&nbsp;diarrhoea or
colitis, nivolumab or nivolumab in combination with ipilimumab must be permanently
discontinued, and corticosteroids should be initiated at a dose of&nbsp;1&nbsp;to&nbsp;2&nbsp;mg/kg/day
methylprednisolone equivalents. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab monotherapy should be withheld
for Grade&nbsp;3&nbsp;diarrhoea or colitis, and corticosteroids initiated at a
dose of&nbsp;1&nbsp;to&nbsp;2&nbsp;mg/kg/day methylprednisolone equivalents.
Upon improvement, nivolumab monotherapy may be resumed after corticosteroid
taper. If worsening or no improvement occurs despite initiation of
corticosteroids, nivolumab monotherapy must be permanently discontinued.
Grade&nbsp;3 diarrhoea or colitis observed with nivolumab in combination with
ipilimumab requires permanent discontinuation of treatment and initiation of
corticosteroids at a dose of 1&nbsp;to&nbsp;2&nbsp;mg/kg/day methylprednisolone
equivalents.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For Grade&nbsp;2&nbsp;diarrhoea or
colitis, nivolumab or nivolumab in combination with ipilimumab should be withheld.
Persistent diarrhoea or colitis should be managed with corticosteroids at a
dose of&nbsp;0.5&nbsp;to&nbsp;1&nbsp;mg/kg/day methylprednisolone equivalents.
Upon improvement, nivolumab or nivolumab in combination with ipilimumab may be resumed
after corticosteroid taper, if needed. If worsening or no improvement occurs
despite initiation of corticosteroids, corticosteroid dose should be increased
to&nbsp;1&nbsp;to&nbsp;2&nbsp;mg/kg/day methylprednisolone equivalents and nivolumab
or nivolumab in combination with ipilimumab must be permanently discontinued.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=BMSHeading3 style='margin:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'>Immune&#8209;related
hepatitis</span></p>

<p class=EMEABodyText><span lang=EN-GB>Severe hepatitis has been observed with
nivolumab monotherapy or nivolumab in combination with ipilimumab (see section&nbsp;4.8).
Patients should be monitored for signs and symptoms of hepatitis such as
transaminase and total bilirubin elevations. Infectious and disease&#8209;related
aetiologies should be ruled out.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For Grade&nbsp;3&nbsp;or&nbsp;4&nbsp;transaminase
or total bilirubin elevation, nivolumab or nivolumab in combination with
ipilimumab must be permanently discontinued, and corticosteroids should be
initiated at a dose of&nbsp;1&nbsp;to&nbsp;2&nbsp;mg/kg/day methylprednisolone
equivalents.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For Grade&nbsp;2&nbsp;transaminase or
total bilirubin elevation, nivolumab or nivolumab in combination with
ipilimumab should be withheld. Persistent elevations in these laboratory values
should be managed with corticosteroids at a dose of&nbsp;0.5&nbsp;to&nbsp;1&nbsp;mg/kg/day
methylprednisolone equivalents. Upon improvement, nivolumab or nivolumab in
combination with ipilimumab may be resumed after corticosteroid taper, if
needed. If worsening or no improvement occurs despite initiation of
corticosteroids, corticosteroid dose should be increased to&nbsp;1&nbsp;to&nbsp;2&nbsp;mg/kg/day
methylprednisolone equivalents and nivolumab or nivolumab in combination with
ipilimumab must be permanently discontinued.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=BMSHeading3 style='margin:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'>Immune&#8209;related
nephritis and renal dysfunction</span></p>

<p class=EMEABodyText><span lang=EN-GB>Severe nephritis and renal dysfunction have
been observed with monotherapy treatment or nivolumab in combination with
ipilimumab (see section&nbsp;4.8). Patients should be monitored for signs and
symptoms of nephritis or renal dysfunction. Most patients present with
asymptomatic increases in serum creatinine. Disease&#8209;related aetiologies
should be ruled out.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For Grade&nbsp;4&nbsp;serum creatinine
elevation, nivolumab or nivolumab in combination with ipilimumab must be permanently
discontinued, and corticosteroids should be initiated at a dose of&nbsp;1&nbsp;to&nbsp;2&nbsp;mg/kg/day
methylprednisolone equivalents.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For Grade&nbsp;2&nbsp;or&nbsp;3&nbsp;serum
creatinine elevation, nivolumab or nivolumab in combination with ipilimumab should
be withheld, and corticosteroids should be initiated at a dose of&nbsp;0.5&nbsp;to&nbsp;1&nbsp;mg/kg/day
methylprednisolone equivalents. Upon improvement, nivolumab or nivolumab in
combination with ipilimumab may be resumed after corticosteroid taper. If
worsening or no improvement occurs despite initiation of corticosteroids, corticosteroid
dose should be increased to&nbsp;1&nbsp;to&nbsp;2&nbsp;mg/kg/day
methylprednisolone equivalents, and nivolumab or nivolumab in combination with
ipilimumab must be permanently discontinued.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=BMSHeading3 style='margin:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'>Immune&#8209;related
endocrinopathies</span></p>

<p class=EMEABodyText><span lang=EN-GB>Severe endocrinopathies, including
hypothyroidism, hyperthyroidism, adrenal insufficiency (including secondary
adrenocortical insufficiency), hypophysitis (including hypopituitarism),
diabetes mellitus, and diabetic ketoacidosis have been observed with nivolumab monotherapy
or nivolumab in combination with ipilimumab (see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Patients should be monitored for
clinical signs and symptoms of endocrinopathies and for </span><span
lang=EN-GB>hyperglycaemia and<i> </i></span><span lang=EN-GB>changes in thyroid
function (at the start of treatment, periodically during treatment, and as
indicated based on clinical evaluation). Patients may present with fatigue,
headache, mental status changes, abdominal pain, unusual bowel habits, and
hypotension, or nonspecific symptoms which may resemble other causes such as
brain metastasis or underlying disease. Unless an alternate aetiology has been
identified, signs or symptoms of endocrinopathies should be considered immune&#8209;related.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=EN-GB>For symptomatic hypothyroidism,
nivolumab or nivolumab in combination with ipilimumab should be withheld, and
thyroid hormone replacement should be initiated as needed. For symptomatic
hyperthyroidism, nivolumab or nivolumab in combination with ipilimumab should
be withheld and antithyroid medication should be initiated as needed. Corticosteroids
at a dose of&nbsp;1&nbsp;to&nbsp;2&nbsp;mg/kg/day methylprednisolone
equivalents should also be considered if acute inflammation of the thyroid is
suspected. Upon improvement, nivolumab or nivolumab in combination with
ipilimumab may be resumed after corticosteroid taper, if needed. Monitoring of
thyroid function should continue to ensure appropriate hormone replacement is utilised.
Nivolumab or nivolumab in combination with ipilimumab must be permanently
discontinued for life&#8209;threatening hyperthyroidism or hypothyroidism.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For symptomatic Grade&nbsp;2&nbsp;adrenal
insufficiency, nivolumab or nivolumab in combination with ipilimumab should be
withheld, and physiologic corticosteroid replacement should be initiated as
needed. Nivolumab or nivolumab in combination with ipilimumab must be
permanently discontinued for severe (Grade&nbsp;3) or life&#8209;threatening
(Grade&nbsp;4) adrenal insufficiency. Monitoring of adrenal function and
hormone levels should continue to ensure appropriate corticosteroid replacement
is utilised.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For symptomatic Grade&nbsp;2&nbsp;or&nbsp;3
hypophysitis, nivolumab or nivolumab in combination with ipilimumab should be
withheld, and hormone replacement should be initiated as needed.
Corticosteroids at a dose of 1&nbsp;to&nbsp;2&nbsp;mg/kg/day&nbsp;methylprednisolone
equivalents should also be considered if acute inflammation of the pituitary
gland is suspected. Upon improvement, nivolumab or nivolumab in combination
with ipilimumab may be resumed after corticosteroid taper, if needed. Nivolumab
or nivolumab in combination with ipilimumab must be permanently discontinued
for life&#8209;threatening (Grade&nbsp;4) hypophysitis. Monitoring of pituitary
function and hormone levels should continue to ensure appropriate hormone
replacement is utilised.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For symptomatic diabetes, nivolumab or
nivolumab in combination with ipilimumab should be withheld, and insulin
replacement should be initiated as needed. Monitoring of blood sugar should
continue to ensure appropriate insulin replacement is utilised. Nivolumab or
nivolumab in combination with ipilimumab must be permanently discontinued for
life&#8209;threatening diabetes.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=BMSHeading3 style='margin:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'>Immune&#8209;related
skin adverse reactions</span></p>

<p class=EMEABodyText><span lang=EN-GB>Severe rash has been observed with
nivolumab in combination with ipilimumab and, less commonly, with nivolumab as
monotherapy (see section&nbsp;4.8). Nivolumab or nivolumab in combination with
ipilimumab should be withheld for Grade&nbsp;3 rash and discontinued for Grade&nbsp;4
rash. Severe rash should be managed with high&#8209;dose corticosteroid at a
dose of 1&nbsp;to&nbsp;2&nbsp;mg/kg/day&nbsp;methylprednisolone equivalents.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span style='color:black'>Rare</span><span lang=EN-GB>
cases of SJS and TEN some of them with fatal outcome have been observed. If
symptoms or signs of SJS or TEN appear, treatment with nivolumab or nivolumab
in combination with ipilimumab should be discontinued and the patient referred
to a specialised unit for assessment and treatment. If the patient has
developed SJS or TEN with the use of nivolumab or nivolumab in combination with
ipilimumab, permanent discontinuation of treatment is recommended (see
section&nbsp;4.2).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>Caution should be used when considering the use of nivolumab
in a patient who has previously experienced a severe or life&#8209;threatening
skin adverse reaction on prior treatment with other immune&#8209;stimulatory
anticancer agents.</p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=BMSHeading3 style='margin:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'>Other
immune&#8209;related adverse reactions</span></p>

<p class=EMEABodyText>The following immune&#8209;related adverse reactions were
reported in less than&nbsp;1% of patients treated with nivolumab monotherapy or
nivolumab in combination with ipilimumab in clinical trials across doses and
tumour types: pancreatitis, uveitis, demyelination, autoimmune neuropathy
(including facial and abducens nerve paresis), Guillain&#8209;Barr syndrome, myasthenia
gravis, myasthenic syndrome, aseptic meningitis, encephalitis, gastritis,
sarcoidosis, duodenitis, myositis, myocarditis, and rhabdomyolysis. Cases of
Vogt&#8209;Koyanagi&#8209;Harada syndrome and hypoparathyroidism have been
reported post&#8209;marketing (see section&nbsp;4.8).</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>For suspected immune&#8209;related adverse reactions,
adequate evaluation should be performed to confirm aetiology or exclude other
causes. Based on the severity of the adverse reaction, nivolumab or nivolumab
in combination with ipilimumab should be withheld and corticosteroids
administered. Upon improvement, nivolumab or nivolumab in combination with
ipilimumab may be resumed after corticosteroid taper. Nivolumab or nivolumab in
combination with ipilimumab must be permanently discontinued for any severe
immune&#8209;related adverse reaction that recurs and for any life&#8209;threatening
immune&#8209;related adverse reaction.</p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Cases of m</span>yotoxicity (myositis,
myocarditis, and rhabdomyolysis), some with fatal outcome, have been reported
with nivolumab or nivolumab in combination with ipilimumab. If a patient
develops signs and symptoms of myotoxicity, close monitoring should be implemented,
and the patient referred to a specialist for assessment and treatment without
delay. Based on the severity of myotoxicity, nivolumab or nivolumab in
combination with ipilimumab should be withheld or discontinued (see
section&nbsp;4.2), and appropriate treatment instituted. </p>

<p class=EMEABodyText><span lang=EN-GB>The diagnosis of myocarditis requires a
high index of suspicion. Patients with cardiac or cardio-pulmonary symptoms
should be assessed for potential myocarditis. If myocarditis is suspected,
prompt initiation of a high dose of steroids (prednisone
1&nbsp;to&nbsp;2&nbsp;mg/kg/day or methylprednisolone
1&nbsp;to&nbsp;2&nbsp;mg/kg/day) and prompt cardiology consultation with
diagnostic workup according to current clinical guidelines should be initiated.
Once a diagnosis of myocarditis is established, nivolumab or nivolumab in
combination with ipilimumab should be withheld or permanently discontinued (see
section&nbsp;4.2).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>Solid organ transplant rejection has been reported in the
post&#8209;marketing setting in patients treated with PD&#8209;1 inhibitors.
Treatment with nivolumab may increase the risk of rejection in solid organ
transplant recipients. The benefit of treatment with nivolumab versus the risk
of possible organ rejection should be considered in these patients. </p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText>Haemophagocytic lymphohistiocytosis (HLH) has been observed
with nivolumab as monotherapy and nivolumab in combination with ipilimumab.
Caution should be taken when nivolumab is administered as monotherapy or in
combination with ipilimumab. If HLH is confirmed, administration of nivolumab
or nivolumab in combination with ipilimumab should be discontinued and
treatment for HLH initiated.</p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Infusion
reactions</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Severe infusion reactions have been
reported in clinical trials of nivolumab </span><span lang=EN-GB>or nivolumab
in combination with ipilimumab</span><span lang=EN-GB> (see section&nbsp;4.8).
In case of a severe or life&#8209;threatening infusion reaction, the nivolumab or
nivolumab in combination with ipilimumab infusion must be discontinued and
appropriate medical therapy administered. Patients with mild or moderate
infusion reaction may receive nivolumab </span><span lang=EN-GB>or nivolumab in
combination with ipilimumab</span><span lang=EN-GB> with close monitoring </span>and
use of premedication according to local treatment guidelines for prophylaxis of
infusion reactions<span lang=EN-GB>.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Disease&#8209;specific
precautions</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Advanced
melanoma</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Patients with a baseline performance
score&nbsp;&#8805;&nbsp;2, active brain metastases or </span><span lang=EN-GB>leptomeningeal
</span><span lang=EN-GB>metastases, autoimmune disease, and patients who had
been receiving systemic immunosuppressants prior to study entry were excluded
from the pivotal clinical trials of nivolumab or nivolumab in combination with
ipilimumab (see sections&nbsp;4.5 and&nbsp;5.1). Patients with ocular/uveal
melanoma were excluded from pivotal clinical trials of melanoma. In addition,
CA209037 excluded patients who have had a Grade</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>4 adverse reaction that was related to anti&#8209;CTLA&#8209;4
therapy (see section&nbsp;5.1). Patients with baseline performance score
of&nbsp;2, treated leptomeningeal </span><span lang=EN-GB>metastases, </span><span
lang=EN-GB>ocular/uveal melanoma, autoimmune disease and patients who have had
a Grade&nbsp;3&#8209;4 adverse reaction that was related to prior anti&#8209;CTLA&#8209;4
therapy were included in study CA209172 (see section&nbsp;5.1). In the absence
of data for patients who had been receiving systemic immunosuppressants prior
to study entry, and for patients with active brain or leptomeningeal
metastases, nivolumab should be used with caution in these populations after
careful consideration of the potential benefit/risk on an individual basis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Relative to nivolumab monotherapy, an
increase in PFS for the combination of nivolumab with ipilimumab is established
only in patients with low tumour PD&#8209;L1 expression. </span><span
lang=EN-GB>The improvement in </span><span lang=EN-GB>OS </span><span
lang=EN-GB>was similar between nivolumab in combination with ipilimumab and
nivolumab monotherapy<b> </b>in patients with high tumour PD&#8209;L1
expression (PD&#8209;L1&nbsp;&#8805;&nbsp;1%). </span><span lang=EN-GB>Before
initiating treatment with the combination, physicians are advised to carefully
evaluate the individual patient and tumour characteristics, taking into
consideration the observed benefits and the toxicity of the combination
relative to nivolumab monotherapy (see sections&nbsp;4.8 and&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Use
of nivolumab in melanoma patients with rapidly progressing disease</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Physicians should consider the delayed
onset of nivolumab effect before initiating treatment in patients with rapidly
progressing disease (see section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Adjuvant
treatment of melanoma</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>There are no
data on adjuvant treatment in patients with melanoma with the following risk
factors (see sections&nbsp;4.5 and&nbsp;5.1):</span></p>

<p class=MsoCommentText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>patients with prior
autoimmune disease, and any condition requiring systemic treatment with either corticosteroids
(&#8805;&nbsp;10&nbsp;mg daily prednisone or equivalent) or other
immunosuppressive medications,</span></p>

<p class=MsoCommentText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>patients with prior
therapy for melanoma (except patients with surgery, adjuvant radiotherapy after
neurosurgical resection for lesions of the central nervous system, and prior
adjuvant interferon completed &#8805;&nbsp;6&nbsp;months prior to
randomisation),</span></p>

<p class=MsoCommentText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>patients treated with
prior therapy with anti&#8209;PD&#8209;1, anti&#8209;PD&#8209;L1, anti&#8209;PD&#8209;L2,
anti&#8209;CD137, or anti CTLA&#8209;4 antibody (including ipilimumab or any
other antibody or drug specifically targeting T&nbsp;cell co&#8209;stimulation or
checkpoint pathways),</span></p>

<p class=MsoCommentText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>subjects under the age
of 18&nbsp;years.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In the absence
of data, nivolumab should be used with caution in these populations after
careful consideration of the potential benefit/risk on an individual basis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Non&#8209;small
cell lung cancer</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>First-line
treatment of NSCLC</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Patients with active autoimmune disease,
symptomatic interstitial lung disease, medical conditions requiring systemic
immunosuppression, active (untreated) brain metastasis, who received prior
systemic treatment for advanced disease, or who had sensitising EGFR mutations
or ALK translocations were excluded from the pivotal trial in first-line
treatment of NSCLC (see sections&nbsp;4.5 and&nbsp;5.1). Limited data are
available in elderly patients (&#8805;&nbsp;75&nbsp;years) (see
section&nbsp;5.1). In these patients, nivolumab in combination with ipilimumab
and chemotherapy<i><span style='color:#0070C0'> </span></i>should be used with
caution after careful consideration of the potential benefit/risk on an
individual basis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Treatment
of NSCLC after prior chemotherapy</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Patients with a baseline performance
score&nbsp;&#8805;&nbsp;2, active brain metastases or autoimmune disease,
symptomatic interstitial lung disease, and patients who had been receiving
systemic immunosuppressants prior to study entry were excluded from the pivotal
clinical trials of NSCLC (see sections&nbsp;4.5 and&nbsp;5.1).</span><span
lang=EN-GB> </span><span lang=EN-GB>Patients with baseline performance score
of&nbsp;2 were included in study CA209171 (see section&nbsp;5.1). In the
absence of data for patients with autoimmune disease, symptomatic interstitial
lung disease, active brain metastases and patients who had been receiving
systemic immunosuppressants prior to study entry, nivolumab should be used with
caution in these populations after careful consideration of the potential benefit/risk
on an individual basis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Physicians should consider the delayed
onset of nivolumab effect before initiating treatment in patients with poorer
prognostic features and/or aggressive disease. In non&#8209;squamous NSCLC, a
higher number of deaths within 3&nbsp;months was observed in nivolumab compared
to docetaxel. Factors associated with early deaths were poorer prognostic
factors and/or more aggressive disease combined with low or no tumour PD&#8209;L1
expression (see section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Renal cell
carcinoma</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Patients with any history of or
concurrent brain metastases, active autoimmune disease, or medical conditions
requiring systemic immunosuppression were excluded from the clinical trials of
nivolumab or nivolumab in combination with ipilimumab (see sections&nbsp;4.5
and&nbsp;5.1). In the absence of data, nivolumab or nivolumab in combination
with ipilimumab should be used with caution in these populations after careful
consideration of the potential benefit/risk on an individual basis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Classical
Hodgkin lymphoma</span></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Patients with active
autoimmune disease and symptomatic interstitial lung disease were excluded from
clinical trials of cHL (see section&nbsp;5.1). </span><span lang=EN-GB>In the
absence of data, nivolumab should be used with caution in these populations
after careful consideration of the potential benefit/risk on an individual
basis.</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Complications
of allogeneic </span><span lang=EN-GB>haematopoietic stem cell transplant</span></u></i><i><u><span
lang=EN-GB> (HSCT) in classical Hodgkin lymphoma</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Preliminary results from the follow&#8209;up
of patients </span><span lang=EN-GB>with cHL</span><span lang=EN-GB> undergoing
allogeneic HSCT after previous exposure to nivolumab showed a higher&nbsp;than
expected number of cases of acute graft&#8209;versus&#8209;host disease (GVHD)
and transplant related mortality (TRM). Until further data become available,
careful consideration to the potential benefits of HSCT and the possible
increased risk of transplant related complications should be made case&#8209;by&#8209;case
(see section&nbsp;4.8).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText>In patients treated with nivolumab after allogeneic HSCT,
rapid&#8209;onset and severe GVHD, some with fatal outcome, have been reported
in the post&#8209;marketing setting. Treatment with nivolumab may increase the
risk of severe GVHD and death in patients who have had prior allogeneic HSCT, mainly
in those with prior history of GVHD. The benefit of treatment with nivolumab
versus the possible risk should be considered in these patients (see
section&nbsp;4.8).</p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Head
and neck cancer</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Patients with a baseline performance
score&nbsp;&#8805;&nbsp;2, </span><span lang=EN-GB>active brain or
leptomeningeal metastases,</span><span lang=EN-GB> </span><span lang=EN-GB>active
autoimmune disease, medical conditions requiring </span><span lang=EN-GB>systemic</span><span
lang=EN-GB> immunosuppression, or carcinoma of the nasopharynx or salivary
gland as the primary tumour sites </span><span lang=EN-GB>were excluded from
the SCCHN clinical trial (see sections&nbsp;4.5 and&nbsp;5.1). In the absence
of data, nivolumab should be used with caution in these populations after careful
consideration of the potential benefit/risk on an individual basis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText>Physicians should consider the delayed onset of nivolumab
effect before initiating treatment in patients with poorer prognostic features
and/or aggressive disease. In head and neck cancer, a higher number of deaths
within 3<span lang=EN-GB>&nbsp;</span>months was observed in nivolumab compared
to docetaxel. Factors associated with early deaths were ECOG performance
status, fast progressive disease on prior platinum therapy and high tumour
burden.</p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Urothelial
carcinoma</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Patients with a baseline performance
score </span><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB>2, active brain metastases or leptomeningeal metastases, active
autoimmune disease, or medical conditions requiring systemic immunosuppression
were excluded from the clinical trials of urothelial carcinoma (see
sections&nbsp;4.5 and&nbsp;5.1). In the absence of data, nivolumab should be
used with caution in these populations after careful consideration of the
potential benefit/risk on an individual basis.</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Oesophageal
squamous cell carcinoma</span></i></p>

<p class=EMEABodyText><span style='color:black'>The majority of clinical data
available in oesophageal squamous cell carcinoma are in patients of Asian
origin (see section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Patients with a
baseline performance score&nbsp;&#8805;&nbsp;2, </span><span lang=EN-GB>brain <span
style='color:black'>metastases that were symptomatic or required treatment, </span></span><span
lang=EN-GB style='color:black'>apparent tumour invasion in organs located
adjacent to the oesophagus (e.g. the aorta or respiratory tract), active </span><span
lang=EN-GB style='color:black'>autoimmune disease, or medical conditions
requiring systemic immunosuppression were excluded from the clinical study in
OSCC (see sections&nbsp;4.5 and&nbsp;5.1). In the absence of data, nivolumab
should be used with caution in these populations </span><span lang=EN-GB>after
careful consideration of the potential benefit/risk on an individual basis.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText>Physicians should consider the delayed onset of nivolumab
effect before initiating treatment in patients with OSCC. A higher number of
deaths within 2.5&nbsp;months after randomisation was observed with nivolumab
compared to chemotherapy. No specific factor(s) <span lang=EN-GB>associated
with early deaths could be identified (see section&nbsp;5.1)</span>.</p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Patients
on controlled sodium diet</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Each mL of this medicinal product
contains&nbsp;0.1&nbsp;mmol (or&nbsp;2.5&nbsp;mg) sodium. </span><span
lang=EN-GB style='color:black'>This medicinal product contains 10&nbsp;mg
sodium per 4&nbsp;ml vial, 25&nbsp;mg sodium per 10&nbsp;ml vial or 60&nbsp;mg
sodium per 24&nbsp;ml vial, which is equivalent to 0.5%, 1.25% or 3%
respectively, of the WHO recommended maximum daily intake of 2&nbsp;g sodium
for an adult.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Patient
alert card</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>All prescribers of OPDIVO must be
familiar with the physician information and management guidelines. The
prescriber must discuss the risks of OPDIVO therapy with the patient. The
patient will be provided with the patient alert card with each prescription.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.5 Interaction with other medicinal
products and other forms of interaction</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab is a human monoclonal antibody,</span><span
lang=EN-GB> as such pharmacokinetic interaction studies have not been conducted.
As monoclonal antibodies are not metabolised by cytochrome P450 (CYP) enzymes
or other drug metabolising enzymes, inhibition or induction of these enzymes by
co&#8209;administered medicinal products is not anticipated to affect the
pharmacokinetics of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Other
forms of interaction</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Systemic
immunosuppression</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>The use of systemic corticosteroids and
other immunosuppressants at baseline, before starting nivolumab, should be
avoided because of their potential interference with the pharmacodynamic
activity. However, systemic corticosteroids and other immunosuppressants can be
used after starting nivolumab to treat immune&#8209;related adverse reactions. The
preliminary results show that systemic immunosuppression after starting
nivolumab treatment does not appear to preclude the response on nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.6 Fertility, pregnancy and
lactation</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>There are no data from the use of
nivolumab in pregnant women. Studies in animals have shown embryofoetal toxicity
(see section&nbsp;5.3). Human IgG4 is known to cross the placental barrier and
nivolumab is an IgG4; therefore, nivolumab has the potential to be transmitted
from the mother to the developing foetus. Nivolumab is not recommended during
pregnancy and in women of childbearing potential not using effective
contraception </span><span lang=EN-GB>unless the clinical benefit outweighs the
potential risk</span><span lang=EN-GB>. Effective contraception should be used
for at least 5&nbsp;months following the last dose of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>It is unknown whether nivolumab is secreted
in human milk. </span><span lang=EN-GB style='color:black'>Because many medicinal
products, including antibodies, can be secreted in human milk, a</span><span
lang=EN-GB> risk to the ne</span><span lang=EN-GB>wborns/infants cannot be
excluded. A decision must be made whether to discontinue breast&#8209;feeding
or to discontinue from nivolumab therapy taking into account the benefit of
breast&#8209;feeding for the child and the benefit of therapy for the woman.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Studies to evaluate the effect of nivolumab
on fertility have not been performed. Thus, the effect of nivolumab on male and
female fertility is unknown.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEAHeading2><span lang=EN-GB>4.7 Effects on ability to drive and
use machines</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab or nivolumab in combination
with ipilimumab may have a minor influence on the ability to drive and use
machines. Because of potential adverse reactions such as fatigue (see
section&nbsp;4.8), patients should be advised to use caution when driving or
operating machinery until they are certain that nivolumab does not adversely
affect them.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.8 Undesirable effects</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Nivolumab
as monotherapy (see section&nbsp;4.2)</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Summary
of the safety profile</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>In the pooled dataset of nivolumab as
monotherapy across tumour types (n&nbsp;=&nbsp;2787) with minimum follow&#8209;up
ranging from 2.3&nbsp;to&nbsp;28&nbsp;months, the most frequent adverse
reactions&nbsp;(&#8805;&nbsp;10%) were fatigue (29%), rash (17%), pruritus
(13%), diarrhoea (13%), and nausea (12%). </span><span lang=EN-GB>The majority
of adverse reactions were mild to moderate (Grade&nbsp;1&nbsp;or&nbsp;2).</span><span
lang=EN-GB> With a minimum of 63&nbsp;months follow&#8209;up in NSCLC, no new
safety signals were identified</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Adjuvant
treatment of melanoma </span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>In the dataset of nivolumab </span><span
lang=EN-GB>3&nbsp;mg/kg as monotherapy for the adjuvant treatment of melanoma (n&nbsp;=&nbsp;452),
the most frequent adverse reactions&nbsp;(&#8805;&nbsp;10%) were fatigue (46%),
rash (29%), diarrhoea (24%), pruritus (23%), nausea (15%), arthralgia (13%),
musculoskeletal pain (11%), and hypothyroidism (11%). The majority of adverse
reactions were mild to moderate (Grade&nbsp;1&nbsp;or&nbsp;2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Tabulated
summary of adverse reactions</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Adverse reactions reported in the pooled
dataset for patients treated with nivolumab monotherapy (n&nbsp;=&nbsp;2787)
are presented in Table&nbsp;5. These reactions are presented by system organ
class and by frequency. Frequencies are defined as: very
common&nbsp;(&#8805;&nbsp;1/10); common&nbsp;(&#8805;&nbsp;1/100&nbsp;to&nbsp;&lt;&nbsp;1/10);
uncommon&nbsp;(&#8805;&nbsp;1/1,000&nbsp;to&nbsp;&lt;&nbsp;1/100);
rare&nbsp;(&#8805;&nbsp;1/10,000&nbsp;to&nbsp;&lt;&nbsp;1/1,000); very
rare&nbsp;(&lt;&nbsp;1/10,000); not known (cannot be estimated from available
post&#8209;marketing data). Within each frequency grouping, adverse reactions
are presented in the order of decreasing seriousness.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=624
 style='width:467.8pt;margin-left:5.4pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:14.2pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:none;
   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:
   14.2pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;5:</span></b><span
   lang=EN-GB> </span><b><span lang=EN-GB>Adverse reactions with
   nivolumab monotherapy</span></b></p>
   </td>
  </tr>
  <tr style='height:29.4pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:29.4pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:29.4pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Nivolumab
   monotherapy</span></b></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Infections and infestations</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>upper respiratory tract infection</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>pneumonia<sup>a</sup>, bronchitis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
   known</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>aseptic meningitis<sup>h</sup></span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Neoplasms benign, malignant and unspecified (including
   cysts and polyps)</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>Rare</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>histiocytic necrotising lymphadenitis (Kikuchi
   lymphadenitis)</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>Blood and lymphatic system
   disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>Very common</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>neutropaenia</span><span
   class=EMEASuperscript><span lang=EN-GB style='color:black'>a,b</span></span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>Uncommon</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>eosinophilia</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>Not known</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>haemophagocytic lymphohistiocytosis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>Immune system disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>infusion related reaction<sup>c</sup>,
   hypersensitivity<sup>c</sup></span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Rare</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>anaphylactic reaction</span><span
   class=EMEASuperscript><span lang=EN-GB style='color:black'>c</span></span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Not known</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>solid organ transplant rejection<span
   class=EMEASuperscript>h</span><span style='letter-spacing:.15pt'>,
   sarcoidosis<sup>h</sup></span></span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Endocrine disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>hypothyroidism, hyperthyroidism</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=FR
   style='color:black;letter-spacing:.15pt'>adrenal insufficiency</span><span
   class=EMEASuperscript><span lang=FR style='color:black'>l</span></span><span
   lang=FR style='color:black;letter-spacing:.15pt'>, hypopituitarism,
   hypophysitis, thyroiditis, diabetes mellitus</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=FR-BE
   style='color:black'>Rare</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=FR-BE
   style='color:black;letter-spacing:.15pt'>diabetic ketoacidosis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=FR-BE
   style='color:black'>Not known</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=FR-BE
   style='color:black;letter-spacing:.15pt'>hypoparathyroidism</span><span
   class=BMSSuperscript><span lang=EN-GB style='color:black'>h</span></span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Metabolism and nutrition disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>decreased appetite</span></p>
   </td>
  </tr>
  <tr style='height:.2in'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:.2in'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:.2in'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>dehydration, metabolic acidosis</span></p>
   </td>
  </tr>
  <tr style='height:.2in'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:.2in'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Not known </span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:.2in'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>tumour lysis syndrome<sup>i </sup></span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Nervous system disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>peripheral neuropathy, headache,
   dizziness</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>polyneuropathy, </span><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>autoimmune neuropathy (including </span><span
   lang=EN-GB style='color:black'>facial and abducens nerve paresis)</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Rare</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=FR
   style='color:black;letter-spacing:.15pt'>Guillain&#8209;Barr syndrome,
   demyelination, myasthenic syndrome, </span><span lang=FR style='color:black'>encephalitis<span
   class=EMEASuperscript>a,c,m</span></span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Eye disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>uveitis, blurred vision, dry eye</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Not known</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>Vogt&#8209;Koyanagi&#8209;Harada
   syndrome</span><span class=EMEASuperscript><span lang=EN-GB
   style='color:black'>h</span></span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Cardiac disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>tachycardia, pericardial disorders<sup>j</sup></span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Rare</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>arrhythmia (including ventricular
   arrhythmia)<sup>d</sup>, atrial fibrillation, myocarditis</span><span
   class=EMEASuperscript><span lang=EN-GB style='color:black'>a,f</span></span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Vascular disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>hypertension</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Rare</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>vasculitis</span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Respiratory, thoracic and mediastinal disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>pneumonitis<sup>a,c</sup>, dyspnoea<sup>a</sup>,
   cough </span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>pleural effusion</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Rare</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>lung infiltration</span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Gastrointestinal disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Very common</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>diarrhoea, nausea </span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>colitis</span><span
   class=EMEASuperscript><span lang=EN-GB style='color:black'>a</span></span><span
   lang=EN-GB style='color:black;letter-spacing:.15pt'>, stomatitis, vomiting,
   abdominal pain, constipation, dry mouth</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>pancreatitis, gastritis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Rare</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>duodenal ulcer</span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Hepatobiliary disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>hepatitis<sup>c</sup></span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Rare</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>cholestasis</span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Skin and subcutaneous tissue disorders </span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Very common</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>rash<sup>e</sup>, pruritus</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>vitiligo, dry skin, erythema,
   alopecia</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=ES
   style='color:black;letter-spacing:.15pt'>erythema multiforme, psoriasis,
   rosacea, urticaria</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Rare</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>toxic epidermal necrolysis<sup>a,f</sup></span><span
   class=EMEASubscript><span lang=EN-GB style='color:black;vertical-align:baseline'>,
   </span></span><span lang=EN-GB style='color:black;letter-spacing:.15pt'>Stevens&#8209;Johnson
   syndrome</span><span class=EMEASuperscript><span lang=EN-GB
   style='color:black'>a,f</span></span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Musculoskeletal and connective tissue disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>musculoskeletal pain<sup>g</sup>, </span><span
   lang=EN-GB style='color:black;letter-spacing:.15pt'>arthralgia</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>polymyalgia rheumatica, arthritis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Rare</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>Sjogrens syndrome, myopathy, myositis
   (including polymyositis)</span><span class=EMEASuperscript><span lang=EN-GB
   style='color:black'>a,f</span></span><span lang=EN-GB style='color:black;
   letter-spacing:.15pt'>, rhabdomyolysis</span><span class=EMEASuperscript><span
   lang=EN-GB style='color:black'>a,f</span></span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Renal and urinary disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText><span lang=EN-GB style='color:black'>Uncommon</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText><span lang=EN-GB style='color:black;letter-spacing:
   .15pt'>tubulointerstitial nephritis,</span><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'> </span><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>renal failure (including acute
   kidney injury)<sup>a,c</sup></span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>General disorders and administration site conditions</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Very common</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>fatigue</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=NL-BE
   style='color:black;letter-spacing:.15pt'>pyrexia, oedema (including
   peripheral oedema)</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText><span lang=EN-GB style='color:black'>Uncommon</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>pain, chest pain</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=624 colspan=2 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>Investigations<sup>b</sup></span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Very common</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>increased AST, increased ALT,
   increased alkaline phosphatase, increased lipase, increased amylase,</span><span
   lang=EN-GB style='color:black'> hypocalcaemia,</span><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'> increased creatinine,
   hyperglycaemia<sup>c</sup>, hypoglycaemia, lymphopaenia, leucopoenia,
   thrombocytopaenia, anaemia<sup>k</sup>, hypercalcaemia, hyperkalaemia,
   hypokalaemia, hypomagnesaemia, hyponatraemia</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width=512 valign=top style='width:383.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>increased total bilirubin,
   hypermagnesaemia, hypernatraemia, weight decreased</span></p>
   </td>
  </tr>
 </thead>
</table>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>a</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Fatal cases have been reported in completed
or ongoing clinical studies.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>b</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Frequencies of laboratory terms reflect the
proportion of patients who experienced a worsening from baseline in laboratory measurements.
See Description of selected adverse reactions; laboratory abnormalities
below.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>c</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Life&#8209;threatening cases have been
reported in completed or ongoing clinical studies.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
class=EMEASuperscript><span lang=EN-GB style='font-size:10.0pt'>d</span></span><span
lang=EN-GB style='font-size:10.0pt'> The frequency of adverse reactions
in the cardiac disorders system organ class regardless of causality was higher
in the nivolumab group than in the chemotherapy group in post&#8209;CTLA4/BRAF
inhibitor metastatic melanoma population. Incidence rates per 100&nbsp;person&#8209;years
of exposure were 9.3&nbsp;vs.&nbsp;0; serious cardiac events were reported by
4.9%&nbsp;patients in the nivolumab group&nbsp;vs.&nbsp;0 in the investigators
choice group. The frequency of cardiac adverse reactions was lower in the
nivolumab group than in the dacarbazine group in the metastatic melanoma
without prior treatment population. All were considered not related to
nivolumab by investigators except arrhythmia (atrial fibrillation, tachycardia
and ventricular arrhythmia).</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
class=BMSSuperscript><span lang=EN-GB style='font-size:10.0pt'>e</span></span><span
lang=EN-GB style='font-size:10.0pt'> Rash is a composite term which
includes maculopapular rash, rash erythematous, rash pruritic, rash follicular,
rash macular, rash morbilliform, rash papular, rash pustular, rash
papulosquamous, rash vesicular, rash generalised, exfoliative rash, dermatitis,
dermatitis acneiform, dermatitis allergic, dermatitis atopic, dermatitis
bullous, dermatitis exfoliative, dermatitis psoriasiform, drug eruption and
pemphigoid.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>f</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Reported also in studies outside the
pooled dataset. The frequency is based on the program&#8209;wide exposure.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>g</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Musculoskeletal pain is a composite term
which includes back pain, bone pain, musculoskeletal chest pain,
musculoskeletal discomfort, myalgia, neck pain, pain in extremity, and spinal
pain.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
class=EMEASuperscript><span lang=EN-GB>h</span></span><span lang=EN-GB
style='font-size:10.0pt'> Post&#8209;marketing event (also see
section&nbsp;4.4).</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
class=EMEASuperscript><span lang=EN-GB>i</span></span><span lang=EN-GB
style='font-size:10.0pt'> Reported in clinical studies and in the
post&#8209;marketing setting. </span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>j Pericardial disorders is a composite
term which includes pericarditis, pericardial effusion, cardiac tamponade, and
Dresslers syndrome.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>k</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Anaemia is a composite term which includes,
among other causes, haemolytic anaemia and autoimmune anaemia.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>l</span></sup><span lang=EN-GB
style='font-size:10.0pt'> </span><span style='font-size:10.0pt'>Includes
adrenal insufficiency and secondary adrenocortical insufficiency.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>m </span></sup><span
style='font-size:10.0pt'>Includes encephalitis and limbic encephalitis.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The overall safety profile of nivolumab
3&nbsp;mg/kg for the adjuvant treatment of melanoma (n&nbsp;=&nbsp;452) was
consistent with that established across tumour types for nivolumab monotherapy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Nivolumab
in combination with ipilimumab (see section&nbsp;4.2)</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Summary
of the safety profile</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>When nivolumab is administered in
combination with ipilimumab, refer to the Summary of Product Characteristics
for ipilimumab prior to initiation of treatment. For additional information on
the safety profile of ipilimumab monotherapy, please refer to the ipilimumab
SmPC.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Melanoma</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>In the pooled dataset of nivolumab
1&nbsp;mg/kg in combination with ipilimumab 3&nbsp;mg/kg in melanoma
(n&nbsp;=&nbsp;448) with minimum follow&#8209;up ranging from
6&nbsp;to&nbsp;28&nbsp;months, the most frequent adverse
reactions&nbsp;(&#8805;&nbsp;10%) were rash (52%), fatigue (46%), diarrhoea
(43%), pruritus (36%), nausea (26%), pyrexia (19%), decreased appetite (16%),
hypothyroidism (16%), colitis (15%), vomiting (14%), arthralgia (13%),
abdominal pain (13%), headache (11%), and dyspnoea (10%). </span><span
lang=EN-GB>The majority of adverse reactions were mild to moderate
(Grade&nbsp;1&nbsp;or&nbsp;2)</span><span lang=EN-GB>.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Among the patients treated with n</span><span
lang=EN-GB>ivolumab 1&nbsp;mg/kg in combination with ipilimumab 3&nbsp;mg/kg in
CA209067</span><span lang=EN-GB>, 154/313&nbsp;(49%) had the first onset of
Grade&nbsp;3&nbsp;or&nbsp;4 adverse reactions during the initial combination
phase. Among the 147&nbsp;patients in this group who continued treatment in the
single&#8209;agent phase, 47&nbsp;(32%)&nbsp;experienced at least one
Grade&nbsp;3&nbsp;or&nbsp;4 adverse reaction during the single&#8209;agent
phase.</span></p>

<p class=EMEABodyText><span lang=EN-GB>With a minimum of 60&nbsp;months follow&#8209;up
from study CA209067, no new safety signals were identified.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>RCC</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>In the dataset of nivolumab 3&nbsp;mg/kg
in combination with ipilimumab 1&nbsp;mg/kg in RCC (n&nbsp;=&nbsp;547), with a
minimum follow&#8209;up of 17.5&nbsp;months, the most frequent adverse
reactions&nbsp;(&#8805;&nbsp;10%) were fatigue&nbsp;(48%), rash&nbsp;(34%),
pruritus&nbsp;(28%), diarrhoea&nbsp;(27%), nausea&nbsp;(20%), <span
style='letter-spacing:.15pt'>hypothyroidism&nbsp;(16%),</span> musculoskeletal
pain&nbsp;(15%), arthralgia&nbsp;(14%), decreased appetite&nbsp;(14%),
pyrexia&nbsp;(14%), vomiting&nbsp;(11%), <span style='letter-spacing:.15pt'>hyperthyroidism&nbsp;(11%)</span>.
The majority of adverse reactions were mild to moderate
(Grade&nbsp;1&nbsp;or&nbsp;2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Among the patients treated with
nivolumab 3&nbsp;mg/kg in combination with ipilimumab 1&nbsp;mg/kg in CA209214,
169/547&nbsp;(31%) had the first onset of Grade&nbsp;3&nbsp;or&nbsp;4 adverse
reactions during the initial combination phase. Among the 382&nbsp;patients in
this group who continued treatment in the single&#8209;agent phase,
144&nbsp;(38%)&nbsp;experienced at least one Grade&nbsp;3&nbsp;or&nbsp;4
adverse reaction during the single&#8209;agent phase.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Tabulated
summary of adverse reactions</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Adverse reactions reported in the pooled
dataset for patients treated with nivolumab 1&nbsp;mg/kg in combination with
ipilimumab 3&nbsp;mg/kg (n&nbsp;=&nbsp;448) and for patients treated with
nivolumab 3&nbsp;mg/kg in combination with ipilimumab 1&nbsp;mg/kg (n&nbsp;=&nbsp;547)
are presented in Table&nbsp;6. These reactions are presented by system organ
class and by frequency. Frequencies are defined as: very
common&nbsp;(&#8805;&nbsp;1/10);
common&nbsp;(&#8805;&nbsp;1/100&nbsp;to&nbsp;&lt;&nbsp;1/10);
uncommon&nbsp;(&#8805;&nbsp;1/1,000&nbsp;to&nbsp;&lt;&nbsp;1/100);
rare&nbsp;(&#8805;&nbsp;1/10,000&nbsp;to&nbsp;&lt;&nbsp;1/1,000); very rare&nbsp;(&lt;&nbsp;1/10,000),
not known (cannot be estimated from available post&#8209;marketing data).
Within each frequency grouping, adverse reactions are presented in the order of
decreasing seriousness.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=624
 style='width:467.8pt;margin-left:5.4pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:14.2pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:none;
   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:
   14.2pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;6:</span></b><span
   lang=EN-GB> </span><b><span lang=EN-GB>Adverse reactions with
   nivolumab in combination with ipilimumab</span></b></p>
   </td>
  </tr>
  <tr style='height:29.4pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:29.4pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.05pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:29.4pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Nivolumab
   1&nbsp;mg/kg in combination with ipilimumab 3&nbsp;mg/kg*</span></b></p>
   </td>
   <td width=256 valign=top style='width:191.65pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:29.4pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Nivolumab
   3&nbsp;mg/kg in combination with ipilimumab 1&nbsp;mg/kg**</span></b></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Infections
   and infestations</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.05pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>pneumonia, upper respiratory tract infection</span></p>
   </td>
   <td width=256 valign=top style='width:191.65pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>pneumonia, upper respiratory tract infection,
   conjunctivitis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.05pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>bronchitis</span></p>
   </td>
   <td width=256 valign=top style='width:191.65pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>bronchitis, aseptic meningitis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
   known</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.05pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>aseptic meningitis<sup>h</sup></span></p>
   </td>
   <td width=256 valign=top style='width:191.65pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='letter-spacing:.15pt'>Blood and lymphatic system disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>Common</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.05pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>eosinophilia</span></p>
   </td>
   <td width=256 valign=top style='width:191.65pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='letter-spacing:.15pt'>&nbsp;</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>Uncommon</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.05pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>&nbsp;</span></p>
   </td>
   <td width=256 valign=top style='width:191.65pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>eosinophilia</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>Not known</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.05pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>haemophagocytic lymphohistiocytosis</span></p>
   </td>
   <td width=256 valign=top style='width:191.65pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>haemophagocytic lymphohistiocytosis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='letter-spacing:.15pt'>Immune system disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.05pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>infusion related reaction, hypersensitivity</span></p>
   </td>
   <td width=256 valign=top style='width:191.65pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>infusion&#8209;related reaction,
   hypersensitivity</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.05pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>sarcoidosis</span></p>
   </td>
   <td width=256 valign=top style='width:191.65pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
   known</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.05pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>solid
   organ transplant rejection<span class=EMEASuperscript>h</span></span></p>
   </td>
   <td width=256 valign=top style='width:191.65pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Endocrine
   disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Very
   common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>hypothyroidism</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>hypothyroidism, hyperthyroidism</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>adrenal insufficiency, hypopituitarism,
   hypophysitis, hyperthyroidism, thyroiditis</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=FR
   style='letter-spacing:.15pt'>adrenal insufficiency<sup>c</sup>, hypophysitis<sup>c</sup>,
   thyroiditis, diabetes mellitus<sup>c</sup></span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>diabetic ketoacidosis<sup>c</sup>, diabetes
   mellitus<sup>c</sup></span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>diabetic ketoacidosis<sup>c</sup>,
   hypopituitarism</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=FR-BE>Not
   known</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=FR-BE
   style='letter-spacing:.15pt'>hypoparathyroidism</span><span
   class=BMSSuperscript><span lang=EN-GB>h</span></span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=FR-BE
   style='letter-spacing:.15pt'>hypoparathyroidism</span><span
   class=BMSSuperscript><span lang=EN-GB>h</span></span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Metabolism
   and nutrition disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Very
   common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>decreased appetite</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>decreased appetite</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>dehydration</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>dehydration</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>&nbsp;</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>metabolic acidosis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
   known </span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>tumour lysis syndrome<sup>i </sup></span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Nervous
   system disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Very
   common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>headache</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>peripheral neuropathy, dizziness</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>headache, peripheral neuropathy, dizziness</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>Guillain&#8209;Barr syndrome, </span><span
   lang=EN-GB>polyneuropathy, neuritis, peroneal nerve palsy, </span><span
   lang=EN-GB style='letter-spacing:.15pt'>autoimmune neuropathy (including </span><span
   lang=EN-GB>facial and abducens nerve paresis), </span>encephalitis<sup>c</sup></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>polyneuropathy,
   </span><span lang=EN-GB style='letter-spacing:.15pt'>autoimmune neuropathy
   (including </span><span lang=EN-GB>facial and abducens nerve paresis),
   myasthenia gravis<sup>c</sup></span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Eye
   disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>uveitis, blurred vision</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>blurred vision</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>&nbsp;</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>uveitis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
   known</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText><span lang=EN-GB style='letter-spacing:.15pt'>Vogt&#8209;Koyanagi&#8209;Harada
   syndrome</span><span class=EMEASuperscript><span lang=EN-GB>h</span></span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText><span lang=EN-GB style='letter-spacing:.15pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Cardiac
   disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>tachycardia</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>tachycardia</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>arrhythmia (including ventricular arrhythmia)<sup>a,d</sup>,
   atrial fibrillation, myocarditis</span><span class=EMEASuperscript><span
   lang=EN-GB>a,f</span></span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>arrhythmia (including ventricular arrhythmia),
   myocarditis<sup>c</sup></span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Not
   known</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>pericardial disorders<sup>j</sup></span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Vascular
   disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>hypertension</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>hypertension</span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Respiratory,
   thoracic and mediastinal disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Very
   common</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.05pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>dyspnoea</span></p>
   </td>
   <td width=256 valign=top style='width:191.65pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>pneumonitis</span><span class=EMEASuperscript><span
   lang=EN-GB>a,c</span></span><span lang=EN-GB style='letter-spacing:.15pt'>,
   pulmonary embolism<sup>a</sup>, cough</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>pneumonitis, dyspnoea, pleural effusion, cough</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>pleural effusion</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Gastrointestinal
   disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Very
   common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>colitis</span><span class=EMEASuperscript><span
   lang=EN-GB>a</span></span><span lang=EN-GB style='letter-spacing:.15pt'>,
   diarrhoea, vomiting, nausea, abdominal pain</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>diarrhoea, vomiting, nausea</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>stomatitis, pancreatitis, constipation, dry
   mouth</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>colitis, stomatitis, pancreatitis, abdominal
   pain, constipation, dry mouth</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>intestinal perforation</span><span
   class=EMEASuperscript><span lang=EN-GB>a</span></span><span lang=EN-GB
   style='letter-spacing:.15pt'>, gastritis, duodenitis</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>gastritis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Hepatobiliary
   disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>hepatitis</span><span class=EMEASuperscript><span
   lang=EN-GB>c</span></span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>hepatitis<sup>c</sup></span></p>
   </td>
  </tr>
  <tr style='height:17.05pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.05pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Skin
   and subcutaneous tissue disorders </span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Very
   common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>rash<sup>e</sup>, pruritus</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>rash<sup>e</sup>, pruritus</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=ES
   style='letter-spacing:.15pt'>vitiligo, dry skin, erythema, alopecia,
   urticaria</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=ES
   style='letter-spacing:.15pt'>dry skin, erythema, urticaria</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>psoriasis</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>Stevens&#8209;Johnson syndrome, vitiligo,
   erythema multiforme, alopecia, psoriasis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Rare</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>toxic epidermal necrolysis</span><sup><span
   lang=EN-GB style='letter-spacing:.15pt'>a,f</span></sup><span
   class=EMEASubscript><span lang=EN-GB style='vertical-align:baseline'>, </span></span><span
   lang=EN-GB style='letter-spacing:.15pt'>Stevens&#8209;Johnson syndrome</span><span
   class=EMEASuperscript><span lang=EN-GB>f</span></span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Musculoskeletal
   and connective tissue disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Very
   common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>arthralgia</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>musculoskeletal pain<sup>g</sup></span><span
   lang=EN-GB style='letter-spacing:.15pt'>, arthralgia</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>musculoskeletal pain<sup>g</sup></span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>arthritis, muscle spasms, muscular weakness</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>spondyloarthropathy, Sjogrens syndrome,
   arthritis, myopathy, </span><span lang=EN-GB style='letter-spacing:.15pt'>myositis
   (including polymyositis)</span><span class=EMEASuperscript><span lang=EN-GB>a,e</span></span><span
   lang=EN-GB style='letter-spacing:.15pt'>, rhabdomyolysis</span><span
   class=EMEASuperscript><span lang=EN-GB>a,f</span></span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>polymyalgia rheumatica, myositis (including polymyositis),
   rhabdomyolysis</span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Renal
   and urinary disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>renal failure (including acute kidney injury)</span><span
   class=EMEASuperscript><span lang=EN-GB>a,c</span></span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>renal failure (including acute kidney injury)<sup>c</sup></span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>tubulointerstitial nephritis</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>tubulointerstitial nephritis</span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>General
   disorders and administration site conditions</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Very
   common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>fatigue, pyrexia</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>fatigue, pyrexia</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>oedema (including peripheral oedema), pain</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>oedema (including peripheral oedema), pain, </span><span
   lang=EN-GB style='letter-spacing:.15pt'>chest pain, chills</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>chest pain</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=624 colspan=4 valign=top style='width:467.8pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='letter-spacing:.15pt'>Investigations<sup>b</sup></span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Very
   common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>increased AST, increased ALT, increased total
   bilirubin, increased alkaline phosphatase, increased lipase, increased
   amylase, increased creatinine, hyperglycaemia<sup>c</sup>, hypoglycaemia,
   lymphopaenia, leucopoenia, neutropaenia, thrombocytopaenia, anaemia</span><sup><span
   lang=EN-GB style='font-size:10.0pt'>k</span></sup><span lang=EN-GB
   style='letter-spacing:.15pt'>, hypocalcaemia, hyperkalaemia, hypokalaemia,
   hypomagnesaemia, hyponatraemia</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>increased AST, increased ALT, increased total
   bilirubin, increased alkaline phosphatase, increased lipase, increased
   amylase, increased creatinine, hyperglycaemia<sup>c</sup>, hypoglycaemia, lymphopaenia,
   leucopoenia, neutropaenia<sup>c</sup>, thrombocytopaenia, anaemia</span><sup><span
   lang=EN-GB style='font-size:10.0pt'>k</span></sup><span lang=EN-GB
   style='letter-spacing:.15pt'>, hypercalcaemia, hypocalcaemia, hyperkalaemia,
   hypokalaemia, hypomagnesaemia, hyponatraemia</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width=112 valign=top style='width:84.1pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width=255 valign=top style='width:191.6pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>hypercalcaemia, hypermagnesaemia, hypernatraemia,
   weight decreased</span></p>
   </td>
   <td width=256 colspan=2 valign=top style='width:192.1pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>hypermagnesaemia, hypernatraemia, weight
   decreased</span></p>
   </td>
  </tr>
 </thead>
 <tr height=0>
  <td width=112 style='border:none'></td>
  <td width=255 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=256 style='border:none'></td>
 </tr>
</table>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>*  nivolumab in combination with
ipilimumab for the first 4&nbsp;doses then followed by nivolumab monotherapy in
melanoma.</span></p>

<p class=EMEABodyText style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB style='font-size:10.0pt'>** nivolumab in combination with
ipilimumab for the first 4&nbsp;doses then followed by nivolumab monotherapy in
RCC.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>a</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Fatal cases have been reported in completed
or ongoing clinical studies.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>b</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Frequencies of laboratory terms reflect the
proportion of patients who experienced a worsening from baseline in laboratory
measurements. See Description of selected adverse reactions; laboratory
abnormalities below.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>c</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Life&#8209;threatening cases have been
reported in completed or ongoing clinical studies.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
class=EMEASuperscript><span lang=EN-GB style='font-size:10.0pt'>d</span></span><span
lang=EN-GB style='font-size:10.0pt'> The frequency of adverse reactions
in the cardiac disorders system organ class regardless of causality was higher
in the nivolumab group than in the chemotherapy group in post&#8209;CTLA4/BRAF
inhibitor metastatic melanoma population. Incidence rates per 100&nbsp;person&#8209;years
of exposure were 9.3&nbsp;vs.&nbsp;0; serious cardiac events were reported by
4.9%&nbsp;patients in the nivolumab group&nbsp;vs.&nbsp;0 in the investigators
choice group. The frequency of cardiac adverse reactions was lower in the
nivolumab group than in the dacarbazine group in the metastatic melanoma
without prior treatment population. All were considered not related to
nivolumab by investigators except arrhythmia (atrial fibrillation, tachycardia
and ventricular arrhythmia).</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
class=BMSSuperscript><span lang=EN-GB style='font-size:10.0pt'>e</span></span><span
lang=EN-GB style='font-size:10.0pt'> Rash is a composite term which
includes maculopapular rash, rash erythematous, rash pruritic, rash follicular,
rash macular, rash morbilliform, rash papular, rash pustular, rash
papulosquamous, rash vesicular, rash generalised, exfoliative rash, dermatitis,
dermatitis acneiform, dermatitis allergic, dermatitis atopic, dermatitis
bullous, dermatitis exfoliative, dermatitis psoriasiform, drug eruption and
pemphigoid.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>f</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Reported also in studies outside the
pooled dataset. The frequency is based on the program&#8209;wide exposure.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>g</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Musculoskeletal pain is a composite term
which includes back pain, bone pain, musculoskeletal chest pain,
musculoskeletal discomfort, myalgia, neck pain, pain in extremity, and spinal
pain.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
class=EMEASuperscript><span lang=EN-GB>h</span></span><span lang=EN-GB
style='font-size:10.0pt'> Post&#8209;marketing event (also see
section&nbsp;4.4)</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
class=EMEASuperscript><span lang=EN-GB>i</span></span><span lang=EN-GB
style='font-size:10.0pt'> Reported in clinical studies and in the
post&#8209;marketing setting. </span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>j Pericardial disorders is a
composite term which includes pericarditis, pericardial effusion, cardiac
tamponade, and Dresslers syndrome.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>k</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Anaemia is a composite term which includes,
among other causes, haemolytic anaemia and autoimmune anaemia.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Nivolumab
in combination with ipilimumab and chemotherapy (see section&nbsp;4.2)</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Summary
of the safety profile</span></i></p>

<p class=MsoNormal><span lang=EN-GB>When nivolumab is administered in
combination, refer to the Summary of Product Characteristics for the respective
combination therapy components prior to initiation of treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the dataset of nivolumab 360&nbsp;mg
every 3&nbsp;weeks in combination </span><span lang=EN-GB>with ipilimumab
1&nbsp;mg/kg every 6&nbsp;weeks </span><span lang=EN-GB>and 2&nbsp;cycles of
chemotherapy in NSCLC (n&nbsp;=&nbsp;358), with a minimum follow-up of
6.5&nbsp;months, the most frequent adverse reactions were fatigue (36%), nausea
(26%), rash (25%), diarrhoea (20%), pruritus (18%), decreased appetite (16%),
hypothyroidism (15%), and vomiting (13%). The majority of adverse reactions
were mild to moderate (Grade&nbsp;1&nbsp;or&nbsp;2). Median duration of therapy
was 6.1&nbsp;months (95%&nbsp;CI&nbsp;4.93,&nbsp;7.06) for nivolumab in combination
with ipilimumab and chemotherapy and 2.4&nbsp;months
(95%&nbsp;CI&nbsp;2.30,&nbsp;2.83) for chemotherapy. </span></p>

<p class=MsoNormal><s><span lang=EN-GB style='background:lightgrey'><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Tabulated
summary of adverse reactions</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Adverse reactions reported in the
dataset for patients treated with nivolumab 360&nbsp;mg every 3&nbsp;weeks in
combination </span><span lang=EN-GB>with ipilimumab 1&nbsp;mg/kg every
6&nbsp;weeks </span><span lang=EN-GB>and 2&nbsp;cycles of chemotherapy in NSCLC
(n&nbsp;=&nbsp;358) are presented in Table&nbsp;7. These reactions are
presented by system organ class and by frequency. Frequencies are defined as:
very common&nbsp;(&#8805;&nbsp;1/10); common&nbsp;(&#8805;&nbsp;1/100&nbsp;to&nbsp;&lt;&nbsp;1/10);
uncommon&nbsp;(&#8805;&nbsp;1/1,000&nbsp;to&nbsp;&lt;&nbsp;1/100);
rare&nbsp;(&#8805;&nbsp;1/10,000&nbsp;to&nbsp;&lt;&nbsp;1/1,000); very
rare&nbsp;(&lt;&nbsp;1/10,000). Within each frequency grouping, adverse
reactions are presented in the order of decreasing seriousness.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:14.2pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:none;
   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:
   14.2pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;7:</span></b><span
   lang=EN-GB> </span><b><span lang=EN-GB>Adverse reactions with
   nivolumab in combination with ipilimumab and chemotherapy</span></b></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Infections and infestations</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='letter-spacing:.15pt'>conjunctivitis, pneumonia, respiratory tract
   infection</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>Blood and lymphatic system
   disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>Common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>febrile neutropaenia</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>Uncommon</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>eosinophilia</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>Immune system disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>infusion-related reaction,
   hypersensitivity</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Endocrine disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Very common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>hypothyroidism</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=FR-BE
   style='color:black;letter-spacing:.15pt'>hyperthyroidism, adrenal
   insufficiency, hypophysitis, thyroiditis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>hypopituitarism, hypoparathyroidism</span></p>
   </td>
  </tr>
  <tr style='height:14.15pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Metabolism and nutrition disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Very common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>decreased appetite</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>dehydration, hypoalbunaemia,
   hypophosphataemia</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Nervous system disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>peripheral neuropathy, dizziness</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>polyneuropathy, autoimmune
   neuropathy (including facial and abducens nerve paresis), encephalitis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Eye disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>dry eye</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>blurred vision, episcleritis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Cardiac disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>tachycardia, atrial fibrillation,
   bradycardia</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Vascular disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>hypertension</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Respiratory, thoracic and mediastinal disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>pneumonitis, dyspnoea, cough</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>pleural effusion</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Gastrointestinal disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Very common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>nausea, diarrhoea, vomiting</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>constipation, stomatitis, abdominal
   pain, colitis, dry mouth, pancreatitis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Hepatobiliary disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>hepatitis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Skin and subcutaneous tissue disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Very common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>rash</span><sup><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>a</span></sup><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>, pruritus</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>alopecia, dry skin, erythema,
   urticaria</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>psoriasis, Stevens-Johnson
   syndrome, vitligo</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Musculoskeletal and connective tissue disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>musculoskeletal pain</span><sup><span
   lang=EN-GB style='color:black;letter-spacing:.15pt'>b</span></sup><span
   lang=EN-GB style='color:black;letter-spacing:.15pt'>, arthralgia, arthritis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>muscular weakness, muscle spasms,
   polymyalgia rheumatica</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Renal and urinary disorders</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>renal failure (including acute
   kidney injury)</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>nephritis</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>General disorders and administration site conditions</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Very common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>fatigue</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>pyrexia, oedema (including
   peripheral oedema)</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>chills, chest pain</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
   style='color:black'>Investigations</span></b></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Very common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>anaemia</span><sup><span
   lang=EN-GB style='color:black'>c,<span style='letter-spacing:.15pt'>d</span></span></sup><span
   lang=EN-GB style='color:black;letter-spacing:.15pt'>, thrombocytopaenia</span><sup><span
   lang=EN-GB style='color:black'>c</span></sup><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>, leucopoenia</span><sup><span
   lang=EN-GB style='color:black'>c</span></sup><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>, lymphopaenia</span><sup><span
   lang=EN-GB style='color:black'>c</span></sup><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>, neutropaenia</span><sup><span
   lang=EN-GB style='color:black'>c</span></sup><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>, increased alkaline phophatases</span><sup><span
   lang=EN-GB style='color:black'>c</span></sup><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>, increased transaminases</span><sup><span
   lang=EN-GB style='color:black'>c</span></sup><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>, increased creatinine</span><sup><span
   lang=EN-GB style='color:black'>c</span></sup><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>, increased amylase</span><sup><span
   lang=EN-GB style='color:black'>c</span></sup><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>, increased lipase</span><sup><span
   lang=EN-GB style='color:black'>c</span></sup><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>, hypokalaemia</span><sup><span
   lang=EN-GB style='color:black'>c</span></sup><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>, hypomagnesaemia</span><sup><span
   lang=EN-GB style='color:black'>c</span></sup><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>, hyponatraemia</span><sup><span
   lang=EN-GB style='color:black'>c</span></sup></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Common</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>increased total bilirubin</span><sup><span
   lang=EN-GB style='color:black'>c</span></sup><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>, increased thyroid stimulating
   hormone</span></p>
   </td>
  </tr>
  <tr style='height:13.45pt'>
   <td width="23%" valign=top style='width:23.44%;border:solid windowtext 1.0pt;
   border-top:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black'>Uncommon</span></p>
   </td>
   <td width="76%" valign=top style='width:76.56%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   background:white;padding:0in 5.4pt 0in 5.4pt;height:13.45pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
   style='color:black;letter-spacing:.15pt'>increased gamma-glutamyltransferase</span></p>
   </td>
  </tr>
 </thead>
</table>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>a</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Rash is a composite term which includes
maculopapular rash, rash erythematous, rash pruritic, rash macular, rash
morbilliform, rash papular, rash generalised, dermatitis, dermatitis acneiform,
dermatitis allergic, dermatitis atopic, dermatitis bullous, and drug eruption.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>b </span></sup><span
lang=EN-GB style='font-size:10.0pt'>Musculoskeletal pain is a composite term
which includes back pain, bone pain, musculoskeletal chest pain, myalgia, neck
pain, pain in extremity, and spinal pain.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>c</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Frequencies of laboratory terms reflect the
proportion of patients who experienced a worsening from baseline in laboratory
measurements.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>d</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Anaemia is a composite term which includes
iron deficiency anaemia and haemoglobin decreased.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Description
of selected adverse reactions</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab or nivolumab in combination is
associated with immune&#8209;related adverse reactions. With appropriate
medical therapy, immune&#8209;related adverse reactions resolved in most cases.
Permanent discontinuation of treatment was required in a greater proportion of
patients receiving nivolumab in combination with ipilimumab than in those
receiving nivolumab monotherapy. Table&nbsp;8 presents the percentage for
immune&#8209;related adverse reactions who were permanently discontinued from
treatment by dosing regimen. Additionally, for patients who experienced an
event, Table&nbsp;8 presents the percentage of patients who required high&#8209;dose
corticosteroids </span><span lang=EN-GB>(at least 40&nbsp;mg daily prednisone
equivalents) by dosing regimen. The management guidelines for these adverse
reactions are described in section&nbsp;4.4.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse'>
 <thead>
  <tr style='height:14.2pt'>
   <td width="100%" colspan=5 valign=top style='width:100.0%;padding:0in 5.4pt 0in 5.4pt;
   height:14.2pt'>
   <p class=EMEABodyText style='margin-left:57.8pt;text-indent:-54.9pt;
   page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;8:</span></b><b><span
   lang=EN-GB> Immune&#8209;related adverse reactions leading to permanent
   discontinuation or requiring high&#8209;dose corticosteroids by dosing
   regimen</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="28%" valign=top style='width:28.86%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.72%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>Nivolumab 3&nbsp;mg/kg or 240&nbsp;mg monotherapy</span></p>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>%</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>Nivolumab 1&nbsp;mg/kg in combination with ipilimumab 3&nbsp;mg/kg
  in melanoma</span></p>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>%</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>Nivolumab 3&nbsp;mg/kg in combination with ipilimumab 1&nbsp;mg/kg
  in RCC</span></p>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>%</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>Nivolumab 360&nbsp;mg in combination with ipilimumab 1&nbsp;mg/kg
  and chemotherapy in NSCLC</span></p>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>%</span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=EN-GB>Immune&#8209;related adverse
  reaction leading to permanent discontinuation </span></b></p>
  </td>
  <td width="17%" valign=top style='width:17.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:13.4pt;text-indent:-5.8pt'><span
  lang=EN-GB>Pneumonitis</span></p>
  </td>
  <td width="17%" valign=top style='width:17.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>1.4</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>2.0</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>2.2</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>2.2</span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:13.4pt;text-indent:-5.8pt'><span
  lang=EN-GB>Colitis</span></p>
  </td>
  <td width="17%" valign=top style='width:17.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>0.8</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>16</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>4.0</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>4.2</span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:16.6pt;text-indent:-9.0pt'><span
  lang=EN-GB>Hepatitis</span></p>
  </td>
  <td width="17%" valign=top style='width:17.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>1.0</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>9</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>4.4</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>3.4</span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:7.6pt'><span lang=EN-GB>Nephritis
  and renal dysfunction</span></p>
  </td>
  <td width="17%" valign=top style='width:17.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>0.3</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>1.1</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>1.3</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>1.4</span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:7.6pt'><span lang=EN-GB>Endocrinopathies</span></p>
  </td>
  <td width="17%" valign=top style='width:17.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>0.2</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>2.7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>2.9</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>2.0</span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:7.65pt'><span lang=EN-GB>Skin</span></p>
  </td>
  <td width="17%" valign=top style='width:17.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>0.4</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>0.9</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>1.5</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>1.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:7.65pt'><span lang=EN-GB>Hypersensitivity/Infusion
  reaction</span></p>
  </td>
  <td width="17%" valign=top style='width:17.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>0.2</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>0</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>0</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>0.6</span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><b><span lang=EN-GB>Immune&#8209;related adverse
  reaction requiring high&#8209;dose corticosteroids<sup>a,b</sup> </span></b></p>
  </td>
  <td width="17%" valign=top style='width:17.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:7.6pt'><span lang=EN-GB>Pneumonitis</span></p>
  </td>
  <td width="17%" valign=top style='width:17.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>67</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>63</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>59</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>68</span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:7.6pt'><span lang=EN-GB>Colitis</span></p>
  </td>
  <td width="17%" valign=top style='width:17.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>14</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>46</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>26</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>20</span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:7.6pt'><span lang=EN-GB>Hepatitis</span></p>
  </td>
  <td width="17%" valign=top style='width:17.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>19</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>46</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>35</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>29</span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:7.6pt'><span lang=EN-GB>Nephritis
  and renal dysfunction</span></p>
  </td>
  <td width="17%" valign=top style='width:17.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>26</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>17</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>27</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>24</span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:7.6pt'><span lang=EN-GB>Endocrinopathies</span></p>
  </td>
  <td width="17%" valign=top style='width:17.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>27</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>25</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>8</span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:7.6pt'><span lang=EN-GB>Skin</span></p>
  </td>
  <td width="17%" valign=top style='width:17.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>4</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>7</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>10</span></p>
  </td>
 </tr>
 <tr>
  <td width="28%" valign=top style='width:28.86%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:7.6pt'><span lang=EN-GB>Hypersensitivity/Infusion
  reaction</span></p>
  </td>
  <td width="17%" valign=top style='width:17.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>20</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>6</span></p>
  </td>
  <td width="17%" valign=top style='width:17.78%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>9</span></p>
  </td>
  <td width="17%" valign=top style='width:17.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB>29</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><sup><span lang=EN-GB>a</span></sup><span lang=EN-GB> at
least 40&nbsp;mg daily prednisone equivalents</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB>b </span></sup><span lang=EN-GB>frequency is based
on the number of patients who experienced the immune&#8209;related adverse
reaction</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Immune&#8209;related
pneumonitis</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab
monotherapy, the incidence of pneumonitis, including interstitial lung disease
and lung infiltration, was 3.6%&nbsp;(99/2787). The majority of cases were
Grade&nbsp;1&nbsp;or&nbsp;2 in severity reported in 0.9%&nbsp;(24/2787) and
1.8%&nbsp;(51/2787) of patients respectively. Grade&nbsp;3 and 4 cases were
reported in 0.8%&nbsp;(21/2787) and &lt;0.1%&nbsp;(1/2787) of patients
respectively. Grade&nbsp;5 cases were reported in &lt;&nbsp;0.1%&nbsp;(2/2787)
of patients in these studies. Median time to onset was 3.3&nbsp;months (range:&nbsp;0.2&#8209;19.6).
Resolution occurred in 66&nbsp;patients (66.7%) with a median time to
resolution of 6.6&nbsp;weeks (range: 0.1<span class=EMEASuperscript>+</span>-96.7<span
class=EMEASuperscript>+</span>);<span class=EMEASuperscript> +</span> denotes a
censored observation.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab 1&nbsp;mg/kg
in combination with ipilimumab 3&nbsp;mg/kg in melanoma, the incidence of
pneumonitis </span><span lang=EN-GB>including interstitial lung disease, was 7.8%&nbsp;(35/448).
Grade&nbsp;2, Grade&nbsp;3, and Grade&nbsp;4 cases were reported in 4.7% (21/448),
1.1% (5/448), and 0.2% (1/448) of patients, respectively. One of the Grade&nbsp;3
pneumonitis cases worsened over 11&nbsp;days with a fatal outcome. Median time
to onset was 2.6&nbsp;months (range:&nbsp;0.7&#8209;12.6). Resolution occurred
in 33&nbsp;patients (94.3%) with a median time to resolution of 6.1&nbsp;weeks
(range:&nbsp;0.3&#8209;35.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab 3&nbsp;mg/kg
in combination with ipilimumab 1&nbsp;mg/kg in RCC, the incidence of
pneumonitis </span><span lang=EN-GB>including interstitial lung disease was 6.2%&nbsp;(34/547).
Grade&nbsp;2 and Grade&nbsp;3 cases were reported in 3.1% (17/547) and 1.1% (6/547),
of patients, respectively. No Grade&nbsp;4&nbsp;or&nbsp;5&nbsp;cases were
reported in this study. Median time to onset was 2.6&nbsp;months (range:&nbsp;0.25&#8209;20.6).
Resolution occurred in 31&nbsp;patients (91.2%) with a median time to
resolution of 6.1&nbsp;weeks (range:&nbsp;0.7&#8209;85.9<sup>+</sup>).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with </span><span
lang=EN-GB>nivolumab 360&nbsp;mg every 3&nbsp;weeks in combination </span><span
lang=EN-GB>with ipilimumab 1&nbsp;mg/kg every 6&nbsp;weeks and chemotherapy in
NSCLC, the incidence of pneumonitis </span><span lang=EN-GB>including
interstitial lung disease was 5.3%&nbsp;(19/358). Grade&nbsp;2, Grade&nbsp;3,
and Grade&nbsp;4 cases were reported in 2.2% (8/358), 1.1% (4/358), and 0.6%
(2/358) of patients, respectively. Median time to onset was 18.1&nbsp;weeks
(range: 0.6-52.4). Resolution occurred in 14&nbsp;patients (74%) with a median
time to resolution of 4.3&nbsp;weeks (range: 0.7-27.9<sup>+</sup>).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Immune&#8209;related
colitis</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab
monotherapy, the incidence of diarrhoea, colitis, or frequent bowel movements
was&nbsp;13%&nbsp;(361/2787). The majority of cases were Grade&nbsp;1 or&nbsp;2
in severity reported in 8.3%&nbsp;(230/2787) and 3.2%&nbsp;(88/2787) of
patients respectively. Grade&nbsp;3&nbsp;cases were reported
in&nbsp;1.5%&nbsp;(43/2787) of patients. No
Grade&nbsp;4&nbsp;or&nbsp;5&nbsp;cases were reported in these studies. Median
time to onset was 1.8&nbsp;months (range:&nbsp;0.0&#8209;26.6). Resolution
occurred in 311&nbsp;patients (86.9%) with a median time to resolution of
2.1&nbsp;weeks (range:&nbsp;0.1&#8209;124.4<span class=EMEASuperscript>+</span>).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab
1&nbsp;mg/kg in combination with ipilimumab 3&nbsp;mg/kg in melanoma, the
incidence of </span><span lang=EN-GB>diarrhoea or colitis was&nbsp;46.7% (209/448).
Grade&nbsp;2, Grade&nbsp;3, and Grade&nbsp;4&nbsp;cases were reported
in&nbsp;13.6% (61/448), 15.8% (71/448), and 0.4% (2/448)&nbsp;of patients,
respectively. No Grade&nbsp;5&nbsp;cases were reported. Median time to onset
was 1.2&nbsp;months (range:&nbsp;0.0&#8209;22.6). Resolution occurred in 186&nbsp;patients
(89.4%) with a median time to resolution of 3.0&nbsp;weeks (range:&nbsp;0.1&#8209;159.4<sup>+</sup>)</span><span
lang=EN-GB>.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab 3&nbsp;mg/kg
in combination with ipilimumab 1&nbsp;mg/kg in RCC, the incidence of </span><span
lang=EN-GB>diarrhoea or colitis was&nbsp;28.2% (154/547). Grade&nbsp;2 and
Grade&nbsp;3 cases were reported in&nbsp;10.4% (57/547) and 4.9% (27/547)&nbsp;of
patients, respectively. No Grade&nbsp;4 or 5&nbsp;cases were reported. Median
time to onset was 1.2&nbsp;months (range:&nbsp;0.0&#8209;24.7). Resolution
occurred in 140&nbsp;patients (91.5%) with a median time to resolution of 2.4&nbsp;weeks
(range:&nbsp;0.1&#8209;103.1<sup>+</sup>)</span><span lang=EN-GB>.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with </span><span
lang=EN-GB>nivolumab 360&nbsp;mg every 3&nbsp;weeks in combination </span><span
lang=EN-GB>with ipilimumab 1&nbsp;mg/kg every 6&nbsp;weeks and chemotherapy in
NSCLC, the incidence of </span><span lang=EN-GB>diarrhoea or colitis
was&nbsp;22.3% (80/358). Grade&nbsp;2, Grade&nbsp;3, Grade&nbsp;4, and
Grade&nbsp;5 cases were reported in&nbsp;7% (25/358), 5% (18/358), 0.3%
(1/358), and 0.3% (1/358)&nbsp;of patients, respectively. Median time to onset
was 5.1&nbsp;weeks (range: 0.1-53.6). Resolution occurred in 70&nbsp;patients
(87.5%) with a median time to resolution of 1.4&nbsp;weeks
(range:&nbsp;0.1-76.9<sup>+</sup>)</span><span lang=EN-GB>.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Immune&#8209;related
hepatitis</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab
monotherapy, the incidence of liver function test abnormalities was 6.7%
(187/2787). The majority of cases were Grade&nbsp;1 or&nbsp;2 in severity
reported in 3.5% (98/2787) and 1.4% (38/2787) of patients respectively.
Grade&nbsp;3 and&nbsp;4 cases were reported in 1.5% (42/2787) and 0.3% (9/2787)
of patients, respectively. No Grade&nbsp;5 cases were reported in these
studies. Median time to onset was 2.1&nbsp;months (range:&nbsp;0.0&#8209;27.6).
Resolution occurred in 142&nbsp;patients (76.3%) with a median time to
resolution of 5.9&nbsp;weeks (range:&nbsp;0.1-94.3<span class=EMEASuperscript>+</span>).</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab 1&nbsp;mg/kg
in combination with ipilimumab 3&nbsp;mg/kg in melanoma, the incidence of</span><span
lang=EN-GB> liver function test abnormalities was 29.5% (132/448).
Grade&nbsp;2, Grade&nbsp;3, and Grade&nbsp;4 cases were reported in 6.7% (30/448),
15.4% (69/448), and 1.8% (8/448) of patients, respectively. No Grade&nbsp;5
cases were reported. Median time to onset was 1.5&nbsp;months (range:&nbsp;0.0&#8209;30.1).
Resolution occurred in 124&nbsp;patients (93.9%) with a median time to
resolution of 5.1&nbsp;weeks (range:&nbsp;0.1&#8209;106.9)</span><span
lang=EN-GB>.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab 3&nbsp;mg/kg
in combination with ipilimumab 1&nbsp;mg/kg in RCC, the incidence of</span><span
lang=EN-GB> liver function test abnormalities was 18.5% (101/547).
Grade&nbsp;2, Grade&nbsp;3, and Grade&nbsp;4 cases were reported in 4.8% (26/547),
6.6% (36/547), and 1.6% (9/547) of patients, respectively. No Grade&nbsp;5
cases were reported. Median time to onset was 2.0&nbsp;months (range:&nbsp;0.4&#8209;26.8).
Resolution occurred in 86&nbsp;patients (85.1%) with a median time to
resolution of 6.1&nbsp;weeks (range:&nbsp;0.1<span class=EMEASuperscript>+</span>&#8209;82.9<span
class=EMEASuperscript>+</span>)</span><span lang=EN-GB>.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with </span><span
lang=EN-GB>nivolumab 360&nbsp;mg every 3&nbsp;weeks in combination </span><span
lang=EN-GB>with ipilimumab 1&nbsp;mg/kg every 6&nbsp;weeks and chemotherapy in
NSCLC, the incidence of</span><span lang=EN-GB> liver function test
abnormalities was 13.4% (48/358). Grade&nbsp;2, Grade&nbsp;3, and Grade&nbsp;4
cases were reported in 3.1% (11/358), 3.4% (12/358), and 1.1% (4/358) of
patients, respectively. Median time to onset was 10.6&nbsp;weeks (range:
1.1-68.3). Resolution occurred in 37&nbsp;patients (80.4%) with a median time
to resolution of 5&nbsp;weeks (range:&nbsp;0.3<sup>+</sup>-45.0<sup>+</sup>)</span><span
lang=EN-GB>.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Immune&#8209;related
nephritis and renal dysfunction</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab
monotherapy, the incidence of nephritis or renal dysfunction was
2.7%&nbsp;(74/2787). The majority of cases were Grade&nbsp;1 or&nbsp;2 in
severity reported in 1.5% (41/2787) and 0.7% (20/2787) of patients
respectively. Grade&nbsp;3 and 4&nbsp;cases were reported in 0.4% (12/2787) and
&lt;0.1% (1/2787) of patients, respectively. No Grade&nbsp;5 nephritis or renal
dysfunction was reported in these studies. Median time to onset was
2.3&nbsp;months (range:&nbsp;0.0&#8209;18.2). Resolution occurred in
45&nbsp;patients (63.4%) with a median time to resolution of 12.1&nbsp;weeks
(range:&nbsp;0.3&#8209;79.1<span class=EMEASuperscript>+</span>).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab 1&nbsp;mg/kg
in combination with ipilimumab 3&nbsp;mg/kg in melanoma,</span><span
lang=EN-GB> the incidence of nephritis or renal dysfunction was 5.1%&nbsp;(23/448).
Grade&nbsp;2, Grade&nbsp;3, and Grade&nbsp;4 cases were reported in 1.6% (7/448),
0.9% (4/448), and 0.7% (3/448) of patients, respectively. No Grade&nbsp;5 cases
were reported. Median time to onset was 2.6&nbsp;months (range:&nbsp;0.5&#8209;21.8).
Resolution occurred in 21&nbsp;patients (91.3%) with a median time to
resolution of 2.1&nbsp;weeks (range:&nbsp;0.1&#8209;125.1<sup>+</sup>).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab 3&nbsp;mg/kg
in combination with ipilimumab 1&nbsp;mg/kg in RCC,</span><span lang=EN-GB> the
incidence of nephritis or renal dysfunction was 8.8%&nbsp;(48/547).
Grade&nbsp;2, Grade&nbsp;3, and Grade&nbsp;4 cases were reported in 4.4% (24/547),
0.7% (4/547), and 0.5% (3/547) of patients, respectively. No Grade&nbsp;5 cases
were reported. Median time to onset was 2.1&nbsp;months (range:&nbsp;0.0&#8209;16.1).
Resolution occurred in 37&nbsp;patients (77.1%) with a median time to resolution
of 13.2&nbsp;weeks (range:&nbsp;0.1<sup>+</sup>&#8209;106.0<sup>+</sup>).</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with </span><span
lang=EN-GB>nivolumab 360&nbsp;mg every 3&nbsp;weeks in combination </span><span
lang=EN-GB>with ipilimumab 1&nbsp;mg/kg every 6&nbsp;weeks and chemotherapy in
NSCLC,</span><span lang=EN-GB> the incidence of nephritis or renal dysfunction
was 7%&nbsp;(25/358). Grade&nbsp;2, Grade&nbsp;3, and Grade&nbsp;4 cases were
reported in 2.2% (8/358), 1.7% (6/358), and 0.6 (2/358) of patients,
respectively. Median time to onset was 10.6 weeks (range: 0.1-51.3). Resolution
occurred in 14&nbsp;patients (56%) with a median time to resolution of
6.3&nbsp;weeks (range:&nbsp;0.1<sup>+</sup>-82.9<sup>+</sup>).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Immune&#8209;related
endocrinopathies</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab
monotherapy, the incidence of thyroid disorders, including hypothyroidism or
hyperthyroidism, was&nbsp;9.7%&nbsp;(270/2787). The majority of cases were
Grade&nbsp;1 or&nbsp;2 in severity reported in 4.2% (118/2787) and 5.4%
(150/2787) of patients, respectively. Grade&nbsp;3 thyroid disorders were
reported in &lt;&nbsp;0.1% (2/2787) of patients. Hypophysitis
(1&nbsp;Grade&nbsp;1, 2&nbsp;Grade&nbsp;2, 5&nbsp;Grade&nbsp;3, and 1&nbsp;Grade&nbsp;4),
hypopituitarism (5&nbsp;Grade&nbsp;2 and 1&nbsp;Grade&nbsp;3), adrenal
insufficiency (including secondary adrenocortical insufficiency)
(1&nbsp;Grade&nbsp;1, 9&nbsp;Grade&nbsp;2, and 5&nbsp;Grade&nbsp;3), diabetes
mellitus (including Type 1 diabetes mellitus) (3&nbsp;Grade&nbsp;2 and
1&nbsp;Grade&nbsp;3), and diabetic ketoacidosis (2&nbsp;Grade&nbsp;3) were
reported. No Grade&nbsp;5 cases were reported in these studies. Median time to
onset of these endocrinopathies was 2.8&nbsp;months (range:&nbsp;0.3&#8209;29.1).
Resolution occurred in 123&nbsp;patients (41.6%). Time to resolution ranged
from 0.4 to 144.1<span class=EMEASuperscript>+</span> weeks.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab
1&nbsp;mg/kg in combination with ipilimumab 3&nbsp;mg/kg in melanoma, the
incidence of</span><span lang=EN-GB> thyroid disorders was&nbsp;25.2%&nbsp;(113/448).
Grade&nbsp;2 and Grade&nbsp;3 thyroid disorders were reported in 14.5% (65/448)
and 1.3% (6/448) of patients, respectively. Grade&nbsp;2&nbsp;and&nbsp;Grade&nbsp;3&nbsp;hypophysitis
(including lymphocytic hypophysitis) occurred in 5.8% (26/448) and 2.0% (9/448)
of patients, respectively. Grade&nbsp;2 and Grade&nbsp;3 hypopituitarism
occurred in 0.4% (2/448) and 0.7% (3/448) of patients, respectively. Grade&nbsp;2,&nbsp;Grade&nbsp;3,
and Grade&nbsp;4&nbsp;adrenal insufficiency (including secondary adrenocortical
insufficiency) occurred in 1.6% (7/448), 1.3% (6/448) and 0.2% (1/448) of
patients, respectively. Grade&nbsp;1, Grade&nbsp;2, Grade&nbsp;3, and
Grade&nbsp;4 diabetes mellitus and Grade&nbsp;4 diabetic ketoacidosis were each
reported in&nbsp;0.2% (1/448) of&nbsp;patients. No Grade&nbsp;5 endocrinopathy
was reported. Median time to onset of these endocrinopathies was 1.9&nbsp;months
(range:&nbsp;0.0&#8209;28.1). Resolution occurred in 64&nbsp;patients (45.4%).
Time to resolution ranged from&nbsp;0.4&nbsp;to&nbsp;155.4<sup>+</sup>&nbsp;weeks.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab
3&nbsp;mg/kg in combination with ipilimumab 1&nbsp;mg/kg in RCC, the incidence
of</span><span lang=EN-GB> thyroid disorders was&nbsp;27.2%&nbsp;(149/547).
Grade&nbsp;2 and Grade&nbsp;3 thyroid disorders were reported in 15.7% (86/547)
and 1.3% (7/547) of patients, respectively. Hypophysitis occurred in 4.0% (22/547)
of patients. Grade&nbsp;2, Grade&nbsp;3, and Grade&nbsp;4 cases were reported
in 0.5% (3/547), 2.4% (13/547), and 0.4% (2/547) of patients, respectively. Grade&nbsp;2
hypopituitarism occurred in 0.4% (2/547) of patients. Grade&nbsp;2,&nbsp;Grade&nbsp;3,
and Grade&nbsp;4&nbsp;adrenal insufficiency (including secondary adrenocortical
insufficiency) occurred in 2.9% (16/547), 2.2% (12/547) and 0.4% (2/547) of
patients, respectively. Diabetes mellitus including Type 1 diabetes mellitus (3&nbsp;Grade&nbsp;2,
2&nbsp;Grade&nbsp;3, and 3&nbsp;Grade&nbsp;4), and diabetic ketoacidosis (1&nbsp;Grade
4) were reported. No Grade&nbsp;5 endocrinopathy was reported. Median time to
onset of these endocrinopathies was 1.9&nbsp;months (range:&nbsp;0.0&#8209;22.3).
Resolution occurred in 76&nbsp;patients (42.7%). Time to resolution ranged
from&nbsp;0.4&nbsp;to&nbsp;130.3<sup>+</sup>&nbsp;weeks.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with </span><span
lang=EN-GB>nivolumab 360&nbsp;mg every 3&nbsp;weeks in combination </span><span
lang=EN-GB>with ipilimumab 1&nbsp;mg/kg every 6&nbsp;weeks and chemotherapy in
NSCLC, the incidence of</span><span lang=EN-GB> thyroid disorders
was&nbsp;24%&nbsp;(86/358). Grade&nbsp;2 and Grade&nbsp;3 thyroid disorders
were reported in 12.3% (44/358) and 0.3% (1/358) of patients, respectively.
Hypophysitis occurred in 1.4% (5/358) of patients. Grade&nbsp;2 and
Grade&nbsp;3 cases were reported in 0.6% (2/358) and 0.8% (3/358) of patients,
respectively. Grade&nbsp;2 hypopituitarism occurred in 0.3% (1/358) of
patients. Grade&nbsp;2 and Grade&nbsp;3&nbsp;adrenal insufficiency occurred in
1.7% (6/358) and 1.4% (5/358) of patients, respectively. Diabetes mellitus
including Type&nbsp;1&nbsp;diabetes&nbsp;mellitus was not reported. Median time
to onset of these endocrinopathies was 12.1&nbsp;weeks (range: 1.9-58.3).
Resolution occurred in 30&nbsp;patients (35.3%). Time to resolution ranged
from&nbsp;1.4&nbsp;to&nbsp;72.4<sup>+</sup>&nbsp;weeks.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Immune&#8209;related
skin adverse reactions</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab
monotherapy, the incidence of rash was 25.9%&nbsp;(722/2787). The majority of
cases were Grade&nbsp;1 in severity reported in 19.6% (546/2787) of patients. </span><span
lang=EN-GB>Grade&nbsp;2 and </span><span lang=EN-GB>Grade&nbsp;3 cases were
reported in 5.0% (139/2787) and 1.3% (37/2787) of patients respectively. No
Grade&nbsp;4&nbsp;or&nbsp;5</span><span class=MsoCommentReference><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></span><span lang=EN-GB>cases
were reported in these studies. </span><span lang=EN-GB>Median time to onset
was&nbsp;1.4</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>months
(range:</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>0.0&#8209;27.9).
Resolution occurred in 448&nbsp;patients (62.8%) with a median time to
resolution of 17.4&nbsp;weeks (0.1&#8209;150.0<sup>+</sup>).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab 1&nbsp;mg/kg
in combination with ipilimumab 3&nbsp;mg/kg in melanoma, </span><span
lang=EN-GB>the incidence of rash was 65.0%&nbsp;(291/448). </span><span
lang=EN-GB>Grade&nbsp;2 and </span><span lang=EN-GB>Grade&nbsp;3 cases were
reported in 20.3% (91/448) and 7.6% (34/448) of patients, respectively. No
Grade&nbsp;4&nbsp;or&nbsp;5</span><span class=MsoCommentReference><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></span><span lang=EN-GB>cases
were reported. </span><span lang=EN-GB>Median time to onset
was&nbsp;0.5&nbsp;months (range:</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>0.0&#8209;19.4). Resolution occurred in 191&nbsp;patients (65.9%)
with a median time to resolution of 11.4&nbsp;</span><span lang=EN-GB>weeks </span><span
lang=EN-GB>(range:&nbsp;0.1&#8209;150.1<sup>+</sup>).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab 3&nbsp;mg/kg
in combination with ipilimumab 1&nbsp;mg/kg in RCC, </span><span lang=EN-GB>the
incidence of rash was 48.8%&nbsp;(267/547). </span><span lang=EN-GB>Grade&nbsp;2
and </span><span lang=EN-GB>Grade&nbsp;3 cases were reported in 13.7% (75/547)
and 3.7% (20/547) of patients, respectively. No Grade&nbsp;4&nbsp;or&nbsp;5</span><span
class=MsoCommentReference><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></span><span
lang=EN-GB>cases were reported. </span><span lang=EN-GB>Median time to onset
was&nbsp;0.9&nbsp;months (range:</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>0.0&#8209;17.9). Resolution occurred in 192&nbsp;patients (72.2%)
with a median time to resolution of 11.6&nbsp;</span><span lang=EN-GB>weeks </span><span
lang=EN-GB>(range:&nbsp;0.1&#8209;126.7<sup>+</sup>).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with </span><span
lang=EN-GB>nivolumab 360&nbsp;mg every 3&nbsp;weeks in combination </span><span
lang=EN-GB>with ipilimumab 1&nbsp;mg/kg every 6&nbsp;weeks and chemotherapy in
NSCLC, </span><span lang=EN-GB>the incidence of rash was 37.7% (135/358). </span><span
lang=EN-GB>Grade&nbsp;2, Grade 3, and </span><span lang=EN-GB>Grade&nbsp;4
cases were reported in 11.5% (41/358), 4.2% (14/358), and 0.3% (1/358) of
patients, respectively. </span><span lang=EN-GB>Median time to onset
was&nbsp;3.3 weeks (range: 0.1-83.1). Resolution occurred in 96&nbsp;patients
(71.6%) with a median time to resolution of 9.4&nbsp;</span><span lang=EN-GB>weeks
</span><span lang=EN-GB>(range:&nbsp;0.1<sup>+</sup>-84.1<sup>+</sup>).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Rare cases of SJS and TEN some of them
with fatal outcome have been observed (see
sections&nbsp;4.2&nbsp;and&nbsp;4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Infusion
reactions</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab monotherapy,
the incidence of hypersensitivity/infusion reactions was 4.4% (123/2787),
including 6&nbsp;Grade&nbsp;3 and 3&nbsp;Grade&nbsp;4 cases.</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab
1&nbsp;mg/kg in combination with ipilimumab 3&nbsp;mg/kg, the incidence of</span><span
lang=EN-GB> hypersensitivity/infusion reactions was 3.8% (17/448); all were
Grade&nbsp;1&nbsp;or&nbsp;2 in severity. Grade&nbsp;2 cases were reported in
2.2% (10/448) of patients. No Grade&nbsp;3&#8209;5&nbsp;cases were reported.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab
3&nbsp;mg/kg in combination with ipilimumab 1&nbsp;mg//kg, the incidence of</span><span
lang=EN-GB> hypersensitivity/infusion reactions was 4.0% (22/547); all were
Grade&nbsp;1&nbsp;or&nbsp;2 in severity. Grade&nbsp;2 cases were reported in 2.4%
(13/547) of patients. No Grade&nbsp;3&#8209;5&nbsp;cases were reported.</span><i><u><span
lang=EN-GB> </span></u></i></p>

<p class=EMEABodyText><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with </span><span
lang=EN-GB>nivolumab&nbsp;360&nbsp;mg every 3&nbsp;weeks in combination </span><span
lang=EN-GB>with ipilimumab 1&nbsp;mg/kg every 6&nbsp;weeks and chemotherapy in
NSCLC, the incidence of</span><span lang=EN-GB> hypersensitivity/infusion
reactions was 4.7% (17/358). Grade&nbsp;2, Grade&nbsp;3, and Grade&nbsp;4 cases
were reported in 2.2% (8/358), 0.3% (1/358), and 0.3% (1/358) of patients,
respectively.</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Complications
of allogeneic HSCT in classical Hodgkin lymphoma </span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Rapid onset of GVHD has been reported
with nivolumab use before and after allogeneic HSCT (see section&nbsp;4.4).</span></p>

<p class=EMEABodyText><span lang=EN-GB>In 49&nbsp;evaluated patients from two
cHL studies who underwent allogeneic HSCT after discontinuing nivolumab
monotherapy, Grade&nbsp;3 or 4 acute GVHD was reported in 13/49&nbsp;patients (26.5%).
Hyperacute GVHD, defined as acute GVHD occurring within 14&nbsp;days after stem
cell infusion, was reported in three&nbsp;patients (6%). A steroid&#8209;requiring
febrile syndrome, without an identified infectious cause, was reported in six&nbsp;patients
(12%) within the first 6&nbsp;weeks post&#8209;transplantation, with three&nbsp;patients
responding to steroids. Hepatic veno&#8209;occlusive disease occurred in one&nbsp;patient,
who died of GVHD and multi&#8209;organ failure. Nine&nbsp;of 49&nbsp;patients (18.4%)
died from complications of allogeneic HSCT after nivolumab. The 49&nbsp;patients
had a median follow&#8209;up from subsequent allogeneic HSCT of 5.6&nbsp;months
(range:&nbsp;0&#8209;19&nbsp;months).</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Laboratory
abnormalities</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>In </span><span lang=EN-GB>patients
treated with nivolumab monotherapy</span><span lang=EN-GB>, the proportion of
patients who experienced a shift from baseline to a Grade&nbsp;3&nbsp;or&nbsp;4
laboratory abnormality was as follows: 5.4%&nbsp;for anaemia (all
Grade&nbsp;3), 0.9% for thrombocytopaenia, 1.0% for leucopoenia, 10.6%&nbsp;for
lymphopaenia, 1.1%&nbsp;for neutropaenia, 2.3%&nbsp;for increased alkaline
phosphatase, 3.0%&nbsp;for increased AST, 2.5%&nbsp;for increased ALT,
1.3%&nbsp;for increased total bilirubin, 0.8%&nbsp;for increased creatinine,
3.8% for hyperglycaemia, 1.4% for hypoglycaemia, 3.5% for increased amylase,
7.9% for increased lipase, 6.7% for hyponatraemia, 1.7% for hyperkalaemia, 1.6%
for hypokalaemia, 1.6% for hypercalcaemia, 0.7% for hypermagnesaemia, 0.5% for
hypomagnesaemia, 0.6% for hypocalcaemia, and 0.1% for hypernatraemia.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab
1&nbsp;mg/kg in combination with ipilimumab 3&nbsp;mg/kg in melanoma, the
proportion of patients who experienced a worsening from baseline to a
Grade&nbsp;3&nbsp;or&nbsp;4 laboratory abnormality was as follows: 2.8%&nbsp;for
anaemia (all Grade&nbsp;3), 1.2% for thrombocytopaenia, 0.5% for leucopoenia,
6.7%&nbsp;for lymphopaenia, 0.7%&nbsp;for neutropaenia, 4.3%&nbsp;for increased
alkaline phosphatase, 12.4%&nbsp;for increased AST, 15.3%&nbsp;for increased
ALT, 1.2%&nbsp;for increased total bilirubin, 2.4%&nbsp;for increased
creatinine, 5.3% for hyperglycaemia, 8.7%&nbsp;for increased amylase, 19.5%&nbsp;for
increased lipase, 1.2%&nbsp;for hypocalcaemia, 0.2% each
for&nbsp;hypernatraemia and hypercalcaemia, 0.5% for hyperkalaemia, 0.3% for hypermagnesaemia,
4.8%&nbsp;for&nbsp;hypokalaemia, and 9.5%&nbsp;for hyponatraemia.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with nivolumab
3&nbsp;mg/kg in combination with ipilimumab 1&nbsp;mg/kg in RCC, the proportion
of patients who experienced a worsening from baseline to a
Grade&nbsp;3&nbsp;or&nbsp;4 laboratory abnormality was as follows: 3.0%&nbsp;for
anaemia (all Grade&nbsp;3), 0.7% for thrombocytopaenia, 0.6% for leucopoenia, 5.1%&nbsp;for
lymphopaenia, 1.1%&nbsp;for neutropaenia, 2.0%&nbsp;for increased alkaline
phosphatase, 4.8%&nbsp;for increased AST, 6.5%&nbsp;for increased ALT, 1.1%&nbsp;for
increased total bilirubin, 2.1%&nbsp;for increased creatinine, 7.2% for
hyperglycaemia, 1.8% for hypoglycaemia, 12.2%&nbsp;for increased amylase, 20.1%&nbsp;for
increased lipase, 0.4%&nbsp;for hypocalcaemia, 1.3% for hypercalcaemia, 2.4%
for hyperkalaemia, 1.1% for hypermagnesaemia, 0.4% for hypomagnesaemia 1.9%&nbsp;for&nbsp;hypokalaemia,
and 9.9%&nbsp;for hyponatraemia.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients treated with </span><span
lang=EN-GB>nivolumab 360&nbsp;mg every 3&nbsp;weeks in combination </span><span
lang=EN-GB>with ipilimumab 1&nbsp;mg/kg every 6&nbsp;weeks and chemotherapy in
NSCLC, the proportion of patients who experienced a worsening from baseline to
a Grade&nbsp;3&nbsp;or&nbsp;4 laboratory abnormality was as follows:
9.2%&nbsp;for anaemia, 4.3% for thrombocytopaenia, 9.8% for leucopoenia,
5.8%&nbsp;for lymphopaenia, 14.7%&nbsp;for neutropaenia, 1.2%&nbsp;for
increased alkaline phosphatase, 3.5%&nbsp;for increased AST, 4.3%&nbsp;for
increased ALT, 0%&nbsp;for increased total bilirubin, 1.2%&nbsp;for increased
creatinine, 7.1% for hyperglycaemia, 0% for hypoglycaemia, 6.7%&nbsp;for
increased amylase, 11.9%&nbsp;for increased lipase, 1.4%&nbsp;for
hypocalcaemia, 1.2% for hypercalcaemia, 1.7% for hyperkalaemia, 0.3% for
hypermagnesaemia, 1.2% for hypomagnesaemia 3.5%&nbsp;for&nbsp;hypokalaemia, and
10.7%&nbsp;for hyponatraemia.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Immunogenicity</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Of the&nbsp;2334&nbsp;patients who were
treated with nivolumab monotherapy&nbsp;3&nbsp;mg/kg or 240&nbsp;mg
every&nbsp;2&nbsp;weeks and evaluable for the presence of anti&#8209;product&#8209;antibodies,
255&nbsp;patients (10.9%) tested positive for treatment&#8209;emergent anti&#8209;product&#8209;antibodies
with fifteen&nbsp;patients (0.6%) testing positive for neutralising antibodies.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Of the&nbsp;patients who were treated
with nivolumab in combination with ipilimumab and evaluable for the presence of
anti&#8209;nivolumab antibodies, the incidence of anti&#8209;nivolumab
antibodies was 26.0% with nivolumab 3&nbsp;mg/kg and ipilimumab 1&nbsp;mg/kg
every 3&nbsp;weeks and 37.8% with nivolumab 1&nbsp;mg/kg and ipilimumab
3&nbsp;mg/kg every 3&nbsp;weeks. The incidence of neutralising antibodies
against nivolumab was 0.5% with nivolumab 3&nbsp;mg/kg and ipilimumab
1&nbsp;mg/kg every 3&nbsp;weeks and 4.6% with nivolumab 1&nbsp;mg/kg and
ipilimumab 3&nbsp;mg/kg every 3&nbsp;weeks. Of patients evaluable for the
presence of anti&#8209;ipilimumab antibodies, the incidence of anti&#8209;ipilimumab
antibodies ranged from 6.3 to 8.4% and neutralising antibodies against
ipilimumab ranged from 0 to 0.3%.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Of the patients who were treated with
nivolumab in combination with ipilimumab and chemotherapy and evaluable for the
presence of anti-nivolumab antibodies or neutralising antibodies against
nivolumab, the incidence of anti-nivolumab antibodies was 33.8% and the
incidence of </span><span lang=EN-GB>neutralising antibodies was </span><span
lang=EN-GB>2.6%. Of the patients who were treated with nivolumab in combination
with ipilimumab and chemotherapy and evaluable for the presence of
anti-ipilimumab antibodies or neutralising antibodies against ipilimumab, the
incidence of anti-ipilimumab antibodies was 7.5%, and the neutralising
antibodies was 1.6%.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Although the clearance of nivolumab was
increased by 20% when anti&#8209;nivolumab&#8209;antibodies were present, there
was no evidence of loss of efficacy or altered toxicity profile in the presence
of nivolumab antibodies based on the pharmacokinetic and exposure&#8209;response
analyses for both monotherapy and combination.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Elderly</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>No overall differences in safety were
reported between elderly (&#8805;&nbsp;65&nbsp;years) and younger patients
(&lt;&nbsp;65&nbsp;years). </span><span lang=EN-GB>Data from </span><span
lang=EN-GB>SCCHN and adjuvant melanoma patients 75&nbsp;years of age or older
are too limited to draw conclusions on this population (see section&nbsp;5.1). Data
from cHL patients 65&nbsp;years of age or older are too limited to draw
conclusions on this population (see section&nbsp;5.1).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Hepatic
or renal impairment</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>In the non&#8209;squamous NSCLC study
(CA209057), the safety profile in patients with baseline renal or hepatic
impairment was comparable to that in the overall population. These results
should be interpreted with caution due to the small sample size within the
subgroups.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Reporting
of suspected adverse reactions</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Reporting suspected adverse reactions
after authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='background:lightgrey'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a></span><span lang=EN-GB>.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>4.9 Overdose</span></p>

<p class=EMEAHeading1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>No cases of overdose have been reported
in clinical trials. In case of overdose, patients should be closely monitored
for signs or symptoms of adverse reactions, and appropriate symptomatic
treatment instituted immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.1 Pharmacodynamic properties</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Pharmacotherapeutic group: Antineoplastic
agents, monoclonal antibodies.</span><span lang=EN-GB> ATC code: L01XC17.</span></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Mechanism
of action</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab is a human immunoglobulin G4
(IgG4) monoclonal antibody (HuMAb), which binds to the programmed death&#8209;1
(PD&#8209;1) receptor and blocks its interaction with PD&#8209;L1 and PD&#8209;L2.
The PD&#8209;1 receptor is a negative regulator of T&#8209;cell activity that
has been shown to be involved in the control of T&#8209;cell immune responses.
Engagement of PD&#8209;1 with the ligands PD&#8209;L1 and PD&#8209;L2, which are
expressed in antigen presenting cells and may be expressed by tumours or other
cells in the tumour microenvironment, results in inhibition of T&#8209;cell
proliferation and cytokine secretion. Nivolumab potentiates T&#8209;cell
responses, including anti&#8209;tumour responses, through blockade of PD&#8209;1
binding to PD&#8209;L1 and PD&#8209;L2 ligands. In syngeneic mouse models,
blocking PD&#8209;1 activity resulted in decreased tumour growth.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Combined nivolumab (anti&#8209;PD&#8209;1)
and ipilimumab (anti&#8209;CTLA&#8209;4) mediated inhibition results in improved
anti&#8209;tumour responses in metastatic melanoma. </span><span lang=EN-GB>In
murine syngeneic tumour models, dual blockade of PD&#8209;1 and CTLA&#8209;4
resulted in synergistic anti&#8209;tumour activity.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Clinical
efficacy and safety</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Based on </span><span lang=EN-GB>modelling
of</span><span lang=EN-GB> dose/exposure efficacy and safety relationships,
there are no clinically significant differences in efficacy and safety between
a nivolumab dose of 240&nbsp;mg every 2&nbsp;weeks or 3&nbsp;mg/kg every
2&nbsp;weeks. Additionally, based on these relationships, there were no
clinically significant differences between a nivolumab dose of 480&nbsp;mg
every 4&nbsp;weeks or 3&nbsp;mg/kg every 2&nbsp;weeks in adjuvant treatment of
melanoma, advanced melanoma and advanced RCC.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Melanoma</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Treatment
of advanced melanoma</span></u></i></p>

<p class=EMEABodyText><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Randomised
phase&nbsp;3 study vs. dacarbazine (CA209066)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of
nivolumab&nbsp;3&nbsp;mg/kg for the treatment of advanced (unresectable or
metastatic) melanoma were evaluated in a phase&nbsp;3, randomised, double&#8209;blind
study (CA209066). The study included adult patients (18&nbsp;years or older)
with confirmed, treatment&#8209;naive, Stage&nbsp;III or&nbsp;IV BRAF wild&#8209;type
melanoma and an ECOG performance&#8209;status score of 0&nbsp;or&nbsp;1.
Patients with active autoimmune disease, ocular melanoma, or active brain or
leptomeningeal metastases were excluded from the study.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>A total of&nbsp;418&nbsp;patients were
randomised </span><span lang=EN-GB>to receive either nivolumab </span><span
lang=EN-GB>(n&nbsp;=&nbsp;210) </span><span lang=EN-GB>administered
intravenously over 60&nbsp;minutes at&nbsp;3&nbsp;mg/kg every 2</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>weeks </span><span lang=EN-GB>or
dacarbazine&nbsp;(n&nbsp;=&nbsp;208) </span><span lang=EN-GB>at&nbsp;1000&nbsp;mg/m<span
class=BMSSuperscript>2 </span><span class=BMSSuperscript><span
style='vertical-align:baseline'>every 3&nbsp;weeks.</span></span> Randomisation
was stratified by tumour PD&#8209;L1 status and M stage (M0/M1a/M1b versus
M1c). Treatment was continued as long as clinical benefit was observed or until
treatment was no longer tolerated. Treatment after disease progression was
permitted for patients who had a clinical benefit and did not have substantial adverse
events with the study drug, as determined by the investigator. Tumour
assessments, according to the Response Evaluation Criteria in Solid Tumours
(RECIST), version&nbsp;1.1, were conducted&nbsp;9&nbsp;weeks after randomisation
and continued every&nbsp;6&nbsp;weeks for the first year and then
every&nbsp;12&nbsp;weeks thereafter. The primary efficacy outcome measure was OS.
Key secondary efficacy outcome measures were investigator&#8209;assessed PFS
and objective response rate (ORR).</span></p>

<p class=EMEABodyText><span lang=EN-GB>Baseline characteristics were balanced
between the two groups. The median age was&nbsp;65&nbsp;years (range:&nbsp;18&#8209;87),
59% were men, and 99.5% were white. Most patients had ECOG performance score of
0 (64%) or 1 (34%). Sixty&#8209;one percent of patients had M1c stage disease
at study entry. Seventy&#8209;four percent of patients had cutaneous melanoma,
and 11% had mucosal melanoma; 35% of patients had PD&#8209;L1 positive melanoma
(<u>&#8805;&nbsp;</u>5% tumour cell membrane expression). Sixteen percent of
patients had received prior adjuvant therapy; the most common adjuvant
treatment was interferon (9%). Four percent of patients had a history of brain
metastasis, and 37% of patients had a baseline LDH level greater than ULN at
study entry.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The Kaplan&#8209;Meier curves for OS are
shown in Figure&nbsp;1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Figure&nbsp;1</span></b><span
lang=EN-GB>: <b>Kaplan&#8209;Meier curves of OS (CA209066)</b></span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><span style='position:absolute;z-index:251660288;left:0px;margin-left:
-7px;margin-top:4px;width:37px;height:347px'><img width=37 height=347
src="OPDIVO-H-3985-IA-099-PI-en_files/image001.png"
alt="Probability of survival"></span><b><img border=0 width=455 height=296
id="Picture 4" src="OPDIVO-H-3985-IA-099-PI-en_files/image002.jpg"></b></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=EN-GB>Overall
survival (months)</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=491
 style='margin-left:33.75pt;border-collapse:collapse'>
 <tr style='height:12.95pt'>
  <td width=436 colspan=7 valign=top style='width:326.95pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.95pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Number of subjects
  at risk</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=55><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=436 colspan=7 valign=top style='width:326.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Nivolumab</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=55><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=85 style='width:63.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>210</span></p>
  </td>
  <td width=66 style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>185</span></p>
  </td>
  <td width=66 style='width:49.65pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>150</span></p>
  </td>
  <td width=66 style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>105</span></p>
  </td>
  <td width=66 style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>45</span></p>
  </td>
  <td width=76 style='width:56.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>8</span></p>
  </td>
  <td width=66 colspan=2 style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>0</span></p>
  </td>
 </tr>
 <tr>
  <td width=436 colspan=7 style='width:326.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Dacarbazine</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=55><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=85 style='width:63.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>208</span></p>
  </td>
  <td width=66 style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>177</span></p>
  </td>
  <td width=66 style='width:49.65pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>123</span></p>
  </td>
  <td width=66 style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>82</span></p>
  </td>
  <td width=66 style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>22</span></p>
  </td>
  <td width=76 style='width:56.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>3</span></p>
  </td>
  <td width=66 colspan=2 style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>0</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=85 style='border:none'></td>
  <td width=66 style='border:none'></td>
  <td width=66 style='border:none'></td>
  <td width=66 style='border:none'></td>
  <td width=66 style='border:none'></td>
  <td width=76 style='border:none'></td>
  <td width=11 style='border:none'></td>
  <td width=55 style='border:none'></td>
 </tr>
</table>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&#9472;&#9472;&#8710;&#9472;&#9472;&#9472;
Nivolumab (events: 50/210), median and 95%&nbsp;CI: N.A.<br>
- - -</span><span lang=EN-GB style='font-family:Wingdings'></span><span
lang=EN-GB>- - - Dacarbazine (events: 96/208), median and 95%&nbsp;CI: 10.84
(9.33, 12.09)<br>
<br>
</span></p>

<p class=EMEABodyText><span lang=EN-GB>The observed OS benefit was consistently
demonstrated across subgroups of patients including baseline ECOG performance
status, M stage, history of brain metastases, and baseline LDH level. Survival
benefit was observed regardless of whether patients had tumours that were
designated PD&#8209;L1 negative or PD&#8209;L1 positive (tumour membrane
expression cut off of&nbsp;5% or&nbsp;10%).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Data available indicate that the onset of
nivolumab effect is delayed such that benefit of nivolumab above chemotherapy
may take 2&#8209;3&nbsp;months.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Efficacy results are shown in Table&nbsp;9.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;9</span></b><span
lang=EN-GB>: <b>Efficacy results (CA209066)</b></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=197 valign=top style='width:147.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=205 colspan=2 valign=top style='width:153.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>nivolumab<br>
  (n&nbsp;=&nbsp;210)</span></b></p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.6pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>dacarbazine<br>
  (n&nbsp;=&nbsp;208)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:453.55pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Overall
  survival </span></b></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Events</span></p>
  </td>
  <td width=205 colspan=2 valign=top style='width:153.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>50 (23.8%)</span></p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>96 (46.2%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Hazard ratio </span></p>
  </td>
  <td width=408 colspan=4 valign=top style='width:306.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.42</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>99.79% CI</span></p>
  </td>
  <td width=408 colspan=4 valign=top style='width:306.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.25, 0.73)</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>95%&nbsp;CI</span></p>
  </td>
  <td width=408 colspan=4 valign=top style='width:306.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.30, 0.60)</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>p&#8209;value</span></p>
  </td>
  <td width=408 colspan=4 valign=top style='width:306.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=101 valign=top style='width:75.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Median
  (95%&nbsp;CI)</span></p>
  </td>
  <td width=205 colspan=2 valign=top style='width:153.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Not reached</span></p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>10.8 (9.33, 12.09)</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Rate
  (95%&nbsp;CI)</span></p>
  </td>
  <td width=103 valign=top style='width:77.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=101 valign=top style='width:75.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> At
  6</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>months</span></p>
  </td>
  <td width=205 colspan=2 valign=top style='width:153.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>84.1 (78.3, 88.5)</span></p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>71.8 (64.9, 77.6)</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> At
  12</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>months</span></p>
  </td>
  <td width=205 colspan=2 valign=top style='width:153.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>72.9 (65.5, 78.9)</span></p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>42.1 (33.0, 50.9)</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Progression&#8209;free
  survival</span></b></p>
  </td>
  <td width=103 valign=top style='width:77.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=101 valign=top style='width:75.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Events</span></p>
  </td>
  <td width=205 colspan=2 valign=top style='width:153.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>108 (51.4%)</span></p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>163 (78.4%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Hazard ratio </span></p>
  </td>
  <td width=408 colspan=4 valign=top style='width:306.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.43</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>95%&nbsp;CI</span></p>
  </td>
  <td width=408 colspan=4 valign=top style='width:306.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.34, 0.56)</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>p&#8209;value</span></p>
  </td>
  <td width=408 colspan=4 valign=top style='width:306.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=101 valign=top style='width:75.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Median
  (95%&nbsp;CI)</span></p>
  </td>
  <td width=205 colspan=2 valign=top style='width:153.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>5.1 (3.48, 10.81)</span></p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>2.2 (2.10, 2.40)</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Rate
  (95%&nbsp;CI)</span></p>
  </td>
  <td width=103 valign=top style='width:77.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=101 valign=top style='width:75.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> At
  6&nbsp;months</span></p>
  </td>
  <td width=205 colspan=2 valign=top style='width:153.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>48.0 (40.8, 54.9)</span></p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>18.5 (13.1, 24.6)</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> At
  12&nbsp;months</span></p>
  </td>
  <td width=205 colspan=2 valign=top style='width:153.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>41.8 (34.0, 49.3)</span></p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>NA</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=101 valign=top style='width:75.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Objective
  response </span></b></p>
  </td>
  <td width=103 valign=top style='width:77.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>84</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(40.0%)</span></p>
  </td>
  <td width=101 valign=top style='width:75.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>29</span></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(13.9%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=205 colspan=2 valign=top style='width:153.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(33.3, 47.0)</span></p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(9.5, 19.4)</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Odds ratio (95%&nbsp;CI)</span></p>
  </td>
  <td width=408 colspan=4 valign=top style='width:306.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>4.06 (2.52, 6.54)</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>p&#8209;value</span></p>
  </td>
  <td width=408 colspan=4 valign=top style='width:306.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=101 valign=top style='width:75.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Complete
  response (CR)</span></p>
  </td>
  <td width=103 valign=top style='width:77.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>16</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(7.6%)</span></p>
  </td>
  <td width=101 valign=top style='width:75.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>2 </span></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(1.0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Partial
  response (PR)</span></p>
  </td>
  <td width=103 valign=top style='width:77.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>68</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(32.4%)</span></p>
  </td>
  <td width=101 valign=top style='width:75.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>27 </span></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(13.0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Stable disease
  (SD)</span></p>
  </td>
  <td width=103 valign=top style='width:77.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>35</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(16.7%)</span></p>
  </td>
  <td width=101 valign=top style='width:75.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>46 </span></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(22.1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=101 valign=top style='width:75.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:453.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Median
  duration of response </span></b></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Months
  (range)</span></p>
  </td>
  <td width=103 valign=top style='width:77.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>Not reached</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(0<sup>+</sup>&#8209;12.5<sup>+</sup>)</span></p>
  </td>
  <td width=101 valign=top style='width:75.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>6.0</span></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(1.1&#8209;10.0<sup>+</sup>)</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=101 valign=top style='width:75.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Median time
  to response</span></b></p>
  </td>
  <td width=103 valign=top style='width:77.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=101 valign=top style='width:75.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=197 valign=top style='width:147.4pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Months
  (range)</span></p>
  </td>
  <td width=103 valign=top style='width:77.05pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>2.1</span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(1.2&#8209;7.6)</span></p>
  </td>
  <td width=101 valign=top style='width:75.5pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>2.1</span></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(1.8&#8209;3.6)</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB><sup>+</sup> denotes a censored
observation.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Randomised
phase&nbsp;3 study vs. chemotherapy (CA209037)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of nivolumab&nbsp;3&nbsp;mg/kg
for the treatment of advanced (unresectable or metastatic) melanoma were
evaluated in a phase&nbsp;3, randomised, open&#8209;label study (CA209037). The
study included adult patients who had progressed on or after ipilimumab and if
BRAF V600 mutation positive had also progressed on or after BRAF kinase
inhibitor therapy. Patients with active autoimmune disease, ocular melanoma, active
brain or leptomeningeal metastases or a known history of prior ipilimumab&#8209;related
high&#8209;grade (Grade&nbsp;4 per CTCAE&nbsp;v4.0) adverse reactions, except
for resolved nausea, fatigue, infusion reactions, or endocrinopathies, were
excluded from the study.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>A total of&nbsp;405&nbsp;patients were
randomised to receive either nivolumab (n&nbsp;=&nbsp;272) administered
intravenously over 60&nbsp;minutes at&nbsp;3&nbsp;mg/kg every&nbsp;2&nbsp;weeks
or chemotherapy (n&nbsp;=&nbsp;133) which consisted of the investigators
choice of either dacarbazine (1000&nbsp;mg/m<sup>2</sup>&nbsp;every&nbsp;3&nbsp;weeks)
or carboplatin (AUC&nbsp;6&nbsp;every&nbsp;3&nbsp;weeks) and paclitaxel (175&nbsp;mg/m<sup>2</sup>&nbsp;every&nbsp;3&nbsp;weeks).
Randomisation was stratified by BRAF and tumour PD&#8209;L1 status and best
response to prior ipilimumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The co&#8209;primary efficacy outcome
measures were confirmed ORR in the first 120&nbsp;patients treated with
nivolumab, as measured by independent radiology review committee (IRRC) using
RECIST, version&nbsp;1.1, and comparison of OS of nivolumab to chemotherapy. Additional
outcome measures included duration and timing of response.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The median age was&nbsp;60&nbsp;years
(range:&nbsp;23&#8209;88). Sixty&#8209;four percent of patients were men and
98% were white. ECOG performance scores were 0&nbsp;for&nbsp;61% of patients
and 1&nbsp;for&nbsp;39% of patients. The majority (75%) of patients had M1c
stage disease at study entry. Seventy&#8209;three percent of patients had
cutaneous melanoma and 10% had mucosal melanoma. The number of prior systemic
regimen received was&nbsp;1&nbsp;for&nbsp;27% of patients, 2&nbsp;for&nbsp;51%
of patients, and&nbsp;&gt;&nbsp;2&nbsp;for&nbsp;21% of patients. Twenty&#8209;two
percent of patients had tumours that tested BRAF mutation positive and&nbsp;50%&nbsp;of
patients had tumours that were considered PD&#8209;L1 positive. Sixty&#8209;four
percent of patients had no prior clinical benefit (CR/PR or SD) on ipilimumab. Baseline
characteristics were balanced between groups except for the proportions of
patients who had a history of brain metastasis (19%&nbsp;and&nbsp;13% in the
nivolumab group and chemotherapy group, respectively) and patients with LDH
greater than ULN at baseline (51%&nbsp;and&nbsp;35%, respectively).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>At the time of this final ORR analysis,
results from&nbsp;120&nbsp;nivolumab&#8209;treated patients and 47&nbsp;chemotherapy&#8209;treated
patients who had a minimum of&nbsp;6&nbsp;months of follow&#8209;up were analysed.
Efficacy results are presented in Table&nbsp;10.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;10</span></b><span
lang=EN-GB>: <b>Best overall response, time and duration of response
(CA209037)</b></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=253 valign=top style='width:189.8pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=180 colspan=2 valign=top style='width:135.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>nivolumab<br>
  (n&nbsp;=&nbsp;120)</span></b></p>
  </td>
  <td width=186 colspan=2 valign=top style='width:139.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>chemotherapy<br>
  (n&nbsp;=&nbsp;47)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Confirmed
  objective response (IRRC)</span></b></p>
  </td>
  <td width=60 valign=top style='width:45.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>38</span></p>
  </td>
  <td width=120 valign=top style='width:89.95pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(31.7%)</span></p>
  </td>
  <td width=74 valign=top style='width:55.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>5</span></p>
  </td>
  <td width=112 valign=top style='width:83.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(10.6%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=180 colspan=2 valign=top style='width:135.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(23.5,&nbsp;40.8)</span></p>
  </td>
  <td width=186 colspan=2 valign=top style='width:139.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(3.5,&nbsp;23.1)</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=60 valign=top style='width:45.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 valign=top style='width:89.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=74 valign=top style='width:55.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:83.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Complete
  response (CR)</span></p>
  </td>
  <td width=60 valign=top style='width:45.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='color:black'>4</span></p>
  </td>
  <td width=120 valign=top style='width:89.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(<span
  style='color:black'>3.3</span>%)</span></p>
  </td>
  <td width=74 valign=top style='width:55.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='color:black'>0</span></p>
  </td>
  <td width=112 valign=top style='width:83.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Partial
  response (PR)</span></p>
  </td>
  <td width=60 valign=top style='width:45.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='color:black'>34</span></p>
  </td>
  <td width=120 valign=top style='width:89.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(<span
  style='color:black'>28.3</span>%)</span></p>
  </td>
  <td width=74 valign=top style='width:55.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='color:black'>5</span></p>
  </td>
  <td width=112 valign=top style='width:83.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(<span
  style='color:black'>10.6</span>%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Stable disease
  (SD)</span></p>
  </td>
  <td width=60 valign=top style='width:45.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='color:black'>28</span></p>
  </td>
  <td width=120 valign=top style='width:89.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(<span
  style='color:black'>23.3</span>%)</span></p>
  </td>
  <td width=74 valign=top style='width:55.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='color:black'>16</span></p>
  </td>
  <td width=112 valign=top style='width:83.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(<span
  style='color:black'>34.0</span>%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=60 valign=top style='width:45.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 valign=top style='width:89.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=74 valign=top style='width:55.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:83.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Median duration
  of response </span></b></p>
  </td>
  <td width=180 colspan=2 valign=top style='width:135.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=74 valign=top style='width:55.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:83.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Months
  (range)</span></p>
  </td>
  <td width=180 colspan=2 valign=top style='width:135.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Not reached</span></p>
  </td>
  <td width=74 valign=top style='width:55.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>3.6</span></p>
  </td>
  <td width=112 valign=top style='width:83.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(Not
  available)</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=60 valign=top style='width:45.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 valign=top style='width:89.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=74 valign=top style='width:55.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:83.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Median time
  to response</span></b></p>
  </td>
  <td width=60 valign=top style='width:45.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=120 valign=top style='width:89.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=74 valign=top style='width:55.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=112 valign=top style='width:83.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=253 valign=top style='width:189.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Months
  (range)</span></p>
  </td>
  <td width=60 valign=top style='width:45.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>2.1</span></p>
  </td>
  <td width=120 valign=top style='width:89.95pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(1.6&#8209;7.4)</span></p>
  </td>
  <td width=74 valign=top style='width:55.55pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>3.5</span></p>
  </td>
  <td width=112 valign=top style='width:83.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(</span><span
  lang=EN-GB>2.1&#8209;6.1)</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Data available indicate that the onset
of nivolumab effect is delayed such that benefit of nivolumab above
chemotherapy may take 2&#8209;3&nbsp;months.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Updated
analysis (24&#8209;month follow&#8209;up)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Among all randomised patients, the ORR
was 27.2% (95%&nbsp;CI:&nbsp;22.0,&nbsp;32.9) in the nivolumab group and 9.8%
(95%&nbsp;CI:&nbsp;5.3,&nbsp;16.1) in the chemotherapy group. Median durations
of response were 31.9&nbsp;months (range:&nbsp;1.4<sup>+</sup>&#8209;31.9) and
12.8&nbsp;months (range:&nbsp;1.3<sup>+</sup>&#8209;13.6<sup>+</sup>),
respectively. The PFS HR for nivolumab vs. chemotherapy was 1.03
(95%&nbsp;CI:&nbsp;0.78,&nbsp;1.36). The ORR and PFS were assessed by IRRC per
RECIST version&nbsp;1.1.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>There was no statistically significant
difference between nivolumab and chemotherapy in the final OS analysis. The
primary OS analysis was not adjusted to account for subsequent therapies, with
54&nbsp;(40.6%)&nbsp;patients in the chemotherapy arm subsequently receiving an
anti&#8209;PD1 treatment. OS may be confounded by dropout, imbalance of
subsequent therapies and differences in baseline factors. More patients in the
nivolumab arm had poor prognostic factors (elevated LDH and brain metastases)
than in the chemotherapy arm.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB>Efficacy by BRAF status</span></u></i><u><span
lang=EN-GB>:</span></u><span lang=EN-GB> Objective responses to nivolumab
(according to the definition of the co&#8209;primary endpoint) were observed in
patients with or without BRAF mutation&#8209;positive melanoma. The ORRs in the
BRAF mutation&#8209;positive subgroup
were&nbsp;17%&nbsp;(95%&nbsp;CI:&nbsp;8.4,&nbsp;29.0) for nivolumab and
11%&nbsp;(95%&nbsp;CI:&nbsp;2.4,&nbsp;29.2) for chemotherapy, and in the BRAF
wild&#8209;type subgroup were 30%&nbsp;(95%&nbsp;CI:&nbsp;24.0,&nbsp;36.7) and
9%&nbsp;(95%&nbsp;CI:&nbsp;4.6,&nbsp;16.7), respectively.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The PFS HRs for nivolumab vs.
chemotherapy were 1.58 (95%&nbsp;CI:&nbsp;0.87,&nbsp;2.87) for BRAF mutation&#8209;positive
patients and 0.82&nbsp;(95%&nbsp;CI:&nbsp;0.60,&nbsp;1.12) for BRAF wild&#8209;type
patients. The OS HRs for nivolumab vs. chemotherapy were 1.32&nbsp;(95%&nbsp;CI:&nbsp;0.75,&nbsp;2.32)
for BRAF mutation&#8209;positive patients and
0.83&nbsp;(95%&nbsp;CI:&nbsp;0.62,&nbsp;1.11) for BRAF wild&#8209;type
patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB>Efficacy by tumour PD&#8209;L1
expression</span></u></i><u><span lang=EN-GB>:</span></u><span lang=EN-GB>
Objective responses to nivolumab were observed regardless of tumour PD&#8209;L1
expression. However, the role of this biomarker (tumour PD&#8209;L1 expression)
has not been fully elucidated.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In patients with tumour PD&#8209;L1
expression&nbsp;&#8805;1%, ORR was 33.5% for nivolumab (n&nbsp;=&nbsp;179;&nbsp;95%&nbsp;CI:&nbsp;26.7,&nbsp;40.9)
and 13.5% for chemotherapy (n&nbsp;=&nbsp;74;&nbsp;95%&nbsp;CI:&nbsp;6.7,&nbsp;23.5).
In patients with tumour PD&#8209;L1 expression&nbsp;&lt;1%, ORR per IRRC was
13.0%&nbsp;(n&nbsp;=&nbsp;69;&nbsp;95%&nbsp;CI:&nbsp;6.1,&nbsp;23.3) and
12.0%&nbsp;(n&nbsp;=&nbsp;25; 95%&nbsp;CI:&nbsp;2.5,&nbsp;31.2), respectively.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The PFS HRs for nivolumab vs.
chemotherapy were 0.76&nbsp;(95%&nbsp;CI:&nbsp;0.54,&nbsp;1.07) in patients
with tumour PD&#8209;L1 expression&nbsp;&#8805;1% and
1.92&nbsp;(95%&nbsp;CI:&nbsp;1.05,&nbsp;3.5) in patients with tumour PD&#8209;L1
expression&nbsp;&lt;1%.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The OS HRs for nivolumab vs.
chemotherapy were 0.69&nbsp;(95%&nbsp;CI:&nbsp;0.49,&nbsp;0.96) in patients
with tumour PD&#8209;L1 expression&nbsp;&#8805;1% and
1.52&nbsp;(95%&nbsp;CI:&nbsp;0.89,&nbsp;2.57) in patients with tumour PD&#8209;L1
expression&nbsp;&lt;1%.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>These subgroup analyses should be
interpreted with caution given the small size of the subgroups and lack of
statistically significant difference in OS in the all randomised population.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Open&#8209;label
phase&nbsp;1&nbsp;dose&#8209;escalation study (MDX1106&#8209;03)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and tolerability of nivolumab
were investigated in a phase&nbsp;1, open&#8209;label dose&#8209;escalation
study in various tumour types, including malignant melanoma. Of
the&nbsp;306&nbsp;previously treated patients enrolled in the study,
107&nbsp;had melanoma and received nivolumab at a dose of&nbsp;0.1&nbsp;mg/kg,
0.3&nbsp;mg/kg, 1 mg/kg, 3&nbsp;mg/kg, or 10&nbsp;mg/kg for a maximum of
2&nbsp;years. In this patient population, objective response was reported
in&nbsp;33&nbsp;patients (31%) with a median duration of response
of&nbsp;22.9&nbsp;months (95%&nbsp;CI:&nbsp;17.0,&nbsp;NR). The median PFS
was&nbsp;3.7&nbsp;months (95%&nbsp;CI:&nbsp;1.9,&nbsp;9.3). The median OS
was&nbsp;17.3&nbsp;months (95%&nbsp;CI:&nbsp;12.5,&nbsp;37.8), and the
estimated OS rates were 42% (95%&nbsp;CI:&nbsp;32,&nbsp;51)&nbsp;at&nbsp;3&nbsp;years,
35% (95%&nbsp;CI:&nbsp;26,&nbsp;44)&nbsp;at&nbsp;4&nbsp;years, and 34%
(95%&nbsp;CI:&nbsp;25,&nbsp;43)&nbsp;at&nbsp;5&nbsp;years (minimum follow&#8209;up
of 45&nbsp;months).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Single&#8209;arm
phase&nbsp;2&nbsp;study (CA209172)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Study&nbsp;CA209172 was a single&#8209;arm,
open label study of nivolumab monotherapy in patients with stage&nbsp;III
(unresectable) or stage&nbsp;IV metastatic melanoma after prior treatment
containing an anti&#8209;CTLA&#8209;4 monoclonal antibody. Safety was the primary
endpoint and efficacy was a secondary endpoint. Of the 1008&nbsp;treated
patients, 103&nbsp;(10%) had ocular/uveal melanoma, 66&nbsp;(7%) had an ECOG
performance score of&nbsp;2, 165&nbsp;(16%) had asymptomatic treated and
untreated CNS metastases, 13&nbsp;(1.3%) had treated leptomeningeal metastases,
25&nbsp;(2%) had autoimmune disease, and 84&nbsp;(8%) had Grade&nbsp;3&#8209;4
immune&#8209;related AEs with prior anti&#8209;CTLA&#8209;4 therapy. </span><span
lang=EN-GB>No new safety signals were identified in all treated patients and
the overall safety profile of nivolumab was similar across subgroups. Efficacy
results based on investigator&#8209;assessed response rates at week&nbsp;12 are
presented in Table&nbsp;11 below.</span></p>

<p class=MsoNormal><span style='font-family:"Calibri",sans-serif'>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:.75in;text-indent:-.75in;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;11</span></b><span lang=EN-GB>: <b>Response
rate at week&nbsp;12 &#8209; all response evaluable patients and by subgroup
(CA209172)</b></span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=623
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=73 valign=top style='width:55.05pt;border-top:windowtext;
  border-left:white;border-bottom:windowtext;border-right:white;border-style:
  solid;border-width:1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:105%;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=94 valign=top style='width:70.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><b><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>Total</span></b></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><b><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>Ocular/</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><b><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>Uveal melanoma</span></b></p>
  </td>
  <td width=85 colspan=2 valign=top style='width:63.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><b><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>ECOG PS 2</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><b><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>&nbsp;</span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><b><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>CNS metastasis</span></b></p>
  </td>
  <td width=95 valign=top style='width:70.9pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><b><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>Autoimmune disease</span></b></p>
  </td>
  <td width=96 valign=top style='width:72.3pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><b><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>Grade</span></b><span
  lang=EN-GB>&nbsp;</span><b><span lang=EN-GB style='font-size:10.0pt;
  line-height:105%'>3&#8209;4 irAEs with anti&#8209;CTLA&#8209;4</span></b></p>
  </td>
 </tr>
 <tr style='height:33.95pt'>
  <td width=73 style='width:55.05pt;border-top:none;border-left:solid white 1.0pt;
  border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:33.95pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>N</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>(%)<sup>a</sup></span></p>
  </td>
  <td width=94 style='width:70.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:33.95pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>161/588</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>(27.4)</span></p>
  </td>
  <td width=96 colspan=2 style='width:72.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:33.95pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4/61</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>(6.6)</span></p>
  </td>
  <td width=83 style='width:62.35pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:33.95pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4/20</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>(20.0)</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:33.95pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>20/73</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>(27.4)</span></p>
  </td>
  <td width=95 style='width:70.9pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:33.95pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>3/16</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>(18.8)</span></p>
  </td>
  <td width=96 style='width:72.3pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid white 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:33.95pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>13/46</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>(28.3)</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=73 style='border:none'></td>
  <td width=94 style='border:none'></td>
  <td width=95 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=83 style='border:none'></td>
  <td width=85 style='border:none'></td>
  <td width=95 style='border:none'></td>
  <td width=96 style='border:none'></td>
 </tr>
</table>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>a</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Responses were assessed per RECIST&nbsp;1.1
for 588/1008 (58.3%) of patients who continued treatment through week&nbsp;12
and had a follow&#8209;up scan at week&nbsp;12. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Randomised
phase&nbsp;3 study of nivolumab in combination with ipilimumab or nivolumab as
monotherapy vs. ipilimumab as monotherapy (CA209067)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of nivolumab 1&nbsp;mg/kg
in combination with ipilimumab 3&nbsp;mg/kg or nivolumab 3&nbsp;mg/kg vs.
ipilimumab 3&nbsp;mg/kg monotherapy for the treatment of advanced (unresectable
or metastatic) melanoma were evaluated in a phase&nbsp;3, randomised, double&#8209;blind
study (CA209067). The differences between the two nivolumab&#8209;containing
groups were evaluated descriptively. The study included adult patients with
confirmed unresectable Stage&nbsp;III or Stage&nbsp;IV melanoma. Patients were
to have ECOG performance status score of&nbsp;0 or&nbsp;1. Patients who had not
received prior systemic anticancer therapy for unresectable or metastatic
melanoma were enrolled. Prior adjuvant or neoadjuvant therapy was allowed if it
was completed at least 6&nbsp;weeks prior to randomisation. Patients with
active autoimmune disease, ocular/uveal melanoma, or active brain or
leptomeningeal metastases were excluded from the study.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>A total of&nbsp;945&nbsp;patients were
randomised to receive nivolumab in combination with ipilimumab
(n&nbsp;=&nbsp;314), nivolumab monotherapy (n&nbsp;=&nbsp;316), or ipilimumab monotherapy
(n&nbsp;=&nbsp;315). Patients in the combination arm received nivolumab 1&nbsp;mg/kg
over 60&nbsp;minutes and ipilimumab 3&nbsp;mg/kg over 90&nbsp;minutes
administered intravenously every 3&nbsp;weeks for the first 4&nbsp;doses,
followed by nivolumab 3&nbsp;mg/kg as monotherapy every 2&nbsp;weeks. Patients
in the nivolumab monotherapy arm received nivolumab 3&nbsp;mg/kg every
2&nbsp;weeks. Patients in the comparator arm received ipilimumab 3&nbsp;mg/kg
and nivolumab&#8209;matched placebo intravenously every 3&nbsp;weeks for
4&nbsp;doses followed by placebo every 2&nbsp;weeks. Randomisation was
stratified by PD&#8209;L1 expression (&#8805;&nbsp;5% vs. &lt;&nbsp;5% tumour
cell membrane expression), BRAF status, and M&nbsp;stage per the American Joint
Committee on Cancer (AJCC) staging system. Treatment was continued as long as
clinical benefit was observed or until treatment was no longer tolerated. Tumour
assessments were conducted 12&nbsp;weeks after randomisation then every 6&nbsp;weeks
for the first year, and every 12&nbsp;weeks thereafter. The primary outcome
measures were progression&#8209;free survival and OS. ORR and the duration of
response were also assessed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Baseline characteristics were balanced across
the three treatment groups. The median age was&nbsp;61&nbsp;years (range:&nbsp;18
to 90&nbsp;years), 65% of patients were men, and 97% were white. ECOG
performance status score was 0 (73%) or 1 (27%). The majority of the patients
had AJCC Stage IV disease (93%); 58% had M1c disease at study entry. Twenty&#8209;two
percent of patients had received prior adjuvant therapy. Thirty&#8209;two
percent of patients had BRAF mutation&#8209;positive melanoma; 26.5% of
patients had PD&#8209;L1 &#8805;&nbsp;5% tumour cell membrane expression. Four
percent of patients had a history of brain metastasis, and 36% of patients had
a baseline LDH level greater than ULN at study entry. Among patients with quantifiable
tumour PD&#8209;L1 expression, the distribution of patients was balanced across
the three treatment groups. Tumour PD&#8209;L1 expression was determined using
the PD&#8209;L1&nbsp;IHC&nbsp;28&#8209;8&nbsp;pharmDx&nbsp;assay.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>At </span>primary analysis (minimum follow&#8209;up
9<span lang=EN-GB>&nbsp;</span>months)<span lang=EN-GB> the median PFS was 6.9&nbsp;months
in the nivolumab group as compared with 2.9&nbsp;months in the ipilimumab group
(HR&nbsp;=&nbsp;0.57, 99.5%&nbsp;CI:&nbsp;0.43,&nbsp;0.76; p&nbsp;&lt;&nbsp;0.0001).
The median PFS was 11.5&nbsp;months in the nivolumab in combination with
ipilimumab group, as compared with 2.9&nbsp;months in the ipilimumab group (HR&nbsp;=&nbsp;0.42,
99.5%&nbsp;CI:&nbsp;0.31,&nbsp;0.57; p&nbsp;&lt;&nbsp;0.0001).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText><span lang=EN-GB>PFS results from descriptive analysis (with
minimum follow up of 60&nbsp;months) are shown in Figure&nbsp;2 (all randomised
population), Figure&nbsp;3 (at the tumour PD&#8209;L1&nbsp;5% cut off), and
Figure&nbsp;4 (at the tumour PD&#8209;L1&nbsp;1% cut off). </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Figure&nbsp;2: Progression&#8209;free
survival (CA209067)</span></b></p>

<p class=EMEABodyText align=center style='text-align:center'><span
style='position:absolute;z-index:251685888;left:0px;margin-left:-8px;
margin-top:14px;width:39px;height:255px'><img width=39 height=255
src="OPDIVO-H-3985-IA-099-PI-en_files/image003.png"
alt="Probability of progression free survival&#13;&#10;&#13;&#10;"></span><b><img
border=0 width=519 height=279 id="Picture 62"
src="OPDIVO-H-3985-IA-099-PI-en_files/image004.png"></b></p>

<p class=EMEABodyText align=center style='text-align:center'><span
style='font-size:10.0pt'>Progression-free survival per investigator (months)</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=525
 style='margin-left:36.4pt;border-collapse:collapse'>
 <tr style='height:7.8pt'>
  <td width=525 colspan=13 valign=top style='width:393.7pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Number of subjects at risk</span></p>
  </td>
 </tr>
 <tr style='height:7.8pt'>
  <td width=525 colspan=13 valign=top style='width:393.7pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Nivolumab + ipilimumab</span></p>
  </td>
 </tr>
 <tr style='height:7.8pt'>
  <td width=61 style='width:45.7pt;padding:0in 5.4pt 0in 5.4pt;height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>314</span></p>
  </td>
  <td width=33 style='width:24.55pt;padding:0in 5.4pt 0in 5.4pt;height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>174</span></p>
  </td>
  <td width=37 style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>136</span></p>
  </td>
  <td width=37 style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>124</span></p>
  </td>
  <td width=37 style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>110</span></p>
  </td>
  <td width=37 style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>101</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>95</span></p>
  </td>
  <td width=44 style='width:32.8pt;padding:0in 5.4pt 0in 5.4pt;height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>90</span></p>
  </td>
  <td width=37 style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>82</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>76</span></p>
  </td>
  <td width=37 style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>45</span></p>
  </td>
  <td width=44 valign=top style='width:32.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>2</span></p>
  </td>
  <td width=44 style='width:33.05pt;padding:0in 5.4pt 0in 5.4pt;height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
 </tr>
 <tr style='height:7.8pt'>
  <td width=525 colspan=13 valign=top style='width:393.7pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Nivolumab</span></p>
  </td>
 </tr>
 <tr style='height:7.8pt'>
  <td width=61 valign=top style='width:45.7pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>316</span></p>
  </td>
  <td width=33 valign=top style='width:24.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>151</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>120</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>106</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>97</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>84</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>78</span></p>
  </td>
  <td width=44 valign=top style='width:32.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>73</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>68</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>65</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>40</span></p>
  </td>
  <td width=44 valign=top style='width:32.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>1</span></p>
  </td>
  <td width=44 valign=top style='width:33.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
 </tr>
 <tr style='height:7.8pt'>
  <td width=525 colspan=13 valign=top style='width:393.7pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Ipilimumab</span></p>
  </td>
 </tr>
 <tr style='height:7.8pt'>
  <td width=61 valign=top style='width:45.7pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>315</span></p>
  </td>
  <td width=33 valign=top style='width:24.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>78</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>46</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>34</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>31</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>28</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>21</span></p>
  </td>
  <td width=44 valign=top style='width:32.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>18</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>17</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>15</span></p>
  </td>
  <td width=37 valign=top style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>11</span></p>
  </td>
  <td width=44 valign=top style='width:32.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>1</span></p>
  </td>
  <td width=44 valign=top style='width:33.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.8pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>- - -*- - - -  Nivolumab+ipilimumab (events:
182/314), median and 95%&nbsp;CI: 11.50 (8.74, 19.32).</span></p>

<p class=MsoNormal style='margin-left:.75in;page-break-after:avoid'><span
lang=EN-GB style='font-size:10.0pt'>PFS rate at 12&nbsp;months and 95%&nbsp;CI:
49% (44, 55), PFS rate at 60&nbsp;months and 95%&nbsp;CI: 36% (32, 42)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>&#9472;&#9472;&#8710;&#9472;&#9472;&#9472; Nivolumab
(events: 203/316), median and 95%&nbsp;CI: 6.93 (5.13, 10.18).</span></p>

<p class=MsoNormal style='margin-left:.75in;page-break-after:avoid'><span
lang=EN-GB style='font-size:10.0pt'>PFS rate at 12&nbsp;months and 95%&nbsp;CI:
42% (36, 47), PFS rate at 60&nbsp;months and 95%&nbsp;CI: 29% (24, 35)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:10.0pt'>- - -</span><span
lang=EN-GB style='font-size:10.0pt;font-family:Wingdings'></span><span
lang=EN-GB style='font-size:10.0pt'>- - -  Ipilimumab (events: 261/315),
median and 95%&nbsp;CI: 2.86 (2.79, 3.15).</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:25.65pt'><span
lang=EN-GB style='font-size:10.0pt'>PFS rate at 12&nbsp;months and 95%&nbsp;CI:
18% (14, 23), PFS rate at 60&nbsp;months and 95%&nbsp;CI: 8% (5, 12)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:10.0pt'>Nivolumab+ipilimumab
vs. ipilimumab - hazard ratio and 95%&nbsp;CI: 0.42 (0.35, 0.51)</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:10.0pt'>Nivolumab vs.
ipilimumab - hazard ratio and 95%&nbsp;CI: 0.53 (0.</span><span
style='font-size:10.0pt'>44, 0.64)</span></p>

<p class=EMEABodyText><span style='font-size:10.0pt'>Nivolumab+ipilimumab vs.
nivolumab - </span><span lang=EN-GB style='font-size:10.0pt'>hazard ratio and
95%&nbsp;CI</span><span style='font-size:10.0pt'>: 0.79 (0.64, 0.96)</span></p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><a name="BMS_FGR_Figure5111_KaplanMeierPlotofPr"></a><a
name="Figure5111_KaplanMeierPlotofPr"></a><a name="_Toc437515411">&nbsp;</a></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Figure&nbsp;3: Progression&#8209;free
survival by PD&#8209;L1 expression: 5% cut off (CA209067)</span></b></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'>

<table cellpadding=0 cellspacing=0 align=left>
 <tr>
  <td width=126 height=240></td>
 </tr>
 <tr>
  <td></td>
  <td><img width=5 height=9 src="OPDIVO-H-3985-IA-099-PI-en_files/image005.png"
  alt="Probability of progression-free survival"></td>
 </tr>
</table>

<span style='font-size:8.0pt'>&nbsp;</span></p>

<br clear=ALL>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><span
style='position:absolute;z-index:251687936;left:0px;margin-left:58px;
margin-top:4px;width:42px;height:230px'><img width=42 height=230
src="OPDIVO-H-3985-IA-099-PI-en_files/image006.png"
alt="Probability of progression free survival&#13;&#10;&#13;&#10;"></span><b><span
style='font-size:10.0pt'>PD&#8209;L1 expression &lt;&nbsp;5%</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><img border=0
width=404 height=219 id="Picture 63"
src="OPDIVO-H-3985-IA-099-PI-en_files/image007.png"></b></p>

<p class=EMEABodyText align=center style='text-align:center'><span
style='font-size:8.0pt'>Progression-free survival (months)</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left
 width=420 style='border-collapse:collapse;margin-left:6.75pt;margin-right:
 6.75pt'>
 <tr style='height:5.65pt'>
  <td width=420 colspan=13 valign=top style='width:315.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Number of subjects at risk</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=420 colspan=13 valign=top style='width:315.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Nivolumab + ipilimumab</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>210</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>113</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>87</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>78</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>71</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>64</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>59</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>55</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>52</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>49</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>33</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>2</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=420 colspan=13 valign=top style='width:315.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Nivolumab</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>208</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>91</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>73</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>66</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>60</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>50</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>48</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>45</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>40</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>38</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>23</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>1</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=420 colspan=13 valign=top style='width:315.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Ipilimumab</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>202</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>45</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>26</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>19</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>18</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>16</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>14</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>13</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>12</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>10</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>6</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt;background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in'><span lang=EN-GB style='font-size:
9.0pt'>- - -*- - - - </span><span lang=EN-GB style='font-size:
9.0pt'>Nivolumab+ipilimumab (events: 123/210), median and 95%&nbsp;CI: 11.17
(7.98, 17.51)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'> &#9472;&#9472;&#8710;&#9472;&#9472;&#9472;
 Nivolumab (events: 136/208), median and 95%&nbsp;CI: 5.39 (2.96,
7.13)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'> - -
-</span><span lang=EN-GB style='font-size:9.0pt;font-family:Wingdings'></span><span
lang=EN-GB style='font-size:9.0pt'>- - -  Ipilimumab (events:
171/202), median and 95%&nbsp;CI: 2.83 (2.76, 3.02)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'> Nivolumab+ipilimumab
vs. ipilimumab - hazard ratio and 95%&nbsp;CI: 0.42 (0.33, 0.53)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'> Nivolumab
vs. ipilimumab - hazard ratio and 95%&nbsp;CI: 0.54 (0.43, 0.68)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'> Nivolumab+ipilimumab
vs. nivolumab - hazard ratio and 95%&nbsp;CI: 0.77 (0.60, 0.98)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><span
style='position:absolute;z-index:251689984;left:0px;margin-left:57px;
margin-top:4px;width:43px;height:248px'><img width=43 height=248
src="OPDIVO-H-3985-IA-099-PI-en_files/image008.png"
alt="Probability of progression free survival&#13;&#10;&#13;&#10;"></span><b><span
style='font-size:10.0pt'>PD-L1 expression &#8805;&nbsp;5%</span></b></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><b><img
border=0 width=392 height=218 id="Picture 64"
src="OPDIVO-H-3985-IA-099-PI-en_files/image009.png"></b></p>

<p class=EMEABodyText align=center style='text-align:center'><span
style='font-size:8.0pt'>Progression-free survival (months)</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left
 width=408 style='border-collapse:collapse;margin-left:6.75pt;margin-right:
 6.75pt'>
 <tr style='height:5.65pt'>
  <td width=408 colspan=13 valign=top style='width:4.25in;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Number of subjects at risk</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=408 colspan=13 valign=top style='width:4.25in;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Nivolumab + ipilimumab</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=42 valign=top style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>68</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>44</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>35</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>33</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>28</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>27</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>26</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>25</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>22</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>19</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>7</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=408 colspan=13 valign=top style='width:4.25in;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Nivolumab</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=42 style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>80</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>52</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>41</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>36</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>33</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>30</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>27</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>25</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>25</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>24</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>15</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=408 colspan=13 valign=top style='width:4.25in;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Ipilimumab</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=42 valign=top style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>75</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>21</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>14</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>10</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>10</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>9</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>5</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>5</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>5</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>5</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>5</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>1</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:9.0pt'>- - -*- - - - </span><span
lang=EN-GB style='font-size:9.0pt'>Nivolumab+ipilimumab (events: 36/68), median
and 95%&nbsp;CI: 22.11 (9.72, N.A.)</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:9.0pt'>&#9472;&#9472;&#8710;&#9472;&#9472;&#9472;  Nivolumab
(events: 46/80), median and 95%&nbsp;CI: 22.34 (9.46, 40.02)</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:9.0pt'>- - -</span><span lang=EN-GB
style='font-size:9.0pt;font-family:Wingdings'></span><span lang=EN-GB
style='font-size:9.0pt'>- - -  Ipilimumab (events: 60/75), median
and 95%&nbsp;CI: 3.94 (2.79, 4.21)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>  Nivolumab+ipilimumab
vs. ipilimumab - hazard ratio and 95%&nbsp;CI: 0.37 (0.24, 0.56)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>  Nivolumab
vs. ipilimumab - hazard ratio and 95%&nbsp;CI: 0.42 (0.28, 0.62)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>  Nivolumab+ipilimumab
vs. nivolumab - hazard ratio and 95%&nbsp;CI: 0.89 (0.57, 1.37)</span></p>

<span lang=EN-GB style='font-size:10.0pt;font-family:"Times New Roman",serif;
background:yellow'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt;color:black;background:yellow'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Figure&nbsp;4: Progression&#8209;free
survival by PD&#8209;L1 expression: 1% cut off (CA209067) </span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB style='font-size:8.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><span
style='position:absolute;z-index:251692032;left:0px;margin-left:42px;
margin-top:16px;width:36px;height:145px'><img width=36 height=145
src="OPDIVO-H-3985-IA-099-PI-en_files/image010.png"
alt="Probability of progression free survival"></span><b><span
style='font-size:10.0pt'>PD&#8209;L1 expression &lt;&nbsp;1%</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:10.0pt'><img border=0 width=431 height=226 id="Picture 65"
src="OPDIVO-H-3985-IA-099-PI-en_files/image011.png"></span></p>

<p class=EMEABodyText align=center style='text-align:center'><span lang=ES
style='font-size:9.0pt'> </span><span style='font-size:8.0pt'>Progression-free
survival (months)</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left
 width=444 style='border-collapse:collapse;margin-left:6.75pt;margin-right:
 6.75pt'>
 <tr style='height:5.65pt'>
  <td width=444 colspan=13 valign=top style='width:333.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Number of subjects at risk</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=444 colspan=13 valign=top style='width:333.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Nivolumab + ipilimumab</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=42 valign=top style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>123</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>65</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>51</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>46</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>41</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>38</span></p>
  </td>
  <td width=34 valign=top style='width:25.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>36</span></p>
  </td>
  <td width=32 valign=top style='width:23.95pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>33</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>30</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>28</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>21</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>1</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=444 colspan=13 valign=top style='width:333.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Nivolumab</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=42 style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>117</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>44</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>35</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>33</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>30</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>25</span></p>
  </td>
  <td width=34 style='width:25.55pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>23</span></p>
  </td>
  <td width=32 valign=top style='width:23.95pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>20</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>17</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>15</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>8</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=444 colspan=13 valign=top style='width:333.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Ipilimumab</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=42 valign=top style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>113</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>20</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>12</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>9</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>9</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>7</span></p>
  </td>
  <td width=34 valign=top style='width:25.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>5</span></p>
  </td>
  <td width=32 valign=top style='width:23.95pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>5</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>4</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>3</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>3</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=ES style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=ES style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=ES style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=ES style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:9.0pt'>- - -*- - - - Nivolumab+ipilimumab
(events: 73/123), median and 95%&nbsp;CI: 11.17 (6.93, 22.18)</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:9.0pt'>&#9472;&#9472;&#8710;&#9472;&#9472;&#9472;  Nivolumab
(events: 82/117), median and 95%&nbsp;CI: 2.83 (2.76, 5.62)</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:9.0pt'>- - -</span><span lang=EN-GB
style='font-size:9.0pt;font-family:Wingdings'></span><span lang=EN-GB
style='font-size:9.0pt'>- - -  Ipilimumab (events: 94/113),
median and 95%&nbsp;CI: 2.76 (2.66, 2.86)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:4.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>  Nivolumab+ipilimumab
vs. ipilimumab - hazard ratio</span><span lang=EN-GB style='font-size:9.0pt'>
and 95%&nbsp;CI</span><span lang=EN-GB style='font-size:9.0pt'>: 0.39 (0.29,
0.54)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>  Nivolumab
vs. ipilimumab - hazard ratio</span><span lang=EN-GB style='font-size:9.0pt'>
and 95%&nbsp;CI</span><span lang=EN-GB style='font-size:9.0pt'>: 0.59 (0.44,
0.80)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:9.0pt'>  Nivolumab+ipilimumab
vs. nivolumab - hazard ratio</span><span lang=EN-GB style='font-size:9.0pt'>
and 95%&nbsp;CI</span><span lang=EN-GB style='font-size:9.0pt'>: 0.66 (0.48,
0.91)</span></p>

<p class=MsoNormal><span lang=ES style='font-size:9.0pt'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><span style='position:relative;z-index:251694080'><span
style='left:0px;position:absolute;left:45px;top:-320px;width:37px;height:1px'><img
width=37 height=1 src="OPDIVO-H-3985-IA-099-PI-en_files/image012.png"
alt="Probability of progression free survival"></span></span><b><span lang=FR
style='font-size:10.0pt'>PD-L1 expression &#8805;&nbsp;1%</span></b></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><b><span
style='font-size:10.0pt'><img border=0 width=419 height=224 id="Picture 66"
src="OPDIVO-H-3985-IA-099-PI-en_files/image013.png"></span></b></p>

<p class=EMEABodyText align=center style='text-align:center'><span
style='font-size:8.0pt'>Progression-free survival (months)</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left
 width=420 style='border-collapse:collapse;margin-left:6.75pt;margin-right:
 6.75pt'>
 <tr style='height:5.65pt'>
  <td width=420 colspan=13 valign=top style='width:315.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Number of subjects at risk</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=420 colspan=13 valign=top style='width:315.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Nivolumab + ipilimumab</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=42 valign=top style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>155</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>92</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>71</span></p>
  </td>
  <td width=35 valign=top style='width:26.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>65</span></p>
  </td>
  <td width=31 valign=top style='width:23.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>58</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>53</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>49</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>47</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>44</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>40</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>19</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>1</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=420 colspan=13 valign=top style='width:315.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Nivolumab</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=42 style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>171</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>99</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>79</span></p>
  </td>
  <td width=35 style='width:26.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>69</span></p>
  </td>
  <td width=31 style='width:23.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>63</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>55</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>52</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>50</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>48</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>47</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>30</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>1</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=420 colspan=13 valign=top style='width:315.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:9.0pt'>Ipilimumab</span></p>
  </td>
 </tr>
 <tr style='height:5.65pt'>
  <td width=42 valign=top style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>164</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>46</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>28</span></p>
  </td>
  <td width=35 valign=top style='width:26.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>20</span></p>
  </td>
  <td width=31 valign=top style='width:23.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>19</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>18</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>14</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>13</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>13</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>12</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>8</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>1</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.65pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:9.0pt'>0</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'> - - -*- - -  </span><span
lang=EN-GB style='font-size:9.0pt'>Nivolumab+ipilimumab (events: 86/155),
median and 95%&nbsp;CI: 16.13 (8.90, 39.06)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'> &#9472;&#9472;&#8710;&#9472;&#9472;&#9472;
 Nivolumab (events: 100/171), median and 95%&nbsp;CI: 16.20 (8.11,
27.66)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'> - - -</span><span lang=EN-GB
style='font-size:9.0pt;font-family:Wingdings'></span><span lang=EN-GB
style='font-size:9.0pt'>- - -  Ipilimumab (events: 137/164),
median and 95%&nbsp;CI: 3.</span><span style='font-size:9.0pt'>48 (2.83, 4.17)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='font-size:9.0pt'> </span><span
lang=EN-GB style='font-size:9.0pt'>Nivolumab+ipilimumab vs. ipilimumab - hazard
ratio and 95%&nbsp;CI: 0.41 (0.31, 0.54)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'> Nivolumab
vs. ipilimumab - hazard ratio and 95%&nbsp;CI: 0.45 (0.35, 0.58)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt'> Nivolumab+ipilimumab
vs. nivolumab - hazard ratio and 95%&nbsp;CI: 0.91 (0.68, 1.22)</span></p>

<span lang=EN-GB style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='page-break-after:avoid'><span lang=ES
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>The
final (primary) OS analysis occurred when all patients had a minimum follow&#8209;up
of 28&nbsp;months. At 28&nbsp;months, </span><span lang=EN-GB style='font-size:
11.0pt;color:windowtext'>median OS was not reached in the nivolumab group as
compared with 19.98&nbsp;months in the ipilimumab group (HR&nbsp;=&nbsp;0.63,
98%&nbsp;CI:&nbsp;0.48,&nbsp;0.81; p-value:&nbsp;&lt;&nbsp;0.0001). Median OS
was not reached in the nivolumab in combination with ipilimumab group as
compared with the ipilimumab group (HR&nbsp;=&nbsp;0.55, 98%&nbsp;CI:&nbsp;0.42,&nbsp;0.72;
p-value:&nbsp;&lt;&nbsp;0.0001).</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>OS
results at an additional descriptive analysis undertaken at a minimum follow&#8209;up
of 60&nbsp;months show outcomes consistent with the original primary analysis.
OS results from this follow&#8209;up analysis are shown in Figure&nbsp;5 (all
randomised), Figure&nbsp;6 and&nbsp;7 (at the tumour PD&#8209;L1&nbsp;5% and 1%
cut off).</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>The
OS analysis was not adjusted to account for subsequent therapies received.
Subsequent systemic therapy was received by 34.7%, 48.1%, and 65.7% of patients
in the combination, nivolumab monotherapy, and ipilimumab arms, respectively.
Subsequent immunotherapy (including anti-PD1 therapy, anti-CTLA-4 antibody, or
other immunotherapy) was received by 17.5%, 33.2%, and 47.3% of patients in the
combination, nivolumab monotherapy, and ipilimumab arms, respectively.</span></p>

<p class=BMSBodyText style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span style='position:
relative;z-index:251714560'><span style='position:absolute;left:-45px;
top:-1085px;width:45px;height:1px'><img width=45 height=1
src="OPDIVO-H-3985-IA-099-PI-en_files/image014.png"></span></span><b><span
lang=EN-GB>Figure&nbsp;5: Overall survival (CA209067) &#8209; Minimum
follow&#8209;up of 60</span></b><span lang=EN-GB>&nbsp;</span><b><span
lang=EN-GB>months</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><span style='font-size:
8.0pt'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center'><span
style='position:relative;z-index:251683840'><span style='left:0px;position:
absolute;left:15px;top:-1116px;width:45px;height:1px'><img width=45 height=1
src="OPDIVO-H-3985-IA-099-PI-en_files/image014.png"
alt="Probability of overall survival&#13;&#10;&#13;&#10;"></span></span><b><span
lang=EN-GB></span></b><b><img border=0 width=487 height=264 id="Picture 67"
src="OPDIVO-H-3985-IA-099-PI-en_files/image015.png"></b></p>

<p class=EMEABodyText align=center style='text-align:center'><span
style='font-size:8.0pt'>Overall survival (months)</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left
 width="83%" style='border-collapse:collapse;margin-left:6.75pt;margin-right:
 6.75pt'>
 <tr style='height:12.75pt'>
  <td width=504 colspan=13 style='width:5.25in;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:8.0pt'>Number of subjects at risk</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=504 colspan=13 style='width:5.25in;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:8.0pt'>Nivolumab+ipilimumab</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=48 style='width:.5in;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>314</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>265</span></p>
  </td>
  <td width=42 style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>227</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>210</span></p>
  </td>
  <td width=42 style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>199</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>187</span></p>
  </td>
  <td width=42 style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>179</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>169</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>163</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>157</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>150</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>14</span></p>
  </td>
  <td width=42 valign=top style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=504 colspan=13 style='width:5.25in;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:8.0pt'>Nivolumab</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=48 style='width:.5in;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>316</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>266</span></p>
  </td>
  <td width=42 style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>231</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>201</span></p>
  </td>
  <td width=42 style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>181</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>171</span></p>
  </td>
  <td width=42 style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>158</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>145</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>141</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>137</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>130</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>14</span></p>
  </td>
  <td width=42 style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=504 colspan=13 style='width:5.25in;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:8.0pt'>Ipilimumab</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=48 style='width:.5in;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>315</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>253</span></p>
  </td>
  <td width=42 style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>203</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>163</span></p>
  </td>
  <td width=42 style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>135</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>113</span></p>
  </td>
  <td width=42 style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>100</span></p>
  </td>
  <td width=36 style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>94</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>87</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>81</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>73</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>12</span></p>
  </td>
  <td width=42 valign=top style='width:31.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:3.0pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:8.0pt'>- - -*- - - - Nivolumab+ipilimumab
(events: 152/314), median and 95%&nbsp;CI: N.A. (38.18, N.A.)</span></p>

<p class=MsoNormal style='margin-left:84.85pt;text-indent:.2pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:8.0pt'>OS rate and 95%&nbsp;CI at
12&nbsp;months: 73% (68, 78), 24&nbsp;months: 64% (59, 69), 36&nbsp;months: 58%
(52, 63), and 60&nbsp;months: 52% (46, 57)</span></p>

<p class=MsoNormal style='margin-left:84.85pt;text-indent:-56.5pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:8.0pt'>&#9472;&#9472;&#8710;&#9472;&#9472;&#9472; Nivolumab
(events: 176/316), median and 95%&nbsp;CI: 36.93&nbsp;months (28.25, 58.71) </span></p>

<p class=MsoNormal style='margin-left:84.85pt;text-indent:.2pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:8.0pt'>OS rate and 95%&nbsp;CI at
12&nbsp;months: 74% (69, 79), 24&nbsp;months: 59% (53, 64), 36&nbsp;months: 52%
(46, 57), and 60&nbsp;months: 44% (39, 50)</span></p>

<p class=EMEABodyText style='text-indent:28.35pt'><span lang=EN-GB
style='font-size:8.0pt'>- - -</span><span lang=EN-GB style='font-size:8.0pt;
font-family:Wingdings'></span><span lang=EN-GB style='font-size:8.0pt'>- - -  Ipilimumab
(events: 230/315), median and 95%&nbsp;CI: 19.94&nbsp;months (16.85, 24.61)</span></p>

<p class=EMEABodyText style='margin-left:85.05pt'><span lang=EN-GB
style='font-size:8.0pt'>OS rate and 95%&nbsp;CI at 12&nbsp;months: 67% (61,
72), 24&nbsp;months: 45% (39, 50), 36&nbsp;months: 34% (29, 39), and
60&nbsp;months: 26% (22, 31)</span></p>

<p class=EMEABodyText style='text-indent:28.35pt'><span lang=EN-GB
style='font-size:8.0pt'>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:85.05pt'><span lang=FR
style='font-size:8.0pt'>Nivolumab+ipilimumab vs ipilimumab - HR (95%&nbsp;CI):
0.63 (0.52, 0.76) </span></p>

<p class=EMEABodyText style='margin-left:85.05pt'><span lang=FR
style='font-size:8.0pt'>Nivolumab vs ipilimumab - HR (95%&nbsp;CI): 0.52 (0.42,
0.64)</span></p>

<p class=EMEABodyText style='margin-left:49.05pt;text-indent:.5in'><span
lang=FR-BE style='font-size:8.0pt'>Nivolumab+ipilimumab vs nivolumab - HR
(95%&nbsp;CI): 0.83 (0.67, 1.03)</span></p>

<span lang=FR-BE style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=FR-BE style='font-size:10.0pt'>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:67.5pt;text-indent:-71.55pt'><b><span
lang=EN-GB>Figure 6:</span></b><b><span lang=EN-GB style='font-size:10.0pt'> </span><span
lang=EN-GB>Overall survival by PD-L1 expression: 5% cut off (CA209067) -
Minimum follow&#8209;up of 60&nbsp;months</span></b></p>

<p class=EMEABodyText style='margin-left:2.2in;text-indent:11.7pt;page-break-after:
avoid'><b><span lang=EN-GB style='font-size:10.0pt'>PD-L1 expression &lt;&nbsp;5%</span></b></p>

<p class=MsoNormal align=center style='margin-left:21.15pt;text-align:center;
punctuation-wrap:simple;text-autospace:none'><span style='position:relative;
z-index:251696128'><span style='left:0px;position:absolute;left:147px;
top:-1711px;width:30px;height:1px'><img width=30 height=1
src="OPDIVO-H-3985-IA-099-PI-en_files/image016.png"
alt="Probability of overall survival&#13;&#10;&#13;&#10;"></span></span><span
style='font-size:10.0pt'><img border=0 width=437 height=236 id="Picture 68"
src="OPDIVO-H-3985-IA-099-PI-en_files/image017.png"></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left
 width="72%" style='border-collapse:collapse;margin-left:6.75pt;margin-right:
 6.75pt'>
 <tr style='height:12.75pt'>
  <td width=438 colspan=13 style='width:328.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:8.0pt'>Number of subjects at risk</span></p>
  </td>
 </tr>
 <tr style='height:7.95pt'>
  <td width=438 colspan=13 style='width:328.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.95pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:8.0pt'>Nivolumab+ipilimumab</span></p>
  </td>
 </tr>
 <tr style='height:2.9pt'>
  <td width=38 style='width:28.3pt;padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>210</span></p>
  </td>
  <td width=28 style='width:21.3pt;padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>178</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>146</span></p>
  </td>
  <td width=34 style='width:25.55pt;padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>139</span></p>
  </td>
  <td width=32 style='width:24.05pt;padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>130</span></p>
  </td>
  <td width=34 style='width:25.45pt;padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>123</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>116</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>109</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>106</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>103</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>101</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>9</span></p>
  </td>
  <td width=36 valign=top style='width:26.95pt;padding:0in 5.4pt 0in 5.4pt;
  height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
 </tr>
 <tr style='height:6.85pt'>
  <td width=438 colspan=13 style='width:328.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:8.0pt'>Nivolumab</span></p>
  </td>
 </tr>
 <tr style='height:7.1pt'>
  <td width=38 style='width:28.3pt;padding:0in 5.4pt 0in 5.4pt;height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>208</span></p>
  </td>
  <td width=28 style='width:21.3pt;padding:0in 5.4pt 0in 5.4pt;height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>169</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>144</span></p>
  </td>
  <td width=34 style='width:25.55pt;padding:0in 5.4pt 0in 5.4pt;height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>123</span></p>
  </td>
  <td width=32 style='width:24.05pt;padding:0in 5.4pt 0in 5.4pt;height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>112</span></p>
  </td>
  <td width=34 style='width:25.45pt;padding:0in 5.4pt 0in 5.4pt;height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>108</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>102</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>92</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>90</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>88</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>82</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>9</span></p>
  </td>
  <td width=36 valign=top style='width:26.95pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
 </tr>
 <tr style='height:7.95pt'>
  <td width=438 colspan=13 style='width:328.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.95pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:8.0pt'>Ipilimumab</span></p>
  </td>
 </tr>
 <tr style='height:5.35pt'>
  <td width=38 style='width:28.3pt;padding:0in 5.4pt 0in 5.4pt;height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>202</span></p>
  </td>
  <td width=28 style='width:21.3pt;padding:0in 5.4pt 0in 5.4pt;height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>158</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>124</span></p>
  </td>
  <td width=34 style='width:25.55pt;padding:0in 5.4pt 0in 5.4pt;height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>99</span></p>
  </td>
  <td width=32 style='width:24.05pt;padding:0in 5.4pt 0in 5.4pt;height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>80</span></p>
  </td>
  <td width=34 style='width:25.45pt;padding:0in 5.4pt 0in 5.4pt;height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>69</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>59</span></p>
  </td>
  <td width=30 style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>57</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>55</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>50</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>45</span></p>
  </td>
  <td width=36 valign=top style='width:27.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>5</span></p>
  </td>
  <td width=36 valign=top style='width:26.95pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
 </tr>
</table>

<p class=BMSBodyText align=center style='margin-bottom:0in;text-align:center'><span
lang=EN-GB style='font-size:8.0pt;line-height:110%'>Overall survival (months)</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:7.0pt'>- - -*- - - - </span><span lang=EN-GB
style='font-size:8.0pt'>Nivolumab+ipilimumab (events: 103/210), median and
95%&nbsp;CI: N.A. (32.72, N.A.)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'> &#9472;&#9472;&#8710;&#9472;&#9472;&#9472;
 Nivolumab (events: 117/208), median and 95%&nbsp;CI: 35.94&nbsp;months (23.06,
59.24.)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'> - - -</span><span lang=EN-GB
style='font-size:8.0pt;font-family:Wingdings'></span><span lang=EN-GB
style='font-size:8.0pt'>- - -  Ipilimumab (events: 154/202), median and
95%&nbsp;CI: 18.40&nbsp;months (13.70, 22.51)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'> </span><span
lang=FR style='font-size:8.0pt'>Nivolumab+ipilimumab vs. ipilimumab - HR
(95%&nbsp;CI): 0.50 (0.39, 0.65)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=FR
style='font-size:8.0pt'> Nivolumab
vs. ipilimumab - HR (95%&nbsp;CI): 0.62 (0.49, 0.79)</span></p>

<p class=EMEABodyText style='margin-left:79.65pt;text-indent:28.35pt;
page-break-after:avoid'><span lang=ES style='font-size:8.0pt'>Nivolumab+ipilimumab
vs. nivolumab - </span><span lang=FR style='font-size:8.0pt'>HR (95%&nbsp;CI)</span><span
lang=ES style='font-size:8.0pt'>: 0.81 (0.62, 1.06)</span></p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><b><span lang=FR style='font-size:10.0pt'>&nbsp;</span></b></p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><span style='position:relative;z-index:251698176'><span
style='left:0px;position:absolute;left:142px;top:-2161px;width:30px;height:
1px'><img width=30 height=1 src="OPDIVO-H-3985-IA-099-PI-en_files/image016.png"
alt="Probability of overall survival&#13;&#10;&#13;&#10;"></span></span><b><span
lang=EN-GB style='font-size:10.0pt'>PD-L1 expression &#8805;&nbsp;5%</span></b></p>

<p class=BMSBodyText align=center style='margin-bottom:0in;text-align:center'><span
style='font-size:11.0pt;line-height:110%'><img border=0 width=437 height=239
id="Picture 69" src="OPDIVO-H-3985-IA-099-PI-en_files/image018.png"></span></p>

<p class=BMSBodyText align=center style='margin-bottom:0in;text-align:center'><span
lang=EN-GB style='font-size:8.0pt;line-height:110%'>Overall survival (months)</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 align=left
 width="73%" style='border-collapse:collapse;margin-left:6.75pt;margin-right:
 6.75pt'>
 <tr style='height:12.75pt'>
  <td width=444 colspan=13 style='width:333.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:8.0pt'>Number of subjects at risk</span></p>
  </td>
 </tr>
 <tr style='height:7.95pt'>
  <td width=444 colspan=13 style='width:333.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.95pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:8.0pt'>Nivolumab+ipilimumab</span></p>
  </td>
 </tr>
 <tr style='height:2.9pt'>
  <td width=38 style='width:28.25pt;padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>68</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>56</span></p>
  </td>
  <td width=28 style='width:21.3pt;padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>52</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>45</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>45</span></p>
  </td>
  <td width=28 style='width:21.25pt;padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>43</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>43</span></p>
  </td>
  <td width=28 valign=top style='width:21.25pt;padding:0in 5.4pt 0in 5.4pt;
  height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>41</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>40</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>37</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>33</span></p>
  </td>
  <td width=28 valign=top style='width:21.25pt;padding:0in 5.4pt 0in 5.4pt;
  height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>2</span></p>
  </td>
  <td width=28 valign=top style='width:21.25pt;padding:0in 5.4pt 0in 5.4pt;
  height:2.9pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
 </tr>
 <tr style='height:6.85pt'>
  <td width=444 colspan=13 style='width:333.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:6.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:8.0pt'>Nivolumab</span></p>
  </td>
 </tr>
 <tr style='height:7.1pt'>
  <td width=38 style='width:28.25pt;padding:0in 5.4pt 0in 5.4pt;height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>80</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>76</span></p>
  </td>
  <td width=28 style='width:21.3pt;padding:0in 5.4pt 0in 5.4pt;height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>69</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>61</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>57</span></p>
  </td>
  <td width=28 style='width:21.25pt;padding:0in 5.4pt 0in 5.4pt;height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>53</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>47</span></p>
  </td>
  <td width=28 style='width:21.25pt;padding:0in 5.4pt 0in 5.4pt;height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>44</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>43</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>41</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>41</span></p>
  </td>
  <td width=28 valign=top style='width:21.25pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>5</span></p>
  </td>
  <td width=28 valign=top style='width:21.25pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.1pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
 </tr>
 <tr style='height:7.95pt'>
  <td width=444 colspan=13 style='width:333.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.95pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:8.0pt'>Ipilimumab</span></p>
  </td>
 </tr>
 <tr style='height:5.35pt'>
  <td width=38 style='width:28.25pt;padding:0in 5.4pt 0in 5.4pt;height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>75</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>66</span></p>
  </td>
  <td width=28 style='width:21.3pt;padding:0in 5.4pt 0in 5.4pt;height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>60</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>46</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>40</span></p>
  </td>
  <td width=28 style='width:21.25pt;padding:0in 5.4pt 0in 5.4pt;height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>34</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>32</span></p>
  </td>
  <td width=28 style='width:21.25pt;padding:0in 5.4pt 0in 5.4pt;height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>29</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>25</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>24</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>22</span></p>
  </td>
  <td width=28 valign=top style='width:21.25pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>5</span></p>
  </td>
  <td width=28 valign=top style='width:21.25pt;padding:0in 5.4pt 0in 5.4pt;
  height:5.35pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.1in;
  margin-bottom:0in;margin-left:-.1in;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-indent:.5in;page-break-after:avoid'><span
lang=EN-GB style='font-size:7.0pt'>- - -*- - - - </span><span lang=EN-GB
style='font-size:8.0pt'>Nivolumab+ipilimumab (events: 30/68), median and
95%&nbsp;CI: N.A. (39.06, N.A.)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'> &#9472;&#9472;&#8710;&#9472;&#9472;&#9472;
 Nivolumab (events: 41/80), median and 95%&nbsp;CI: 61.57&nbsp;months (33.64,
N.A.)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'> - - -</span><span lang=EN-GB
style='font-size:8.0pt;font-family:Wingdings'></span><span lang=EN-GB
style='font-size:8.0pt'>- - -  Ipilimumab (events: 50/75), median and
95%&nbsp;CI: 28.88&nbsp;months (18.10, 44.16)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'> </span><span
lang=FR style='font-size:8.0pt'>Nivolumab+ipilimumab vs. ipilimumab - HR
(95%&nbsp;CI): 0.58 (0.37, 0.91)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=FR
style='font-size:8.0pt'> Nivolumab
vs. ipilimumab - HR (95%&nbsp;CI): 0.63 (0.42, 0.96)</span></p>

<p class=EMEABodyText style='margin-left:79.65pt;text-indent:28.35pt;
page-break-after:avoid'><span lang=ES style='font-size:8.0pt'>Nivolumab+ipilimumab
vs. nivolumab - </span><span lang=FR style='font-size:8.0pt'>HR (95%&nbsp;CI)</span><span
lang=ES style='font-size:8.0pt'>: 0.91 (0.657, 1.46)</span></p>

<span lang=ES style='font-size:8.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABodyText style='text-align:justify;page-break-after:avoid'><span
lang=ES style='font-size:8.0pt'>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:63.0pt;text-indent:-63.0pt;page-break-after:
avoid'><b><span lang=EN-GB>Figure&nbsp;7: Overall survival by PD&#8209;L1
expression: 1% cut off (CA209067) &#8209; Minimum follow&#8209;up of 60&nbsp;months</span></b></p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><b><span lang=EN-GB style='font-size:10.0pt'>PD-L1 expression &lt;&nbsp;1%</span></b></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><span
style='position:relative;z-index:251702272'><span style='left:0px;position:
absolute;left:115px;top:-2711px;width:30px;height:1px'><img width=30 height=1
src="OPDIVO-H-3985-IA-099-PI-en_files/image016.png"
alt="Probability of overall survival&#13;&#10;&#13;&#10;"></span></span><b><span
style='font-size:10.0pt'><img border=0 width=484 height=226 id="Picture 70"
src="OPDIVO-H-3985-IA-099-PI-en_files/image019.png"></span></b></p>

<p class=EMEABodyText align=center style='text-align:center'><span
style='font-size:8.0pt'>Overall survival (months)</span></p>

<table class=MsoTableGrid border=0 cellspacing=0 cellpadding=0
 style='margin-left:53.45pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=481 colspan=13 valign=top style='width:360.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span style='font-size:8.0pt'>Number of subjects at
  risk</span></p>
  </td>
 </tr>
 <tr>
  <td width=481 colspan=13 valign=top style='width:360.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=EN-GB style='font-size:8.0pt'>Nivolumab+ipilimumab</span></p>
  </td>
 </tr>
 <tr>
  <td width=47 style='width:35.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>123</span></p>
  </td>
  <td width=32 style='width:23.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>102</span></p>
  </td>
  <td width=35 style='width:25.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>82</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>79</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>74</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>70</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>65</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>63</span></p>
  </td>
  <td width=34 valign=top style='width:25.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>62</span></p>
  </td>
  <td width=41 valign=top style='width:30.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>61</span></p>
  </td>
  <td width=38 valign=top style='width:28.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>59</span></p>
  </td>
  <td width=35 valign=top style='width:26.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>6</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
 </tr>
 <tr>
  <td width=481 colspan=13 valign=top style='width:360.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=EN-GB style='font-size:8.0pt'>Nivolumab</span></p>
  </td>
 </tr>
 <tr>
  <td width=47 style='width:35.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>117</span></p>
  </td>
  <td width=32 style='width:23.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>86</span></p>
  </td>
  <td width=35 style='width:25.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>73</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>62</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>57</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>53</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>49</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>43</span></p>
  </td>
  <td width=34 valign=top style='width:25.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>43</span></p>
  </td>
  <td width=41 valign=top style='width:30.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>42</span></p>
  </td>
  <td width=38 valign=top style='width:28.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>41</span></p>
  </td>
  <td width=35 valign=top style='width:26.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>5</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
 </tr>
 <tr style='height:6.9pt'>
  <td width=481 colspan=13 valign=top style='width:360.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:6.9pt'>
  <p class=EMEABodyText><span lang=EN-GB style='font-size:8.0pt'>Ipilimumab</span></p>
  </td>
 </tr>
 <tr>
  <td width=47 style='width:35.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>113</span></p>
  </td>
  <td width=32 style='width:23.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>87</span></p>
  </td>
  <td width=35 style='width:25.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>71</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>57</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>44</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>36</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>33</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>32</span></p>
  </td>
  <td width=34 valign=top style='width:25.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>31</span></p>
  </td>
  <td width=41 valign=top style='width:30.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>28</span></p>
  </td>
  <td width=38 valign=top style='width:28.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>27</span></p>
  </td>
  <td width=35 valign=top style='width:26.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>3</span></p>
  </td>
  <td width=30 valign=top style='width:22.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:6.0pt'> -
- -*- - - - </span><span lang=EN-GB style='font-size:8.0pt'>Nivolumab+ipilimumab
(events:&nbsp;62/123), median and 95%&nbsp;CI: 61.44 (26.45, N.A.)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt'> &#9472;&#9472;&#8710;&#9472;&#9472;&#9472;
 Nivolumab (events:&nbsp;74/117), median and 95%&nbsp;CI: 23.46&nbsp;months
(13.01, 36.53)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt'> - -
-</span><span lang=EN-GB style='font-size:8.0pt;font-family:Wingdings'></span><span
lang=EN-GB style='font-size:8.0pt'>- - -  Ipilimumab (events:&nbsp;86/113),
median and 95%&nbsp;CI: 18.56&nbsp;months (13.67, 23.20)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt'> </span><span
lang=FR style='font-size:8.0pt'>Nivolumab+ipilimumab vs. ipilimumab - HR
(95%&nbsp;CI): 0.53 (0.38, 0.74)</span></p>

<p class=MsoNormal><span lang=FR style='font-size:8.0pt'> Nivolumab
vs. ipilimumab - HR (95%&nbsp;CI): 0.77 (0.56, 1.05)</span></p>

<p class=MsoNormal><span lang=FR style='font-size:8.0pt'> Nivolumab+ipilimumab
vs. nivolumab - HR (95%&nbsp;CI): 0.69 (0.50, 0.97)</span></p>

<p class=EMEABodyText><span lang=FR style='font-size:7.0pt'>&nbsp;</span></p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><span style='position:relative;z-index:251700224'><span
style='left:0px;position:absolute;left:106px;top:-3144px;width:39px;height:
1px'><img width=39 height=1 src="OPDIVO-H-3985-IA-099-PI-en_files/image020.png"
alt="Probability of overall survival&#13;&#10;&#13;&#10;&#13;&#10;"></span></span><b><span
lang=EN-GB style='font-size:10.0pt'>PD-L1 expression &#8805;&nbsp;1%</span></b></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><b><span
style='font-size:10.0pt'><img border=0 width=492 height=260 id="Picture 71"
src="OPDIVO-H-3985-IA-099-PI-en_files/image021.png"></span></b></p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><span style='font-size:8.0pt'>Overall survival (months)</span></p>

<table class=MsoTableGrid border=0 cellspacing=0 cellpadding=0 align=left
 width=492 style='border-collapse:collapse;border:none;margin-left:6.75pt;
 margin-right:6.75pt'>
 <tr>
  <td width=492 colspan=13 valign=top style='width:369.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span style='font-size:8.0pt'>Number of subjects at
  risk</span></p>
  </td>
 </tr>
 <tr>
  <td width=492 colspan=13 valign=top style='width:369.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=EN-GB style='font-size:8.0pt'>Nivolumab+ipilimumab</span></p>
  </td>
 </tr>
 <tr>
  <td width=37 style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>155</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>132</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>116</span></p>
  </td>
  <td width=47 style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>105</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>101</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>96</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>94</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>87</span></p>
  </td>
  <td width=38 valign=top style='width:28.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>84</span></p>
  </td>
  <td width=38 valign=top style='width:28.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>79</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>75</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>5</span></p>
  </td>
  <td width=29 valign=top style='width:21.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
 </tr>
 <tr>
  <td width=492 colspan=13 valign=top style='width:369.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=EN-GB style='font-size:8.0pt'>Nivolumab</span></p>
  </td>
 </tr>
 <tr>
  <td width=37 style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>171</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>159</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>140</span></p>
  </td>
  <td width=47 style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>122</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>112</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>108</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>100</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>93</span></p>
  </td>
  <td width=38 valign=top style='width:28.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>90</span></p>
  </td>
  <td width=38 valign=top style='width:28.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>87</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>82</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>9</span></p>
  </td>
  <td width=29 valign=top style='width:21.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
 </tr>
 <tr>
  <td width=492 colspan=13 valign=top style='width:369.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=EN-GB style='font-size:8.0pt'>Ipilimumab</span></p>
  </td>
 </tr>
 <tr>
  <td width=37 style='width:28.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>164</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>137</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>113</span></p>
  </td>
  <td width=47 style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>88</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>76</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>67</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>58</span></p>
  </td>
  <td width=38 style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>54</span></p>
  </td>
  <td width=38 valign=top style='width:28.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>49</span></p>
  </td>
  <td width=38 valign=top style='width:28.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  style='font-size:8.0pt'>46</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>40</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><span
  lang=EN-GB style='font-size:8.0pt'>7</span></p>
  </td>
  <td width=29 valign=top style='width:21.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText><span lang=EN-GB style='font-size:8.0pt'>0</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:7.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:7.0pt'> - - -*- - - - </span><span
lang=EN-GB style='font-size:8.0pt'>Nivolumab+ipilimumab (events:&nbsp;71/155),
median and 95%&nbsp;CI: N.A. (39.06, N.A.)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'> &#9472;&#9472;&#8710;&#9472;&#9472;&#9472;
 Nivolumab (events:&nbsp;84/171), median and 95%&nbsp;CI: 66.99&nbsp;months
(39.00, N.A.)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'> - - -</span><span lang=EN-GB
style='font-size:8.0pt;font-family:Wingdings'></span><span lang=EN-GB
style='font-size:8.0pt'>- - -  Ipilimumab (events:&nbsp;118/164), median and
95%&nbsp;CI: 21.49&nbsp;months (16.85, 29.08)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'> </span><span
lang=FR style='font-size:8.0pt'>Nivolumab+ipilimumab vs. ipilimumab - HR
(95%&nbsp;CI): 0.51 (0.38, 0.69)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=FR
style='font-size:8.0pt'> Nivolumab
vs. ipilimumab - HR (95%&nbsp;CI): 0.53 (0.40, 0.70)</span></p>

<p class=EMEABodyText style='margin-left:79.65pt;text-indent:28.35pt;
page-break-after:avoid'><span lang=FR style='font-size:8.0pt'>Nivolumab+ipilimumab
vs. nivolumab - HR (95%&nbsp;CI): 0.97 (0.70, 1.32)</span></p>

<span lang=FR style='font-size:7.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=FR style='font-size:7.0pt'>&nbsp;</span></p>

<p class=BMSBodyText style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;line-height:110%'>Minimum follow&#8209;up for the
analysis of ORR was 60&nbsp;months. Responses are summarised in Table&nbsp;12.</span></p>

<p class=BMSBodyText style='margin-bottom:0in'><span lang=EN-GB
style='font-size:10.0pt;line-height:110%'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="99%"
 style='margin-left:5.45pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:17.5pt'>
   <td width="100%" colspan=4 style='width:100.0%;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:17.5pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;12: Objective
   response (CA209067)</span></b></p>
   </td>
  </tr>
  <tr style='height:15.6pt'>
   <td width="36%" style='width:36.84%;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:15.6pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=NL-BE style='font-size:10.0pt'>&nbsp;</span></b></p>
   </td>
   <td width="22%" valign=top style='width:22.32%;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.6pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span style='font-size:10.0pt'>nivolumab</span></b><b><span
   lang=NL-BE style='font-size:10.0pt'> +<br>
   </span></b><b><span style='font-size:10.0pt'>i</span></b><b><span
   lang=NL-BE style='font-size:10.0pt'>pilimumab </span></b><b><span
   style='font-size:10.0pt'><br>
   </span></b><b><span lang=NL-BE style='font-size:10.0pt'>(n&nbsp;=&nbsp;</span></b><b><span
   style='font-size:10.0pt'>314</span></b><b><span lang=NL-BE style='font-size:
   10.0pt'>)</span></b></p>
   </td>
   <td width="20%" valign=top style='width:20.4%;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.6pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span style='font-size:10.0pt'>&nbsp;</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span style='font-size:10.0pt'>nivolumab</span></b><b><span
   lang=NL-BE style='font-size:10.0pt'> <br>
   (n&nbsp;=&nbsp;</span></b><b><span style='font-size:10.0pt'>316</span></b><b><span
   lang=NL-BE style='font-size:10.0pt'>)</span></b></p>
   </td>
   <td width="20%" valign=top style='width:20.44%;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.6pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span style='font-size:10.0pt'>&nbsp;</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span style='font-size:10.0pt'>ipilimumab <br>
   (n&nbsp;=&nbsp;315)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:12.15pt'>
  <td width="36%" style='width:36.84%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal style='margin-bottom:2.0pt;page-break-after:avoid'><b><span
  lang=NL-BE style='font-size:10.0pt'>Objective response </span></b></p>
  </td>
  <td width="22%" style='width:22.32%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>183 (58%)</span></p>
  </td>
  <td width="20%" style='width:20.4%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>141 (45%)</span></p>
  </td>
  <td width="20%" style='width:20.44%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:0in;
  margin-bottom:2.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><span
  lang=NL-BE style='font-size:10.0pt'>60 (19%)</span></p>
  </td>
 </tr>
 <tr style='height:12.15pt'>
  <td width="36%" style='width:36.84%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  2.0pt;margin-left:0in;page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'> (95%&nbsp;CI)</span></p>
  </td>
  <td width="22%" style='width:22.32%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>(52.6, 63.8)</span></p>
  </td>
  <td width="20%" style='width:20.4%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>(39.1, 50.3)</span></p>
  </td>
  <td width="20%" style='width:20.44%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>(14.9,
  23.8)</span></p>
  </td>
 </tr>
 <tr style='height:12.15pt'>
  <td width="36%" style='width:36.84%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  2.0pt;margin-left:0in;page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'> Odds ratio (vs. ipilimumab)</span></p>
  </td>
  <td width="22%" style='width:22.32%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>6.35</span></p>
  </td>
  <td width="20%" style='width:20.4%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>3.5</span></p>
  </td>
  <td width="20%" style='width:20.44%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:12.15pt'>
  <td width="36%" style='width:36.84%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  2.0pt;margin-left:0in;page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'> (95%&nbsp;CI)</span></p>
  </td>
  <td width="22%" style='width:22.32%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>(4.38,
  9.22)</span></p>
  </td>
  <td width="20%" style='width:20.4%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>(2.46,
  5.10)</span></p>
  </td>
  <td width="20%" style='width:20.44%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:12.15pt'>
  <td width="36%" style='width:36.84%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  2.0pt;margin-left:0in;page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'> Complete response (CR)</span></p>
  </td>
  <td width="22%" style='width:22.32%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>69(22%)</span></p>
  </td>
  <td width="20%" style='width:20.4%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>60 (19%)</span></p>
  </td>
  <td width="20%" style='width:20.44%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>18 (6%)</span></p>
  </td>
 </tr>
 <tr style='height:12.15pt'>
  <td width="36%" style='width:36.84%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  2.0pt;margin-left:0in;page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'> Partial response (PR)</span></p>
  </td>
  <td width="22%" style='width:22.32%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>114 (36%)</span></p>
  </td>
  <td width="20%" style='width:20.4%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>81 (26%)</span></p>
  </td>
  <td width="20%" style='width:20.44%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>42 (13%)</span></p>
  </td>
 </tr>
 <tr style='height:12.15pt'>
  <td width="36%" style='width:36.84%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  2.0pt;margin-left:0in;page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'> Stable disease (SD)</span></p>
  </td>
  <td width="22%" style='width:22.32%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>38 (12%)</span></p>
  </td>
  <td width="20%" style='width:20.4%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>30 (10%)</span></p>
  </td>
  <td width="20%" style='width:20.44%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>69 (22%)</span></p>
  </td>
 </tr>
 <tr style='height:13.85pt'>
  <td width="36%" style='width:36.84%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.85pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  2.0pt;margin-left:0in;page-break-after:avoid;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>Duration of response</span></b></p>
  </td>
  <td width="22%" style='width:22.32%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.85pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" style='width:20.4%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.85pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" style='width:20.44%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.85pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width="36%" style='width:36.84%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  2.0pt;margin-left:0in;page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'> Median (range),&nbsp;months</span></p>
  </td>
  <td width="22%" style='width:22.32%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>N.A.</span></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>(0&#8209;65.2)</span></p>
  </td>
  <td width="20%" style='width:20.4%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>N.A. </span></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>(0&#8209;63.3)
  </span></p>
  </td>
  <td width="20%" style='width:20.44%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>14.39</span></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>(0&#8209;61.9)</span></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width="36%" style='width:36.84%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  2.0pt;margin-left:0in;page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'> Proportion &#8805;12&nbsp;months
  in duration</span></p>
  </td>
  <td width="22%" style='width:22.32%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>67%</span></p>
  </td>
  <td width="20%" style='width:20.4%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>71%</span></p>
  </td>
  <td width="20%" style='width:20.44%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>47%</span></p>
  </td>
 </tr>
 <tr style='height:13.5pt'>
  <td width="36%" style='width:36.84%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  2.0pt;margin-left:0in;page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'> Proportion &#8805;24&nbsp;months
  in duration</span></p>
  </td>
  <td width="22%" style='width:22.32%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>57%</span></p>
  </td>
  <td width="20%" style='width:20.4%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>55%</span></p>
  </td>
  <td width="20%" style='width:20.44%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>36%</span></p>
  </td>
 </tr>
 <tr style='height:19.85pt'>
  <td width="59%" colspan=2 style='width:59.16%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:19.85pt'>
  <p class=MsoNormal style='margin-bottom:2.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>ORR (95%&nbsp;CI) by tumour PD-L1
  expression </span></b></p>
  </td>
  <td width="20%" style='width:20.4%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:19.85pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="20%" style='width:20.44%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:19.85pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:12.15pt'>
  <td width="36%" style='width:36.84%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  2.0pt;margin-left:0in;page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'> &lt;5%</span></p>
  </td>
  <td width="22%" style='width:22.32%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>56% (48.7,
  62.5)<br>
  n&nbsp;=&nbsp;210</span></p>
  </td>
  <td width="20%" style='width:20.4%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>43% (36,
  49.8)<br>
  n&nbsp;=&nbsp;208</span></p>
  </td>
  <td width="20%" style='width:20.44%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>18% (12.8,
  23.8)<br>
  n&nbsp;=&nbsp;202</span></p>
  </td>
 </tr>
 <tr style='height:12.15pt'>
  <td width="36%" style='width:36.84%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  2.0pt;margin-left:0in;page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'> &#8805;5%</span></p>
  </td>
  <td width="22%" style='width:22.32%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>72% (59.9,
  82.3)<br>
  n&nbsp;=&nbsp;68</span></p>
  </td>
  <td width="20%" style='width:20.4%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>58% (45.9,
  68.5)<br>
  n&nbsp;=&nbsp;80</span></p>
  </td>
  <td width="20%" style='width:20.44%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>21% (12.7,
  32.3)<br>
  n&nbsp;=&nbsp;75</span></p>
  </td>
 </tr>
 <tr style='height:12.15pt'>
  <td width="36%" style='width:36.84%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  2.0pt;margin-left:0in;page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'> &lt;1%</span></p>
  </td>
  <td width="22%" style='width:22.32%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>54% (44.4,
  62.7)<br>
  n&nbsp;=&nbsp;123</span></p>
  </td>
  <td width="20%" style='width:20.4%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>36% (27.2,
  45.3)<br>
  n&nbsp;=&nbsp;117</span></p>
  </td>
  <td width="20%" style='width:20.44%;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>18% (11.2,
  26.0)<br>
  n&nbsp;=&nbsp;113</span></p>
  </td>
 </tr>
 <tr style='height:12.15pt'>
  <td width="36%" style='width:36.84%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.15pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0in;margin-bottom:
  2.0pt;margin-left:0in;page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'> &#8805;1%</span></p>
  </td>
  <td width="22%" style='width:22.32%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>65% (56.4,
  72)<br>
  n&nbsp;=&nbsp;155</span></p>
  </td>
  <td width="20%" style='width:20.4%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>54% (46.6,
  62)<br>
  n&nbsp;=&nbsp;171</span></p>
  </td>
  <td width="20%" style='width:20.44%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.15pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  page-break-after:avoid'><span lang=NL-BE style='font-size:10.0pt'>20% (13.7,
  26.4)<br>
  n&nbsp;=&nbsp;164</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Both nivolumab&#8209;containing arms
demonstrated a significant PFS and OS benefit and greater ORR compared with
ipilimumab alone. The observed PFS results at 18&nbsp;months of follow&#8209;up
and ORR and OS results at 28&nbsp;months of follow&#8209;up were consistently
demonstrated across subgroups of patients including baseline ECOG performance
status, BRAF status, M&nbsp;stage, age, history of brain metastases, and
baseline LDH level. This observation was maintained with the OS results with a
minimum follow&#8209;up of 60&nbsp;months.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Among 131&nbsp;patients who discontinued
the combination due to adverse reaction after 28&nbsp;months of follow-up, the
ORR was 71% (93/131) with 20% (26/131) achieving a complete response and median
OS was not reached. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Both nivolumab-containing arms
demonstrated greater objective response rates than ipilimumab regardless of PD&#8209;L1
expression levels. ORRs were higher for the combination of nivolumab and
ipilimumab relative to nivolumab monotherapy across tumour PD&#8209;L1
expression levels (Table&nbsp;12) after 60&nbsp;months of follow-up, with a best
overall response of complete response correlating to an improved survival rate.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>After 60&nbsp;months of follow-up,
median durations of response for patients with tumour PD&#8209;L1 expression
level &#8805;5% were not reached (range:&nbsp;18.07&#8209;N.A.) in the
combination arm, not reached</span><span lang=EN-GB> (</span><span lang=EN-GB>range:&nbsp;</span><span
lang=EN-GB>26.71</span><span lang=EN-GB>&#8209;</span><span lang=EN-GB>N.A.) in
the nivolumab monotherapy arm and 31.28&nbsp;months (</span><span lang=EN-GB>range:&nbsp;</span><span
lang=EN-GB>6.08</span><span lang=EN-GB>&#8209;</span><span lang=EN-GB>N.A.) in
the ipilimumab arm. At tumour PD-L1&nbsp;expression &lt;5%, median durations of
response were n</span><span lang=EN-GB>ot reached (range: 40.08&#8209;N.A.) in
the combination arm, were not reached</span><span lang=EN-GB> (</span><span
lang=EN-GB>range:&nbsp;</span><span lang=EN-GB>50.43</span><span lang=EN-GB>&#8209;</span><span
lang=EN-GB>N.A.) in the nivolumab monotherapy arm and 12.75&nbsp;</span><span
lang=EN-GB>months </span><span lang=EN-GB>(</span><span lang=EN-GB>range:&nbsp;5.32&#8209;53.65</span><span
lang=EN-GB>) in the ipilimumab monotherapy arm.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>No clear cut off for PD&#8209;L1
expression can reliably be established when considering the relevant endpoints
of tumour response and PFS and OS. Results from exploratory multivariate
analyses identified patient and tumour characteristics (ECOG performance
status, M&nbsp;stage, baseline LDH, BRAF mutation status, PD&#8209;L1 status,
and gender) which might contribute to the survival outcome.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:yellow'>&nbsp;</span></p>

<p class=EMEABodyText><i><u><span lang=EN-GB>Efficacy by BRAF status</span></u></i><u><span
lang=EN-GB>: </span></u></p>

<p class=EMEABodyText><span lang=EN-GB>After 60&nbsp;months of follow-up,
BRAF[V600] mutation&#8209;positive and BRAF wild&#8209;type patients randomised
to nivolumab in combination with ipilimumab had a median PFS of 16.76&nbsp;months
(95%&nbsp;CI:&nbsp;8.28,&nbsp;32.0) and 11.7&nbsp;months (95%&nbsp;CI:&nbsp;7.0,&nbsp;18.14),
while those in the nivolumab monotherapy arm had a median PFS of
5.6&nbsp;months (95%&nbsp;CI:&nbsp;2.79,&nbsp;9.46) and 8.18&nbsp;months
(95%&nbsp;CI:&nbsp;5.13,&nbsp;19.55), respectively. BRAF[V600] mutation&#8209;positive
and BRAF wild&#8209;type patients randomised to ipilimumab monotherapy had a
median PFS of 3.38&nbsp;months (95%&nbsp;CI: 2.79, 5.19) and 2.83&nbsp;months
(95%&nbsp;CI: 2.76, 3.06), respectively.</span></p>

<p class=EMEABodyText><span lang=EN-GB>After 60&nbsp;months of follow&#8209;up,
BRAF[V600] mutation&#8209;positive and BRAF wild&#8209;type patients randomised
to nivolumab in combination with ipilimumab had an ORR of 67.0%
(95%&nbsp;CI:&nbsp;57.0,&nbsp;75.9; n&nbsp;=&nbsp;103) and 54.0%
(95%&nbsp;CI:&nbsp;47.1,&nbsp;60.9; n&nbsp;=&nbsp;211), while those in the
nivolumab monotherapy arm had an ORR of 37.87% (95%&nbsp;CI:&nbsp;28.2,&nbsp;48.1;
n&nbsp;=&nbsp;98) and 47.7% (95%&nbsp;CI:&nbsp;40.9,&nbsp;54.6;
n&nbsp;=&nbsp;218), respectively. BRAF[V600] mutation&#8209;positive and BRAF
wild&#8209;type patients randomised to ipilimumab monotherapy had an ORR of
23.0% (95%&nbsp;CI:&nbsp;15.2,&nbsp;32.5; n&nbsp;=&nbsp;100) and 17.2%
(95%&nbsp;CI:&nbsp;12.4,&nbsp;22.9; n&nbsp;=&nbsp;215).</span></p>

<p class=EMEABodyText><span lang=EN-GB>After 60&nbsp;months of follow&#8209;up,
in BRAF [V600] mutation&#8209;positive patients median OS was not reached in the
combination arm and 45.5&nbsp;months in the nivolumab monotherapy arm. Median
OS for BRAF [V600] mutation&#8209;positive patients in the ipilimumab monotherapy
arm was 24.6&nbsp;months. In BRAF wild&#8209;type patients median OS was 39.06&nbsp;months
in the combination arm, 34.37&nbsp;months in the nivolumab monotherapy arm and
18.5&nbsp;months in the ipilimumab monotherapy arm. The OS HRs for nivolumab in
combination with ipilimumab vs. nivolumab monotherapy were 0.70
(95%&nbsp;CI:&nbsp;0.46,&nbsp;1.05) for BRAF[V600] mutation&#8209;positive
patients and 0.89 (95%&nbsp;CI:&nbsp;0.69,&nbsp;1.15) for BRAF wild&#8209;type
patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Randomised
phase 2 study of nivolumab in combination with ipilimumab and ipilimumab
(CA209069)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Study CA209069 was a randomised,
Phase&nbsp;2, double&#8209;blind study comparing the combination of nivolumab
and ipilimumab with ipilimumab alone in 142&nbsp;patients with advanced
(unresectable or metastatic) melanoma with similar inclusion criteria to study
CA209067 and the primary analysis in patients with BRAF&nbsp;wild&#8209;type
melanoma (77%&nbsp;of&nbsp;patients). Investigator assessed ORR was
61%&nbsp;(95%&nbsp;CI:&nbsp;48.9,&nbsp;72.4) in the combination arm (n&nbsp;=&nbsp;72)
versus 11%&nbsp;(95%&nbsp;CI:&nbsp;3.0,&nbsp;25.4) for the ipilimumab arm (n&nbsp;=&nbsp;37).
The estimated&nbsp;2 and 3&nbsp;year OS rates were 68% (95%&nbsp;CI:&nbsp;56,&nbsp;78)
and 61% (95%&nbsp;CI:&nbsp;49,&nbsp;71), respectively, for the combination (n&nbsp;=&nbsp;73)
and 53% (95%&nbsp;CI:&nbsp;36,&nbsp;68) and 44% (95%&nbsp;CI:&nbsp;28,&nbsp;60),
respectively, for ipilimumab (n&nbsp;=&nbsp;37).</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Adjuvant
treatment of melanoma</span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Randomised
phase&nbsp;3 study of nivolumab vs ipilimumab 10&nbsp;mg/kg (CA209238)</span></u></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The safety and
efficacy of nivolumab&nbsp;3&nbsp;mg/kg as a single agent for the treatment of
patients with completely resected melanoma were evaluated in a phase&nbsp;3,
randomised, double&#8209;blind study (CA209238). The study included adult
patients, who had an ECOG performance status score of 0 or 1, with Stage
IIIB/C&nbsp;or&nbsp;Stage IV American Joint Committee on Cancer (AJCC), 7<span
class=EMEASuperscript>th</span> edition, histologically confirmed melanoma that
is completely surgically resected. Per the AJCC 8<span class=EMEASuperscript>th</span>
edition, this corresponds to patients with lymph node involvement or
metastases. Patients were enrolled regardless of their tumour PD&#8209;L1&nbsp;status.
Patients with prior autoimmune disease, and any condition requiring systemic
treatment with either corticosteroids (&#8805;&nbsp;10&nbsp;mg daily prednisone
or equivalent) or other immunosuppressive medications, as well as patients with
prior therapy for melanoma (except patients with surgery, adjuvant radiotherapy
after neurosurgical resection for lesions of the central nervous system, and
prior adjuvant interferon completed &#8805;6&nbsp;months prior to randomisation)</span><span
lang=EN-GB> prior therapy with, anti&#8209;PD&#8209;1, anti&#8209;PD&#8209;L1,
anti&#8209;PD&#8209;L2, anti&#8209;CD137, or anti CTLA&#8209;4 antibody
(including ipilimumab or any other antibody or drug specifically targeting T
cell co&#8209;stimulation or checkpoint pathways),</span><span lang=EN-GB> were
excluded from the study.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>A total of 906&nbsp;patients
were randomised to receive either nivolumab 3&nbsp;mg/kg (n&nbsp;=&nbsp;453)
administered every 2&nbsp;weeks or ipilimumab 10&nbsp;mg/kg (n&nbsp;=&nbsp;453)
administered every 3&nbsp;weeks for 4&nbsp;doses then every 12&nbsp;weeks
beginning at week&nbsp;24 for up to 1&nbsp;year. Randomisation was stratified
by tumour PD&#8209;L1 expression (&#8805;&nbsp;5% vs. &lt;&nbsp;5%/indeterminate),
and stage of disease per the AJCC staging system. Tumour assessments were
conducted every 12&nbsp;weeks for the first 2&nbsp;years then every 6&nbsp;months
thereafter. The primary endpoint was recurrence&#8209;free survival (RFS). RFS,
assessed by investigator, was defined as the time between the date of randomisation
and the date of first recurrence (local, regional, or distant metastasis), new
primary melanoma, or death due to any cause, whichever occurred first.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Baseline characteristics were generally
balanced between the two&nbsp;groups. The median age was 55&nbsp;years
(range:&nbsp;18&#8209;86), 58% were men, and 95% were white. Baseline ECOG
performance status score was 0&nbsp;(90%) or 1&nbsp;(10%). </span><span
style='color:black'>The majority of patients had AJCC Stage&nbsp;III disease
(81%), and 19% had Stage&nbsp;IV disease</span><span lang=EN-GB>. Forty&#8209;eight
percent of patients had macroscopic lymph nodes and 32% had tumour ulceration.
Forty&#8209;two percent of patients were BRAF&nbsp;V600 mutation positive while
45% were BRAF&nbsp;wild&nbsp;type and 13%&nbsp;BRAF were status unknown. For <span
style='color:black'>tumour PD&#8209;L1&nbsp;expression,</span> 34%<span
style='color:black'> of patients had PD&#8209;L1&nbsp;expression
&#8805;&nbsp;5% and 62% had &lt;&nbsp;5% as determined by clinical trial assay.
</span>Among patients with quantifiable tumour PD&#8209;L1 expression, the
distribution of patients was balanced across the treatment groups. Tumour PD&#8209;L1
expression was determined using the PD&#8209;L1&nbsp;IHC&nbsp;28&#8209;8&nbsp;pharmDx&nbsp;assay.</span><span
lang=EN-GB> </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Minimum follow&#8209;up was approximately
24&nbsp;months. OS was not mature at the time of this analysis. RFS results are
shown in Table&nbsp;13 and Figure&nbsp;8 (all randomised population).</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;13: Efficacy
results (CA209238)</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=197 valign=top style='width:147.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=205 colspan=2 valign=top style='width:153.65pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>nivolumab<br>
  (n&nbsp;=&nbsp;453)</span></b></p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>ipilimumab 10&nbsp;mg/kg<br>
  (n&nbsp;=&nbsp;453)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Recurrence&#8209;free survival</b></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=102 valign=top style='width:76.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=101 valign=top style='width:1.05in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=102 valign=top style='width:76.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Events</span></p>
  </td>
  <td width=205 colspan=2 style='width:153.65pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>171 (37.7%)</p>
  </td>
  <td width=203 colspan=2 style='width:152.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>221 (48.8%)</p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Hazard ratio<sup>a</sup> </span></p>
  </td>
  <td width=408 colspan=4 valign=top style='width:306.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>0.66</p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>95%&nbsp;CI</span></p>
  </td>
  <td width=408 colspan=4 valign=top style='width:306.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>(0.54,<b><span lang=EN-GB>&nbsp;</span></b>0.81)</p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>p&#8209;value</span></p>
  </td>
  <td width=408 colspan=4 valign=top style='width:306.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>p&lt;0.0001</p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=103 valign=top style='width:77.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=102 valign=top style='width:76.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=101 valign=top style='width:1.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=102 valign=top style='width:76.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Median
  (95%&nbsp;CI) months</span></p>
  </td>
  <td width=205 colspan=2 valign=top style='width:153.65pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in'><span style='font-size:11.0pt'>Not
  Available</span><sup><span lang=ES style='font-size:11.0pt'>b</span></sup></p>
  <p class=BMSTableText style='margin:0in'><span lang=ES style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in'><span style='font-size:11.0pt'>24.08
  <br>
  (16.56, NR)</span></p>
  <p class=BMSTableText style='margin:0in'><span lang=ES style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Rate
  (95%&nbsp;CI) at 12&nbsp;months</span></p>
  </td>
  <td width=205 colspan=2 valign=top style='width:153.65pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>70.4 (65.9, 74.4)</p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>60.0 (55.2, 64.5)</p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Rate
  (95%&nbsp;CI) at 18&nbsp;months</span></p>
  </td>
  <td width=205 colspan=2 valign=top style='width:153.65pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>65.8 (61.2, 70.0)</p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>53.0 (48.1, 57.6)</p>
  </td>
 </tr>
 <tr>
  <td width=197 valign=top style='width:147.5pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Rate
  (95%&nbsp;CI) at 24&nbsp;months</span></p>
  </td>
  <td width=205 colspan=2 valign=top style='width:153.65pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>62.6 (57.9, 67.0)</p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.4pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>50.2 (45.3, 54.8)</p>
  </td>
 </tr>
</table>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>a </span></sup><span
lang=EN-GB style='font-size:9.0pt'>Derived from a stratified proportional
hazards model.</span></p>

<p class=MsoCommentText><sup><span lang=EN-GB style='font-size:9.0pt'>b </span></sup><span
lang=EN-GB style='font-size:9.0pt'>Not available as median unstable due to low
number of patients and censoring with 24&nbsp;months of follow&#8209;up</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Figure&nbsp;8: Recurrence&#8209;free
survival (CA209238)</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:28.35pt;line-height:110%'><span style='position:relative;
z-index:251673600'><span style='left:0px;position:absolute;left:-11px;
top:-6151px;width:35px;height:1px'><img width=35 height=1
src="OPDIVO-H-3985-IA-099-PI-en_files/image022.png"
alt="Probability of recurrence-free survival&#13;&#10;F&#13;&#10;"></span></span><img
border=0 width=564 height=411 id="Picture 20"
src="OPDIVO-H-3985-IA-099-PI-en_files/image023.jpg"></p>

<p class=MsoNormal style='margin-bottom:6.0pt;text-align:justify;text-indent:
28.35pt;line-height:110%'><img width=270 height=1
src="OPDIVO-H-3985-IA-099-PI-en_files/image024.png" align=left hspace=12
vspace=5 alt="Recurrence-free survival (months)"></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=593
 style='margin-left:22.7pt;border-collapse:collapse'>
 <tr style='height:12.95pt'>
  <td width=591 colspan=13 valign=top style='width:443.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.95pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Number of subjects
  at risk</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=591 colspan=13 valign=top style='width:443.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Nivolumab </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=27><p class='MsoNormal'>&nbsp;</td>
  <td width=46 style='width:34.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>453</span></p>
  </td>
  <td width=46 style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>394</span></p>
  </td>
  <td width=46 style='width:34.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>353</span></p>
  </td>
  <td width=46 style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>331</span></p>
  </td>
  <td width=46 style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>311</span></p>
  </td>
  <td width=46 style='width:34.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>291</span></p>
  </td>
  <td width=51 style='width:38.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>280</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>264</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>205</span></p>
  </td>
  <td width=47 valign=top style='width:35.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>28</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>7</span></p>
  </td>
  <td width=47 colspan=2 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>0</span></p>
  </td>
 </tr>
 <tr>
  <td width=593 colspan=14 style='width:444.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Ipilimumab
  </span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=27><p class='MsoNormal'>&nbsp;</td>
  <td width=46 style='width:34.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>453</span></p>
  </td>
  <td width=46 style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>363</span></p>
  </td>
  <td width=46 style='width:34.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>314</span></p>
  </td>
  <td width=46 style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>270</span></p>
  </td>
  <td width=46 style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>251</span></p>
  </td>
  <td width=46 style='width:34.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>230</span></p>
  </td>
  <td width=51 style='width:38.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>216</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>204</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>149</span></p>
  </td>
  <td width=47 valign=top style='width:35.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>23</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>5</span></p>
  </td>
  <td width=47 colspan=2 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>0</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=27 style='border:none'></td>
  <td width=46 style='border:none'></td>
  <td width=46 style='border:none'></td>
  <td width=46 style='border:none'></td>
  <td width=46 style='border:none'></td>
  <td width=46 style='border:none'></td>
  <td width=46 style='border:none'></td>
  <td width=51 style='border:none'></td>
  <td width=47 style='border:none'></td>
  <td width=47 style='border:none'></td>
  <td width=47 style='border:none'></td>
  <td width=47 style='border:none'></td>
  <td width=45 style='border:none'></td>
  <td width=2 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:6.0pt;text-align:justify;text-indent:
28.35pt;line-height:110%'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;text-align:justify;text-indent:
28.35pt;line-height:110%'><span lang=EN-GB>- - - &#8710;- - - Nivolumab
&#9472;&#9472;</span><span lang=EN-GB style='font-family:Wingdings'></span><span
lang=EN-GB>&#9472;&#9472; Ipilimumab</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The trial demonstrated a statistically
significant improvement in RFS for patients randomised to the nivolumab arm
compared with the ipilimumab 10&nbsp;mg/kg arm. RFS benefit was consistently
demonstrated across subgroups, including tumour PD&#8209;L1&nbsp;expression,
BRAF status, and stage of disease.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Quality of life (QoL) with nivolumab remained
stable and close to baseline values during treatment, as assessed by valid and
reliable scales like the European Organization for Research and Treatment of
Cancer (EORTC) QLQ&#8209;C30 and the EQ&#8209;5D utility index and visual
analog scale (VAS).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Non&#8209;small
cell lung cancer</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>First-line
treatment of NSCLC</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><i><u><span lang=EN-GB>Randomised phase&nbsp;3 study of
nivolumab in combination with ipilimumab and 2&nbsp;cycles of platinum-based
chemotherapy vs. 4&nbsp;cycles of platinum-based chemotherapy (CA2099LA)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of nivolumab 360&nbsp;mg
every 3&nbsp;weeks in combination with ipilimumab 1&nbsp;mg/kg every
6&nbsp;weeks and 2&nbsp;cycles of platinum-based chemotherapy were evaluated in
a phase&nbsp;3, randomised, open-label study (CA2099LA). The study included
patients (18&nbsp;years or older) with histologically confirmed non-squamous or
squamous Stage&nbsp;IV or recurrent NSCLC (per the 7<span
class=EMEASuperscript>th</span> International Association for the Study of Lung
Cancer classification), ECOG performance status 0&nbsp;or&nbsp;1, and no prior
anticancer therapy (including EGFR and ALK inhibitors). Patients were enrolled
regardless of their tumour PD-L1 status. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Patients with sensitising EGFR mutations
or ALK translocations, active (untreated) brain metastases, carcinomatous
meningitis, active autoimmune disease, or medical conditions requiring systemic
immunosuppression were excluded from the study. Patients with treated brain
metastases were eligible if neurologically returned to baseline at least
2&nbsp;weeks prior to enrolment, and either off corticosteroids, or on a stable
or decreasing dose of &lt;&nbsp;10&nbsp;mg daily prednisone equivalents.
Randomisation was stratified by histology (squamous vs non-squamous), tumour
PD-L1&nbsp;expression level (&#8805;&nbsp;1%&nbsp;vs&nbsp;&lt;&nbsp;1%), and
gender </span><span lang=EN-GB>(male vs female)</span><span lang=EN-GB>. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=BMSBodyText style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>A total of
719&nbsp;patients were randomised to receive either nivolumab in combination with
ipilimumab and platinum-based chemotherapy (n&nbsp;=&nbsp;361) or
platinum-based chemotherapy (n&nbsp;=&nbsp;358). Patients in the nivolumab in
combination with ipilimumab and platinum-based chemotherapy arm received
nivolumab 360&nbsp;mg administered intravenously over 30&nbsp;minutes every
3&nbsp;weeks in combination with ipilimumab 1&nbsp;mg/kg administered
intravenously over 30&nbsp;minutes every 6&nbsp;weeks and platinum-based
chemotherapy administered every 3&nbsp;weeks for 2&nbsp;cycles. Patients in the
chemotherapy arm received platinum-based chemotherapy administered every
3&nbsp;weeks for 4&nbsp;cycles; non-squamous patients could receive optional
pemetrexed maintenance therapy.</span></p>

<p class=BMSBodyText style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>Platinum-based
chemotherapy consisted of carboplatin (AUC</span><span lang=ES
style='font-size:11.0pt'>&nbsp;</span><span lang=EN-GB style='font-size:11.0pt;
color:windowtext'>5 or 6) and pemetrexed 500</span><span lang=ES
style='font-size:11.0pt'>&nbsp;</span><span lang=EN-GB style='font-size:11.0pt;
color:windowtext'>mg/m</span><span class=EMEASuperscript><span lang=EN-GB
style='font-size:11.0pt'>2</span></span><span lang=EN-GB style='font-size:11.0pt;
color:windowtext'>; or cisplatin 75&nbsp;mg/m</span><span
class=EMEASuperscript><span lang=EN-GB style='font-size:11.0pt'>2</span></span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'> and pemetrexed
500&nbsp;mg/m</span><span class=EMEASuperscript><span lang=EN-GB
style='font-size:11.0pt'>2</span></span><span lang=EN-GB style='font-size:11.0pt;
color:windowtext'> for non-squamous NSCLC; or carboplatin (AUC&nbsp;6) and
paclitaxel 200&nbsp;mg/m</span><span class=EMEASuperscript><span lang=EN-GB
style='font-size:11.0pt'>2</span></span><span lang=EN-GB style='font-size:11.0pt;
color:windowtext'> for squamous NSCLC.</span></p>

<p class=BMSBullets style='margin:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=BMSBullets style='margin:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>Treatment continued until disease
progression, unacceptable toxicity, or for up to 24&nbsp;months. Treatment
could continue beyond disease progression if the patient was clinically stable
and was considered to be deriving clinical benefit by the investigator.
Patients who discontinued combination therapy because of an adverse event
attributed to ipilimumab were permitted to continue nivolumab monotherapy.
Tumour assessments were performed every 6&nbsp;weeks after first dose of study
treatment for the first 12&nbsp;months, then every 12&nbsp;weeks until disease
progression or study treatment was discontinued. </span></p>

<p class=BMSBullets style='margin:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=BMSBullets style='margin:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>CA2099LA baseline characteristics
were generally balanced across all treatment groups. The median age was
65&nbsp;years (range:&nbsp;26-86) with 51%&nbsp;&#8805;&nbsp;65&nbsp;years of
age and 10%&nbsp;&#8805;&nbsp;75&nbsp;years of age. The majority of patients
were white (89%) and male (70%). Baseline ECOG performance status was
0&nbsp;(31%) or 1&nbsp;(68%), 57% of patients with PD-L1&nbsp;</span><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol;color:windowtext'></span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;1% and 37% with
PD-L1&nbsp;&lt;&nbsp;1%, 31% had squamous and 69% had non-squamous histology,
17% had brain metastases, and 86% were former/current smokers. No patients
received prior immunotherapy.</span></p>

<p class=BMSBullets style='margin:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=BMSBullets style='margin:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>CA2099LA primary efficacy outcome
measure was OS. Additional efficacy endpoints were PFS, ORR, and duration of
response as assessed by BICR.</span></p>

<p class=EMEABodyText style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='text-align:justify'><span lang=EN-GB>The study
demonstrated a statistically significant benefit in OS, PFS, and ORR for
patients randomised to nivolumab in combination with ipilimumab and platinum-based
chemotherapy as compared to platinum-based chemotherapy alone at the
prespecified interim analysis when 351 events were observed (87% of the planned
number of events for final analysis). Minimum follow-up for OS was
8.1&nbsp;months.</span></p>

<p class=EMEABodyText style='text-align:justify'><span lang=EN-GB
style='background:yellow'>&nbsp;</span></p>

<p class=EMEABodyText style='text-align:justify'><span lang=EN-GB>Efficacy
results are shown in Figure&nbsp;9 (updated OS analysis with a minimum
follow-up of 12.7 months) and Table&nbsp;14 (primary analysis with a minimum
follow-up of 8.1 months).</span></p>

<p class=EMEABodyText style='text-align:justify'><span lang=EN-GB>An updated
efficacy analysis was performed when all patients had a minimum follow&#8209;up
of 12.7&nbsp;months (see Figure&nbsp;9). At the time of this analysis, the
hazard ratio for OS was 0.66 (95% CI: 0.55, 0.80) and the hazard ratio for PFS
was 0.68 (95% CI: 0.57, 0.82).</span></p>

<p class=EMEABodyText style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Figure 9: Kaplan-Meier
plot of OS (CA2099LA)</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><span style='position:
relative;z-index:251716608'><span style='position:absolute;left:49px;
top:-7926px;width:37px;height:1px'><img width=37 height=1
src="OPDIVO-H-3985-IA-099-PI-en_files/image012.png" alt="Probabilty of Survival"></span></span><img
border=0 width=591 height=410 id="Picture 42"
src="OPDIVO-H-3985-IA-099-PI-en_files/image025.jpg"></p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><span lang=EN-GB>Overall Survival (Months)</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>Number of Subjects at Risk</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=592
 style='margin-left:1.4pt;border-collapse:collapse'>
 <tr>
  <td width=514 colspan=10 valign=top style='width:385.6pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Nivolumab + ipilimumab + chemotherapy</span></p>
  </td>
  <td width=54 valign=top style='width:40.5pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=24 valign=top style='width:.25in;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=17 valign=top style='width:12.55pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText align=center style='margin-left:1.7pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=53 valign=top style='width:40.05pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='margin-left:1.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>361</span></p>
  </td>
  <td width=60 valign=top style='width:45.0pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='margin-left:1.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>326</span></p>
  </td>
  <td width=42 valign=top style='width:31.5pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>292</span></p>
  </td>
  <td width=42 valign=top style='width:31.5pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> 250</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> 227</span></p>
  </td>
  <td width=54 valign=top style='width:40.5pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>153</span></p>
  </td>
  <td width=54 valign=top style='width:40.5pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>86</span></p>
  </td>
  <td width=54 valign=top style='width:40.5pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>33</span></p>
  </td>
  <td width=54 valign=top style='width:40.5pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>10</span></p>
  </td>
  <td width=54 valign=top style='width:40.5pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>1</span></p>
  </td>
  <td width=24 valign=top style='width:.25in;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>0</span></p>
  </td>
 </tr>
 <tr>
  <td width=514 colspan=10 valign=top style='width:385.6pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Chemotherapy</span></p>
  </td>
  <td width=54 valign=top style='width:40.5pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=24 valign=top style='width:.25in;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=17 valign=top style='width:12.55pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText align=center style='margin-left:1.7pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=53 style='width:40.05pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='margin-left:1.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>358</span></p>
  </td>
  <td width=60 style='width:45.0pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='margin-left:1.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>319</span></p>
  </td>
  <td width=42 style='width:31.5pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>260</span></p>
  </td>
  <td width=42 style='width:31.5pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> 208</span></p>
  </td>
  <td width=84 style='width:63.0pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> 166</span></p>
  </td>
  <td width=54 style='width:40.5pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>116</span></p>
  </td>
  <td width=54 style='width:40.5pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>67</span></p>
  </td>
  <td width=54 style='width:40.5pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>26</span></p>
  </td>
  <td width=54 style='width:40.5pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>11</span></p>
  </td>
  <td width=54 valign=top style='width:40.5pt;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>0</span></p>
  </td>
  <td width=24 valign=top style='width:.25in;padding:0in 1.4pt 0in 1.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>0</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><img border=0 width=40
height=19 id="Picture 44" src="OPDIVO-H-3985-IA-099-PI-en_files/image026.jpg"><span
lang=EN-GB style='font-size:10.0pt'>Nivolumab + ipilimumab + chemotherapy
(events: 190/361), median and 95% CI: 15.64 (13.93, 19.98)</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><img border=0 width=38
height=13 id="Picture 45" src="OPDIVO-H-3985-IA-099-PI-en_files/image027.jpg"><span
lang=EN-GB style='font-size:10.0pt'>Chemotherapy (events: 242/358), median and
95% CI: 10.91 (9.46, 12.55)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=0
 style='margin-left:-.25pt;border-collapse:collapse'>
 <thead>
  <tr>
   <td width=624 colspan=3 valign=bottom style='width:6.5in;border:none;
   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table
   14: Efficacy results (CA2099LA)</span></b></p>
   </td>
  </tr>
  <tr>
   <td width=218 style='width:163.3pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader style='margin:0in'><span lang=ES>&nbsp;</span></p>
   </td>
   <td width=198 style='width:148.7pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader style='margin:0in'>nivolumab + ipilimumab +
   chemotherapy<br>
   <span lang=ES>(n&nbsp;=&nbsp;</span>361<span lang=ES>)</span></p>
   </td>
   <td width=208 style='width:156.0pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader style='margin:0in'>chemotherapy<br>
   <span lang=ES>(n&nbsp;=&nbsp;</span>358<span lang=ES>)</span></p>
   </td>
  </tr>
 </thead>
 <tr style='height:14.15pt'>
  <td width=624 colspan=3 style='width:6.5in;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.15pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><b><span
  lang=ES>Overall survival</span></b></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:.5in;text-align:left;text-indent:-.5in'><span
  lang=ES> Events</span></p>
  </td>
  <td width=198 style='width:148.7pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>156 (43.2%)</span></p>
  </td>
  <td width=208 style='width:156.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>195 (54.5%)</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:64.35pt;text-align:left;text-indent:-.5in'><span
  lang=ES>Hazard ratio </span></p>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:64.35pt;text-align:left;text-indent:-.5in'><span
  lang=ES>(96.71% CI)</span><span class=BMSSuperscript><span lang=ES
  style='font-size:14.0pt'>a</span></span></p>
  </td>
  <td width=406 colspan=2 style='width:304.7pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>0.69 </span></p>
  <p class=BMSTableText style='margin:0in'><span lang=ES>(0.55, 0.87)</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:64.35pt;text-align:left;text-indent:-.5in'><span
  lang=ES>Stratified log-rank p-value</span><span class=BMSSuperscript><span
  lang=ES style='font-size:14.0pt'>b</span></span></p>
  </td>
  <td width=406 colspan=2 style='width:304.7pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span class=MsoCommentReference><span
  lang=ES>0.0006</span></span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:.5in;text-align:left;text-indent:-.5in'><span
  lang=ES> Median (months)</span></p>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:.5in;text-align:left;text-indent:-.5in'><span
  lang=ES> (95% CI)</span></p>
  </td>
  <td width=198 style='width:148.7pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>14.1<br>
  (13.24, 16.16)</span></p>
  </td>
  <td width=208 style='width:156.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>10.7<br>
  (9.46, 12.45)</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:.5in;text-align:left;text-indent:-.5in'><span
  lang=ES> Rate (95% CI) at 6 months</span></p>
  </td>
  <td width=198 style='width:148.7pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>80.9 (76.4,84.6)</span></p>
  </td>
  <td width=208 style='width:156.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>72.3 (67.4,76.7)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:.5in;text-align:left;text-indent:-.5in'><span
  lang=ES>&nbsp;</span></p>
  </td>
  <td width=198 style='width:148.7pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=208 style='width:156.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=624 colspan=3 style='width:6.5in;padding:0in 5.4pt 0in 5.4pt;
  height:14.15pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><b><span
  lang=ES>Progression-free survival</span></b></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=ES> Events</span></p>
  </td>
  <td width=198 style='width:148.7pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>232 (64.3%)</span></p>
  </td>
  <td width=208 style='width:156.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>249 (69.6%)</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:64.35pt;text-align:left;text-indent:-.5in'><span
  lang=ES>Hazard ratio </span></p>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:28.35pt;text-align:left'><span lang=ES>(97.48%
  CI)</span><span class=BMSSuperscript><span lang=ES style='font-size:14.0pt'>a</span></span></p>
  </td>
  <td width=406 colspan=2 style='width:304.7pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>0.70 </span></p>
  <p class=BMSTableText style='margin:0in'><span lang=ES>(0.57, 0.86)</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:28.35pt;text-align:left'><span lang=ES>Stratified
  log-rank p-value</span><span class=BMSSuperscript><span lang=ES
  style='font-size:14.0pt'>c</span></span></p>
  </td>
  <td width=406 colspan=2 style='width:304.7pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>0.0001</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=ES> Median (months)</span><span class=BMSSuperscript><span
  lang=ES style='font-size:14.0pt'>d<br>
  </span></span><span lang=ES> (95% CI)</span></p>
  </td>
  <td width=198 style='width:148.7pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>6.83<br>
  (5.55, 7.66)</span></p>
  </td>
  <td width=208 style='width:156.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>4.96<br>
  (4.27, 5.55)</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>Rate (95% CI) at 6 months</span></p>
  </td>
  <td width=198 style='width:148.7pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>51.7 (46.2, 56.8)</span></p>
  </td>
  <td width=208 style='width:156.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>35.9 (30.5, 41.3)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=ES>&nbsp;</span></p>
  </td>
  <td width=198 style='width:148.7pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=208 style='width:156.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><b><span
  lang=ES>Overall response rate</span></b><span class=BMSSuperscript><span
  lang=ES style='font-size:14.0pt'>e</span></span></p>
  </td>
  <td width=198 style='width:148.7pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>136 (37.7%)</span></p>
  </td>
  <td width=208 style='width:156.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>90 (25.1%)</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=ES> (95% CI)</span></p>
  </td>
  <td width=198 style='width:148.7pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>(32.7, 42.9)</span></p>
  </td>
  <td width=208 style='width:156.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>(20.7, 30.0)</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>Stratified CMH test
  p-value</span><span class=BMSSuperscript><span lang=ES style='font-size:14.0pt'>f</span></span></p>
  </td>
  <td width=406 colspan=2 style='width:304.7pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>0.0003</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=ES> Complete response (CR)</span></p>
  </td>
  <td width=198 style='width:148.7pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>7 (1.9%)</span></p>
  </td>
  <td width=208 style='width:156.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>3 (0.8%)</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=ES> Partial response (PR)</span></p>
  </td>
  <td width=198 style='width:148.7pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>129 (35.7%)</span></p>
  </td>
  <td width=208 style='width:156.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>87 (24.3%)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=ES>&nbsp;</span></p>
  </td>
  <td width=198 style='width:148.7pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=208 style='width:156.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=624 colspan=3 style='width:6.5in;padding:0in 5.4pt 0in 5.4pt;
  height:14.15pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><b><span
  lang=ES>Duration of response</span></b></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=218 style='width:163.3pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=ES> Median (months) <br>
 (95% CI)</span><span class=BMSSuperscript><span lang=ES
  style='font-size:14.0pt'>d</span></span></p>
  </td>
  <td width=198 style='width:148.7pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>10.02<br>
  (8.21, 13.01)</span></p>
  </td>
  <td width=208 style='width:156.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>5.09<br>
  (4.34, 7.00)</span></p>
  </td>
 </tr>
 <tr style='height:14.15pt'>
  <td width=218 style='width:163.3pt;border:none;border-bottom:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=ES> % with duration &#8805; 6 months</span><span
  class=BMSSuperscript><span lang=ES style='font-size:14.0pt'>g</span></span></p>
  </td>
  <td width=198 style='width:148.7pt;border:none;border-bottom:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>74</span></p>
  </td>
  <td width=208 style='width:156.0pt;border:none;border-bottom:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.15pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>41</span></p>
  </td>
 </tr>
</table>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span class=BMSSuperscript><span lang=ES style='font-size:
10.0pt'>a</span></span><span lang=ES style='font-size:10.0pt'> B</span><span
lang=ES style='font-size:10.0pt'>ased on a stratified Cox proportional hazard
model.<br>
<span class=BMSSuperscript>b</span> p-value is compared with the
allocated alpha of 0.0329 for this interim analysis.<br>
<span class=BMSSuperscript>c</span> p-value is compared with the
allocated alpha of 0.0252 for this interim analysis.<br>
</span><span class=BMSSuperscript><span lang=ES style='font-size:10.0pt'>d</span></span><span
lang=ES style='font-size:10.0pt'> Kaplan-Meier estimate.<br>
</span><span class=BMSSuperscript><span lang=ES style='font-size:10.0pt'>e</span></span><span
lang=ES style='font-size:10.0pt'> Proportion with complete or
partial response; CI based on the Clopper and Pearson Method.</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span class=BMSSuperscript><span lang=ES style='font-size:
10.0pt'>f</span></span><span lang=ES style='font-size:10.0pt'> p-value
is compared with the allocated alpha of 0.025 for this interim analysis.<br>
</span><span class=BMSSuperscript><span lang=ES style='font-size:10.0pt'>g</span></span><span
lang=ES style='font-size:10.0pt'> Based on Kaplan-Meier estimates
of duration of response.</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=ES style='font-size:10.0pt'>CMH =
Cochran-Mantel-Haenszel</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=ES style='font-size:9.0pt'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Subsequent systemic therapy was received
by 28.8% and 41.1% of patients in the combination and chemotherapy arms,
respectively. Subsequent immunotherapy (including anti-PD-1, anti-PD-L1, and
anti-CTLA4) was received by 3.9% and 27.9% of patients in the combination and
chemotherapy arms, respectively.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In study CA2099LA, subgroup descriptive
analysis relative to chemotherapy, OS benefit was shown in patients treated
with nivolumab in combination with ipilimumab and chemotherapy with squamous
histology (HR [95% CI] 0.65 [0.46, 0.93], n&nbsp;=&nbsp;227) and in patients
with non-squamous histology (HR [95% CI] 0.72 [0.55, 0.93], n&nbsp;=&nbsp;492).</span></p>

<p class=BMSBodyText style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt;line-height:110%'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Table&nbsp;15
summarises efficacy results of OS, PFS, and ORR by tumour PD-L1 expression in
pre-specified subgroup analyses.</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=0
 style='margin-left:-5.65pt;border-collapse:collapse;border:none'>
 <tr style='height:17.1pt'>
  <td width=669 colspan=9 style='width:501.6pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:17.1pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;15: Efficacy
  results by tumour PD-L1 expression (CA2099LA)</span></b></p>
  </td>
 </tr>
 <tr style='height:23.4pt'>
  <td width=77 style='width:57.4pt;border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=82 style='width:61.65pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 2.85pt 0in 2.85pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>nivolumab </span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>+ </span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>ipilimumab </span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>+ chemotherapy</span></b></p>
  </td>
  <td width=66 style='width:49.35pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 2.85pt 0in 2.85pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>chemo-therapy</span></b></p>
  </td>
  <td width=85 style='width:64.05pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 2.85pt 0in 2.85pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>nivolumab </span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>+ </span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>ipilimumab </span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>+ chemotherapy</span></b></p>
  </td>
  <td width=63 style='width:46.95pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 2.85pt 0in 2.85pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>chemo-therapy</span></b></p>
  </td>
  <td width=89 style='width:66.45pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 2.85pt 0in 2.85pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>nivolumab </span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>+ </span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>ipilimumab </span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>+ </span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>chemotherapy</span></b></p>
  </td>
  <td width=59 style='width:44.55pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 2.85pt 0in 2.85pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>chemo-therapy</span></b></p>
  </td>
  <td width=82 style='width:61.8pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 2.85pt 0in 2.85pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>nivolumab </span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>+ </span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>ipilimumab </span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>+ chemotherapy</span></b></p>
  </td>
  <td width=66 style='width:49.4pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 2.85pt 0in 2.85pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>chemo-therapy</span></b></p>
  </td>
 </tr>
 <tr style='height:23.4pt'>
  <td width=77 style='width:57.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=148 colspan=2 style='width:111.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:9.0pt'>PD-L1&nbsp;&lt;&nbsp;1%</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:9.0pt'>(n&nbsp;=&nbsp;264)</span></b></p>
  </td>
  <td width=148 colspan=2 style='width:111.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:9.0pt'>PD-L1</span></b><b><span lang=EN-GB
  style='font-size:9.0pt'>&nbsp;<span style='color:black'>&#8805;&nbsp;1%</span></span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:9.0pt;color:black'>(n&nbsp;=&nbsp;406)</span></b></p>
  </td>
  <td width=148 colspan=2 style='width:111.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:9.0pt'>PD-L1&nbsp;</span></b><b><span lang=EN-GB
  style='font-size:9.0pt;color:black'>&#8805;&nbsp;1%&nbsp;to&nbsp;49%</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:9.0pt;color:black'>(n&nbsp;=&nbsp;233)</span></b></p>
  </td>
  <td width=148 colspan=2 style='width:111.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=EMEABodyText align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:9.0pt'>PD-L1&nbsp;</span></b><b><span lang=EN-GB
  style='font-size:9.0pt;color:black'>&#8805;&nbsp;50%</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:9.0pt;color:black'>(n&nbsp;=&nbsp;173)</span></b></p>
  </td>
 </tr>
 <tr style='height:23.4pt'>
  <td width=77 style='width:57.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span lang=PL
  style='font-size:9.0pt'>OS hazard ratio</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span lang=PL
  style='font-size:9.0pt'>(95% CI)</span></b><b><sup><span lang=PL
  style='font-size:14.0pt'>a</span></sup></b></p>
  </td>
  <td width=148 colspan=2 style='width:111.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.0pt'>0.65<br>
  (0.46, 0.92)</span></p>
  </td>
  <td width=148 colspan=2 style='width:111.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.0pt'>0.67<br>
  (0.51, 0.89)</span></p>
  </td>
  <td width=148 colspan=2 style='width:111.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.0pt'>0.69<br>
  (0.48, 0.98)</span></p>
  </td>
  <td width=148 colspan=2 style='width:111.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.0pt'>0.64<br>
  (0.41, 1.02)</span></p>
  </td>
 </tr>
 <tr style='height:23.4pt'>
  <td width=77 style='width:57.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span lang=PL
  style='font-size:9.0pt'>PFS hazard ratio </span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span lang=PL
  style='font-size:9.0pt'>(95% CI)</span></b><b><sup><span lang=PL
  style='font-size:14.0pt'>a</span></sup></b></p>
  </td>
  <td width=148 colspan=2 style='width:111.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.0pt'>0.77<br>
  (0.57, 1.03)</span></p>
  </td>
  <td width=148 colspan=2 style='width:111.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.0pt'>0.67<br>
  (0.53, 0.85)</span></p>
  </td>
  <td width=148 colspan=2 style='width:111.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.0pt'>0.71<br>
  (0.52, 0.97)</span></p>
  </td>
  <td width=148 colspan=2 style='width:111.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.0pt'>0.59<br>
  (0.40, 0.86)</span></p>
  </td>
 </tr>
 <tr style='height:23.4pt'>
  <td width=77 style='width:57.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='font-size:9.0pt'>ORR %</span></b></p>
  </td>
  <td width=82 style='width:61.65pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.0pt'>31.1</span></p>
  </td>
  <td width=66 style='width:49.35pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.0pt'>20.9</span></p>
  </td>
  <td width=85 style='width:64.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.0pt'>41.9</span></p>
  </td>
  <td width=63 style='width:46.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.0pt'>27.6</span></p>
  </td>
  <td width=89 style='width:66.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.0pt'>37.8</span></p>
  </td>
  <td width=59 style='width:44.55pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.0pt'>24.5</span></p>
  </td>
  <td width=82 style='width:61.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.0pt'>48.7</span></p>
  </td>
  <td width=66 style='width:49.4pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:23.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.0pt'>30.9</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><sup><span style='font-size:14.0pt'>a<b> </b></span></sup><span
style='font-size:10.0pt'>Hazard ratio based on unstratified Cox proportional
hazards model.</span></p>

<p class=EMEABodyText style='text-align:justify'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='text-align:justify'>A total of 70&nbsp;NSCLC
patients aged&nbsp;&#8805;&nbsp;75 years were enrolled in study CA2099LA
(37&nbsp;patients in the nivolumab in combination with ipilimumab and chemotherapy
arm and 33&nbsp;patients in the chemotherapy arm). A HR of 1.36 (95%
CI:&nbsp;0.74, 2.52) in OS and a HR of 1.12 (95% CI:&nbsp;0.64, 1.96) in PFS
was observed for nivolumab in combination with ipilimumab and chemotherapy vs.
chemotherapy within this study subgroup. ORR was 27.0% in the nivolumab in
combination with ipilimumab and chemotherapy arm and 15.2% in the chemotherapy
arm. Forty-three&nbsp;percent of patients aged &#8805;&nbsp;75&nbsp;years
discontinued treatment with nivolumab in combination with ipilimumab and
chemotherapy. Efficacy and safety data of nivolumab in combination with
ipilimumab and chemotherapy are limited in this patient population.</p>

<p class=EMEABodyText style='text-align:justify'>&nbsp;</p>

<p class=EMEABodyText style='text-align:justify'>In a subgroup analysis, a
reduced survival benefit for nivolumab in combination with ipilimumab and
chemotherapy compared to chemotherapy was observed in patients who were never
smokers. However, due to the small numbers of patients, no definitive
conclusions can be drawn from these data.</p>

<p class=EMEABodyText style='text-align:justify'>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Treatment
of NSCLC after prior chemotherapy</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Squamous
NSCLC</span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Randomised
phase&nbsp;3 study vs. docetaxel (CA209017)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of
nivolumab&nbsp;3&nbsp;mg/kg as a single agent for the treatment of advanced or
metastatic squamous NSCLC were evaluated in a phase&nbsp;3, randomised, open&#8209;label
study (CA209017). The study included patients (18&nbsp;years or older) who have
experienced disease progression during or after one prior platinum doublet&#8209;based
chemotherapy regimen and an ECOG performance status score of 0&nbsp;or&nbsp;1.
Patients were enrolled regardless of their tumour PD&#8209;L1 status. Patients
with active autoimmune disease, symptomatic interstitial lung disease, or active
brain metastases were excluded from the study. Patients with treated brain
metastases were eligible if neurologically returned to baseline at least
2&nbsp;weeks prior to enrolment, and either off corticosteroids, or on a stable
or decreasing dose of &lt;&nbsp;10&nbsp;mg daily prednisone equivalents.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>A total of 272&nbsp;patients were
randomised to receive either nivolumab 3&nbsp;mg/kg (n&nbsp;=&nbsp;135)
administered intravenously over&nbsp;60&nbsp;minutes every&nbsp;2&nbsp;weeks or
docetaxel (n&nbsp;=&nbsp;137) 75&nbsp;mg/m<sup>2</sup> every 3&nbsp;weeks.
Treatment was continued as long as clinical benefit was observed or until
treatment was no longer tolerated. </span><span lang=EN-GB>T</span><span
lang=EN-GB>umour assessments,</span><span lang=EN-GB> according to the RECIST,
version&nbsp;1.1, </span><span lang=EN-GB>were conducted&nbsp;9 weeks after
randomisation and continued every&nbsp;6&nbsp;weeks thereafter. The primary
efficacy outcome measure was OS. Key secondary efficacy outcome measures were
investigator&#8209;assessed ORR and PFS. In addition, symptom improvement and
overall health status were assessed using the Lung cancer symptom score (LCSS)
average symptom burden index and the EQ&#8209;5D Visual Analogue Scale (EQ&#8209;VAS),
respectively.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Baseline characteristics were generally
balanced between the two groups. The median age was&nbsp;63&nbsp;years
(range:&nbsp;39&#8209;85) with 44% </span><span lang=EN-GB style='font-family:
Symbol'></span><span lang=EN-GB>65&nbsp;years of age and 11% </span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>75&nbsp;years of
age. The majority of patients were white (93%) and male (76%). Thirty&#8209;one
percent had progressive disease reported as the best response to their most
recent prior regimen and 45% received nivolumab within 3&nbsp;months of
completing their most recent prior regimen. Baseline ECOG performance status
score was 0&nbsp;(24%) or 1&nbsp;(76%).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The Kaplan&#8209;Meier curves for OS are
shown in Figure&nbsp;10.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b>Figure&nbsp;10: Kaplan&#8209;Meier
curves of OS (CA209017)</b></p>

<p class=EMEABodyText style='page-break-after:avoid'><b>&nbsp;</b></p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><span style='position:relative;z-index:251658240'><span
style='left:0px;position:absolute;left:25px;top:-10517px;width:35px;height:
1px'><img width=35 height=1 src="OPDIVO-H-3985-IA-099-PI-en_files/image022.png"
alt="Probability of survival"></span></span><img border=0 width=452 height=298
id="Imagen 8" src="OPDIVO-H-3985-IA-099-PI-en_files/image028.jpg"></p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><span lang=EN-GB>Overall survival (months)</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=568
 style='margin-left:33.75pt;border-collapse:collapse'>
 <tr style='height:12.95pt'>
  <td width=436 colspan=11 valign=top style='width:326.95pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.95pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Number
  of subjects at risk</span></p>
  </td>
  <td width=66 colspan=3 valign=top style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.95pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.95pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=436 colspan=11 valign=top style='width:326.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Nivolumab
  3 mg/kg</span></p>
  </td>
  <td width=66 colspan=3 valign=top style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=66 valign=top style='width:49.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=27><p class='MsoNormal'>&nbsp;</td>
  <td width=56 style='width:42.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>135</span></p>
  </td>
  <td width=52 style='width:38.75pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>113</span></p>
  </td>
  <td width=54 colspan=2 style='width:40.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>86</span></p>
  </td>
  <td width=48 style='width:.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>69</span></p>
  </td>
  <td width=54 style='width:40.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>52</span></p>
  </td>
  <td width=54 colspan=2 style='width:40.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>31</span></p>
  </td>
  <td width=48 style='width:.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>15</span></p>
  </td>
  <td width=48 colspan=2 valign=top style='width:.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>7</span></p>
  </td>
  <td width=60 valign=top style='width:44.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>0</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=67 colspan=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=155 colspan=4 style='width:116.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Docetaxel</span></p>
  </td>
  <td width=147 colspan=4 valign=top style='width:109.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=140 colspan=4 valign=top style='width:104.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=127 colspan=3><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=27><p class='MsoNormal'>&nbsp;</td>
  <td width=56 style='width:42.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>137</span></p>
  </td>
  <td width=52 style='width:38.75pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>103</span></p>
  </td>
  <td width=54 colspan=2 style='width:40.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>68</span></p>
  </td>
  <td width=48 style='width:.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>45</span></p>
  </td>
  <td width=54 style='width:40.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>30</span></p>
  </td>
  <td width=54 colspan=2 style='width:40.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>14</span></p>
  </td>
  <td width=48 style='width:.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>7</span></p>
  </td>
  <td width=48 colspan=2 valign=top style='width:.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>2</span></p>
  </td>
  <td width=60 valign=top style='width:44.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>0</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=67 colspan=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr height=0>
  <td width=27 style='border:none'></td>
  <td width=56 style='border:none'></td>
  <td width=52 style='border:none'></td>
  <td width=20 style='border:none'></td>
  <td width=34 style='border:none'></td>
  <td width=48 style='border:none'></td>
  <td width=54 style='border:none'></td>
  <td width=10 style='border:none'></td>
  <td width=44 style='border:none'></td>
  <td width=48 style='border:none'></td>
  <td width=43 style='border:none'></td>
  <td width=5 style='border:none'></td>
  <td width=60 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=66 style='border:none'></td>
 </tr>
</table>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&#9472;&#9472;&#8710;&#9472;&#9472;&#9472;
Nivolumab 3&nbsp;mg/kg (events: 86/135), median and 95%&nbsp;CI:&nbsp;9.23&nbsp;(7.33,
13.27)</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>- - -</span><span
lang=EN-GB style='font-family:Wingdings'></span><span lang=EN-GB>- - -
Docetaxel (events: 113/137), median and 95%&nbsp;CI:&nbsp;6.01&nbsp;(5.13,
7.33)</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>The observed OS benefit was consistently
demonstrated across subgroups of patients. Survival benefit was observed
regardless of whether patients had tumours that were designated PD&#8209;L1
negative or PD&#8209;L1 positive (tumour membrane expression cut off of 1%, 5%
or 10%). However, the role of this biomarker (tumour PD&#8209;L1 expression)
has not been fully elucidated. With a minimum of 62.6&nbsp;months follow&#8209;up,
OS benefit remains consistently demonstrated across subgroups.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Study CA209017 included a limited number
of patients &#8805;&nbsp;75&nbsp;years (11&nbsp;in the nivolumab group and
18&nbsp;in the docetaxel group). Nivolumab showed numerically less effect on OS
(HR&nbsp;1.85; 95%&nbsp;CI: 0.76, 4.51), PFS (HR&nbsp;=&nbsp;1.76; 95%&#8209;CI:
0.77, 4.05) and ORR (9.1% vs. 16.7%). Because of the small sample size, no
definitive conclusions can be drawn from these data.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Efficacy results are shown in
Table&nbsp;16.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;16</span></b><span
lang=EN-GB>: <b>Efficacy results (CA209017)</b></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=202 valign=top style='width:151.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>nivolumab<br>
  (n&nbsp;=&nbsp;135)</span></b></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>docetaxel<br>
  (n&nbsp;=&nbsp;137)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=7 valign=top style='width:464.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:10.0pt'>Primary analysis</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:9.0pt'>Minimum follow&#8209;up: 10.6&nbsp;months</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Overall
  survival </span></b></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Events</span></p>
  </td>
  <td width=209 colspan=3 style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>86 (63.7%)</span></p>
  </td>
  <td width=209 colspan=3 style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>113 (82.5%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Hazard ratio </span></p>
  </td>
  <td width=417 colspan=6 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.59</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>96.85% CI</span></p>
  </td>
  <td width=417 colspan=6 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(0.43, 0.81)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>p&#8209;value</span></p>
  </td>
  <td width=417 colspan=6 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.0002</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Median (95%&nbsp;CI)
  months</span></p>
  </td>
  <td width=209 colspan=3 style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>9.23 (7.33, 13.27)</span></p>
  </td>
  <td width=209 colspan=3 style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>6.01 (5.13, 7.33)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Rate (95%&nbsp;CI)
  at 12&nbsp;months</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>42.1 (33.7, 50.3)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>23.7 (16.9, 31.1)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Confirmed
  objective response </span></b></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>27</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(20.0%)</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>12</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(8.8%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(13.6, 27.7)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(4.6, 14.8)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Odds ratio (95%&nbsp;CI)</span></p>
  </td>
  <td width=417 colspan=6 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2.64 (1.27, 5.49)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>p&#8209;value</span></p>
  </td>
  <td width=417 colspan=6 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.0083</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Complete
  response (CR)</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>1</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(0.7%)</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>0 </span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Partial
  response (PR)</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>26</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(19.3%)</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>12 </span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(8.8%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Stable
  disease (SD)</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>39</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(28.9%)</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>47 </span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(34.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Median
  duration of response </span></b></p>
  </td>
  <td width=139 colspan=2 valign=top style='width:104.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=139 colspan=2 valign=top style='width:104.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=139 colspan=2 valign=top style='width:104.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Months
  (range)</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>Not reached</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(2.9&#8209;20.5<sup>+</sup>)</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>8.4</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(1.4<sup>+</sup>&#8209;15.2<sup>+</sup>)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Median time
  to response</span></b></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Months
  (range)</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>2.2</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(1.6&#8209;11.8)</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>2.1</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>(1.8&#8209;9.5)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Progression&#8209;free
  survival</span></b></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Events</span></p>
  </td>
  <td width=209 colspan=3 style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>105 (77.8%)</span></p>
  </td>
  <td width=209 colspan=3 style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>122 (89.1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Hazard ratio </span></p>
  </td>
  <td width=417 colspan=6 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.62 </span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>95%&nbsp;CI</span></p>
  </td>
  <td width=417 colspan=6 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(0.47, 0.81)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>p&#8209;value</span></p>
  </td>
  <td width=417 colspan=6 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&lt;&nbsp;0.0004</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 colspan=2 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=104 valign=top style='width:78.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Median (95%&nbsp;CI)
  (months)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>3.48 (2.14, 4.86)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>2.83 (2.10, 3.52)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Rate (95%&nbsp;CI)
  at 12&nbsp;months</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>20.8 (14.0, 28.4)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>6.4 (2.9, 11.8)</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=7 style='width:464.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:10.0pt'>Updated analysis</span></b></p>
  <p class=BMSTableText style='margin:0in'><span lang=EN-GB>Minimum follow&#8209;up:
  24.2&nbsp;months</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 style='width:151.55pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Overall
  survival</span></b><span class=EMEASuperscript><span lang=EN-GB>a</span></span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;border:none;
  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Events</span></p>
  </td>
  <td width=209 colspan=3 style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>110 (81.4%)</span></p>
  </td>
  <td width=209 colspan=3 style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>128 (93.4%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Hazard ratio </span></p>
  </td>
  <td width=417 colspan=6 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.62</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>95%&nbsp;CI</span></p>
  </td>
  <td width=417 colspan=6 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(0.47, 0.80)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Rate (95%&nbsp;CI)
  at 24&nbsp;months</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>22.9 (16.2, 30.3)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>8 (4.3, 13.3)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Confirmed
  objective response</span></b></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>20.0%</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>8.8%</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(13.6, 27.7)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(4.6, 14.8)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Median
  duration of response</span></b></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Months
  (range)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>25.2 (2.9&#8209;30.4)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>8.4 (1.4<span
  class=EMEASuperscript>+</span>&#8209;18.0<span class=EMEASuperscript>+</span>)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Progression&#8209;free
  survival</span></b></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES style='font-size:9.0pt'>&nbsp;</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Rate (95%&nbsp;CI)
  at 24&nbsp;months</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>15.6 (9.7, 22.7)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'>All patients had either progressed,
  were censored, or lost to follow&#8209;up</p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=619 colspan=7 valign=top style='width:464.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:10.0pt'>Updated analysis</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Minimum follow&#8209;up: 62.6 months</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Overall
  survival</span></b><span class=EMEASuperscript><span lang=EN-GB>a</span></span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=ES>&nbsp;</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Events</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>118 (87.4%)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'>133 (97.1%)</p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB
  style='font-size:10.0pt'>Hazard ratio </span></p>
  </td>
  <td width=417 colspan=6 rowspan=2 valign=top style='width:312.8pt;padding:
  0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText style='margin:0in'>0.62</p>
  <p class=BMSTableText style='margin:0in'>(0.48, 0.79)</p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB
  style='font-size:10.0pt;color:black'>95%&nbsp;CI</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Rate (95%&nbsp;CI)
  at 60&nbsp;months</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>12.3 (7.4, 18.5)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'>3.6 (1.4, 7.8)</p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Confirmed
  objective response</span></b></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>20.0%</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>8.8%</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB
  style='font-size:10.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>(13.6, 27.7)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>(4.6, 14.8)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Median
  duration of response</span></b></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Months
  (range)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>25.2 (2.9&#8209;70.6<span
  class=BMSSuperscript>+</span>)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'>7.5 (0.0<span class=BMSSuperscript><span
  lang=ES>+</span></span>&#8209;18.0<span class=BMSSuperscript><span lang=ES>+</span></span>)</p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Progression&#8209;free
  survival</span></b></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=202 valign=top style='width:151.55pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Rate (95%&nbsp;CI)
  at 60&nbsp;months</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText style='margin:0in'><span lang=ES>9.4 (4.8, 15.8)</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.4pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText style='margin:0in'>All patients had either progressed,
  were censored, or lost to follow&#8209;up</p>
  </td>
 </tr>
 <tr height=0>
  <td width=202 style='border:none'></td>
  <td width=104 style='border:none'></td>
  <td width=35 style='border:none'></td>
  <td width=70 style='border:none'></td>
  <td width=69 style='border:none'></td>
  <td width=35 style='border:none'></td>
  <td width=104 style='border:none'></td>
 </tr>
</table>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>a</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Six patients (4%) randomised to docetaxel
crossed over at any time to receive nivolumab treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:10.0pt'><sup>+</sup> </span><span
lang=EN-GB style='font-size:10.0pt'>Denotes a censored observation.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The rate of disease&#8209;related
symptom improvement, as measured by LCSS, was similar between the nivolumab
group (18.5%) and the docetaxel group (21.2%). The average EQ&#8209;VAS
increased over time for both treatment groups, indicating better overall health
status for patients remaining on treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Single&#8209;arm
phase&nbsp;2&nbsp;study (CA209063)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Study CA209063 was a single&#8209;arm,
open&#8209;label study conducted in 117&nbsp;patients with locally advanced or
metastatic squamous NSCLC after two or more lines of therapy; otherwise similar
inclusion criteria as study CA209017 were applied. Nivolumab 3&nbsp;mg/kg
showed an ORR of 14.5% (95%&nbsp;CI: 8.7,22.2%), a median OS of
8.21&nbsp;months (95%&nbsp;CI: 6.05,10.9), and a median PFS of 1.87&nbsp;months
(95%&nbsp;CI 1.77,3.15). The PFS was measured by RECIST, version&nbsp;1.1. The
estimated 1&#8209;year survival rate was 41%.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Single&#8209;arm
phase&nbsp;2&nbsp;study (CA209171)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Study&nbsp;CA209171 was a single&#8209;arm,
open label study of nivolumab monotherapy in patients with previously treated
advanced or metastatic squamous NSCLC. Safety was the primary endpoint and
efficacy was a secondary endpoint. Of the 811&nbsp;treated patients,
103&nbsp;(13%) had an ECOG performance score of&nbsp;2,<span
class=MsoCommentReference> 686&nbsp;(85%) were &lt;&nbsp;75&nbsp;years old </span>and
125&nbsp;(15%) were&nbsp;&#8805;&nbsp;75&nbsp;years old. N</span><span
lang=EN-GB>o new safety signals were identified in all treated patients and the
overall safety profile of nivolumab was similar across subgroups. Efficacy
results based on investigator&#8209;assessed ORR are presented in Table&nbsp;17
below.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Table&nbsp;17</span></b><span
lang=EN-GB>: </span><b><span lang=EN-GB>ORR based on response evaluable
patients </span></b><span lang=EN-GB style='color:black'></span><b><span
lang=EN-GB> total and by subgroup (CA209171)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=584
 style='border-collapse:collapse;border:none'>
 <tr style='height:11.65pt'>
  <td width=168 valign=top style='width:125.9pt;border-top:windowtext;
  border-left:white;border-bottom:windowtext;border-right:white;border-style:
  solid;border-width:1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.65pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><b><span
  lang=EN-GB>Results</span></b></p>
  </td>
  <td width=104 valign=top style='width:78.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.65pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><b><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>Total</span></b></p>
  </td>
  <td width=104 valign=top style='width:78.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.65pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><b><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>ECOG PS 2</span></b></p>
  </td>
  <td width=104 valign=top style='width:78.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.65pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><b><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>&lt;&nbsp;75&nbsp;years</span></b></p>
  </td>
  <td width=104 valign=top style='width:78.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.65pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><b><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>&#8805;&nbsp;75&nbsp;years</span></b></p>
  </td>
 </tr>
 <tr style='height:57.35pt'>
  <td width=168 style='width:125.9pt;border-top:none;border-left:solid white 1.0pt;
  border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:57.35pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>N responders/ N
  evaluable<sup>a</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>(%)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>95%&nbsp;CI<sup>b</sup></span></p>
  </td>
  <td width=104 style='width:78.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:57.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>66/671</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(9.8)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>(7.7, 12.3)</span></p>
  </td>
  <td width=104 style='width:78.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:57.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1/64</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(6.1)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>(0.0, 8.4)</span></p>
  </td>
  <td width=104 style='width:78.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:57.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>55/568</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(9.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>(7.4, 12.4)</span></p>
  </td>
  <td width=104 style='width:78.1pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid white 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:57.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>11/103</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(10.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%'><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>(5.5, 18.3)</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>a </span></sup><span
lang=EN-GB style='font-size:10.0pt'>includes confirmed and unconfirmed
responses, scans were mandatory only at week 8/9 and week&nbsp;52.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>b</span></sup><span lang=EN-GB
style='font-size:10.0pt'> CR+PR, confidence interval based on the
Clopper and Pearson method</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Non&#8209;squamous
NSCLC</span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Randomised
phase&nbsp;3 study vs. docetaxel (CA209057)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of nivolumab&nbsp;3&nbsp;mg/kg
as a single agent for the treatment of advanced or metastatic non&#8209;squamous
NSCLC were evaluated in a phase&nbsp;3, randomised, open&#8209;label study
(CA209057). The study included patients (18&nbsp;years or older) who have
experienced disease progression during or after one prior platinum doublet&#8209;based
chemotherapy regimen which may have included maintenance therapy and who had an
ECOG performance status score of&nbsp;0&nbsp;or&nbsp;1. An additional line of
TKI therapy was allowed for patients with known EGFR mutation or ALK
translocation. Patients were enrolled regardless of their tumour PD&#8209;L1
status. Patients with active autoimmune disease, symptomatic interstitial lung
disease, or active brain metastases were excluded from the study. Patients with
treated brain metastases were eligible if neurologically returned to baseline
at least 2&nbsp;weeks prior to enrolment, and either off corticosteroids, or on
a stable or decreasing dose of &lt;&nbsp;10&nbsp;mg daily prednisone
equivalents.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>A total of 582&nbsp;patients were
randomised to receive either nivolumab 3&nbsp;mg/kg administered intravenously
over&nbsp;60&nbsp;minutes every&nbsp;2&nbsp;weeks (n&nbsp;=&nbsp;292) or
docetaxel 75&nbsp;mg/m<sup>2</sup> every 3&nbsp;weeks (n&nbsp;=&nbsp;290).
Treatment was continued as long as clinical benefit was observed or until
treatment was no longer tolerated. Tumour assessments were conducted according
to the RECIST version 1.1. The primary efficacy outcome measure was OS. Key
secondary efficacy outcome measures were investigator&#8209;assessed ORR and PFS.
Additional prespecified subgroup analyses were conducted to evaluate the
efficacy of tumour PD&#8209;L1 expression at predefined levels of 1%, 5% and
10%. Assessment according to discrete PD&#8209;L1 expression intervals were not
included in the prespecified analyses due to the small sample sizes within the
intervals.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Pre&#8209;study tumour tissue specimens
were systematically collected prior to randomisation in order to conduct pre&#8209;planned
analyses of efficacy according to tumour PD&#8209;L1 expression. Tumour PD&#8209;L1
expression was determined using the PD&#8209;L1&nbsp;IHC&nbsp;28&#8209;8
pharmDx&nbsp;assay.</span></p>

<p class=EMEABodyText><s><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=EMEABodyText><span lang=EN-GB>The median age was 62&nbsp;years
(range:&nbsp;21 to 85) with 34% </span><span lang=EN-GB style='font-family:
Symbol'></span><span lang=EN-GB>65&nbsp;years of age and&nbsp;7% </span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>75&nbsp;years of
age. The majority of patients were white (92%) and male (55%). Baseline ECOG
performance status was 0&nbsp;(31%) or 1&nbsp;(69%). Seventy&#8209;nine percent
of patients were former/current smokers.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The Kaplan&#8209;Meier curves for OS are
shown in Figure&nbsp;11.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Figure&nbsp;11:</span></b><span
lang=EN-GB> <b>Kaplan&#8209;Meier curves of OS (CA209057)</b></span></p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><span style='position:relative;z-index:251664384'><span
style='left:0px;position:absolute;left:-11px;top:-13501px;width:37px;
height:1px'><img width=37 height=1
src="OPDIVO-H-3985-IA-099-PI-en_files/image012.png"
alt="Probability of survival"></span></span><img border=0 width=451 height=298
id="Picture 2" src="OPDIVO-H-3985-IA-099-PI-en_files/image029.jpg"></p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><span lang=EN-GB>Overall survival (months)</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=504
 style='margin-left:33.75pt;border-collapse:collapse'>
 <tr style='height:12.95pt'>
  <td width=504 colspan=13 valign=top style='width:378.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.95pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Number
  of subjects at risk</span></p>
  </td>
 </tr>
 <tr>
  <td width=504 colspan=13 valign=top style='width:378.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Nivolumab&nbsp;3
  mg/kg</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=27><p class='MsoNormal'>&nbsp;</td>
  <td width=46 style='width:34.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>292</span></p>
  </td>
  <td width=46 style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>232</span></p>
  </td>
  <td width=46 style='width:34.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>194</span></p>
  </td>
  <td width=46 style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>169</span></p>
  </td>
  <td width=46 style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>146</span></p>
  </td>
  <td width=46 style='width:34.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>123</span></p>
  </td>
  <td width=46 style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>62</span></p>
  </td>
  <td width=46 valign=top style='width:34.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>32</span></p>
  </td>
  <td width=46 valign=top style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>9</span></p>
  </td>
  <td width=46 colspan=2 valign=top style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=13><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=454 colspan=11 style='width:340.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Docetaxel</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=50 colspan=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=27><p class='MsoNormal'>&nbsp;</td>
  <td width=46 style='width:34.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>290</span></p>
  </td>
  <td width=46 style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>244</span></p>
  </td>
  <td width=46 style='width:34.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>194</span></p>
  </td>
  <td width=46 style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>150</span></p>
  </td>
  <td width=46 style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>111</span></p>
  </td>
  <td width=46 style='width:34.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>88</span></p>
  </td>
  <td width=46 style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>34</span></p>
  </td>
  <td width=46 valign=top style='width:34.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>10</span></p>
  </td>
  <td width=46 valign=top style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>5</span></p>
  </td>
  <td width=46 colspan=2 valign=top style='width:34.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=13><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr height=0>
  <td width=27 style='border:none'></td>
  <td width=46 style='border:none'></td>
  <td width=46 style='border:none'></td>
  <td width=46 style='border:none'></td>
  <td width=46 style='border:none'></td>
  <td width=46 style='border:none'></td>
  <td width=46 style='border:none'></td>
  <td width=46 style='border:none'></td>
  <td width=46 style='border:none'></td>
  <td width=46 style='border:none'></td>
  <td width=9 style='border:none'></td>
  <td width=38 style='border:none'></td>
  <td width=13 style='border:none'></td>
 </tr>
</table>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&#9472;&#9472;&#8710;&#9472;&#9472;&#9472;
Nivolumab&nbsp;3&nbsp;mg/kg (events: 190/292), median and 95%&nbsp;CI: 12.19 (9.66,
14.98)</span></p>

<p class=EMEABodyText><span lang=EN-GB>- - -</span><span lang=EN-GB
style='font-family:Wingdings'></span><span lang=EN-GB>- - - Docetaxel (events:&nbsp;223/290),
median and 95%&nbsp;CI: 9.36 (8.05, 10.68)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The trial demonstrated a statistically
significant improvement in OS for patients randomised to nivolumab as compared
with docetaxel at the prespecified interim analysis when 413&nbsp;events were
observed (93%&nbsp;of the planned number of events for final analysis).
Efficacy results are shown in Table&nbsp;18.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;18</span></b><span
lang=EN-GB>: <b>Efficacy results (CA209057)</b></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=247 valign=top style='width:185.05pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>nivolumab<br>
  (n&nbsp;=&nbsp;292)</span></b></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>docetaxel<br>
  (n&nbsp;=&nbsp;290)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:453.55pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:10.0pt'>Prespecified interim analysis</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Minimum follow&#8209;up: 13.2&nbsp;months</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Overall
  survival</span></b></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Events</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>190 (65.1%)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>223 (76.9%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Hazard
  ratio</span><sup><span lang=EN-GB>a</span></sup></p>
  </td>
  <td width=358 colspan=2 valign=top style='width:268.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.73</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>  (95.92%
  CI)</span></p>
  </td>
  <td width=358 colspan=2 valign=top style='width:268.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(0.59, 0.89)</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>  </span></b><span
  lang=EN-GB style='font-size:10.0pt'>p&#8209;value</span><sup><span
  lang=EN-GB>b</span></sup></p>
  </td>
  <td width=358 colspan=2 valign=top style='width:268.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.0015</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Median (95%&nbsp;CI)
  months</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>12.19 (9.66, 14.98)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>9.36 (8.05, 10.68)</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Rate (95%&nbsp;CI)
  at 12</span><span lang=EN-GB style='color:black'>&nbsp;</span><span
  lang=EN-GB style='font-size:10.0pt'>months</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>50.5 (44.6, 56.1)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>39.0 (33.3, 44.6)</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Confirmed
  objective response</span></b></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>56 (19.2%)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>36 (12.4%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> (95%&nbsp;CI)</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(14.8, 24.2)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(8.8, 16.8)</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Odds
  ratio (95%&nbsp;CI)</span></p>
  </td>
  <td width=358 colspan=2 valign=top style='width:268.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1.68 (1.07, 2.64)</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> p&#8209;value</span></p>
  </td>
  <td width=358 colspan=2 valign=top style='width:268.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.0246</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Complete
  response (CR)</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4 (1.4%)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1 (0.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Partial
  response (PR)</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>52 (17.8%)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>35 (12.1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Stable
  disease (SD)</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>74 (25.3%)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>122 (42.1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Median
  duration of response </span></b></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Months
  (range)</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>17.15 (1.8&#8209;22.6</span><span
  class=EMEASuperscript><span lang=EN-GB>+</span></span><span lang=EN-GB
  style='font-size:10.0pt'>)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>5.55 (1.2</span><span class=EMEASuperscript><span
  lang=EN-GB>+</span></span><span lang=EN-GB style='font-size:10.0pt'>&#8209;15.2</span><span
  class=EMEASuperscript><span lang=EN-GB>+</span></span><span lang=EN-GB
  style='font-size:10.0pt'>)</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Median time
  to response</span></b></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Months
  (range)</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2.10 (1.2&#8209;8.6)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2.61 (1.4&#8209;6.3)</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Progression&#8209;free
  survival</span></b></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Events</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>234 (80.1%)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>245 (84.5%)</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Hazard
  ratio</span></p>
  </td>
  <td width=358 colspan=2 valign=top style='width:268.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.92</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> 95%&nbsp;CI</span></p>
  </td>
  <td width=358 colspan=2 valign=top style='width:268.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(0.77, 1.11)</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> p&#8209;value</span></p>
  </td>
  <td width=358 colspan=2 valign=top style='width:268.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.3932</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Median (95%&nbsp;CI)
  (months)</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2.33 (2.17, 3.32)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>4.21 (3.45, 4.86)</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=247 valign=top style='width:185.05pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Rate (95%&nbsp;CI)
  at 12 months</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>18.5 (14.1, 23.4)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>8.1 (5.1, 12.0)</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=605 colspan=3 valign=top style='width:453.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:10.0pt'>Updated analysis</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Minimum follow&#8209;up: 24.2&nbsp;months</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 style='width:185.05pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Overall
  survival</span></b><span class=EMEASuperscript><span lang=EN-GB>c</span></span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Events</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>228 (78.1%)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>247 (85.1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Hazard
  ratio<sup>a</sup></span></p>
  </td>
  <td width=358 colspan=2 valign=top style='width:268.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.75</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> (95%&nbsp;CI)</span></p>
  </td>
  <td width=358 colspan=2 valign=top style='width:268.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(0.63, 0.91)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Rate (95%&nbsp;CI)
  at 24&nbsp;months</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>28.7 (23.6, 34.0)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>15.8 (11.9, 20.3)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Confirmed
  objective response</span></b></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>19.2%</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>12.4%</span></p>
  </td>
 </tr>
 <tr>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> (95%&nbsp;CI)</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(14.8, 24.2)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(8.8, 16.8)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Median
  duration of response</span></b></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Months
  (range)</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>17.2 (1.8&#8209;33.7<span class=EMEASuperscript>+</span>)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>5.6 (1.2<span class=EMEASuperscript>+</span>&#8209;16.8)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Progression&#8209;free
  survival</span></b></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 valign=top style='width:185.05pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Rate (95%&nbsp;CI)
  at 24&nbsp;months</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>11.9 (8.3, 16.2)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>1.0 (0.2, 3.3)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=605 colspan=3 valign=top style='width:453.55pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><b><span
  lang=EN-GB>Updated analysis</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>Minimum follow&#8209;up: 62.7</span><span
  lang=EN-GB style='color:black'>&nbsp;</span><span lang=EN-GB
  style='font-size:10.0pt'>months</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><b><span
  lang=EN-GB>Overall survival</span></b><span class=EMEASuperscript><span
  lang=EN-GB style='font-size:11.0pt'>d</span></span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB> Events</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>250 (85.6%)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>279 (96.2%)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB
  style='font-size:10.0pt'>Hazard ratio</span><span class=EMEASuperscript><span
  lang=EN-GB>a</span></span></p>
  </td>
  <td width=358 colspan=2 valign=top style='width:268.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>0.70</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB
  style='font-size:10.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=358 colspan=2 valign=top style='width:268.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(0.58, 0.83)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB> Rate (95%&nbsp;CI) at 60&nbsp;months</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>14.0 (10.2, 18.3)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>2.1 (0.9, 4.4)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Confirmed
  objective response</span></b></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>19.5%</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>12.4%</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB
  style='font-size:10.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(15.1, 24.5)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>(8.8, 16.8)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Median
  duration of response</span></b></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Months
  (range)</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>17.2 (1.8&#8209;70.4</span><span
  class=EMEASuperscript><span lang=EN-GB>+</span></span><span lang=EN-GB
  style='font-size:10.0pt'>)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>5.6 (0.0</span><span class=EMEASuperscript><span
  lang=EN-GB>+</span></span><span lang=EN-GB style='font-size:10.0pt'>&#8209;33.4)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 valign=top style='width:185.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Progression&#8209;free
  survival</span></b></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=247 valign=top style='width:185.05pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Rate (95%&nbsp;CI)
  at 60&nbsp;months</span></p>
  </td>
  <td width=156 valign=top style='width:117.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>7.5 (4.5, 11.4)</span></p>
  </td>
  <td width=202 valign=top style='width:151.15pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:10.0pt'>All patients had either progressed, were censored,
  or lost to follow&#8209;up</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>a</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Derived from a stratified proportional
hazards model.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>b </span></sup><span
lang=EN-GB style='font-size:10.0pt'>P&#8209;value is derived from a log&#8209;rank
test stratified by prior maintenance therapy and line of therapy; the corresponding
OBrien&#8209;Fleming efficacy boundary significance level is 0.0408.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
class=EMEASuperscript><span lang=EN-GB style='font-size:10.0pt'>c</span></span><span
lang=EN-GB style='font-size:10.0pt'> Sixteen patients (6%) randomised
to docetaxel crossed over at any time to receive nivolumab treatment.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
class=EMEASuperscript><span lang=EN-GB style='font-size:10.0pt'>d</span></span><span
lang=EN-GB style='font-size:10.0pt'> Seventeen patients (6%)
randomised to docetaxel crossed over at any time to receive nivolumab
treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB><sup>+</sup> </span><span
lang=EN-GB style='font-size:10.0pt'>Denotes a censored observation.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Quantifiable tumour PD&#8209;L1
expression was measured in 79% of patients in the nivolumab group and 77% of
patients in the docetaxel group. Tumour PD&#8209;L1 expression levels were
balanced between the two treatment groups (nivolumab vs. docetaxel) at each of
the predefined tumour PD&#8209;L1 expression levels of&nbsp;&#8805;&nbsp;1%
(53% vs. 55%), &#8805;&nbsp;5% (41% vs. 38%), or &#8805;&nbsp;10% (37% vs. 35%).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Patients with tumour PD&#8209;L1
expression by all predefined expression levels in the nivolumab group
demonstrated greater likelihood of improved survival compared to docetaxel,
whereas survival was similar to docetaxel in patients with low or no tumour PD&#8209;L1
expression. In terms of ORR, increasing PD&#8209;L1 expression was associated
with larger ORR. Comparable to the overall population, median duration of
response was increased with nivolumab vs. docetaxel for patients with no PD&#8209;L1
expression (18.3&nbsp;months vs. 5.6&nbsp;months) and for patients with PD&#8209;L1
expression (16.0&nbsp;months vs. 5.6&nbsp;months).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Table&nbsp;19 summarises results of ORR
and OS by tumour PD&#8209;L1 expression.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;19: ORR
and OS by tumour PD&#8209;L1 expression (CA209057)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=612
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=144 valign=top style='width:1.5in;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableHeader align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>PD&#8209;L1 expression</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableHeader style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>nivolumab</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableHeader style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>docetaxel</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableHeader style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=4 valign=top style='width:459.0pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>ORR by tumour PD&#8209;L1 expression</span></b></p>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB>Minimum
  follow&#8209;up: 13.2&nbsp;months</span></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Odds ratio (95%&nbsp;CI)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>&lt;&nbsp;1%</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>10/108 (9.3%)</span></p>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>95%&nbsp;CI: </span><span lang=EN-GB style='color:black'>4.5,
  16.4</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>15/101 (14.9%)</span></p>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>95%&nbsp;CI: </span><span lang=EN-GB style='color:black'>8.6,
  23.3</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>0.59 (0.22, 1.48)</span></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>&#8805;&nbsp;1%</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>38/123 (30.9%)</span></p>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>95%&nbsp;CI: 22.9, 39.9</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>15/123 (12.2%)</span></p>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>95%&nbsp;CI: 7.0, 19.3</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>3.22 (1.60, 6.71)</span></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin-left:.25in;text-align:left;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>&#8805;&nbsp;1%
  to &lt;&nbsp;10%</span><sup><span lang=EN-GB style='font-size:12.0pt;
  color:black'>a</span></sup></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>6/37 (16.2%)</span></p>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>95%&nbsp;CI: 6.2, 32.0</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>5/44 (11.4%)</span></p>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>95%&nbsp;CI: 3.8, 24.6</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>1.51 (0.35, 6.85)</span></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin-left:.25in;text-align:left;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>&#8805;&nbsp;10%
  to &lt;&nbsp;50%</span><sup><span lang=EN-GB style='font-size:12.0pt;
  color:black'>a</span></sup></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>5/20 (25.0%)</span></p>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>95%&nbsp;CI: 8.7</span><span lang=EN-GB>, 49.1</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>7/33 (21.2%)</span></p>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>95%&nbsp;CI: </span><span lang=EN-GB>9.0, 38.9</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>1.24 (0.26, 5.48)</span></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin-left:.25in;text-align:left;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>&#8805;&nbsp;50%</span><sup><span
  lang=EN-GB style='font-size:12.0pt;color:black'>a</span></sup></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>27/66 (40.9%)</span></p>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>95%&nbsp;CI: 29.0, 53.7</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>3/46 (6.5%)</span></p>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>95%&nbsp;CI: </span><span lang=EN-GB>1.4, 17.9</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>9.92 (2.68, 54.09)</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=4 valign=top style='width:459.0pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>OS by tumour PD&#8209;L1 expression</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=4 valign=top style='width:459.0pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=612
   style='border-collapse:collapse;border:none'>
   <tr>
    <td width=612 valign=top style='width:459.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
    <p class=MsoNormal align=center style='text-align:center;text-autospace:
    none'><span lang=EN-GB style='font-size:10.0pt'>Minimum follow&#8209;up:
    13.2&nbsp;months</span></p>
    </td>
   </tr>
  </table>
  <p class=BMSTableText style='page-break-after:avoid'></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=312 colspan=2 valign=top style='width:3.25in;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Number of events (number of patients)</span></b></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Unstratified hazard ratio (95%&nbsp;CI)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>&lt;&nbsp;1%</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>77 (108)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>75 (101)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>0.90 (0.66, 1.24)</span></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>&#8805;&nbsp;1%</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>68 (123)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>93 (123)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>0.59 (0.43, 0.82)</span></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin-left:.25in;text-align:left;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>&#8805;&nbsp;1%
  to &lt;&nbsp;10%</span><sup><span lang=EN-GB style='font-size:12.0pt;
  color:black'>a</span></sup></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>27 (37)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>30 (44)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>1.33 (0.79, 2.24)</span></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin-left:.25in;text-align:left;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>&#8805;&nbsp;10%
  to &lt;&nbsp;50%</span><sup><span lang=EN-GB style='font-size:12.0pt;
  color:black'>a</span></sup></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>11 (20)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>26 (33)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>0.61 (0.30, 1.23)</span></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin-left:.25in;text-align:left;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>&#8805;&nbsp;50%</span><sup><span
  lang=EN-GB style='font-size:12.0pt;color:black'>a</span></sup></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>30 (66)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>37 (46)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>0.32 (0.20, 0.53)</span></p>
  </td>
 </tr>
 <tr style='height:11.35pt'>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:.25in;text-align:left;page-break-after:avoid'><span
  lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:11.35pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=4 valign=top style='width:459.0pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
  lang=EN-GB style='font-size:10.0pt'>Updated analysis </span></b></p>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB style='font-size:10.0pt'>Minimum follow&#8209;up: 24.2&nbsp;months</span></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>&lt;&nbsp;1%</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>91 (108)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>86 (101)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>0.91 (0.67, 1.22)</span></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>&#8805;&nbsp;1%</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>87 (123)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>103 (123)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>0.62 (0.47, 0.83)</span></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=4 valign=top style='width:459.0pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Updated analysis</span></b></p>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Minimum follow&#8209;up: 62.7&nbsp;months</span></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>&lt;&nbsp;1%</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>100 (109)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>96 (101)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>0.87 (0.66, 1.16)</span></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>&#8805;1%</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>96 (122)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>119 (123)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>0.55 (0.42, 0.73)</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText style='margin-left:9.0pt;text-indent:-9.0pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>a</span></sup><span lang=EN-GB
style='font-size:10.0pt'> </span><span lang=EN-GB style='font-size:10.0pt'>Post&#8209;hoc&nbsp;analysis;
results should be interpreted with caution as the subgroup samples sizes are
small and, at the time of the analysis, the PD&#8209;L1 IHC 28&#8209;8 pharmDx
assay was not analytically validated at the 10% or 50% expression levels.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>A higher proportion of patients
experienced death within the first 3&nbsp;months in the nivolumab arm (59/292,
20.2%) as compared to the docetaxel arm (44/290, 15.2%). Results of a post&#8209;hoc,
exploratory multivariate analysis indicated that nivolumab&#8209;treated
patients with poorer prognostic features and/or aggressive disease when
combined with lower (e.g.,&nbsp;&lt;&nbsp;50%) or no tumour PD&#8209;L1
expression may be at higher risk of death within the first 3&nbsp;months.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In subgroup analyses, survival benefit compared
to docetaxel was not shown for patients who were never&#8209;smokers or whose
tumours harboured EGFR activating mutations; however, due to the small numbers
of patients, no definitive conclusions can be drawn from these data.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Renal cell
carcinoma </span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Randomised
phase&nbsp;3 study of nivolumab as monotherapy vs. everolimus (CA209025)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of nivolumab
3&nbsp;mg/kg as a single agent for the treatment of advanced RCC with a clear
cell component was evaluated in a Phase 3, randomised, open&#8209;label study
(CA209025). The study included patients (18&nbsp;years or older) who have experienced
disease progression during or after 1&nbsp;or 2&nbsp;prior anti&#8209;angiogenic
therapy regimens and no more than&nbsp;3 total prior systemic treatment
regimens. Patients had to have a Karnofsky Performance Score (KPS) </span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;70%. This
study included patients regardless of their tumour PD&#8209;L1 status. Patients
with any history of or concurrent brain metastases, prior treatment with an
mammalian target of rapamycin (mTOR) inhibitor, active autoimmune disease, or
medical conditions requiring systemic immunosuppression were excluded from the
study.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>A total of 821&nbsp;patients were
randomised to receive either nivolumab 3&nbsp;mg/kg (n&nbsp;=&nbsp;410)
administered intravenously over 60&nbsp;minutes every </span><span lang=EN-GB>2&nbsp;weeks
or everolimus (n&nbsp;=&nbsp;411) 10&nbsp;mg daily, administered orally.
Treatment was continued as long as clinical benefit was observed or until
treatment was no longer tolerated. The first tumour assessments were conducted
8&nbsp;weeks after randomisation and continued every 8&nbsp;weeks thereafter
for the first year and then every 12&nbsp;weeks until progression or treatment
discontinuation, whichever occurred later. Tumour assessments were continued
after treatment discontinuation in patients who discontinued treatment for
reasons other than progression. Treatment beyond initial investigator&#8209;assessed
RECIST, version&nbsp;1.1&#8209;defined progression was permitted if the patient
had a clinical benefit and was tolerating study drug as determined by the
investigator. The primary efficacy outcome measure was OS. Secondary efficacy
assessments included investigator&#8209;assessed ORR and PFS.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Baseline characteristics were generally
balanced between the two groups. The median age was 62&nbsp;years (range:</span><span
lang=EN-GB>&nbsp;18&#8209;88) with 40%&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;65&nbsp;years of age
and 9%&nbsp;</span><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB>&nbsp;75&nbsp;years of age. The majority of patients were male (75%)
and white (88%), all Memorial Sloan Kettering Cancer Center (MSKCC) risk groups
were represented, and 34% and 66% of patients had a baseline KPS of 70&nbsp;to
80% and 90&nbsp;to 100%, respectively. The majority of patients (72%) were
treated with one prior anti&#8209;angiogenic therapy. The median duration of
time from initial diagnosis to randomisation was 2.6&nbsp;years in both the
nivolumab and everolimus groups. The median duration of treatment was 5.5&nbsp;months
(range:</span><span lang=EN-GB>&nbsp;0&#8209;29.6+ months) in nivolumab&#8209;treated
patients and was 3.7&nbsp;months (range:&nbsp;6&nbsp;days&#8209;25.7+&nbsp;months)
in everolimus&#8209;treated patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab was continued beyond
progression in 44% of patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The Kaplan&#8209;Meier curves for OS are
shown in Figure&nbsp;12.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b>Figure&nbsp;12:</b><b><span
lang=EN-GB> </span></b><b>Kaplan&#8209;Meier curves of OS (CA209025)</b></p>

<p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><span style='position:relative;z-index:251662336'><span
style='left:0px;position:absolute;left:-11px;top:-17115px;width:307px;
height:1px'><img width="40%" src="OPDIVO-H-3985-IA-099-PI-en_files/image030.png"
alt="Probability of survival"></span></span><b><img border=0 width=483
height=314 id="Picture 8" src="OPDIVO-H-3985-IA-099-PI-en_files/image031.png"></b></p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><span lang=EN-GB>Overall survival (months)</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Number of
subjects at risk</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=501
 style='margin-left:40.85pt;border-collapse:collapse'>
 <tr>
  <td width=501 colspan=12 valign=top style='width:375.65pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Nivolumab</span></p>
  </td>
 </tr>
 <tr>
  <td width=57 valign=top style='width:42.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='margin-left:1.7pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>410</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>389</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>359</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>337</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>305</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>275</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>213</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>139</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>73</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>29</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>3</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0</span></p>
  </td>
 </tr>
 <tr>
  <td width=501 colspan=12 valign=top style='width:375.65pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:1.7pt;page-break-after:avoid'><span
  lang=EN-GB>Everolimus</span></p>
  </td>
 </tr>
 <tr>
  <td width=57 valign=top style='width:42.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='margin-left:1.7pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>411</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>366</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>324</span></p>
  </td>
  <td width=38 valign=top style='width:28.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>287</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>265</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>241</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>187</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>115</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>61</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>20</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText style='page-break-after:avoid'><img border=0 width=49
height=19 id="Picture 5" src="OPDIVO-H-3985-IA-099-PI-en_files/image032.jpg"><span
lang=EN-GB>Nivolumab 3&nbsp;mg/kg (events: 183/410), median and 95%&nbsp;CI:
25.00 (21.75, N.A.)</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><img border=0 width=47
height=19 id="Imagen 12" src="OPDIVO-H-3985-IA-099-PI-en_files/image033.jpg"><span
lang=EN-GB>Everolimus 10&nbsp;mg (events: 215/411), median and 95%&nbsp;CI:
19.55 (17.64, 23.06)</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>The trial demonstrated a statistically significant
improvement in OS for patients randomised to nivolumab as compared with
everolimus at the prespecified interim analysis when <span lang=EN-GB>398&nbsp;events</span>
were observed (70% of the planned number of events for final analysis)
(Table&nbsp;20 and Figure&nbsp;12). OS benefit was observed regardless of tumour
PD&#8209;L1 expression level.</p>

<p class=EMEABodyText>Efficacy results are shown in Table&nbsp;20.</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;20</span></b><span
lang=EN-GB>: <b>Efficacy results (CA209025)</b></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=202 valign=top style='width:151.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=225 colspan=2 valign=top style='width:168.8pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>nivolumab<br>
  (n&nbsp;=&nbsp;410)</span></b></p>
  </td>
  <td width=192 colspan=2 valign=top style='width:2.0in;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>everolimus<br>
  (n&nbsp;=&nbsp;411)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Overall
  survival </span></b></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Events</span></p>
  </td>
  <td width=225 colspan=2 valign=top style='width:168.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>183 (45%)</span></p>
  </td>
  <td width=192 colspan=2 valign=top style='width:2.0in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>215 (52%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Hazard ratio </span></p>
  </td>
  <td width=417 colspan=4 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.73</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>98.52% CI</span></p>
  </td>
  <td width=417 colspan=4 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.57, 0.93)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>p&#8209;value</span></p>
  </td>
  <td width=417 colspan=4 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0018</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Median
  (95%&nbsp;CI)</span></p>
  </td>
  <td width=225 colspan=2 valign=top style='width:168.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>25.0 (21.7, NE)</span></p>
  </td>
  <td width=192 colspan=2 valign=top style='width:2.0in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>19.6 (17.6, 23.1)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Rate
  (95%&nbsp;CI)</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> At
  6&nbsp;months</span></p>
  </td>
  <td width=225 colspan=2 valign=top style='width:168.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>89.2 (85.7, 91.8)</span></p>
  </td>
  <td width=192 colspan=2 valign=top style='width:2.0in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>81.2 (77.0, 84.7)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> At
  12&nbsp;months</span></p>
  </td>
  <td width=225 colspan=2 valign=top style='width:168.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>76.0 (71.5, 79.9)</span></p>
  </td>
  <td width=192 colspan=2 valign=top style='width:2.0in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>66.7 (61.8, 71.0)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Objective
  response </span></b></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>103</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(25.1%)</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>22</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(5.4%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=225 colspan=2 valign=top style='width:168.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(21.0, 29.6)</span></p>
  </td>
  <td width=192 colspan=2 valign=top style='width:2.0in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(3.4, 8.0)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Odds ratio (95%&nbsp;CI)</span></p>
  </td>
  <td width=417 colspan=4 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>5.98 (3.68, 9.72)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>p&#8209;value</span></p>
  </td>
  <td width=417 colspan=4 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Complete
  response (CR)</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>4</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(1.0%)</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>2</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(0.5%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Partial
  response (PR)</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>99</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(24.1%)</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>20</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(4.9%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Stable
  disease (SD)</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>141</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(34.4%)</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>227</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>(55.2%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Median
  duration of response </span></b></p>
  </td>
  <td width=225 colspan=2 valign=top style='width:168.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Months
  (range)</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>11.99</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:-6.05pt;page-break-after:avoid'><span
  lang=EN-GB>(0.0&#8209;27.6<sup>+</sup>)</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>11.99</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:-2.85pt;page-break-after:avoid'><span
  lang=EN-GB>(0.0<sup>+</sup>&#8209;22.2<sup>+</sup>)</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Median
  time to response</span></b></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Months
  (range)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=106 valign=top style='width:79.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>3.5</span></p>
  </td>
  <td width=119 valign=top style='width:89.3pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='margin-left:-6.05pt;page-break-after:avoid'><span
  lang=EN-GB>(1.4&#8209;24.8)</span></p>
  </td>
  <td width=81 valign=top style='width:60.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>3.7</span></p>
  </td>
  <td width=111 valign=top style='width:83.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='margin-left:-2.85pt;page-break-after:avoid'><span
  lang=EN-GB>(1.5&#8209;11.2)</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Progression&#8209;free
  survival</span></b></p>
  </td>
  <td width=225 colspan=2 valign=top style='width:168.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=192 colspan=2 valign=top style='width:2.0in;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Events</span></p>
  </td>
  <td width=225 colspan=2 valign=top style='width:168.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>318 (77.6%)</span></p>
  </td>
  <td width=192 colspan=2 valign=top style='width:2.0in;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>322 (78.3%)</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Hazard ratio </span></p>
  </td>
  <td width=417 colspan=4 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.88</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>95%&nbsp;CI</span></p>
  </td>
  <td width=417 colspan=4 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.75, 1.03)</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=202 valign=top style='width:151.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>p&#8209;value</span></p>
  </td>
  <td width=417 colspan=4 valign=top style='width:312.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.1135</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=202 valign=top style='width:151.55pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Median
  (95%&nbsp;CI)</span></p>
  </td>
  <td width=225 colspan=2 valign=top style='width:168.8pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>4.6 (3.71, 5.39)</span></p>
  </td>
  <td width=192 colspan=2 valign=top style='width:2.0in;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>4.4 (3.71, 5.52)</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><a name="Table7_EfficacyResultsTrial4"></a><span lang=FR
style='font-size:10.0pt'></span><span class=EMEASuperscript><span lang=FR>+</span></span><span
lang=FR style='font-size:10.0pt'> denotes a censored observation.</span></p>

<p class=EMEABodyText><span lang=FR style='font-size:10.0pt'>NE&nbsp;=&nbsp;non&#8209;estimable
</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The median time to onset of objective
response was 3.5&nbsp;months (range:</span><span lang=EN-GB>&nbsp;1.4&#8209;24.8&nbsp;months)
after the start of nivolumab treatment. Fourty&#8209;nine (47.6%) responders
had ongoing responses with a duration ranging from 0.0&#8209;27.6<span
class=EMEASuperscript>+</span>&nbsp;months.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Overall survival could be accompanied by
an improvement over time in disease related symptoms and non&#8209;disease
specific QoL as assessed using valid and reliable scales in the Functional
Assessment of Cancer Therapy&#8209;Kidney Symptom Index&#8209;Disease Related
Symptoms (FKSI&#8209;DRS) and the EuroQoL EQ&#8209;5D. Apparently meaningful
symptom improvement (MID&nbsp;=&nbsp;2 point change in FKSI&#8209;DRS score; p&nbsp;&lt;&nbsp;0.001)
and time to improvement (HR&nbsp;=&nbsp;1.66 (1.33, 2.08), p&nbsp;&lt;&nbsp;0.001)
were significantly better for patients on the nivolumab arm. While both arms of
the study received active therapy, the QoL data should be interpreted in the
context of the open&#8209;label study design and therefore cautiously taken.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Phase
3b/4 safety study (CA209374)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Additional safety and descriptive
efficacy data are available from study CA209374, an open&#8209;label Phase&nbsp;3b/4
safety study of nivolumab monotherapy (treated with 240&nbsp;mg every 2&nbsp;weeks)
for the treatment of patients with advanced or metastatic RCC
(n&nbsp;=&nbsp;142), including 44&nbsp;patients with non&#8209;clear cell
histology. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In subjects with non&#8209;clear cell
histology, at a minimum follow&#8209;up of approximately 16.7&nbsp;months ORR and
median duration of response were 13.6% and 10.2&nbsp;months, respectively.
Clinical activity was observed regardless of tumour PD&#8209;L1 expression
status.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Randomised
phase&nbsp;3 study of nivolumab in combination with ipilimumab vs. sunitinib
(CA209214)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of nivolumab
3&nbsp;mg/kg in combination with ipilimumab 1&nbsp;mg/kg for the treatment of advanced/metastatic
RCC was evaluated in a phase&nbsp;3, randomised, open&#8209;label study
(CA209214). The study included patients (18&nbsp;years or older) with
previously untreated, advanced or metastatic renal cell carcinoma</span><span
lang=EN-GB> with a clear&#8209;cell component. The primary efficacy population
included those intermediate/poor risk patients with at least&nbsp;1&nbsp;or
more of 6&nbsp;prognostic risk factors as per the International Metastatic RCC
Database Consortium (IMDC) criteria (less than one year from time of initial
renal cell carcinoma diagnosis to randomisation, Karnofsky performance status
&lt;80%, haemoglobin less than the lower limit of normal, corrected calcium of
greater than 10&nbsp;mg/dL, platelet count greater than the upper limit of
normal, and absolute neutrophil count greater than the upper limit of normal).
This study included patients regardless of their tumour PD&#8209;L1 status.
Patients with Karnofsky performance status &lt;&nbsp;70% and patients with any
history of or concurrent brain metastases, active autoimmune disease, or
medical conditions requiring systemic immunosuppression were excluded from the
study. Patients were stratified by IMDC prognostic score and region.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>A total of 1096&nbsp;patients were
randomised in the trial, of which 847&nbsp;patients had intermediate/poor&#8209;risk
RCC and received either nivolumab 3&nbsp;mg/kg (n&nbsp;=&nbsp;425) administered
intravenously over 60&nbsp;minutes in combination with ipilimumab 1&nbsp;mg/kg
administered intravenously over 30&nbsp;minutes every </span><span lang=EN-GB>3&nbsp;weeks
for 4&nbsp;doses followed by nivolumab monotherapy 3&nbsp;mg/kg every
2&nbsp;weeks or sunitinib (n&nbsp;=&nbsp;422) 50&nbsp;mg daily, administered
orally for 4&nbsp;weeks followed by 2&nbsp;weeks off, every cycle. Treatment
was continued as long as clinical benefit was observed or until treatment was
no longer tolerated. The first tumour assessments were conducted 12&nbsp;weeks
after randomisation and continued every 6&nbsp;weeks thereafter for the first
year and then every 12&nbsp;weeks until progression or treatment
discontinuation, whichever occurred later. Treatment beyond initial
investigator&#8209;assessed RECIST, version&nbsp;1.1&#8209;defined progression
was permitted if the patient had a clinical benefit and was tolerating study
drug as determined by the investigator. The primary efficacy outcome measures
were OS, ORR and PFS as determined by a Blinded Independent Central Review
(BICR) in intermediate/poor risk patients. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Baseline characteristics were generally
balanced between the two groups. The median age was 61&nbsp;years (range:</span><span
lang=EN-GB>&nbsp;21&#8209;85) with 38%&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;65&nbsp;years of age
and 8%&nbsp;</span><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB>&nbsp;75&nbsp;years of age. The majority of patients were male (73%)
and white (87%), and 31% and 69% of patients had a baseline KPS of 70&nbsp;to
80% and 90&nbsp;to 100%, respectively. The median duration of time from initial
diagnosis to randomisation was 0.4&nbsp;years in both the nivolumab
3&nbsp;mg/kg in combination with ipilimumab 1&nbsp;mg/kg and sunitinib groups.
The median duration of treatment was 7.9&nbsp;months (range:</span><span
lang=EN-GB>&nbsp;1&nbsp;day&#8209;21.4<sup>+</sup>&nbsp;months) in nivolumab
with ipilimumab&#8209;treated patients and was 7.8&nbsp;months (range:&nbsp;1&nbsp;days&#8209;20.2<sup>+</sup>&nbsp;months)
in sunitinib&#8209;treated patients. Nivolumab with ipilimumab was continued
beyond progression in 29% of patients.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The Kaplan&#8209;Meier curves for OS
(with a minimum follow&#8209;up of&nbsp;24&nbsp;months) in intermediate/poor
risk patients are shown in Figure&nbsp;13.</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b>Figure&nbsp;13:</b><b><span
lang=EN-GB> </span></b><b>Kaplan&#8209;Meier curves of OS in
intermediate/poor risk patients (CA209214)</b></p>

<p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><span style='position:relative;z-index:251671552'><span
style='left:0px;position:absolute;left:-28px;top:-19353px;width:307px;
height:1px'><img width="40%" src="OPDIVO-H-3985-IA-099-PI-en_files/image030.png"
alt="Probability of survival"></span></span><span style='font-size:12.0pt'><img
border=0 width=562 height=410 id="Picture 195"
src="OPDIVO-H-3985-IA-099-PI-en_files/image034.png"></span></p>

<p class=EMEABodyText align=center style='text-align:center;page-break-after:
avoid'><span lang=EN-GB>Overall survival (months)</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Number of
subjects at risk</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=558
 style='margin-left:26.7pt;border-collapse:collapse'>
 <tr>
  <td width=558 colspan=14 valign=top style='width:418.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>Nivolumab
  + ipilimumab</span></p>
  </td>
 </tr>
 <tr>
  <td width=47 valign=top style='width:35.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:1.7pt;page-break-after:avoid'><span
  lang=EN-GB>425</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>399</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>372</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>348</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>332</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>317</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>306</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>282</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>257</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>201</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>102</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>33</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>4</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0</span></p>
  </td>
 </tr>
 <tr>
  <td width=482 colspan=12 valign=top style='width:361.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:1.7pt;page-break-after:avoid'><span
  lang=EN-GB>Sunitinib</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:1.7pt;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:1.7pt;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=47 valign=top style='width:35.4pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText style='margin-left:1.7pt;page-break-after:avoid'><span
  lang=EN-GB>422</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>387</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>352</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>316</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>288</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>253</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>233</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>216</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>196</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>147</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>87</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>36</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>3</span></p>
  </td>
  <td width=38 valign=top style='width:28.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText style='page-break-after:avoid'><img border=0 width=48
height=19 id="Picture 27" src="OPDIVO-H-3985-IA-099-PI-en_files/image035.jpg"><span
lang=EN-GB>Nivolumab + ipilimumab (events: 166/425), median and 95.0% CI: NA
(32.49, NA)</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><img border=0 width=48
height=19 id="Picture 28" src="OPDIVO-H-3985-IA-099-PI-en_files/image036.jpg"><span
lang=EN-GB>Sunitinib (events: 209/422), median and 95.0% CI: 26.97 (22.08,
34.83)</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>In intermediate/poor&#8209;risk patients, OS benefit was
observed in the nivolumab in combination with ipilimumab arm vs. sunitinib
regardless of tumour PD&#8209;L1 expression. Median OS for tumour PD&#8209;L1
expression &#8805;<span lang=EN-GB>&nbsp;</span>1% was not reached for
nivolumab in combination with ipilimumab, and was 19.61&nbsp;months in the
sunitinib arm (HR<span lang=EN-GB>&nbsp;</span>=<span lang=EN-GB>&nbsp;</span>0.52;
95%<span lang=EN-GB>&nbsp;</span>CI:<span lang=EN-GB>&nbsp;</span>0.34,<span
lang=EN-GB>&nbsp;</span>0.78). For tumour PD&#8209;L1 expression&nbsp;&lt;<span
lang=EN-GB>&nbsp;</span>1%, <span lang=EN-GB>the median OS was 34.7&nbsp;months
for the nivolumab in combination with ipilimumab, and was 32.2&nbsp;months in
the sunitinib arm (HR&nbsp;=&nbsp;0.70;&nbsp;95%&nbsp;CI:&nbsp;0.54,&nbsp;0.92)</span>.</p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>CA209214 also randomised 249&nbsp;favourable
risk patients as per IMDC criteria to nivolumab plus ipilimumab
(n&nbsp;=&nbsp;125) or to sunitinib (n&nbsp;=&nbsp;124). These patients were
not evaluated as part of the primary efficacy population. OS in favourable risk
patients receiving nivolumab plus ipilimumab compared to sunitinib had a hazard
ratio of&nbsp;1.13
(95%&nbsp;CI:&nbsp;0.64,&nbsp;1.99;&nbsp;p&nbsp;=&nbsp;0.6710).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>There are no data on the use of
nivolumab in combination with ipilimumab in patients with only a non clear&#8209;cell
histology in first line RCC.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText>Efficacy results for the intermediate/poor risk patients
from the primary analysis (minimum follow&#8209;up 17.5<span lang=EN-GB>&nbsp;</span>months)
are shown in Table&nbsp;21.</p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;21</span></b><span
lang=EN-GB>: <b>Efficacy results in intermediate/poor risk patients
(CA209214)</b></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=612
 style='width:458.7pt;border-collapse:collapse'>
 <tr>
  <td width=204 valign=top style='width:153.0pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>nivolumab + ipilimumab<br>
  (n&nbsp;=&nbsp;425)</span></b></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>sunitinib<br>
  (n&nbsp;=&nbsp;422)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Overall
  survival </span></b></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Events</span></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>140 (33%)</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>188 (45%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Hazard ratio<sup>a</sup> </span></p>
  </td>
  <td width=408 colspan=2 valign=top style='width:305.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.63</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>99.8% CI</span></p>
  </td>
  <td width=408 colspan=2 valign=top style='width:305.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.44, 0.89)</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>p&#8209;value<sup>b, c</sup></span></p>
  </td>
  <td width=408 colspan=2 valign=top style='width:305.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:458.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Median
  (95%&nbsp;CI)</span></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>NE (28.2, NE)</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>25.9 (22.1, NE)</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Rate
  (95%&nbsp;CI)</span></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> At
  6&nbsp;months</span></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>89.5 (86.1, 92.1)</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>86.2 (82.4, 89.1)</span></p>
  </td>
 </tr>
 <tr style='height:13.1pt'>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.1pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> At
  12&nbsp;months</span></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>80.1 (75.9, 83.6)</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.1pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>72.1 (67.4, 76.2)</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Progression&#8209;free
  survival</span></b></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Events</span></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>228 (53.6%)</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>228 (54.0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Hazard ratio<sup>a</sup></span></p>
  </td>
  <td width=408 colspan=2 valign=top style='width:305.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.82</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>99.1% CI</span></p>
  </td>
  <td width=408 colspan=2 valign=top style='width:305.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.64, 1.05)</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>p&#8209;value<sup>b,h</sup></span></p>
  </td>
  <td width=408 colspan=2 valign=top style='width:305.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0331</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Median
  (95%&nbsp;CI)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>11.6 (8.71, 15.51)</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>8.4 (7.03, 10.81)</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Confirmed
  objective response (BICR) </span></b></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>177 (41.6%)</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>112 (26.5%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(36.9, 46.5)</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(22.4, 31.0)</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Difference in ORR (95%&nbsp;CI)<sup>d</sup></span></p>
  </td>
  <td width=408 colspan=2 valign=top style='width:305.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>16.0 (9.8, 22.2)</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>p&#8209;value<sup>e,f</sup></span></p>
  </td>
  <td width=408 colspan=2 valign=top style='width:305.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:458.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Complete
  response (CR)</span></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>40 (9.4%)</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>5 (1.2%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Partial
  response (PR)</span></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>137 (32.2%)</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>107 (25.4%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Stable
  disease (SD)</span></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>133 (31.3%)</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>188 (44.5%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:458.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Median
  duration of response<sup>g</sup> </span></b></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Months
  (range)</span></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>NE (1.4<sup>+</sup>&#8209;25.5<sup>+</sup>)</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>18.17 (1.3<sup>+</sup>&#8209;23.6<sup>+</sup>)</span></p>
  </td>
 </tr>
 <tr>
  <td width=612 colspan=3 valign=top style='width:458.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=204 valign=top style='width:153.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Median
  time to response</span></b></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=204 valign=top style='width:153.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Months
  (range)</span></p>
  </td>
  <td width=219 valign=top style='width:164.55pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2.8 (0.9&#8209;11.3)</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>3.0 (0.6&#8209;15.0)</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span class=EMEASuperscript><span lang=EN-GB>a</span></span><span
lang=EN-GB> </span><span lang=EN-GB style='font-size:10.0pt'>Based on
a stratified proportional hazards model.</span></p>

<p class=EMEABodyText><sup><span lang=EN-GB>b</span></sup><span lang=EN-GB> </span><span
lang=EN-GB style='font-size:10.0pt'>Based on a stratified log&#8209;rank test.</span></p>

<p class=EMEABodyText><sup><span lang=EN-GB>c</span></sup><span lang=EN-GB> </span><span
lang=EN-GB style='font-size:10.0pt'>p&#8209;value is compared to alpha 0.002 in
order to achieve statistical significance.</span></p>

<p class=EMEABodyText><sup><span lang=EN-GB>d</span></sup><span lang=EN-GB> </span><span
lang=EN-GB style='font-size:10.0pt'>Strata adjusted difference.</span></p>

<p class=EMEABodyText><sup><span lang=EN-GB>e</span></sup><span lang=EN-GB> </span><span
lang=EN-GB style='font-size:10.0pt'>Based on the stratified DerSimonian&#8209;Laird
test.</span></p>

<p class=EMEABodyText><sup><span lang=EN-GB>f</span></sup><span lang=EN-GB> </span><span
lang=EN-GB style='font-size:10.0pt'>p&#8209;value is compared to alpha 0.001 in
order to achieve statistical significance.</span></p>

<p class=EMEABodyText><sup><span lang=EN-GB>g</span></sup><span lang=EN-GB> </span><span
lang=EN-GB style='font-size:10.0pt'>Computed using Kaplan&#8209;Meier method.</span></p>

<p class=EMEABodyText><sup><span lang=EN-GB>h</span></sup><span lang=EN-GB> </span><span
lang=EN-GB style='font-size:10.0pt'>p&#8209;value is compared to alpha 0.009 in
order to achieve statistical significance.</span></p>

<p class=EMEABodyText><span lang=FR-BE style='font-size:10.0pt'></span><span
class=EMEASuperscript><span lang=FR-BE>+</span></span><span lang=FR-BE
style='font-size:10.0pt'> denotes a censored observation.</span></p>

<p class=EMEABodyText><span lang=FR style='font-size:10.0pt'>NE&nbsp;=&nbsp;non&#8209;estimable
</span></p>

<p class=EMEABodyText><span lang=FR>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>An updated OS analysis was performed
when all patients had a minimum follow&#8209;up of 24&nbsp;months (see figure&nbsp;13).
At the time of this analysis, the hazard ratio was 0.66; (99.8% CI 0.48&#8209;0.91)
with 166/425 events in the combination arm and 209/422 events in the sunitinib
arm. At 18&nbsp;months, the OS rate was 74.3 (95%&nbsp;CI 69.8&#8209;78.2) for
nivolumab in combination with ipilimumab and 59.9 (95%&nbsp;CI 54.9&#8209;64.5)
for sunitinib. At 24&nbsp;months, the OS rate was 66.5 (95%&nbsp;CI 61.8&#8209;70.9)
for nivolumab in combination with ipilimumab and 52.9 (95%&nbsp;CI 47.9&#8209;57.7)
for sunitinib.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Patients </span><span lang=EN-GB>&#8805;&nbsp;75&nbsp;years
of age represented 8% of all intermediate/poor risk patients in CA209214, and
the combination of nivolumab and ipilimumab showed numerically less effect on
OS (HR&nbsp;0.97, 95%&nbsp;CI: 0.48, 1.95) in this subgroup versus the overall
population. Because of the small size of this subgroup, no definitive
conclusions can be drawn from these data.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Classical
Hodgkin lymphoma</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of nivolumab
3&nbsp;mg/kg as a single agent for the treatment of relapsed or refractory cHL
following ASCT was evaluated in two multi&#8209;centre, open&#8209;label,
single&#8209;arm studies (CA209205 and CA209039).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>CA209205 is an ongoing Phase&nbsp;2,
open&#8209;label, multi&#8209;cohort, single&#8209;arm study of nivolumab in
cHL. It includes 243&nbsp;patients who had ASCT; Cohort&nbsp;A included
63&nbsp;(26%)&nbsp;patients who were brentuximab vedotin nave; Cohort&nbsp;B
included 80&nbsp;(33%)&nbsp;patients who had received brentuximab vedotin after
ASCT failure; and Cohort&nbsp;C included 100&nbsp;(41%)&nbsp;patients who had
received brentuximab vedotin before and/or after ASCT out of which
33&nbsp;(14%)&nbsp;patients received brentuximab vedotin only prior to ASCT. All
patients received nivolumab 3&nbsp;mg/kg monotherapy intravenously over 60&nbsp;minutes
every 2&nbsp;weeks. The first tumour assessments were conducted 9&nbsp;weeks
after the start of treatment and continued thereafter until disease progression
or treatment discontinuation. The primary efficacy outcome measure was ORR as
determined by an IRRC. Additional efficacy measures included duration of
response, PFS and OS.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>CA209039 is a Phase&nbsp;1b open&#8209;label,
multi&#8209;centre, dose&#8209;escalation, and multidose study of nivolumab in
relapsed/refractory hematologic malignancies, including 23&nbsp;patients with
cHL treated with nivolumab 3&nbsp;mg/kg monotherapy; amongst which, 15&nbsp;patients
received prior brentuximab vedotin treatment as a salvage therapy following ASCT,
similar to Cohort&nbsp;B of study CA209205. The first tumour assessments were
conducted 4&nbsp;weeks after the start of treatment and continued thereafter
until disease progression or treatment discontinuation.</span><span lang=EN-GB
style='font-size:12.0pt;color:black'> </span><span lang=EN-GB>Efficacy
assessments included investigator&#8209;assessed ORR, retrospectively evaluated
by an IRRC, and duration of response. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Data from the 80&nbsp;patients from
CA209205 Cohort&nbsp;B and from the 15&nbsp;patients from CA209039 who received
prior brentuximab vedotin treatment following ASCT were integrated. Additional
data from 100&nbsp;patients from CA209205 Cohort&nbsp;C who received
brentuximab before and/or after ASCT are also presented. Baseline
characteristics were similar across the two studies and cohorts (see
Table&nbsp;22 below).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;22</span></b><span
lang=EN-GB>: <b>Baseline patient characteristics in CA209205 Cohort&nbsp;B,
Cohort&nbsp;C and CA209039</b></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;background:white;border-collapse:collapse'>
 <tr>
  <td width=180 valign=top style='width:134.7pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%;
  page-break-after:avoid'><b><span lang=EN-GB style='line-height:105%;
  color:black'>CA209205 Cohort&nbsp;B</span></b><span class=EMEASuperscript><span
  lang=EN-GB style='line-height:105%;color:black'> </span></span><b><span
  lang=EN-GB style='line-height:105%;color:black'>and CA209039</span></b></p>
  </td>
  <td width=101 valign=top style='width:75.9pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%;
  page-break-after:avoid'><b><span lang=EN-GB style='line-height:105%;
  color:black'>CA209205 Cohort&nbsp;B</span></b><span class=EMEASuperscript><span
  lang=EN-GB style='line-height:105%;color:black'>a</span></span></p>
  </td>
  <td width=92 valign=top style='width:69.3pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%;
  page-break-after:avoid'><b><span lang=EN-GB style='line-height:105%;
  color:black'>CA209039</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.2pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-right:1.7pt;text-align:center;
  line-height:105%;page-break-after:avoid'><b><span lang=EN-GB
  style='line-height:105%;color:black'>CA209205 Cohort&nbsp;C<sup>b</sup></span></b></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=180 valign=top style='width:134.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%;
  page-break-after:avoid'><b><span lang=EN-GB style='line-height:105%;
  color:black'>(n&nbsp;=&nbsp;95)</span></b></p>
  </td>
  <td width=101 valign=top style='width:75.9pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%;
  page-break-after:avoid'><b><span lang=EN-GB style='line-height:105%;
  color:black'>(n&nbsp;=&nbsp;80)</span></b></p>
  </td>
  <td width=92 valign=top style='width:69.3pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%;
  page-break-after:avoid'><b><span lang=EN-GB style='line-height:105%;
  color:black'>(n&nbsp;=&nbsp;15)</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:14.2pt'>
  <p class=MsoNormal align=center style='margin-right:1.7pt;text-align:center;
  line-height:105%;page-break-after:avoid'><b><span lang=EN-GB
  style='line-height:105%;color:black'>(n&nbsp;=&nbsp;100)</span></b></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=180 valign=top style='width:134.7pt;border:none;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Median age, years (range)</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>37.0 (1872)</span></p>
  </td>
  <td width=101 valign=top style='width:75.9pt;border:none;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>37.0 (1872)</span></p>
  </td>
  <td width=92 valign=top style='width:69.3pt;border:none;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>40.0 (2454)</span></p>
  </td>
  <td width=122 valign=top style='width:91.2pt;border:none;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-right:1.7pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>32.0 (19&#8209;69)</span></p>
  </td>
 </tr>
 <tr>
  <td width=180 valign=top style='width:134.7pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Gender</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>61 (64%)&nbsp;M</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>34 (36%)&nbsp;F</span></p>
  </td>
  <td width=101 valign=top style='width:75.9pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>51 (64%)&nbsp;M</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>29 (36%)&nbsp;F</span></p>
  </td>
  <td width=92 valign=top style='width:69.3pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>10 (67%)&nbsp;M</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>5 (33%)&nbsp;F</span></p>
  </td>
  <td width=122 valign=top style='width:91.2pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-right:1.7pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>56 (56%) M</span></p>
  <p class=MsoNormal align=center style='margin-right:1.7pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>44 (44%) F</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=180 valign=top style='width:134.7pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>ECOG status</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=101 valign=top style='width:75.9pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:69.3pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=122 valign=top style='width:91.2pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-right:1.7pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=180 valign=top style='width:134.7pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'> 0</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>49 (52%)</span></p>
  </td>
  <td width=101 valign=top style='width:75.9pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>42 (52.5%)</span></p>
  </td>
  <td width=92 valign=top style='width:69.3pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>7 (47%)</span></p>
  </td>
  <td width=122 valign=top style='width:91.2pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-right:1.7pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>50 (50%)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=180 valign=top style='width:134.7pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'> 1</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>46 (48%)</span></p>
  </td>
  <td width=101 valign=top style='width:75.9pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>38 (47.5%)</span></p>
  </td>
  <td width=92 valign=top style='width:69.3pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>8 (53%)</span></p>
  </td>
  <td width=122 valign=top style='width:91.2pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-right:1.7pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>50 (50%)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=180 valign=top style='width:134.7pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>&#8805;&nbsp;5 prior lines of systemic therapy</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>49 (52%)</span></p>
  </td>
  <td width=101 valign=top style='width:75.9pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>39 (49%)</span></p>
  </td>
  <td width=92 valign=top style='width:69.3pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>10 (67%)</span></p>
  </td>
  <td width=122 valign=top style='width:91.2pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-right:1.7pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>30 (30%)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=180 valign=top style='width:134.7pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Prior radiation therapy</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>72 (76%)</span></p>
  </td>
  <td width=101 valign=top style='width:75.9pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>59 (74%)</span></p>
  </td>
  <td width=92 valign=top style='width:69.3pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>13 (87%)</span></p>
  </td>
  <td width=122 valign=top style='width:91.2pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-right:1.7pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>69 (69%)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=180 valign=top style='width:134.7pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Prior ASCT</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=101 valign=top style='width:75.9pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=92 valign=top style='width:69.3pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=122 valign=top style='width:91.2pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-right:1.7pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=180 valign=top style='width:134.7pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'> 1</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>87 (92%)</span></p>
  </td>
  <td width=101 valign=top style='width:75.9pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>74 (92.5%)</span></p>
  </td>
  <td width=92 valign=top style='width:69.3pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>13 (87%)</span></p>
  </td>
  <td width=122 valign=top style='width:91.2pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-right:1.7pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>100 (100%)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=180 valign=top style='width:134.7pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'> &#8805;&nbsp;2</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>8 (8%)</span></p>
  </td>
  <td width=101 valign=top style='width:75.9pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>6 (7.5%)</span></p>
  </td>
  <td width=92 valign=top style='width:69.3pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>2 (13%)</span></p>
  </td>
  <td width=122 valign=top style='width:91.2pt;padding:0in 2.85pt 0in 2.85pt;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-right:1.7pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>0 (0%)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=180 valign=top style='width:134.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Years from most recent transplant to first dose of study
  therapy, median (min&#8209;max)</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>3.5 (0.219.0)</span></p>
  </td>
  <td width=101 valign=top style='width:75.9pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>3.4 (0.219.0)</span></p>
  </td>
  <td width=92 valign=top style='width:69.3pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>5.6 (0.515.0)</span></p>
  </td>
  <td width=122 valign=top style='width:91.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:14.2pt'>
  <p class=MsoNormal align=center style='margin-right:1.7pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='color:black'>1.7 (0.2&#8209;17.0)</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span class=EMEASuperscript><span lang=EN-GB
style='font-size:10.0pt'>a</span></span><span lang=EN-GB style='font-size:10.0pt'>
18/80 (22.5%) of the patients in CA209205 Cohort&nbsp;B presented B&#8209;Symptoms
at baseline.</span></p>

<p class=EMEABodyText><sup><span lang=EN-GB style='font-size:10.0pt'>b</span></sup><span
lang=EN-GB style='font-size:10.0pt'> 25/100 (25%) of the patients in CA209205
Cohort&nbsp;C presented B&#8209;Symptoms at baseline.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Efficacy from both studies was evaluated
by the same IRRC. Results are shown in Table&nbsp;23.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=613
 style='margin-left:-5.4pt;border-collapse:collapse'>
 <tr>
  <td width=612 colspan=4 valign=top style='width:459.0pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;23:</span></b><span
  lang=EN-GB> <b>Efficacy results in patients with relapsed/refractory
  classical Hodgkin lymphoma </b></span></p>
  </td>
  <td style='border:none;border-bottom:solid windowtext 1.0pt' width=1><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=262 valign=top style='width:196.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
  line-height:105%'>&nbsp;</span></b></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
  line-height:105%'>CA209205 Cohort&nbsp;B</span></b><span
  class=EMEASuperscript><span lang=EN-GB style='font-size:10.0pt;line-height:
  105%'>a</span></span><b><span lang=EN-GB style='font-size:10.0pt;line-height:
  105%'> and CA209039</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
  line-height:105%'>CA209205 Cohort&nbsp;B</span></b><span
  class=EMEASuperscript><span lang=EN-GB style='font-size:10.0pt;line-height:
  105%'>a</span></span></p>
  </td>
  <td width=94 colspan=2 valign=top style='width:70.85pt;border:none;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
  line-height:105%'>CA209039</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=262 valign=top style='width:196.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:105%;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt;line-height:105%'>Number (n)/ minimum
  follow&#8209;up (months)</span></b></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
  line-height:105%'>(n&nbsp;=&nbsp;95/12.0)</span></b></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
  line-height:105%'>(n&nbsp;=&nbsp;80/12.0)</span></b></p>
  </td>
  <td width=94 colspan=2 valign=top style='width:70.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;line-height:105%;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt;
  line-height:105%'>(n&nbsp;=&nbsp;15/12.0)</span></b></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=262 valign=top style='width:196.8pt;border:none;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Objective response, </span></b><span lang=EN-GB
  style='font-size:10.0pt'>n (%);<b>&nbsp;</b></span><span lang=EN-GB
  style='font-size:10.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border:none;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>63 (66%);&nbsp;(56, 76)</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>54 (68%);&nbsp;(56, 78)</span></p>
  </td>
  <td width=94 colspan=2 valign=top style='width:70.85pt;border:none;
  padding:0in 0in 0in 0in;height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>9 (60%); (32, 84)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=262 valign=top style='width:196.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR-BE
  style='font-size:10.0pt'> </span><span lang=FR-BE style='font-size:10.0pt'>Complete
  remission (CR), n<b> </b>(%);&nbsp;(95%&nbsp;CI)</span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>6 (6%);&nbsp;(2, 13)</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>6 (8%);&nbsp;(3, 16)</span></p>
  </td>
  <td width=94 colspan=2 valign=top style='width:70.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0 (0%);&nbsp;(0, 22)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=262 valign=top style='width:196.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR-BE
  style='font-size:10.0pt'> Partial remission (PR), n (%);&nbsp;(95%&nbsp;CI)</span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>57 (60%);&nbsp;(49, 70)</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>48 (60%);&nbsp;(48, 71)</span></p>
  </td>
  <td width=94 colspan=2 valign=top style='width:70.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>9 (60%);&nbsp;(32, 84)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=262 valign=top style='width:196.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Stable disease, </span></b><span
  lang=EN-GB style='font-size:10.0pt'>n (%)</span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>22 (23)</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>17 (21)</span></p>
  </td>
  <td width=94 colspan=2 valign=top style='width:70.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>5 (33)</span></p>
  </td>
 </tr>
 <tr style='height:20.05pt'>
  <td width=262 valign=top style='width:196.8pt;padding:0in 0in 0in 0in;
  height:20.05pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Duration of response (months)</span></b><span
  class=EMEASuperscript><span lang=EN-GB style='font-size:10.0pt'>b</span></span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;padding:0in 0in 0in 0in;
  height:20.05pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;padding:0in 0in 0in 0in;
  height:20.05pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=94 colspan=2 valign=top style='width:70.85pt;padding:0in 0in 0in 0in;
  height:20.05pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=262 valign=top style='width:196.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> </span><span lang=EN-GB style='font-size:10.0pt'>Median
  (95%&nbsp;CI)</span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>13.1 (9.5, NE)</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>13.1 (8.7, NE)</span></p>
  </td>
  <td width=94 colspan=2 valign=top style='width:70.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>12.0 (1.8, NE)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=262 valign=top style='width:196.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> </span><span lang=EN-GB style='font-size:10.0pt'>Range</span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0.0<span
  class=EMEASuperscript><span style='vertical-align:baseline'>+</span></span>&#8209;23.1<span
  class=EMEASuperscript><span style='vertical-align:baseline'>+</span></span></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0.0<span
  class=EMEASuperscript><span style='vertical-align:baseline'>+</span></span>&#8209;14.2<span
  class=EMEASuperscript><span style='vertical-align:baseline'>+</span></span></span></p>
  </td>
  <td width=94 colspan=2 valign=top style='width:70.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>1.8&#8209;23.1<span
  class=EMEASuperscript><span style='vertical-align:baseline'>+</span></span></span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=262 valign=top style='width:196.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Median time to response </span></b></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=94 colspan=2 valign=top style='width:70.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=262 valign=top style='width:196.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> </span><span lang=EN-GB style='font-size:10.0pt'>Months
  (range)</span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>2.0 (0.7&#8209;11.1)</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>2.1 (1.6&#8209;11.1)</span></p>
  </td>
  <td width=94 colspan=2 valign=top style='width:70.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0.8 (0.7&#8209;4.1)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=262 valign=top style='width:196.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Median duration of follow&#8209;up </span></b></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=94 colspan=2 valign=top style='width:70.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=262 valign=top style='width:196.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> </span><span lang=EN-GB style='font-size:10.0pt'>Months
  (range)</span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>15.8 (1.9&#8209;27.6)</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>15.4 (1.9&#8209;18.5)</span></p>
  </td>
  <td width=94 colspan=2 valign=top style='width:70.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>21.9 (11.2&#8209;27.6)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=262 valign=top style='width:196.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Progression&#8209;free survival</span></b><b><span
  lang=EN-GB style='font-size:10.0pt'> </span></b></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'></span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'></span></p>
  </td>
  <td width=94 colspan=2 valign=top style='width:70.85pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=262 valign=top style='width:196.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> </span><span lang=EN-GB style='font-size:10.0pt'>Rate
  (95%&nbsp;CI) at 12&nbsp;months</span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>57 (45, 68)</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>55 (41, 66)</span></p>
  </td>
  <td width=94 colspan=2 valign=top style='width:70.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>69 (37, 88)</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=262 style='border:none'></td>
  <td width=124 style='border:none'></td>
  <td width=132 style='border:none'></td>
  <td width=93 style='border:none'></td>
  <td width=1 style='border:none'></td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB></span><span lang=EN-GB
style='font-size:10.0pt'>+</span><span lang=EN-GB> d</span><span lang=EN-GB
style='font-size:10.0pt'>enotes a censored observation.</span></p>

<p class=EMEABodyText><sup><span lang=EN-GB style='font-size:10.0pt'>a</span></sup><span
lang=EN-GB style='font-size:10.0pt'> Follow&#8209;up was ongoing
at the time of data submission. </span></p>

<p class=EMEABodyText><span class=EMEASuperscript><span lang=EN-GB
style='font-size:10.0pt'>b</span></span><span lang=EN-GB style='font-size:10.0pt'> Data
unstable due to the limited duration of response for Cohort&nbsp;B resulting
from censoring.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:10.0pt'>NE&nbsp;=&nbsp;non&#8209;estimable
</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:yellow'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Longer</span><span
class=MsoCommentReference><span lang=EN-GB style='font-size:8.0pt'> </span></span><span
lang=EN-GB>follow&#8209;up data from Cohort&nbsp;B (minimum 20.5&nbsp;months)
and efficacy of Cohort&nbsp;C from CA209205 are presented below in Table&nbsp;24.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:.75in;text-indent:-.75in;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;24:</span></b><span lang=EN-GB>  <b>Updated
efficacy results in patients with relapsed/refractory classical Hodgkin
lymphoma from longer follow up of study CA209205</b></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.02%;border-collapse:collapse'>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.2pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:14.2pt'>
  <p class=MsoNormal align=center style='margin-bottom:6.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>CA209205
  Cohort&nbsp;B</span></b><span class=EMEASuperscript><span lang=EN-GB
  style='font-size:10.0pt'>a</span></span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:14.2pt'>
  <p class=MsoNormal align=center style='margin-bottom:6.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>CA209205
  Cohort C</span></b><span class=EMEASuperscript><span lang=EN-GB
  style='font-size:10.0pt'>a</span></span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Number (n)/ minimum
  follow&#8209;up (months)</span></b></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;80/20.5)</span></b></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;100/13.7)<sup>b</sup></span></b></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Objective response, </span></b><span lang=EN-GB
  style='font-size:10.0pt'>n (%);<b>&nbsp;</b></span><span lang=EN-GB
  style='font-size:10.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;border:none;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>54 (68%); (56, 78)</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;border:none;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>73 (73%); (63, 81)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR-BE
  style='font-size:10.0pt'> </span><span lang=FR-BE style='font-size:10.0pt'>Complete
  remission (CR), n (%);&nbsp;(95%&nbsp;CI)</span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>10 (13%); (6, 22)</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>12 (12%); (6, 20)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 2.85pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR-BE
  style='font-size:10.0pt'> Partial remission (PR), n (%);&nbsp;(95%&nbsp;CI)</span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>44 (55%); (44, 66)</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>61 (61%); (51, 71)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 2.85pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Stable disease, </span></b><span
  lang=EN-GB style='font-size:10.0pt'>n (%)</span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>17 (21)</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>15 (15%)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 2.85pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Duration of response</span></b><b><span
  lang=EN-GB style='font-size:10.0pt'> in all responders (months)</span></b><span
  class=EMEASuperscript><span lang=EN-GB style='font-size:10.0pt'>c</span></span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 2.85pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> Median </span><span lang=EN-GB style='font-size:
  10.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>15.9 (7.8, 20.3)</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>14.5 (9.5, 16.6)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 2.85pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> Range</span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0.0<span
  class=EMEASuperscript><span style='vertical-align:baseline'>+</span></span>&#8209;21.0<span
  class=EMEASuperscript><span style='vertical-align:baseline'>+</span></span></span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(0.0+, 16.8+)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 2.85pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Duration of response in CR (months)<s> </s></span></b></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 2.85pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> Median </span><span lang=EN-GB style='font-size:
  10.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>20.3 (3.8, NE)</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>14.5 (8.2, NE)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 2.85pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> Range</span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>1.6+&#8209;21.0+</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(0.0+, 16.5+)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 2.85pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Duration of response</span></b><b><span
  lang=EN-GB style='font-size:10.0pt'> in PR (months)<s> </s></span></b></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 2.85pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> Median </span><span lang=EN-GB style='font-size:
  10.0pt'>(95%&nbsp;CI)</span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>10.6 (6.8, 18.0)</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>13.2 (9.4, 16.6)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 2.85pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> Range</span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>0.0<span
  class=EMEASuperscript><span style='vertical-align:baseline'>+</span></span>&#8209;20.7<span
  class=EMEASuperscript><span style='vertical-align:baseline'>+</span></span></span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>(0.0+, 16.8<span
  class=EMEASuperscript><span style='vertical-align:baseline'>+</span></span>)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 2.85pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Median time to response</span></b></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 2.85pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> Months (range)</span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>2.2 (1.6&#8209;9.1)</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>2.1 (0.8, 8.6)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 2.85pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Median duration of follow&#8209;up</span></b></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> Months (range)</span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>22.7 (1.9&#8209;27.2)</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>16.2 (1.4, 20.4)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Progression&#8209;free survival</span></b></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> </span><span lang=EN-GB style='font-size:10.0pt'>Rate
  </span><span lang=EN-GB style='font-size:10.0pt'>(95%&nbsp;CI) at 12&nbsp;months</span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>51 (38, 62)</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>49 (37, 60)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> </span><span lang=EN-GB style='font-size:10.0pt'>Rate
  </span><span lang=EN-GB style='font-size:10.0pt'>(95%&nbsp;CI) at 18&nbsp;months</span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>47 (35, 59)</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif'></span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Overall survival</span></b></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> Median </span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Not reached</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>Not reached</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> Rate (95%&nbsp;CI) at 12&nbsp;months</span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>95 (87, 98)</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;padding:0in 0in 0in 0in;
  height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>90 (82, 94)</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width=265 valign=top style='width:198.45pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'> Rate (95%&nbsp;CI) at 18&nbsp;months</span></p>
  </td>
  <td width=142 valign=top style='width:106.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt;color:black'>91 (82, 96)</span></p>
  </td>
  <td width=198 valign=top style='width:148.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif'></span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB></span><span lang=EN-GB
style='font-size:10.0pt'>+</span><span lang=EN-GB> d</span><span lang=EN-GB
style='font-size:10.0pt'>enotes a censored observation.</span></p>

<p class=EMEABodyText><sup><span lang=EN-GB style='font-size:10.0pt'>a</span></sup><span
lang=EN-GB style='font-size:10.0pt'> Follow&#8209;up was ongoing
at the time of data submission. </span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>b</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Patients in Cohort&nbsp;C
(n&nbsp;=&nbsp;33) who have received brentuximab vedotin only prior to ASCT had
ORR of 70% (95%&nbsp;CI: 51, 84), CR of 15% (95%&nbsp;CI: 5, 32), PR of 55%
(95%&nbsp;CI: 36, 72). Median duration of response was 13.2&nbsp;months
(95%&nbsp;CI: 8.2, NE)</span></p>

<p class=EMEABodyText><sup><span lang=EN-GB style='font-size:10.0pt;color:black'>c</span></sup><span
lang=EN-GB style='font-size:10.0pt;color:black'> Determined for
subjects with CR or PR</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:10.0pt'>NE&nbsp;=&nbsp;non&#8209;estimable</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:yellow'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>B&#8209;symptoms were present in 22% (53/243)
of the patients in CA209205 at baseline. Nivolumab treatment resulted in rapid
resolution of B&#8209;symptoms in 88.7% (47/53) of the patients, with a median
time to resolution of 1.9&nbsp;months.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In a post&#8209;hoc analysis of the 80&nbsp;patients
in CA209205 Cohort&nbsp;B, 37 had no response to prior brentuximab vedotin
treatment. Among these 37&nbsp;patients, treatment with nivolumab resulted in
an ORR of 59.5% (22/37). The median duration of response is 18.0&nbsp;months (6.6,
NE) for the 22&nbsp;responders to nivolumab who had failed to achieve response
with prior brentuximab vedotin treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Squamous
cell cancer of the head and neck</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of
nivolumab&nbsp;3&nbsp;mg/kg as a single agent for the treatment of metastatic
or recurrent SCCHN were evaluated in a phase&nbsp;3, randomised, open&#8209;label
study (CA209141). The study included patients (18&nbsp;years or older), with
histologically confirmed recurrent or metastatic SCCHN (oral cavity, pharynx,
larynx), stage III/IV and not amenable to local therapy with curative intent
(surgery or radiation therapy with or without chemotherapy) and who have
experienced disease progression during or within 6&nbsp;months of receiving
platinum&#8209;based therapy regimen and had an ECOG performance status score
of 0 or 1. Prior platinum&#8209;based therapy was administered in either the
adjuvant, neo&#8209;adjuvant, primary, recurrent, or metastatic setting.
Patients were enrolled regardless of their tumour PD&#8209;L1 or human
papilloma virus (HPV) status. Patients with active autoimmune disease, medical
conditions requiring immunosuppression, recurrent or metastatic carcinoma of
the nasopharynx, squamous cell carcinoma of unknown primary, salivary gland or
non&#8209;squamous histologies (e.g., mucosal melanoma), or active brain or
leptomeningeal metastases were excluded from the study. Patients with treated
brain metastases were eligible if neurologically returned to baseline at least 2&nbsp;weeks
prior to enrolment, and either off corticosteroids, or on a stable or
decreasing dose of &lt;&nbsp;10&nbsp;mg daily prednisone equivalents.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>A total of 361&nbsp;patients were
randomised to receive either nivolumab 3&nbsp;mg/kg (n&nbsp;=&nbsp;240)
administered intravenously over&nbsp;60&nbsp;minutes every&nbsp;2&nbsp;weeks or
investigators choice of either cetuximab (n&nbsp;=&nbsp;15), 400&nbsp;mg/m<span
class=EMEASuperscript>2</span> loading dose followed by 250&nbsp;mg/m2 weekly
or methotrexate (n&nbsp;=&nbsp;52) 40 to 60&nbsp;mg/m<span
class=EMEASuperscript>2</span> weekly, or docetaxel (n&nbsp;=&nbsp;54) 30 to
40&nbsp;mg/m<span class=EMEASuperscript>2</span> weekly. Randomisation was
stratified by prior cetuximab treatment. Treatment was continued as long as
clinical benefit was observed or until treatment was no longer tolerated. Tumour
assessments, according to RECIST version&nbsp;1.1, were
conducted&nbsp;9&nbsp;weeks after randomisation and continued
every&nbsp;6&nbsp;weeks thereafter. Treatment beyond initial investigator&#8209;assessed
RECIST version&nbsp;1.1&#8209;defined progression was permitted in patients
receiving nivolumab, if the patient had a clinical benefit and was tolerating
study drug, as determined by the investigator. The primary efficacy outcome
measure was OS. Key secondary efficacy outcome measures were investigator&#8209;assessed
PFS and ORR. Additional prespecified subgroup analyses were conducted to
evaluate the efficacy by tumour PD&#8209;L1 expression at predefined levels of
1%, 5%, and 10%.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Pre&#8209;study tumour tissue specimens
were systematically collected prior to randomisation in order to conduct pre&#8209;planned
analyses of efficacy according to tumour PD&#8209;L1 expression. Tumour PD&#8209;L1
expression was determined using the PD&#8209;L1&nbsp;IHC&nbsp;28&#8209;8
pharmDx&nbsp;assay.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Baseline characteristics were generally
balanced between the two groups. The median age was&nbsp;60&nbsp;years
(range:&nbsp;28&#8209;83) with 31%&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;65&nbsp;years of age
and 5%&nbsp;</span><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB>&nbsp;75&nbsp;years of age, 83% were male, and 83% were white.
Baseline ECOG performance status score was 0&nbsp;(20%) or 1&nbsp;(78%), 77%
were former/current smokers, 90% had Stage IV disease, 66% had two or more
lesions, 45%, 34% and 20% received 1, 2, or 3 or more prior lines of systemic
therapy, respectively, and 25% were HPV&#8209;16 status positive.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>With a minimum follow&#8209;up of 11.4&nbsp;months,
the trial demonstrated a statistically significant improvement in OS for
patients randomised to nivolumab as compared with investigators choice. The Kaplan&#8209;Meier
curves for OS are shown in Figure&nbsp;14. Efficacy results are shown in
Table&nbsp;25.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b>Figure</b><span
lang=EN-GB>&nbsp;</span><b>14: Kaplan&#8209;Meier curves of OS (CA209141)
</b></p>

<p class=EMEABodyText style='page-break-after:avoid'>&nbsp;</p>

<p class=EMEABodyText align=center style='text-align:center'><span
style='position:relative;z-index:251668480'><span style='left:0px;position:
absolute;left:4px;top:-24262px;width:307px;height:1px'><img width="40%"
src="OPDIVO-H-3985-IA-099-PI-en_files/image030.png"
alt="Probability of survival&#13;&#10;&#13;&#10;"></span></span><img border=0
width=494 height=365 id="Picture 16"
src="OPDIVO-H-3985-IA-099-PI-en_files/image037.jpg"></p>

<p class=MsoNormal align=center style='text-align:center;page-break-after:avoid'><span
lang=EN-GB>Overall survival (months)</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=541
 style='margin-left:33.75pt;border-collapse:collapse'>
 <tr style='height:12.95pt'>
  <td width=522 colspan=10 valign=top style='width:391.7pt;padding:0in 5.4pt 0in 5.4pt;
  height:12.95pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Number of subjects
  at risk</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=18><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=522 colspan=10 valign=top style='width:391.7pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Nivolumab</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=18><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=57 style='width:42.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>240</span></p>
  </td>
  <td width=54 style='width:40.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>169</span></p>
  </td>
  <td width=54 style='width:40.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>132</span></p>
  </td>
  <td width=48 style='width:.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>98</span></p>
  </td>
  <td width=48 style='width:.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>76</span></p>
  </td>
  <td width=48 style='width:.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>45</span></p>
  </td>
  <td width=53 style='width:39.65pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>27</span></p>
  </td>
  <td width=54 valign=top style='width:40.65pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>12</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>3</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=78 colspan=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=541 colspan=11 valign=top style='width:405.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Investigators
  choice</span></p>
  </td>
 </tr>
 <tr>
  <td width=57 style='width:42.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>121</span></p>
  </td>
  <td width=54 style='width:40.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>88</span></p>
  </td>
  <td width=54 style='width:40.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>51</span></p>
  </td>
  <td width=48 style='width:.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>32</span></p>
  </td>
  <td width=48 style='width:.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>22</span></p>
  </td>
  <td width=48 style='width:.5in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>9</span></p>
  </td>
  <td width=53 style='width:39.65pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>4</span></p>
  </td>
  <td width=54 valign=top style='width:40.65pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>3</span></p>
  </td>
  <td width=47 valign=top style='width:35.45pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB>0</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=78 colspan=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr height=0>
  <td width=57 style='border:none'></td>
  <td width=54 style='border:none'></td>
  <td width=54 style='border:none'></td>
  <td width=48 style='border:none'></td>
  <td width=48 style='border:none'></td>
  <td width=48 style='border:none'></td>
  <td width=53 style='border:none'></td>
  <td width=54 style='border:none'></td>
  <td width=47 style='border:none'></td>
  <td width=59 style='border:none'></td>
  <td width=18 style='border:none'></td>
 </tr>
</table>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:.5in;page-break-after:avoid'><span
style='position:relative;z-index:251670528'><span style='left:0px;position:
absolute;left:7px;top:-24750px;width:37px;height:1px'><img width=37 height=1
src="OPDIVO-H-3985-IA-099-PI-en_files/image038.png"></span></span><span
lang=EN-GB>Nivolumab 3&nbsp;mg/kg (events: 184/240), median and 95%&nbsp;CI:
7.72 (5.68,&nbsp;8.77)</span></p>

<p class=EMEABodyText style='margin-left:.5in;page-break-after:avoid'><span
lang=EN-GB>Investigators choice (events: 105/121), median and 95%&nbsp;CI:
5.06 (4.04,&nbsp;6.24)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table</span></b><span
lang=EN-GB>&nbsp;</span><b><span lang=EN-GB>25</span></b><span lang=EN-GB>: <b>Efficacy
results (CA209141)</b></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=253 valign=top style='width:189.8pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=183 colspan=2 valign=top style='width:137.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>nivolumab<br>
  (n&nbsp;=&nbsp;240)</span></b></p>
  </td>
  <td width=183 valign=top style='width:137.3pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>investigators choice<br>
  (n&nbsp;=&nbsp;121)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Overall
  survival</span></b></p>
  </td>
  <td width=183 colspan=2 valign=top style='width:137.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=183 valign=top style='width:137.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Events</span></p>
  </td>
  <td width=183 colspan=2 valign=top style='width:137.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>184 (76.7%)</span></p>
  </td>
  <td width=183 valign=top style='width:137.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>105 (86.8%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Hazard
  ratio<sup>a</sup></span></p>
  </td>
  <td width=366 colspan=3 valign=top style='width:274.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.71</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> (95%&nbsp;CI)</span></p>
  </td>
  <td width=366 colspan=3 valign=top style='width:274.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.55, 0.90)</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB> </span></b><span
  lang=EN-GB>p&#8209;value<sup>b</sup></span></p>
  </td>
  <td width=366 colspan=3 valign=top style='width:274.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.0048</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><span
  lang=EN-GB> Median (95%&nbsp;CI) (months)</span></p>
  </td>
  <td width=183 colspan=2 valign=bottom style='width:137.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>7.72 (5.68, 8.77)</span></p>
  </td>
  <td width=183 valign=bottom style='width:137.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>5.06 (4.04, 6.24)</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><span
  lang=EN-GB> Rate (95%&nbsp;CI) at 6&nbsp;months</span></p>
  </td>
  <td width=183 colspan=2 valign=bottom style='width:137.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>56.5 (49.9, 62.5)</span></p>
  </td>
  <td width=183 valign=bottom style='width:137.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>43.0 (34.0, 51.7)</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><span
  lang=EN-GB> Rate (95%&nbsp;CI) at 12&nbsp;months</span></p>
  </td>
  <td width=183 colspan=2 valign=bottom style='width:137.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>34.0 (28.0, 40.1)</span></p>
  </td>
  <td width=183 valign=bottom style='width:137.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>19.7 (13.0, 27.3)</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><span
  lang=EN-GB> Rate (95%&nbsp;CI) at 18&nbsp;months</span></p>
  </td>
  <td width=183 colspan=2 valign=bottom style='width:137.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>21.5 (16.2, 27.4)</span></p>
  </td>
  <td width=183 valign=bottom style='width:137.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8.3 (3.6, 15.7)</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB>Progression&#8209;free survival</span></b></p>
  </td>
  <td width=180 valign=top style='width:135.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=186 colspan=2 valign=top style='width:139.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Events</span></p>
  </td>
  <td width=180 valign=top style='width:135.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>204 (85.0%)</span></p>
  </td>
  <td width=186 colspan=2 valign=top style='width:139.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>104 (86.0%)</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Hazard
  ratio</span></p>
  </td>
  <td width=366 colspan=3 valign=top style='width:274.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.87</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> 95%&nbsp;CI</span></p>
  </td>
  <td width=366 colspan=3 valign=top style='width:274.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(0.69, 1.11)</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> p&#8209;value</span></p>
  </td>
  <td width=366 colspan=3 valign=top style='width:274.55pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.2597</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><span
  lang=EN-GB> Median (95%&nbsp;CI) (months)</span></p>
  </td>
  <td width=180 valign=bottom style='width:135.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2.04 (1.91, 2.14)</span></p>
  </td>
  <td width=186 colspan=2 valign=bottom style='width:139.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2.33 (1.97, 3.12)</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><span
  lang=EN-GB> Rate (95%&nbsp;CI) at 6&nbsp;months</span></p>
  </td>
  <td width=180 valign=bottom style='width:135.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>21.0 (15.9, 26.6)</span></p>
  </td>
  <td width=186 colspan=2 valign=bottom style='width:139.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>11.1 (5.9, 18.3)</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><span
  lang=EN-GB> Rate (95%&nbsp;CI) at 12&nbsp;months</span></p>
  </td>
  <td width=180 valign=bottom style='width:135.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>9.5 (6.0, 13.9)</span></p>
  </td>
  <td width=186 colspan=2 valign=bottom style='width:139.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2.5 (0.5, 7.8)</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB>Confirmed objective response</span></b><sup><span lang=EN-GB>c</span></sup></p>
  </td>
  <td width=180 valign=top style='width:135.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>32 (13.3%)</span></p>
  </td>
  <td width=186 colspan=2 valign=top style='width:139.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>7 (5.8%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> (95%&nbsp;CI)</span></p>
  </td>
  <td width=183 colspan=2 valign=top style='width:137.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(9.3, 18.3)</span></p>
  </td>
  <td width=183 valign=top style='width:137.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(2.4, 11.6)</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Odds
  ratio (95%&nbsp;CI)</span></p>
  </td>
  <td width=366 colspan=3 valign=top style='width:274.55pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2.49 (1.07, 5.82)</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><span
  lang=EN-GB> Complete response (CR)</span></p>
  </td>
  <td width=180 valign=bottom style='width:135.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>6 (2.5%)</span></p>
  </td>
  <td width=186 colspan=2 valign=bottom style='width:139.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1 (0.8%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Partial
  response (PR)</span></p>
  </td>
  <td width=180 valign=top style='width:135.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>26 (10.8%)</span></p>
  </td>
  <td width=186 colspan=2 valign=top style='width:139.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>6 (5.0%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Stable
  disease (SD)</span></p>
  </td>
  <td width=180 valign=top style='width:135.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>55 (22.9%)</span></p>
  </td>
  <td width=186 colspan=2 valign=top style='width:139.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>43 (35.5%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB>Median time to response</span></b></p>
  </td>
  <td width=180 valign=top style='width:135.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=186 colspan=2 valign=top style='width:139.35pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Months
  (range)</span></p>
  </td>
  <td width=180 valign=top style='width:135.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2.1 (1.8&#8209;7.4)</span></p>
  </td>
  <td width=186 colspan=2 valign=top style='width:139.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2.0 (1.9&#8209;4.6)</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=253 valign=top style='width:189.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Median
  duration of response</span></b></p>
  </td>
  <td width=180 valign=top style='width:135.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=186 colspan=2 valign=top style='width:139.35pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=253 valign=top style='width:189.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB> Months
  (range)</span></p>
  </td>
  <td width=180 valign=top style='width:135.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>9.7 (2.8&#8209;20.3+)</span></p>
  </td>
  <td width=186 colspan=2 valign=top style='width:139.35pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:13.05pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>4.0 (1.5+-8.5+)</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=253 style='border:none'></td>
  <td width=180 style='border:none'></td>
  <td width=3 style='border:none'></td>
  <td width=183 style='border:none'></td>
 </tr>
</table>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>a</span></sup><span lang=EN-GB
style='font-size:10.0pt'> Derived from a stratified proportional
hazards model.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>b </span></sup><span
lang=EN-GB style='font-size:10.0pt'>P&#8209;value is derived from a log&#8209;rank
test stratified by prior cetuximab; the corresponding OBrien&#8209;Fleming
efficacy boundary significance level is 0.0227.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>c </span></sup><span
lang=EN-GB style='font-size:10.0pt'>In the nivolumab group there were two
patients with CRs and seven patients with PRs who had tumour PD&#8209;L1
expression &lt;&nbsp;1%.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Quantifiable tumour PD&#8209;L1
expression was measured in 67%&nbsp;of patients in the nivolumab group and 82%&nbsp;of
patients in the investigators choice group. Tumour PD&#8209;L1 expression
levels were balanced between the two treatment groups (nivolumab vs.
investigators choice) at each of the predefined tumour PD&#8209;L1 expression
levels of&nbsp;&#8805;&nbsp;1% (55% vs. 62%), &#8805;&nbsp;5% (34% vs. 43%), or
&#8805;&nbsp;10% (27% vs. 34%).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Patients with tumour PD&#8209;L1
expression by all predefined expression levels in the nivolumab group
demonstrated greater likelihood of improved survival compared to investigators
choice. </span>The magnitude of OS benefit was consistent for &#8805;<span
lang=EN-GB>&nbsp;</span>1%, &#8805;<span lang=EN-GB>&nbsp;</span>5% or &#8805;<span
lang=EN-GB>&nbsp;</span>10% tumour PD&#8209;L1 expression levels (see Table<span
lang=EN-GB>&nbsp;</span>26).</p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;26: OS
by tumour PD&#8209;L1 expression (CA209141)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=612
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=144 valign=top style='width:1.5in;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader align=left style='text-align:left;page-break-after:
   avoid'><span lang=EN-GB style='font-size:11.0pt;color:black'>PD&#8209;L1
   Expression</span></p>
   </td>
   <td width=156 valign=top style='width:117.0pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:11.0pt;color:black'>nivolumab</span></p>
   </td>
   <td width=156 valign=top style='width:117.0pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:11.0pt;color:black'>investigators choice</span></p>
   </td>
   <td width=156 valign=top style='width:117.0pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:11.0pt;color:black'>&nbsp;</span></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=612 colspan=4 valign=top style='width:459.0pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>OS by tumour PD&#8209;L1 expression</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;color:black'>&nbsp;</span></p>
  </td>
  <td width=312 colspan=2 valign=top style='width:3.25in;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Number of events (number of patients)</span></b></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;color:black'>Unstratified hazard ratio (95%&nbsp;CI)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;color:black'>&lt;&nbsp;1%</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:black'>56 (73)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:black'>32 (38)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:black'>0.83 (0.54, 1.29)</span></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;color:black'>&#8805;&nbsp;1%</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:black'>66 (88)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:black'>55 (61)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:black'>0.53 (0.37, 0.77)</span></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;color:black'>&#8805;&nbsp;5% </span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:black'>39 (54)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:black'>40 (43)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:black'>0.51 (0.32, 0.80)</span></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:1.5in;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left'><span lang=EN-GB
  style='font-size:11.0pt;color:black'>&#8805;&nbsp;10%</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='font-size:11.0pt;color:black'>30
  (43)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='font-size:11.0pt;color:black'>31
  (34)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='font-size:11.0pt;color:black'>0.57
  (0.34, 0.95)</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In an exploratory post&#8209;hoc
analysis using a non&#8209;validated assay, both tumour cell PD&#8209;L1
expression and tumour&#8209;associated immune cell (TAIC) PD&#8209;L1
expression were analysed in relation to the magnitude of treatment effect of
nivolumab compared to investigators choice. This analysis showed that not only
tumour cell PD&#8209;L1 expression but also TAIC PD&#8209;L1 expression
appeared to be associated with benefit from nivolumab relative to
investigators choice (see Table&nbsp;27).</span><span lang=EN-GB> Due to the
small numbers of patients in the subgroups, and exploratory nature of the
analysis, no definitive conclusions can be drawn from these data.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>Table&nbsp;27: Efficacy by
tumour cell and TAIC PD&#8209;L1 expression (CA209141)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="101%"
 style='width:101.9%;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="23%" valign=top style='width:23.54%;border:none;border-top:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader align=left style='text-align:left'><span lang=EN-GB
   style='color:black'>&nbsp;</span></p>
   </td>
   <td width="24%" colspan=3 valign=top style='width:24.24%;border:none;
   border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader><span lang=EN-GB style='color:black'>Median OS<sup>a</sup>
   (months)</span></p>
   </td>
   <td width="24%" colspan=3 valign=top style='width:24.26%;border:none;
   border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader><span lang=EN-GB style='color:black'>Median PFS<sup>a</sup>
   (months)</span></p>
   </td>
   <td width="27%" colspan=3 valign=top style='width:27.96%;border:none;
   border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader><span lang=EN-GB style='color:black'>ORR (%)</span></p>
   </td>
  </tr>
  <tr>
   <td width="23%" valign=top style='width:23.54%;border:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader align=left style='text-align:left'><span lang=EN-GB
   style='color:black'>&nbsp;</span></p>
   </td>
   <td width="24%" colspan=3 valign=top style='width:24.24%;border:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader><span lang=EN-GB style='color:black'>HR<sup>b</sup>
   (95%&nbsp;CI)</span></p>
   </td>
   <td width="24%" colspan=3 valign=top style='width:24.26%;border:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader><span lang=EN-GB style='color:black'>HR<sup>b</sup>
   (95%&nbsp;CI)</span></p>
   </td>
   <td width="27%" colspan=3 valign=top style='width:27.96%;border:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader><span lang=EN-GB style='color:black'>(95%&nbsp;CI)<sup>c</sup></span></p>
   </td>
  </tr>
  <tr>
   <td width="23%" valign=top style='width:23.54%;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader align=left style='text-align:left'><span lang=EN-GB
   style='color:black'>&nbsp;</span></p>
   </td>
   <td width="10%" valign=top style='width:10.96%;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader><span lang=EN-GB style='font-size:9.0pt;color:black'>nivolumab</span></p>
   </td>
   <td width="13%" colspan=2 valign=top style='width:13.28%;border:none;
   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader><span lang=EN-GB style='font-size:9.0pt'>investigators
   choice</span></p>
   </td>
   <td width="10%" valign=top style='width:10.98%;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader><span lang=EN-GB style='font-size:9.0pt;color:black'>nivolumab</span></p>
   </td>
   <td width="13%" colspan=2 valign=top style='width:13.28%;border:none;
   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader><span lang=EN-GB style='font-size:9.0pt'>investigators
   choice</span></p>
   </td>
   <td width="11%" valign=top style='width:11.62%;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader><span lang=EN-GB style='font-size:9.0pt;color:black'>nivolumab</span></p>
   </td>
   <td width="16%" colspan=2 valign=top style='width:16.34%;border:none;
   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader><span lang=EN-GB style='font-size:9.0pt'>investigators
   choice</span></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="23%" rowspan=2 valign=top style='width:23.54%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left'><b><span lang=EN-GB
  style='font-size:9.0pt;color:black'>PD&#8209;L1&nbsp;</span></b><b><span
  lang=EN-GB style='font-size:9.0pt;font-family:Symbol;color:black'></span></b><b><span
  lang=EN-GB style='font-size:9.0pt;color:black'>&nbsp;1%,<br>
  PD&#8209;L1+ TAIC abundant<sup>d</sup></span></b><sup><span lang=EN-GB
  style='font-size:9.0pt;color:black'><br>
  </span></sup><span lang=EN-GB style='font-size:9.0pt;color:black'>(61
  nivolumab,<br>
  47 investigators choice)</span></p>
  </td>
  <td width="10%" valign=top style='width:10.96%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>9.10</span></p>
  </td>
  <td width="13%" colspan=2 valign=top style='width:13.28%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>4.60</span></p>
  </td>
  <td width="10%" valign=top style='width:10.98%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>3.19</span></p>
  </td>
  <td width="13%" colspan=2 valign=top style='width:13.28%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>1.97</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.5%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>19.7</span></p>
  </td>
  <td width="13%" valign=top style='width:13.46%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>0</span></p>
  </td>
 </tr>
 <tr>
  <td width="24%" colspan=3 valign=top style='width:24.24%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>0.43 (0.28, 0.67)</span></p>
  </td>
  <td width="24%" colspan=3 valign=top style='width:24.26%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>0.48 (0.31, 0.75)</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.5%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>(10.6, 31.8)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.46%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>(0, 7.5)</span></p>
  </td>
 </tr>
 <tr>
  <td width="23%" rowspan=2 valign=top style='width:23.54%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left'><b><span lang=EN-GB
  style='font-size:9.0pt;color:black'>PD&#8209;L1&nbsp;</span></b><b><span
  lang=EN-GB style='font-size:9.0pt;font-family:Symbol;color:black'></span></b><b><span
  lang=EN-GB style='font-size:9.0pt;color:black'>&nbsp;1%,<br>
  PD&#8209;L1+ TAIC rare<sup>d</sup></span></b><sup><span lang=EN-GB
  style='font-size:9.0pt;color:black'><br>
  </span></sup><span lang=EN-GB style='font-size:9.0pt;color:black'>(27
  nivolumab,<br>
  14 investigators choice)</span></p>
  </td>
  <td width="11%" colspan=2 valign=top style='width:11.38%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>6.67</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>4.93</span></p>
  </td>
  <td width="11%" colspan=2 valign=top style='width:11.4%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>1.99</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>2.04</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.5%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>11.1</span></p>
  </td>
  <td width="13%" valign=top style='width:13.46%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>7.1</span></p>
  </td>
 </tr>
 <tr>
  <td width="24%" colspan=3 valign=top style='width:24.24%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>0.89 (0.44, 1.80)</span></p>
  </td>
  <td width="24%" colspan=3 valign=top style='width:24.26%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>0.93 (0.46, 1.88)</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.5%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>(2.4, 29.2)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.46%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>(0.2, 33.9)</span></p>
  </td>
 </tr>
 <tr>
  <td width="23%" rowspan=2 valign=top style='width:23.54%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left'><b><span lang=EN-GB
  style='font-size:9.0pt;color:black'>PD&#8209;L1&nbsp;&lt;&nbsp;1%,<br>
  PD&#8209;L1+ TAIC abundant<sup>d</sup></span></b><span lang=EN-GB
  style='font-size:9.0pt;color:black'><br>
  (43 nivolumab,<br>
  25 investigators choice)</span></p>
  </td>
  <td width="11%" colspan=2 valign=top style='width:11.38%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>11.73</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>6.51</span></p>
  </td>
  <td width="11%" colspan=2 valign=top style='width:11.4%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>2.10</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>2.73</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.5%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>18.6 </span></p>
  </td>
  <td width="13%" valign=top style='width:13.46%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>12.0</span></p>
  </td>
 </tr>
 <tr>
  <td width="24%" colspan=3 valign=top style='width:24.24%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>0.67 (0.38, 1.18)</span></p>
  </td>
  <td width="24%" colspan=3 valign=top style='width:24.26%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>0.96 (0.55, 1.67)</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.5%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>(8.4, 33.4)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.46%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>(2.5, 31.2)</span></p>
  </td>
 </tr>
 <tr>
  <td width="23%" rowspan=2 valign=top style='width:23.54%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='text-align:left'><b><span lang=EN-GB
  style='font-size:9.0pt;color:black'>PD&#8209;L1&nbsp;&lt;&nbsp;1%,<br>
  PD&#8209;L1+ TAIC rare<sup>d</sup></span></b><span lang=EN-GB
  style='font-size:9.0pt;color:black'><br>
  (27 nivolumab,<br>
  10 investigators choice)</span></p>
  </td>
  <td width="11%" colspan=2 valign=top style='width:11.38%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>3.71</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>4.85</span></p>
  </td>
  <td width="11%" colspan=2 valign=top style='width:11.4%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>1.84</span></p>
  </td>
  <td width="12%" valign=top style='width:12.86%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>2.12</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.5%;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>3.7</span></p>
  </td>
  <td width="13%" valign=top style='width:13.46%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>10.0</span></p>
  </td>
 </tr>
 <tr>
  <td width="24%" colspan=3 valign=top style='width:24.24%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>1.09 (0.50, 2.36)</span></p>
  </td>
  <td width="24%" colspan=3 valign=top style='width:24.26%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>1.91 (0.84, 4.36)</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.5%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>(&lt;&nbsp;0.1,
  19.0)</span></p>
  </td>
  <td width="13%" valign=top style='width:13.46%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText><span lang=EN-GB style='color:black'>(0.3, 44.5)</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=170 style='border:none'></td>
  <td width=79 style='border:none'></td>
  <td width=3 style='border:none'></td>
  <td width=93 style='border:none'></td>
  <td width=79 style='border:none'></td>
  <td width=3 style='border:none'></td>
  <td width=93 style='border:none'></td>
  <td width=84 style='border:none'></td>
  <td width=21 style='border:none'></td>
  <td width=97 style='border:none'></td>
 </tr>
</table>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='color:black'>a </span></sup><span lang=EN-GB
style='font-size:10.0pt'>OS and PFS were estimated using Kaplan&#8209;Meier
method.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='color:black'>b </span></sup><span lang=EN-GB
style='font-size:10.0pt'>Hazard ratio in each subgroup derived from a Cox
proportional hazards model with treatment as the only covariate.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='color:black'>c </span></sup><span lang=EN-GB
style='font-size:10.0pt'>Confidence interval for ORR calculated using the
Clopper&#8209;Pearson method.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>d </span></sup><span
lang=EN-GB style='font-size:10.0pt'>PD&#8209;L1+ TAIC in the tumour
microenvironment were qualitatively assessed, and characterised as numerous,
intermediate, and rare based on pathologist assessments. Numerous and
intermediate groups were combined to define the abundant group.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Patients with investigator&#8209;assessed
primary site of oropharyngeal cancer were tested for HPV (determined by p16
immunohistochemistry [IHC]). OS&nbsp;benefit was observed regardless of HPV
status (HPV&#8209;positive: HR&nbsp;=&nbsp;0.63; 95%&nbsp;CI: 0.38, 1.04, HPV&#8209;negative:
HR&nbsp;=&nbsp;0.64; 95%&nbsp;CI: 0.40, 1.03, and HPV&#8209;unknown: HR&nbsp;=&nbsp;0.78;
95%&nbsp;CI: 0.55, 1.10).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patient&#8209;reported outcomes (PROs) were
assessed using the EORTC QLQ&#8209;C30, EORTC QLQ&#8209;H&amp;N35, and 3&#8209;level
EQ&#8209;5D. Over 15 weeks of follow&#8209;up, patients treated with nivolumab
exhibited stable PROs, while those assigned to investigators choice therapy
exhibited significant declines in functioning (e.g., physical, role, social)
and health status as well as increased symptomatology (e.g., fatigue, dyspnoea,
appetite loss, pain, sensory problems, social contact problems). The PRO data
should be interpreted in the context of the open&#8209;label study design and
therefore taken cautiously.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Urothelial
carcinoma</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Open&#8209;label
phase&nbsp;2 study (CA209275)</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The safety and efficacy of nivolumab
3&nbsp;mg/kg as a single agent for the treatment of patients with locally
advanced or metastatic urothelial carcinoma was evaluated in a phase&nbsp;2, multicentre,
open&#8209;label, single&#8209;arm study (CA209275).</span></p>

<p class=EMEABodyText><span lang=EN-GB>The study included patients
(18&nbsp;years or older) who had disease progression during or following
platinum&#8209;containing chemotherapy for advanced or metastatic disease or
had disease progression within 12&nbsp;months of neoadjuvant or adjuvant
treatment with platinum&#8209;containing chemotherapy. Patients had an ECOG
performance status score of&nbsp;0 or&nbsp;1 and were enrolled regardless of
their tumour PD&#8209;L1 status. Patients with active brain metastases or
leptomeningeal metastases, active autoimmune disease, or medical conditions
requiring systemic immunosuppression were excluded from the study. Patients
that received more than 2&nbsp;prior lines of chemotherapy with liver
metastases were excluded.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>A total of 270&nbsp;patients who received
nivolumab 3&nbsp;mg/kg administered intravenously over 60&nbsp;minutes every
2&nbsp;weeks with a minimum follow&#8209;up of 8.3&nbsp;months were evaluable
for efficacy. Treatment was continued as long as clinical benefit was observed
or until treatment was no longer tolerated. The first tumour assessments were
conducted 8&nbsp;weeks after the start of treatment and continued every
8&nbsp;weeks thereafter up to 48&nbsp;weeks, then every 12&nbsp;weeks until
disease progression or treatment discontinuation, whichever occurred later.
Tumour assessments were continued after treatment discontinuation in patients
who discontinued treatment for reasons other than progression. Treatment beyond
initial investigator&#8209;assessed RECIST, version&nbsp;1.1&#8209;defined
progression was permitted if the patient had a clinical benefit, did not have
rapid disease progression, and was tolerating study drug as determined by the
investigator. The primary efficacy outcome measure was ORR as determined by BICR.
Additional efficacy measures included duration of response, PFS and OS.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The median age was 66&nbsp;years
(range:&nbsp;38&nbsp;to&nbsp;90) with 55% </span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB>65&nbsp;years of age
and&nbsp;14% </span><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB>75&nbsp;years of age. The majority of patients were white (86%) and
male (78%). Baseline ECOG performance status was 0&nbsp;(54%) or 1&nbsp;(46%).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;28:
 Efficacy results (CA209275)<sup>a</sup></span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <thead>
  <tr>
   <td width=310 colspan=2 valign=top style='width:232.2pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:10.0pt'>&nbsp;</span></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>nivolumab<br>
   (n&nbsp;=&nbsp;270)</span></b></p>
   </td>
  </tr>
  <tr>
   <td width=310 colspan=2 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-top:6.0pt;margin-right:-23.75pt;margin-bottom:
   0in;margin-left:0in;margin-bottom:.0001pt;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Confirmed objective response</span></b></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
   page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>54 (20.0%)</span></p>
   </td>
  </tr>
  <tr>
   <td width=310 colspan=2 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:10.0pt'> (95%&nbsp;CI)</span></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB style='font-size:10.0pt'>(15.4, 25.3)</span></p>
   </td>
  </tr>
  <tr>
   <td width=310 colspan=2 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:10.0pt'> Complete response (CR)</span></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB style='font-size:10.0pt'>8 (3.0%)</span></p>
   </td>
  </tr>
  <tr>
   <td width=310 colspan=2 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:10.0pt'> Partial response (PR)</span></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB style='font-size:10.0pt'>46 (17.0%)</span></p>
   </td>
  </tr>
  <tr style='height:17.5pt'>
   <td width=310 colspan=2 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
   height:17.5pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Stable
   disease (SD)</span></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt;
   height:17.5pt'>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>60 (22.2%)</span></p>
   </td>
  </tr>
  <tr>
   <td width=310 colspan=2 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-top:6.0pt'><b><span lang=EN-GB
   style='font-size:10.0pt'>Median duration of response</span></b><span
   class=EMEASuperscript><span lang=EN-GB style='font-size:10.0pt'>b</span></span></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center'><span
   lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='height:15.35pt'>
   <td width=310 colspan=2 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
   height:15.35pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Months
   (range)</span></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt;
   height:15.35pt'>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>10.4 (1.9<sup>+</sup>&#8209;12.0<sup>+</sup>)</span></p>
   </td>
  </tr>
  <tr>
   <td width=310 colspan=2 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-top:6.0pt'><b><span lang=EN-GB
   style='font-size:10.0pt'>Median time to response</span></b></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center'><span
   lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='height:17.45pt'>
   <td width=310 colspan=2 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
   height:17.45pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Months
   (range)</span></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt;
   height:17.45pt'>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>1.9 (1.6, 7.2)</span></p>
   </td>
  </tr>
  <tr style='height:13.05pt'>
   <td width=310 colspan=2 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
   height:13.05pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:10.0pt'>Progression&#8209;free survival</span></b></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt;
   height:13.05pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='height:13.05pt'>
   <td width=310 colspan=2 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
   height:13.05pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:10.0pt'> Events (%)</span></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt;
   height:13.05pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB style='font-size:10.0pt'>216 (80%)</span></p>
   </td>
  </tr>
  <tr style='height:9.6pt'>
   <td width=310 colspan=2 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
   height:9.6pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:10.0pt'> Median (95%&nbsp;CI) months</span></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt;
   height:9.6pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB style='font-size:10.0pt'>2.0 (1.9, 2.6)</span></p>
   </td>
  </tr>
  <tr style='height:16.7pt'>
   <td width=310 colspan=2 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
   height:16.7pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:10.0pt'> Rate (95%&nbsp;CI) at 6&nbsp;months</span></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt;
   height:16.7pt'>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>26.1 (20.9, 31.5)</span></p>
   </td>
  </tr>
  <tr>
   <td width=310 colspan=2 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:10.0pt'>Overall survival<sup>c</sup></span></b></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr>
   <td width=310 colspan=2 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:21.3pt;page-break-after:avoid'><span
   lang=EN-GB style='font-size:10.0pt'> Events (%)</span></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB style='font-size:10.0pt'>154 (57%)</span></p>
   </td>
  </tr>
  <tr>
   <td width=310 colspan=2 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-left:21.3pt;page-break-after:avoid'><span
   lang=EN-GB style='font-size:10.0pt'> Median (95%&nbsp;CI) months</span></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB style='font-size:10.0pt'>8.6 (6.05, 11.27)</span></p>
   </td>
  </tr>
  <tr style='height:20.55pt'>
   <td width=310 colspan=2 valign=top style='width:232.2pt;border:none;
   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:
   20.55pt'>
   <p class=MsoNormal style='margin-left:21.3pt'><span lang=EN-GB
   style='font-size:10.0pt'> Rate (95%&nbsp;CI) at 12&nbsp;months</span></p>
   </td>
   <td width=293 colspan=2 valign=top style='width:219.75pt;border:none;
   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:
   20.55pt'>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>41.0 (34.8, 47.1)</span></p>
   </td>
  </tr>
  <tr style='height:18.35pt'>
   <td width=603 colspan=4 style='width:451.95pt;border:none;padding:0in 5.4pt 0in 5.4pt;
   height:18.35pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:10.0pt'>Tumour PD&#8209;L1 expression level</span></b></p>
   </td>
  </tr>
  <tr style='height:18.35pt'>
   <td width=201 valign=top style='width:150.65pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:18.35pt'>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>&nbsp;</span></p>
   </td>
   <td width=201 colspan=2 valign=top style='width:150.65pt;border:none;
   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:
   18.35pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:10.0pt'>&lt;&nbsp;1%</span></b></p>
   </td>
   <td width=201 valign=top style='width:150.65pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:18.35pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB style='font-size:10.0pt'>&#8805;&nbsp;1%</span></b></p>
   </td>
  </tr>
  <tr style='height:18.35pt'>
   <td width=603 colspan=4 valign=top style='width:451.95pt;border:none;
   padding:0in 5.4pt 0in 5.4pt;height:18.35pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Confirmed
   objective response</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>(95%&nbsp;CI)</span></b></p>
   </td>
  </tr>
  <tr style='height:32.35pt'>
   <td width=201 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:32.35pt'>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>&nbsp;</span></p>
   </td>
   <td width=201 colspan=2 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:32.35pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB style='font-size:10.0pt'>16% (10.3, 22.7)</span></p>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>n&nbsp;=&nbsp;146</span></p>
   </td>
   <td width=201 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:32.35pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB style='font-size:10.0pt'>25% (17.7, 33.6)</span></p>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>n&nbsp;=&nbsp;124</span></p>
   </td>
  </tr>
  <tr style='height:18.35pt'>
   <td width=603 colspan=4 valign=top style='width:451.95pt;padding:0in 5.4pt 0in 5.4pt;
   height:18.35pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Median
   duration of response</span></b></p>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Months
   (range)</span></b></p>
   </td>
  </tr>
  <tr style='height:32.45pt'>
   <td width=201 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:32.45pt'>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>&nbsp;</span></p>
   </td>
   <td width=201 colspan=2 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:32.45pt'>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>10.4 (3.7, 12.0<span class=EMEASuperscript>+</span>)</span></p>
   </td>
   <td width=201 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:32.45pt'>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>Not Reached (1.9<span class=EMEASuperscript>+</span>,
   12.0<span class=EMEASuperscript>+</span>)</span></p>
   </td>
  </tr>
  <tr style='height:18.35pt'>
   <td width=603 colspan=4 valign=top style='width:451.95pt;padding:0in 5.4pt 0in 5.4pt;
   height:18.35pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Progression&#8209;free
   survival</span></b></p>
   </td>
  </tr>
  <tr style='height:18.35pt'>
   <td width=201 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:18.35pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:10.0pt'> Median (95%&nbsp;CI) months</span></p>
   </td>
   <td width=201 colspan=2 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:18.35pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB style='font-size:10.0pt'>1.9 (1.8, 2.0)</span></p>
   </td>
   <td width=201 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:18.35pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB style='font-size:10.0pt'>3.6 (1.9, 3.7)</span></p>
   </td>
  </tr>
  <tr style='height:32.65pt'>
   <td width=201 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:32.65pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:10.0pt'> Rate (95%&nbsp;CI) at 6&nbsp;months</span></p>
   </td>
   <td width=201 colspan=2 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:32.65pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB style='font-size:10.0pt'>22.0 (15.6, 29.2)</span></p>
   </td>
   <td width=201 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:32.65pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><span lang=EN-GB style='font-size:10.0pt'>30.8 (22.7, 39.3)</span></p>
   </td>
  </tr>
  <tr style='height:18.35pt'>
   <td width=201 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:18.35pt'>
   <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Overall
   survival</span></b></p>
   </td>
   <td width=201 colspan=2 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:18.35pt'>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>&nbsp;</span></p>
   </td>
   <td width=201 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:18.35pt'>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='height:18.35pt'>
   <td width=201 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:18.35pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Median (95%&nbsp;CI)
   months</span></p>
   </td>
   <td width=201 colspan=2 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:18.35pt'>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>5.9 (4.37, 8.08)</span></p>
   </td>
   <td width=201 valign=top style='width:150.65pt;padding:0in 5.4pt 0in 5.4pt;
   height:18.35pt'>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>11.6 (9.10, NE)</span></p>
   </td>
  </tr>
  <tr style='height:18.35pt'>
   <td width=201 valign=top style='width:150.65pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:18.35pt'>
   <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'> Rate (95%&nbsp;CI)
   at&nbsp;12&nbsp;months</span></p>
   </td>
   <td width=201 colspan=2 valign=top style='width:150.65pt;border:none;
   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:
   18.35pt'>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>34.0 (26.1, 42.1)</span></p>
   </td>
   <td width=201 valign=top style='width:150.65pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:18.35pt'>
   <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
   style='font-size:10.0pt'>49.2 (39.6, 58.1)</span></p>
   </td>
  </tr>
 </thead>
 <tr height=0>
  <td width=201 style='border:none'></td>
  <td width=109 style='border:none'></td>
  <td width=92 style='border:none'></td>
  <td width=201 style='border:none'></td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB><sup>+</sup> d</span><span lang=EN-GB
style='font-size:10.0pt'>enotes a censored observation.</span></p>

<p class=EMEABodyText><sup><span lang=EN-GB style='font-size:10.0pt'>a</span></sup><span
lang=EN-GB style='font-size:10.0pt'> median follow&#8209;up
11.5&nbsp;months.</span></p>

<p class=EMEABodyText><sup><span lang=EN-GB style='font-size:10.0pt'>b</span></sup><span
lang=EN-GB style='font-size:10.0pt'> Data unstable due to the
limited duration of response.</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>c</span></sup><span class=EMEASuperscript><span
lang=EN-GB style='vertical-align:baseline'> </span></span><span
lang=EN-GB style='font-size:10.0pt'>included 4&nbsp;drug&#8209;related deaths:
1&nbsp;pneumonitis, 1&nbsp;acute respiratory failure, 1&nbsp;respiratory
failure, and 1&nbsp;cardiovascular failure.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:10.0pt'>NE: non&#8209;estimable</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>Results from post&#8209;hoc, exploratory analyses indicate that in
patients with low (e.g. &lt;1%) to no tumour PD&#8209;L1 expression, other patient
characteristics (e.g. liver metastases, visceral metastases, baseline
haemoglobin&nbsp;&lt;10g/dL and ECOG performance status&nbsp;=&nbsp;1) might
contribute to the clinical outcome.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;layout-grid-mode:
line'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u>Open&#8209;label
phase&nbsp;1/2 study (CA209032)</u></i></p>

<p class=EMEABodyText><span lang=EN-GB>CA209032 was a Phase&nbsp;1/2 open&#8209;label
multi&#8209;cohort study which included a cohort of 78&nbsp;patients (including
18&nbsp;subjects who received planned crossover treatment with nivolumab
3&nbsp;mg/kg plus ipilimumab 1&nbsp;mg/kg combination) with similar inclusion
criteria to study CA209275 treated with nivolumab monotherapy 3&nbsp;mg/kg for
urothelial carcinoma. At a minimum follow&#8209;up of 9&nbsp;months,
investigator&#8209;assessed confirmed ORR was 24.4% (95%&nbsp;CI: 15.3, 35.4).
The median duration of response was not reached (range:</span><span lang=EN-GB>&nbsp;4.4&#8209;16.6<sup>+</sup>&nbsp;months).
The median OS was 9.7&nbsp;months (95%&nbsp;CI:7.26, 16.16) and the estimated
OS rates were 69.2% (CI: 57.7, 78.2) at 6&nbsp;months and 45.6% (CI: 34.2,
56.3) at 12&nbsp;months. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Oesophageal
squamous cell carcinoma</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt'>The safety and
efficacy of nivolumab 240&nbsp;mg monotherapy for the treatment of </span><span
lang=EN-GB style='font-size:11.0pt'>unresectable advanced, recurrent or
metastatic oesophageal squamous cell carcinoma (OSCC) was evaluated in a
phase&nbsp;3<s> </s></span><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>randomised
active-controlled, open-label study (ONO-4538-24/CA209473). The study included
adult patients (20&nbsp;years or older) who were</span><span lang=EN-GB
style='font-size:11.0pt'> refractory or intolerant to at least one
fluoropyrimidine- and platinum&#8209;based combination regimen, and p</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>atients were enrolled
regardless of tumour PD-L1 expression level. Patients who were refractory or
intolerant to taxane therapy, had brain metastases that were symptomatic or
required treatment, had active autoimmune disease</span><span lang=EN-GB
style='font-size:11.0pt'>, </span><span lang=ES style='font-size:11.0pt'>medical
conditions requiring systemic immunosuppression</span><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>, and patients with </span><span
lang=EN-GB style='font-size:11.0pt'>apparent tumour invasion in organs located
adjacent to the oesophagus (e.g. the aorta or respiratory tract), </span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>were excluded from the
study.</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>A
total of 419&nbsp;patients were randomised 1:1 to receive either nivolumab
240&nbsp;mg administered intravenously over 30&nbsp;minutes every 2&nbsp;weeks
(n=210) or investigators choice of taxane chemotherapy: either docetaxel
(n=65) 75&nbsp;mg/m<span class=BMSSuperscript>2</span></span><span lang=EN-GB
style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:11.0pt;
color:windowtext'>intravenously</span><span lang=EN-GB style='font-size:11.0pt'>
</span><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>every
3&nbsp;weeks, or paclitaxel (n=144) 100&nbsp;mg/m<span class=BMSSuperscript>2</span>
intravenously once a week for 6&nbsp;weeks followed by 1&nbsp;week off.
Randomisation was stratified by location (Japan vs. rest of world), number of
organs with metastases (&#8804;1&nbsp;vs.&nbsp;&#8805;2) and tumour PD-L1
expression (&#8805;1%&nbsp;vs.&nbsp;&lt;1% or indeterminate). Treatment
continued until </span><span lang=EN-GB style='font-size:11.0pt'>disease
progression, assessed by the investigator per RECIST version&nbsp;1.1, or
unacceptable toxicity. Tumour assessments were conducted every 6&nbsp;weeks for
1&nbsp;year, and every 12&nbsp;weeks thereafter. Treatment beyond initial
investigator-assessed progression was permitted in patients receiving nivolumab
with no rapid progression, investigator-assessed benefit, tolerance to
treatment, stable performance status, and for whom treatment beyond progression
would not delay an imminent intervention to prevent serious complications
associated with disease progression (e.g brain metastasis). The primary
efficacy outcome measure was OS. Key secondary efficacy outcome measures were
investigator-assessed ORR and PFS. Additional prespecified subgroup analyses
were conducted to evaluate the efficacy by tumour PD-L1 expression at a
predefined level of&nbsp;1%.</span><span lang=EN-GB style='font-size:11.0pt;
color:windowtext'> </span><span lang=EN-GB style='font-size:11.0pt'>Tumour
PD-L1 expression was determined using the PD-L1 IHC 28-8 pharmDx assay.</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt'>Baseline
characteristics were generally balanced between the two groups</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>. The median age was 65&nbsp;years
(range: 33 to 87&nbsp;years), 53% were </span><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:windowtext'></span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>65&nbsp;years of age, 10%
were aged </span><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol;
color:windowtext'></span><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>75
years, 87% were male, 96% were Asian and 4% were white. Baseline ECOG
performance status was 0&nbsp;(50%) or&nbsp;1&nbsp;(50%)</span><span
lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>With
a minimum follow-up of 17.6&nbsp;months, the study demonstrated a statistically
significant improvement in OS for patients randomised to nivolumab as compared
with investigators choice taxane chemotherapy. Efficacy results are shown in
Table&nbsp;29 and Figure&nbsp;15.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=ES style='font-size:11.0pt'>A higher proportion
of patients experienced death within the first 2.5&nbsp;months in the nivolumab
arm (32/210, 15.2%) as compared to the chemotherapy arm (15/209, 7.2%). </span><span
style='font-size:11.0pt'>No specific factor(s) </span><span lang=ES
style='font-size:11.0pt'>associated with early deaths could be identified</span><span
style='font-size:11.0pt'>.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=624 colspan=3 valign=top style='width:6.5in;border:none;
   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableTitle style='margin-top:0in;margin-right:0in;margin-bottom:
   6.0pt;margin-left:52.75pt;text-indent:-52.75pt'><span lang=EN-GB
   style='font-size:11.0pt'>Table 29: Efficacy results (ONO-4538-24/CA209473)</span></p>
   </td>
  </tr>
  <tr>
   <td width=293 valign=top style='width:219.75pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader align=left style='margin-top:2.0pt;margin-right:
   0in;margin-bottom:2.0pt;margin-left:0in;text-align:left;page-break-after:
   avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=161 style='width:120.45pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader style='margin-top:2.0pt;margin-right:0in;margin-bottom:
   2.0pt;margin-left:0in;page-break-after:avoid'><span lang=EN-GB>nivolumab<br>
   (n&nbsp;=&nbsp;210)</span></p>
   </td>
   <td width=170 style='width:127.8pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=BMSTableHeader style='margin-top:2.0pt;margin-right:0in;margin-bottom:
   2.0pt;margin-left:0in;page-break-after:avoid'><span lang=EN-GB>investigators
   choice<br>
   (n&nbsp;=&nbsp;209)</span></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=293 valign=top style='width:219.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left;
  page-break-after:avoid'><b><span lang=EN-GB>Overall Survival</span></b><span
  class=BMSSuperscript><span lang=EN-GB style='font-size:14.0pt'>a</span></span></p>
  </td>
  <td width=161 style='width:120.45pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=170 style='width:127.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=293 valign=top style='width:219.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left;
  text-indent:8.1pt;page-break-after:avoid'><span lang=EN-GB>Events (%)</span></p>
  </td>
  <td width=161 style='width:120.45pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>160 (76%)</span></p>
  </td>
  <td width=170 style='width:127.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>173 (83%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=293 valign=top style='width:219.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left;
  text-indent:15.9pt;page-break-after:avoid'><span lang=EN-GB>Hazard ratio
  (95%&nbsp;CI)</span><span class=BMSSuperscript><span lang=EN-GB
  style='font-size:14.0pt'>b</span></span></p>
  </td>
  <td width=331 colspan=2 style='width:248.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>0.77 (0.62, 0.96)</span></p>
  </td>
 </tr>
 <tr>
  <td width=293 valign=top style='width:219.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left;
  text-indent:15.9pt;page-break-after:avoid'><span lang=EN-GB>p-value</span><span
  class=BMSTableNote><span lang=EN-GB style='font-size:14.0pt'>c </span></span></p>
  </td>
  <td width=331 colspan=2 style='width:248.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>0.0189</span></p>
  </td>
 </tr>
 <tr>
  <td width=293 valign=top style='width:219.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left;
  text-indent:8.8pt;page-break-after:avoid'><span lang=EN-GB>Median
  (95%&nbsp;CI) (months)</span></p>
  </td>
  <td width=161 style='width:120.45pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>10.9 (9.2, 13.3)</span></p>
  </td>
  <td width=170 style='width:127.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>8.4 (7.2, 9.9)</span></p>
  </td>
 </tr>
 <tr>
  <td width=293 valign=top style='width:219.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin-bottom:0in;text-align:left;
  page-break-after:avoid'><b><span lang=EN-GB>Objective Response Rate</span></b><span
  class=BMSSuperscript><span lang=EN-GB style='font-size:14.0pt'>d,e</span></span></p>
  </td>
  <td width=161 style='width:120.45pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>33 (19.3%)</span></p>
  </td>
  <td width=170 style='width:127.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>34 (21.5%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=293 valign=top style='width:219.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:9.0pt;text-align:left;page-break-after:avoid'><span
  lang=EN-GB>(95%&nbsp;CI)</span></p>
  </td>
  <td width=161 style='width:120.45pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>(13.7, 26.0)</span></p>
  </td>
  <td width=170 style='width:127.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>(15.4, 28.8)</span></p>
  </td>
 </tr>
 <tr>
  <td width=293 valign=top style='width:219.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:9.0pt;text-align:left;page-break-after:avoid'><span
  lang=EN-GB>Complete response</span></p>
  </td>
  <td width=161 style='width:120.45pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>1 (0.6%)</span></p>
  </td>
  <td width=170 style='width:127.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>2 (1.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=293 valign=top style='width:219.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:9.0pt;text-align:left;page-break-after:avoid'><span
  lang=EN-GB>Partial response </span></p>
  </td>
  <td width=161 style='width:120.45pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>32 (18.7%)</span></p>
  </td>
  <td width=170 style='width:127.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>32 (20.3%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=293 valign=top style='width:219.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:9.0pt;text-align:left;page-break-after:avoid'><span
  lang=EN-GB>Stable disease</span></p>
  </td>
  <td width=161 style='width:120.45pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>31 (18.1%)</span></p>
  </td>
  <td width=170 style='width:127.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>65 (41.1%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=293 valign=top style='width:219.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:9.0pt;text-align:left;page-break-after:avoid'><span
  lang=EN-GB>Median duration of response (95%&nbsp;CI) (months)</span></p>
  </td>
  <td width=161 style='width:120.45pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>6.9 (5.4, 11.1)</span></p>
  </td>
  <td width=170 style='width:127.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>3.9 (2.8, 4.2)</span></p>
  </td>
 </tr>
 <tr>
  <td width=293 valign=top style='width:219.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin-bottom:0in;text-align:left;
  page-break-after:avoid'><b><span lang=EN-GB>Progression-Free Survival</span></b><span
  class=BMSTableNote><span lang=EN-GB style='font-size:14.0pt'>a</span></span></p>
  </td>
  <td width=161 style='width:120.45pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=170 style='width:127.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=293 valign=top style='width:219.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left;
  text-indent:8.1pt;page-break-after:avoid'><span lang=EN-GB>Events (%)</span></p>
  </td>
  <td width=161 style='width:120.45pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>187 (89%)</span></p>
  </td>
  <td width=170 style='width:127.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>176 (84%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=293 valign=top style='width:219.75pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText align=left style='margin:0in;text-align:left;
  text-indent:8.1pt;page-break-after:avoid'><span lang=EN-GB>Median
  (95%&nbsp;CI) (months)</span></p>
  </td>
  <td width=161 style='width:120.45pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>1.7 (1.5, 2.7)</span></p>
  </td>
  <td width=170 style='width:127.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>3.4 (3.0, 4.2)</span></p>
  </td>
 </tr>
 <tr style='height:18.2pt'>
  <td width=293 valign=top style='width:219.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:18.2pt'>
  <p class=BMSTableText align=left style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:8.8pt;text-align:left;page-break-after:avoid'><span
  lang=EN-GB>Hazard ratio (95%&nbsp;CI)</span><span class=BMSSuperscript><span
  lang=EN-GB style='font-size:14.0pt'>b</span></span></p>
  </td>
  <td width=331 colspan=2 style='width:248.25pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.2pt'>
  <p class=BMSTableText style='margin:0in;page-break-after:avoid'><span
  lang=EN-GB>1.1 (0.9, 1.3)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=BMSTableNoteInfo style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:10.75pt;margin-bottom:.0001pt;text-indent:-10.75pt'><sup><span
lang=EN-GB>a</span></sup><span lang=EN-GB> Based on ITT analysis.</span></p>

<p class=BMSTableNoteInfo style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:10.75pt;margin-bottom:.0001pt;text-indent:-10.75pt'><sup><span
lang=EN-GB>b</span></sup><span lang=EN-GB> Based on a stratified proportional
hazards model.</span></p>

<p class=BMSTableNoteInfo style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:10.75pt;margin-bottom:.0001pt;text-indent:-10.75pt'><sup><span
lang=EN-GB>c</span></sup><span lang=EN-GB> Based on a stratified log-rank
test.</span></p>

<p class=BMSTableNoteInfo style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:10.75pt;margin-bottom:.0001pt;text-indent:-10.75pt'><sup><span
lang=EN-GB>d</span></sup><span lang=EN-GB> Based on Response Evaluable Set
(RES) analysis, n=171 in nivolumab group and n=158 in investigators choice
group.</span></p>

<p class=BMSTableNoteInfo style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:10.75pt;margin-bottom:.0001pt;text-indent:-10.75pt'><sup><span
lang=EN-GB>e</span></sup><span lang=EN-GB> Not significant, p-value 0.6323.</span></p>

<p class=BMSBodyText style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BMSFigureCaption style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:63.8pt;text-indent:-63.8pt'><span lang=ES style='font-size:
11.0pt'>Figure 15: </span><span style='font-size:11.0pt'>Kaplan-Meier
curves of OS</span><span style='font-size:11.0pt;font-weight:normal'> </span><span
style='font-size:11.0pt'>(ONO-4538-24/CA209473)</span></p>

<p class=BMSBodyText style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;line-height:normal;page-break-after:avoid'><span
style='position:relative;z-index:251718656'><span style='left:0px;position:
absolute;left:-2px;top:-29377px;width:37px;height:1px'><img width=37 height=1
src="OPDIVO-H-3985-IA-099-PI-en_files/image012.png"
alt="Probability of Overall Survival (%)"></span></span><img border=0
width=605 height=353 id="Picture 3"
src="OPDIVO-H-3985-IA-099-PI-en_files/image039.png"></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:28.35pt;
page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>Overall
Survival (Months)</span></p>

<p class=MsoNormal align=center style='text-align:center;text-indent:28.35pt;
page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=0
 style='margin-left:35.45pt;border-collapse:collapse'>
 <tr style='height:14.75pt'>
  <td width=373 colspan=12 valign=top style='width:280.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Number of Subjects at Risk</span></p>
  </td>
  <td width=30 colspan=3 valign=top style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=30 colspan=3 valign=top style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=30 colspan=3 valign=top style='width:22.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=31 colspan=3 valign=top style='width:22.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=30 colspan=3 valign=top style='width:22.6pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=30 colspan=3 valign=top style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:14.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=50 colspan=4><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=373 colspan=12 valign=top style='width:280.05pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Nivolumab</span></p>
  </td>
  <td width=30 colspan=3 valign=top style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=30 colspan=3 valign=top style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=30 colspan=3 valign=top style='width:22.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=31 colspan=3 valign=top style='width:22.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=30 colspan=3 valign=top style='width:22.6pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=30 colspan=3 valign=top style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=50 colspan=4><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=61 style='width:45.55pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>210</span></p>
  </td>
  <td width=30 style='width:22.8pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=right style='margin-left:-5.4pt;text-align:right;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>182</span></p>
  </td>
  <td width=30 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=right style='margin-left:-5.4pt;text-align:right;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>167</span></p>
  </td>
  <td width=30 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=right style='margin-left:-12.45pt;text-align:right;
  text-indent:7.05pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>147</span></p>
  </td>
  <td width=30 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=right style='margin-left:-5.4pt;text-align:right;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>126</span></p>
  </td>
  <td width=30 style='width:22.8pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-.3pt;
  margin-bottom:0in;margin-left:-18.1pt;margin-bottom:.0001pt;text-align:center;
  text-indent:.2pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'> 111</span></p>
  </td>
  <td width=30 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=right style='margin-top:0in;margin-right:-.4pt;
  margin-bottom:0in;margin-left:-11.0pt;margin-bottom:.0001pt;text-align:right;
  text-indent:-1.5pt;page-break-after:avoid'><span lang=EN-GB style='font-size:
  10.0pt'>95</span></p>
  </td>
  <td width=30 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=right style='margin-left:-5.4pt;text-align:right;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>82</span></p>
  </td>
  <td width=30 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.4pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>70</span></p>
  </td>
  <td width=30 style='width:22.15pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.95pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>60</span></p>
  </td>
  <td width=31 style='width:23.4pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='margin-left:-4.85pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>43</span></p>
  </td>
  <td width=30 colspan=3 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
  0in;margin-left:-5.4pt;margin-bottom:.0001pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>25</span></p>
  </td>
  <td width=30 colspan=3 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-left:-12.5pt;text-indent:7.1pt;page-break-after:
  avoid'><span lang=EN-GB style='font-size:10.0pt'>17</span></p>
  </td>
  <td width=30 colspan=3 style='width:22.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.4pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>13</span></p>
  </td>
  <td width=31 colspan=3 style='width:22.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.3pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>7</span></p>
  </td>
  <td width=30 colspan=3 style='width:22.6pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.55pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>4</span></p>
  </td>
  <td width=20 colspan=2 style='width:15.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.4pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>3</span></p>
  </td>
  <td width=30 colspan=3 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>0</span></p>
  </td>
  <td width=19 colspan=2 style='width:.2in;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>0</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=20><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=393 colspan=13 style='width:294.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Investigators choice</span></p>
  </td>
  <td width=30 colspan=3 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.4pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=30 colspan=3 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.4pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=30 colspan=3 style='width:22.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.4pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=31 colspan=3 style='width:22.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.4pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=30 colspan=4 style='width:22.6pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.4pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=30 colspan=3 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.4pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width=30 colspan=2 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.4pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:13.15pt'>
  <td width=61 style='width:45.55pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>209</span></p>
  </td>
  <td width=30 style='width:22.8pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=right style='margin-left:-5.4pt;text-align:right;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>196</span></p>
  </td>
  <td width=30 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=right style='margin-left:-10.9pt;text-align:right;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>169</span></p>
  </td>
  <td width=30 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:-7.4pt;
  margin-bottom:0in;margin-left:-10.95pt;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>126</span></p>
  </td>
  <td width=30 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-7.35pt;margin-bottom:
  0in;margin-left:-3.9pt;margin-bottom:.0001pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>105</span></p>
  </td>
  <td width=30 style='width:22.8pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:1.25pt;
  margin-bottom:0in;margin-left:-5.45pt;margin-bottom:.0001pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>84</span></p>
  </td>
  <td width=30 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=right style='margin-left:-7.0pt;text-align:right;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>68</span></p>
  </td>
  <td width=30 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal align=right style='text-align:right;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>57</span></p>
  </td>
  <td width=30 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.4pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>49</span></p>
  </td>
  <td width=30 style='width:22.15pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.95pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>40</span></p>
  </td>
  <td width=31 style='width:23.4pt;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='margin-left:-6.35pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>27</span></p>
  </td>
  <td width=30 colspan=3 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-5.4pt;margin-bottom:
  0in;margin-left:-5.4pt;margin-bottom:.0001pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>17</span></p>
  </td>
  <td width=30 colspan=3 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.4pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>12</span></p>
  </td>
  <td width=30 colspan=3 style='width:22.8pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.4pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>6</span></p>
  </td>
  <td width=31 colspan=3 style='width:22.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.3pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>2</span></p>
  </td>
  <td width=30 colspan=3 style='width:22.6pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.55pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1</span></p>
  </td>
  <td width=20 colspan=2 style='width:15.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='margin-left:-5.4pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1</span></p>
  </td>
  <td width=30 colspan=3 style='width:22.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>1</span></p>
  </td>
  <td width=19 colspan=2 style='width:.2in;padding:0in 5.4pt 0in 5.4pt;
  height:13.15pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>0</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=20><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr height=0>
  <td width=61 style='border:none'></td>
  <td width=30 style='border:none'></td>
  <td width=30 style='border:none'></td>
  <td width=30 style='border:none'></td>
  <td width=30 style='border:none'></td>
  <td width=30 style='border:none'></td>
  <td width=30 style='border:none'></td>
  <td width=30 style='border:none'></td>
  <td width=30 style='border:none'></td>
  <td width=30 style='border:none'></td>
  <td width=31 style='border:none'></td>
  <td width=9 style='border:none'></td>
  <td width=20 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=9 style='border:none'></td>
  <td width=20 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=9 style='border:none'></td>
  <td width=20 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=9 style='border:none'></td>
  <td width=20 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=9 style='border:none'></td>
  <td width=20 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=9 style='border:none'></td>
  <td width=11 style='border:none'></td>
  <td width=8 style='border:none'></td>
  <td width=11 style='border:none'></td>
  <td width=11 style='border:none'></td>
  <td width=9 style='border:none'></td>
  <td width=12 style='border:none'></td>
  <td width=20 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='text-align:justify;text-indent:28.35pt'><span
lang=EN-GB style='font-size:9.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:35.45pt;text-align:justify'><span
lang=EN-GB>&#9472;&#9472;&#9472;&#9472; Nivolumab - - - - - -
Investigators choice</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=BMSBodyText align=left style='margin-bottom:0in;text-align:left;
line-height:normal'><span lang=EN-GB style='font-size:11.0pt'>Of the
419&nbsp;patients, 48% had tumour PD-L1 expression &#8805;1%. The remaining 52%
of patients had tumour PD-L1 expression &lt;1%. The hazard ratio (HR) for OS
was 0.69 (95%&nbsp;CI: 0.51, 0.94) with median survivals of&nbsp;10.9 and
8.1&nbsp;months for the nivolumab and investigators choice taxane chemotherapy
arms, respectively, in the tumour PD-L1 positive subgroup. In the tumour PD&#8209;L1
negative OSCC subgroup, the HR for OS was 0.84 (95%&nbsp;CI: 0.62, 1.14) with
median survivals of 10.9 and 9.3&nbsp;months for the nivolumab and chemotherapy
arms, respectively.</span></p>

<p class=EMEABodyText style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u>Safety and efficacy in
elderly patients</u></p>

<p class=EMEABodyText><span lang=EN-GB>No overall differences in safety or
efficacy were reported between elderly (&#8805;&nbsp;65&nbsp;years) and younger
patients (&lt;&nbsp;65&nbsp;years). </span><span lang=EN-GB>Data from SCCHN and
adjuvant melanoma patients 75&nbsp;years of age or older are too limited to
draw conclusions on this population. </span><span lang=EN-GB>Data from cHL
patients 65&nbsp;years of age or older are too limited to draw conclusions on
this population.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>The European Medicines Agency has
deferred the obligation to submit the results of studies with nivolumab in all
subsets of the paediatric population in the treatment of malignant solid
tumours, </span><span lang=EN-GB>malignant neoplasms of lymphoid tissue and
malignant neoplasms of the central nervous system (see section&nbsp;4.2 for
information on paediatric use).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.2 Pharmacokinetic properties</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Nivolumab
monotherapy</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>The pharmacokinetics (PK) of nivolumab
is linear in the dose range of&nbsp;0.1&nbsp;to&nbsp;10&nbsp;mg/kg. The
geometric mean clearance (CL), terminal half&#8209;life, and average exposure
at steady state at 3&nbsp;mg/kg every&nbsp;2&nbsp;weeks of nivolumab
were&nbsp;7.9&nbsp;mL/h,&nbsp;25.0&nbsp;days, and 86.6&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>g/mL,
respectively, based on a population PK analysis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab CL in cHL patients was
approximately&nbsp;32% lower relative to NSCLC. Nivolumab baseline CL in
adjuvant melanoma patients was approximately 40% lower and steady state CL
approximately 20&nbsp;% lower relative to advanced melanoma. With available safety
data, these decreases in CL were not clinically meaningful.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The metabolic pathway of nivolumab has
not been characterised. Nivolumab is expected to be degraded into small
peptides and amino acids via catabolic pathways in the same manner as
endogenous IgG.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Nivolumab
in combination with ipilimumab </span></u></p>

<p class=EMEABodyText><span lang=EN-GB>When nivolumab 1&nbsp;mg/kg was
administered in combination with ipilimumab 3&nbsp;mg/kg, the CL of nivolumab
was increased by&nbsp;29% and the CL of ipilimumab was increased by 9%, which
was not considered clinically relevant. When nivolumab 3&nbsp;mg/kg was
administered in combination with ipilimumab 1&nbsp;mg/kg, the CL of nivolumab
was increased by 1% and the CL of ipilimumab was decreased by 1.5%, which were
not considered clinically relevant. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>When administered in combination with
ipilimumab, the CL of nivolumab increased by&nbsp;20% in the presence of anti&#8209;nivolumab
antibodies and the CL of ipilimumab increased by 5.7% in the presence of anti&#8209;ipilimumab
antibodies. These changes were not considered clinically relevant.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Nivolumab
in combination with ipilimumab and chemotherapy</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>When nivolumab 360&nbsp;mg every
3&nbsp;weeks was administered in combination </span><span lang=EN-GB>with
ipilimumab 1&nbsp;mg/kg every 6&nbsp;weeks</span><span lang=EN-GB> and with
2&nbsp;cycles of chemotherapy, the CL of nivolumab decreased approximately 10%
and the CL of ipilimumab increased approximately 22%, which were not considered
clinically relevant. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>A population PK analysis suggested no
difference in CL of nivolumab based on age, gender, race, solid tumour type,
tumour size, and hepatic impairment. Although ECOG status, baseline glomerular
filtration rate (GFR), albumin, body weight, and mild hepatic impairment had an
effect on nivolumab CL, the effect was not clinically meaningful.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>The effect of renal impairment on the CL
of nivolumab was evaluated in patients with mild (GFR&nbsp;&lt;&nbsp;90&nbsp;and&nbsp;&#8805;&nbsp;60&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>;
n&nbsp;=&nbsp;379), moderate (GFR&nbsp;&lt;&nbsp;60 and&nbsp;&#8805;&nbsp;30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>;
n&nbsp;=&nbsp;179), or severe (GFR&nbsp;&lt;&nbsp;30 and&nbsp;&#8805;&nbsp;15&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>;
n&nbsp;=&nbsp;2) renal impairment compared to patients with normal renal
function (GFR&nbsp;&#8805;&nbsp;90&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>; n&nbsp;=&nbsp;342)
in population PK analyses. No clinically important differences in the CL of
nivolumab were found between patients with mild or moderate renal impairment
and patients with normal renal function. Data from patients with severe renal
impairment are too limited to draw conclusions on this population (see section&nbsp;4.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>The effect of hepatic impairment on the
CL of nivolumab was evaluated in patients with mild hepatic impairment (total
bilirubin&nbsp;1.0&nbsp;&nbsp;to&nbsp;1.5&nbsp;&nbsp;ULN or AST&nbsp;&gt;&nbsp;ULN
as defined using the National Cancer Institute criteria of hepatic dysfunction;
n&nbsp;=&nbsp;92) compared to patients with normal hepatic function (total
bilirubin and AST&nbsp;&#8804;&nbsp;ULN; n&nbsp;=&nbsp;804) in the population
PK analyses. No clinically important differences in the CL of nivolumab were
found between patients with mild hepatic impairment and normal hepatic
function. Nivolumab has not been studied in patients with moderate (total
bilirubin&nbsp;&gt;&nbsp;1.5&nbsp;&nbsp;to&nbsp;3&nbsp;&nbsp;ULN and any AST)
or severe hepatic impairment (total bilirubin&nbsp;&gt;&nbsp;3&nbsp;&nbsp;ULN
and any AST) (see section&nbsp;4.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>5.3 Preclinical safety data</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='font-size:11.5pt;color:black'>Blockade
of PD&#8209;L1 signalling has been shown in murine models of pregnancy to
disrupt tolerance to the foetus and to increase foetal loss. </span><span
lang=EN-GB>The effects of nivolumab on prenatal and postnatal development were
evaluated in monkeys that received nivolumab twice weekly from the onset of
organogenesis in the first trimester through delivery, at exposure levels
either&nbsp;8&nbsp;or&nbsp;35&nbsp;times higher than those observed at the
clinical dose of&nbsp;3&nbsp;mg/kg of nivolumab (based on AUC). </span><span
lang=EN-GB>There was a </span><span lang=EN-GB>dose&#8209;dependent increase in
foetal losses and increased neonatal mortality </span><span lang=EN-GB>beginning
in the third trimester</span><span lang=EN-GB>.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>The remaining offspring of nivolumab&#8209;treated
females survived to scheduled termination, with no treatment&#8209;related
clinical signs, alterations to normal development, organ&#8209;weight effects,
or gross and microscopic pathology changes</span><span lang=EN-GB>. Results for
growth indices, as well as teratogenic, neurobehavioral, immunological, and
clinical pathology parameters throughout the 6&#8209;month postnatal period
were comparable to the control group. However, b<span style='color:black'>ased
on its mechanism of action, foetal exposure to nivolumab may increase the risk
of developing immune&#8209;related disorders or altering the normal immune
response and immune&#8209;related disorders have been reported in PD&#8209;1
knockout mice.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Fertility studies have not been
performed with </span><span lang=EN-GB>nivolumab</span><span lang=EN-GB>.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>6. PHARMACEUTICAL PARTICULARS</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.1 List of excipients</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEABodyText><span lang=EN-GB>Sodium citrate dihydrate</span></p>

<p class=EMEABodyText><span lang=EN-GB>Sodium chloride</span></p>

<p class=EMEABodyText><span lang=EN-GB>Mannitol (E421)</span></p>

<p class=EMEABodyText><span lang=EN-GB>Pentetic acid
(diethylenetriaminepentaacetic acid)</span></p>

<p class=EMEABodyText><span lang=EN-GB>Polysorbate&nbsp;80&nbsp;(E433)</span></p>

<p class=EMEABodyText><span lang=EN-GB>Sodium hydroxide (for pH adjustment)</span></p>

<p class=EMEABodyText><span lang=EN-GB>Hydrochloric acid (for pH adjustment)</span></p>

<p class=EMEABodyText><span lang=EN-GB>Water for injections</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.2 Incompatibilities</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>In the absence of compatibility studies,
this medicinal product must not be mixed with other medicinal products. OPDIVO
should not be infused concomitantly in the same intravenous line with other
medicinal products.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.3 Shelf life</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Unopened
vial</span></u></p>

<p class=EMEABodyText><span lang=EN-GB>3&nbsp;years</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>After
opening</span></u></p>

<p class=EMEABodyTextIndent><span lang=EN-GB>From a microbiological point of
view, once opened, the medicinal product should be infused or diluted and
infused immediately.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>After preparation
of infusion</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Chemical and
physical in-use stability from the time of preparation has been demonstrated as
follows (times are inclusive of the administration period):</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=586
 style='width:439.45pt;margin-left:12.5pt;border-collapse:collapse;border:none'>
 <tr style='height:13.1pt'>
  <td width=219 rowspan=2 style='width:164.45pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.1pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Infusion preparation</span></b></p>
  </td>
  <td width=367 colspan=2 valign=top style='width:275.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:13.1pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='color:black'>In-use stability</span></b></p>
  </td>
 </tr>
 <tr style='height:31.75pt'>
  <td width=149 valign=top style='width:111.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:31.75pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Storage at 2C to 8C protected from light</span></b></p>
  </td>
  <td width=217 valign=top style='width:163.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:31.75pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Storage at room temperature (&#8804;&nbsp;25C) and room
  light</span></b></p>
  </td>
 </tr>
 <tr style='height:31.45pt'>
  <td width=219 valign=top style='width:164.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:31.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Undiluted or diluted with sodium chloride 9&nbsp;mg/mL
  (0.9%) solution for injection</span></p>
  </td>
  <td width=149 style='width:111.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:31.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>30&nbsp;days</span></p>
  </td>
  <td width=217 style='width:163.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:31.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>24&nbsp;hours</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>(of total 30&nbsp;days storage)</span></p>
  </td>
 </tr>
 <tr style='height:28.05pt'>
  <td width=219 valign=top style='width:164.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Diluted with 50&nbsp;mg/mL (5%) glucose solution for injection</span></p>
  </td>
  <td width=149 style='width:111.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>24&nbsp;hours</span></p>
  </td>
  <td width=217 style='width:163.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>8&nbsp;hours</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>(of total 24&nbsp;hours storage)</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>From a microbiological point of view the
prepared solution for infusion, regardless of the diluent, should be used
immediately. If not used immediately, </span><span lang=EN-GB style='color:
black'>in-use storage times and conditions prior to use are the responsibility
of the user and would normally not be longer than 24&nbsp;hours at 2</span><span
lang=EN-GB style='color:black'>C to 8C or 8&nbsp;hours (of the total 24&nbsp;hours
of storage) at room temperature (&#8804;&nbsp;25C), unless infusion
preparation has taken place in controlled and validated aseptic conditions.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.4 Special precautions for storage</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Store in a refrigerator (2C&#8209;8C).</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not freeze.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Store in the original package in order
to protect from light.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The unopened vial
can be stored at controlled room temperature up to 25C with room light for up
to 48&nbsp;hours.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>For storage conditions after preparation
of the infusion, see section&nbsp;6.3.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><span lang=EN-GB>6.5 Nature and contents of container</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>4&nbsp;mL of concentrate in a&nbsp;10&nbsp;mL
vial (Type&nbsp;I&nbsp;glass) with a stopper (coated butyl rubber) and a dark
blue flip&#8209;off seal (aluminium). Pack size of&nbsp;1&nbsp;vial.</span></p>

<p class=EMEABodyText><span lang=EN-GB>10&nbsp;mL of concentrate in a&nbsp;10&nbsp;mL
vial (Type&nbsp;I&nbsp;glass) with a stopper (coated butyl rubber) and a grey flip&#8209;off
seal (aluminium). Pack size of&nbsp;1&nbsp;vial.</span></p>

<p class=EMEABodyText><span lang=EN-GB>24&nbsp;mL of concentrate in a&nbsp;25&nbsp;mL
vial (Type&nbsp;I&nbsp;glass) with a stopper (coated butyl rubber) and a red
matte flip&#8209;off seal (aluminium). Pack size of&nbsp;1&nbsp;vial.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2><a name="OLE_LINK1"><span lang=EN-GB>6.6 Special
precautions for disposal and other handling</span></a></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Preparation should be performed by
trained personnel in accordance with good practices rules, especially with respect
to asepsis.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Preparation
and administration</span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><span lang=EN-GB>Calculating
the dose</span></i></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>More than
one vial of OPDIVO concentrate may be needed to give the total dose for the
patient.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Nivolumab
monotherapy</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The prescribed dose for the patient is
240&nbsp;mg or 480&nbsp;mg given regardless of body weight depending on
indication (see section&nbsp;4.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Nivolumab
in combination with ipilimumab</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>The prescribed dose for the patient is
given in mg/kg. Based on this prescribed dose, calculate the total dose to be
given. </span></p>

<p class=EMEABodyTextIndent style='margin-left:.25in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>The total nivolumab dose in mg&nbsp;=&nbsp;the
patients weight in kg&nbsp;&nbsp;the prescribed dose in mg/kg. </span></p>

<p class=EMEABodyTextIndent style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>The volume of OPDIVO concentrate to prepare the
dose (mL)&nbsp;=&nbsp;the total dose in mg, divided by&nbsp;10 (the OPDIVO
concentrate strength is&nbsp;10&nbsp;mg/mL). </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Nivolumab
in combination with ipilimumab and chemotherapy</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The prescribed dose
for the patient is 360&nbsp;mg given regardless of body weight.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Preparing
the infusion</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Take care to ensure aseptic handling
when you prepare the infusion.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>OPDIVO
can be used for intravenous administration either:</span></p>

<p class=EMEABodyTextIndent style='margin-left:27.0pt;text-indent:-27.0pt;
text-autospace:none'><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>without
dilution, after transfer to an infusion container using an appropriate sterile
syringe; or</span></p>

<p class=EMEABodyTextIndent style='margin-left:.25in;text-indent:-.25in;
text-autospace:none'><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>after
diluting according to the following instructions:</span></p>

<p class=EMEABodyTextIndent style='margin-left:.5in;text-indent:-.25in;
text-autospace:none'><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>the
final infusion concentration should range between&nbsp;1&nbsp;and&nbsp;10&nbsp;mg/mL.</span></p>

<p class=EMEABodyTextIndent style='margin-left:.5in;text-indent:-.25in;
text-autospace:none'><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>the
total volume of infusion must not exceed 160&nbsp;mL.&nbsp;For patients
weighing less than 40&nbsp;kg, the total volume of infusion must not exceed
4&nbsp;mL per kilogram of patient weight. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO concentrate may be diluted with
either:</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.35pt;text-indent:-27.0pt;
text-autospace:none'><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>sodium
chloride&nbsp;9&nbsp;mg/mL (0.9%) solution for injection; or</span></p>

<p class=EMEABodyTextIndent style='margin-left:55.35pt;text-indent:-27.0pt;
text-autospace:none'><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>50&nbsp;mg/mL
(5%) glucose solution for injection.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>STEP 1</span></p>

<p class=EMEABodyTextIndent style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Inspect the OPDIVO concentrate for particulate
matter or discoloration. Do not shake the vial. OPDIVO concentrate is a clear
to opalescent, colourless to pale yellow liquid. Discard the vial if the
solution is cloudy, is discoloured, or contains particulate matter other than a
few translucent&#8209;to&#8209;white particles.</span></p>

<p class=EMEABodyTextIndent style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Withdraw the required volume of OPDIVO concentrate
using an appropriate sterile syringe.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>STEP 2</span></p>

<p class=EMEABodyTextIndent style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Transfer the concentrate into a sterile,
evacuated glass bottle or intravenous container (PVC or polyolefin).</span></p>

<p class=EMEABodyTextIndent style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>If applicable, dilute with the required volume
of sodium chloride&nbsp;9&nbsp;mg/mL (0.9%) solution for injection
or&nbsp;50&nbsp;mg/mL (5%) glucose solution for injection. <span
style='color:black'>For ease of preparation, the concentrate can also be
transferred directly into a pre&#8209;filled bag containing the appropriate
volume of sodium chloride&nbsp;9&nbsp;mg/mL (0.9%) solution for injection
or&nbsp;50&nbsp;mg/mL (5%) glucose solution for injection.</span></span></p>

<p class=EMEABodyTextIndent style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Gently mix the infusion by manual rotation. Do
not shake.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Administration</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO </span><span lang=EN-GB>infusion
must not be administered as an intravenous push or bolus injection.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Administer the OPDIVO infusion
intravenously over a period of&nbsp;30&nbsp;or 60&nbsp;minutes depending on the
dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO </span><span lang=EN-GB>infusion
should not be infused at the same time in the same intravenous line with other
agents. Use a separate infusion line for the infusion.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Use an infusion set and an in&#8209;line,
sterile, non&#8209;pyrogenic, low protein binding filter (pore size of&nbsp;0.2&nbsp;&#956;m
to&nbsp;1.2 &#956;m).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO </span><span lang=EN-GB>infusion
is compatible with PVC and polyolefin containers, glass bottles, PVC infusion
sets and in&#8209;line filters with polyethersulfone membranes with pore sizes
of&nbsp;0.2&nbsp;m to 1.2&nbsp;m.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>After administration of the nivolumab dose,
flush the line with sodium chloride&nbsp;9&nbsp;mg/mL (0.9%) solution for
injection or&nbsp;50&nbsp;mg/mL (5%) glucose solution for injection.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><i><u><span lang=EN-GB>Disposal</span></u></i></p>

<p class=EMEABodyText><span lang=EN-GB>Do not store any unused portion of the
infusion solution for reuse. </span><span lang=EN-GB>Any unused medicinal
product or waste material should be disposed of in accordance with local
requirements.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>7. MARKETING AUTHORISATION HOLDER</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress><span lang=EN-GB>Bristol&#8209;Myers Squibb Pharma EEIG<br>
</span><span lang=EN-GB>Plaza 254<br>
Blanchardstown Corporate Park 2<br>
Dublin 15, D15 T867</span></p>

<p class=EMEAAddress><span lang=EN-GB>Ireland</span></p>

<p class=EMEAAddress><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>8. MARKETING AUTHORISATION
NUMBER(S)</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>EU/1/15/1014/001</span></p>

<p class=EMEABodyText><span lang=EN-GB>EU/1/15/1014/002</span></p>

<p class=EMEABodyText><span lang=EN-GB>EU/1/15/1014/003</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>9. DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Date of first authorisation:
19&nbsp;June&nbsp;2015</span></p>

<p class=EMEABodyText><span lang=EN-GB>Date of latest renewal: 23&nbsp;April&nbsp;2020</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>10. DATE OF REVISION OF THE TEXT</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Detailed information on this medicinal
product is available on the website of the European Medicines Agency </span><span
lang=EN-GB><a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a><span
class=MsoHyperlink><br clear=all style='page-break-before:always'>
</span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span class=MsoHyperlink><span lang=EN-GB style='color:windowtext'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle><span lang=EN-GB>ANNEX II</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle align=left style='margin-left:85.05pt;text-align:left;
text-indent:-35.4pt'><span lang=EN-GB>A. </span><span lang=EN-GB>MANUFACTURERS
OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH
RELEASE</span></p>

<p class=EMEABodyText style='margin-left:85.05pt;text-indent:-35.4pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle align=left style='margin-left:85.05pt;text-align:left;
text-indent:-35.4pt'><span lang=EN-GB>B. CONDITIONS OR RESTRICTIONS
REGARDING SUPPLY AND USE</span></p>

<p class=EMEABodyText style='margin-left:85.05pt;text-indent:-35.4pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle align=left style='margin-left:85.05pt;text-align:left;
text-indent:-35.4pt'><span lang=EN-GB>C. OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>

<p class=EMEABodyText style='margin-left:85.05pt;text-indent:-35.4pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle align=left style='margin-left:85.05pt;text-align:left;
text-indent:-35.4pt'><span lang=EN-GB>D. CONDITIONS OR RESTRICTIONS WITH
REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeading1 style='margin-left:0in;text-indent:0in'><span lang=EN-GB>A. MANUFACTURERS
</span><span lang=EN-GB>OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><u><span lang=EN-GB>Name
and address of the manufacturers of the biological active substance</span></u></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>Bristol&#8209;Myers
Squibb Company</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>6000
Thompson Road</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>East
Syracuse, New York 13057</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>USA</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>Lonza
Biologics, Inc.</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>101
International Drive</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>Portsmouth,
New Hampshire 03801</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>USA</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>Samsung
Biologics Co. Ltd.</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>300,
Songdo Bio Way (Daero)</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>Yeonsu&#8209;gu,
Incheon, 21987</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><span lang=EN-GB>Korea</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress><span lang=EN-GB>Swords Laboratories t/a Bristol-Myers
Squibb Cruiserath Biologics</span></p>

<p class=EMEAAddress><span lang=EN-GB>Cruiserath Road, Mulhuddart</span></p>

<p class=EMEAAddress><span lang=EN-GB>Dublin 15, D15 H6EF</span></p>

<p class=EMEAAddress><span lang=EN-GB>Ireland</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress style='page-break-after:avoid'><u><span lang=EN-GB>Name
and address of the manufacturer responsible for batch release</span></u></p>

<p class=EMEAAddress><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress><span lang=EN-GB>Swords Laboratories t/a Bristol&#8209;Myers
Squibb Cruiserath Biologics<br>
Cruiserath Road, Mulhuddart<br>
Dublin 15, D15 H6EF<br>
Ireland</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><a name="OLE_LINK2"><span lang=EN-GB>B.</span></a><span
lang=EN-GB> CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE </span></p>

<p class=EMEAAddress><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress><span lang=EN-GB>Medicinal product subject to restricted
medical prescription (see Annex&nbsp;I: Summary of Product Characteristics, section&nbsp;4.2).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>C.  OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>

<p class=EMEAAddress><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic safety update reports (PSURs)</span></b></p>

<p class=EMEAAddress><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress><span lang=EN-GB>The requirements for submission of PSURs for
this medicinal product are set out in the list of Union reference dates (EURD list)
provided for under Article&nbsp;107c(7) of Directive&nbsp;2001/83/EC and any
subsequent updates published on the European medicines web&#8209;portal.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1><span lang=EN-GB>D. CONDITIONS OR RESTRICTIONS WITH
REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p>

<p class=EMEAAddress><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk management plan (RMP)</span></b></p>

<p class=EMEAAddress><span lang=ES>&nbsp;</span></p>

<p class=EMEAAddress><span lang=EN-GB>The marketing authorisation holder (MAH) shall
perform the required pharmacovigilance activities and interventions detailed in
the agreed RMP presented in Module&nbsp;1.8.2 of the marketing authorisation and
any agreed subsequent updates of the RMP.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress><span lang=EN-GB>An updated RMP should be submitted:</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=EMEABodyText style='margin-left:28.35pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Additional risk minimisation measures </span></b></p>

<p class=EMEAAddress><span lang=ES>&nbsp;</span></p>

<p class=EMEAAddress><span lang=EN-GB>The MAH shall ensure that in each Member
State where OPDIVO is marketed, all healthcare professionals and
patients/carers who are expected to prescribe and use OPDIVO have access to/are
provided with the patient alert card. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>The patient alert card</span></b><span
lang=EN-GB> shall contain the following key messages:</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>That OPDIVO treatment may increase the risk of: </span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune&#8209;related pneumonitis</span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune&#8209;related colitis</span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune&#8209;related hepatitis</span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune&#8209;related nephritis and renal
dysfunction</span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune&#8209;related endocrinopathies </span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Immune&#8209;related skin adverse reactions</span></p>

<p class=EMEABodyTextIndent style='margin-left:63.8pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Other immune&#8209;related ARs</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Signs or symptoms of the safety concern and when
to seek attention from a HCP</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:28.35pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Contact details of the OPDIVO prescriber</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyTextIndent style='margin-left:.25in;text-indent:-.25in;
page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Obligation to conduct post&#8209;authorisation
measures </span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>The MAH
shall complete, within the stated timeframe, the below measures:</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=604
 style='margin-left:1.2pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:21.5pt'>
  <td width=462 style='width:346.35pt;border:solid black 1.0pt;background:white;
  padding:0in 4.25pt 0in 4.25pt;height:21.5pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Description</span></b></p>
  </td>
  <td width=142 style='width:106.3pt;border:solid black 1.0pt;border-left:none;
  background:white;padding:0in 4.25pt 0in 4.25pt;height:21.5pt'>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Due date</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:38.4pt'>
  <td width=462 valign=top style='width:346.35pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 4.25pt 0in 4.25pt;height:38.4pt'>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>1. Post
  authorisation efficacy study (PAES): </span><span style='color:black'>The MAH
  should submit the</span><span lang=EN-GB style='color:black'> addendum to the
  CA209205 Final CSR reporting the OS data and data from the discontinuation
  schedule in Cohort C</span><span style='color:black'>.</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:dashed windowtext 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 4.25pt 0in 4.25pt;height:38.4pt'>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>30<sup>th</sup>
  June 2021</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:38.4pt'>
  <td width=462 valign=top style='width:346.35pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 4.25pt 0in 4.25pt;height:38.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>2. The MAH should submit the final OS data for study
  CA209238: A Phase&nbsp;3, randomised double&#8209;blind study of OPDIVO
  versus Yervoy in</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>patients who have
  undergone complete resection of Stage&nbsp;IIIb/c or Stage&nbsp;IV melanoma.</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:dashed windowtext 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 4.25pt 0in 4.25pt;height:38.4pt'>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>4Q2020</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:3.5pt'>
  <td width=462 valign=top style='width:346.35pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:dashed black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 4.25pt 0in 4.25pt;height:3.5pt'>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>3. </span><span
  lang=EN-GB style='color:black'>Post authorisation efficacy study (PAES): </span><span
  lang=EN-GB style='color:black'>In order to further elucidate the contribution
  of ipilimumab to the efficacy and toxicity of the combination regimen of
  nivolumab and ipilimumab, the MAH should conduct and submit the results of a
  randomised, clinical study comparing the efficacy and safety of the
  combination of nivolumab and ipilimumab to nivolumab monotherapy in
  previously untreated adult patients with intermediate/poor&#8209;risk
  advanced renal cell carcinoma and with an appropriate spectrum of PD&#8209;L1
  expression levels. This study should be conducted according to an agreed
  protocol.</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:dashed black 1.0pt;border-right:solid black 1.0pt;
  background:white;padding:0in 4.25pt 0in 4.25pt;height:3.5pt'>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>30<sup>th</sup>
  September 2021</span></p>
  </td>
 </tr>
</table>

<span class=MsoHyperlink><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:black'><br clear=all style='page-break-before:
always'>
</span></span>

<p class=MsoNormal><span class=MsoHyperlink><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=MsoNormal><span class=MsoHyperlink><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEABodyText><span class=MsoHyperlink><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=EMEATitle align=left style='text-align:left'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>ANNEX III</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEATitle><span lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEATitle align=left style='text-align:left'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>A. LABELLING</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></p>

<p class=EMEATitlePAC><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitlePAC><span lang=EN-GB>OUTER CARTON</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT </span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO&nbsp;10&nbsp;mg/mL concentrate
for solution for infusion</span></p>

<p class=EMEABodyText><span lang=EN-GB>nivolumab</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Each mL of concentrate contains&nbsp;10&nbsp;mg
of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Each vial of 4&nbsp;mL
contains&nbsp;40&nbsp;mg of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Each vial
of 10&nbsp;mL contains&nbsp;100&nbsp;mg of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Each vial
of 24&nbsp;mL contains&nbsp;240&nbsp;mg of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Excipients: sodium citrate dihydrate,
sodium chloride, mannitol&nbsp;(E421), pentetic acid, polysorbate&nbsp;80&nbsp;(E433),
sodium hydroxide, hydrochloric acid, water for injections.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>See leaflet
for further information.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
CONTENTS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Concentrate
for solution for infusion.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=DE-CH>40&nbsp;mg/4&nbsp;mL</span></p>

<p class=EMEABodyText><span lang=DE-CH style='background:lightgrey'>100&nbsp;mg/10&nbsp;mL</span></p>

<p class=EMEABodyText><span lang=DE-CH style='background:lightgrey'>240&nbsp;mg/24&nbsp;mL</span></p>

<p class=EMEABodyText><span lang=DE-CH>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>1&nbsp;vial</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Intravenous use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>For single use only.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED
OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>8. EXPIRY DATE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not freeze.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Store in the original package in order
to protect from light.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress><span lang=EN-GB>Bristol&#8209;Myers Squibb Pharma EEIG<br>
</span><span lang=EN-GB>Plaza 254<br>
Blanchardstown Corporate Park 2<br>
Dublin 15, D15 T867</span></p>

<p class=EMEAAddress><span lang=EN-GB>Ireland</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=FR>EU/1/15/1014/001&nbsp;<span
style='background:lightgrey'>40&nbsp;mg vial</span></span></p>

<p class=EMEABodyText><span lang=FR style='background:lightgrey'>EU/1/15/1014/002&nbsp;100&nbsp;mg
vial</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>EU/1/15/1014/003&nbsp;240&nbsp;mg
vial</span></p>

<p class=EMEABodyText>&nbsp;</p>

<p class=EMEABodyText>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>13. BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>16. INFORMATION IN BRAILLE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:lightgrey'>Justification
for not including Braille accepted</span><span lang=EN-GB style='color:black;
background:#CCCCCC'>.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>2D barcode
carrying the unique identifier included.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>18. UNIQUE IDENTIFIER &#8209;
HUMAN READABLE DATA</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>PC</span></p>

<p class=EMEABodyText><span lang=EN-GB>SN</span></p>

<p class=EMEABodyText><span lang=EN-GB>NN</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>PARTICULARS TO APPEAR ON THE IMMEDIATE
PACKAGING</span></p>

<p class=EMEATitlePAC><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitlePAC><span lang=EN-GB>VIAL LABEL</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO&nbsp;10&nbsp;mg/mL sterile
concentrate</span></p>

<p class=EMEABodyText><span lang=EN-GB>nivolumab</span></p>

<p class=EMEABodyText><span lang=ES>&nbsp;</span></p>

<p class=EMEABodyText><span lang=ES>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Each mL of concentrate contains&nbsp;10&nbsp;mg
of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Each vial of 24&nbsp;mL contains&nbsp;240&nbsp;mg
of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Excipients: sodium citrate dihydrate,
sodium chloride, mannitol&nbsp;(E421), pentetic acid, polysorbate&nbsp;80&nbsp;(E433),
sodium hydroxide, hydrochloric acid, water for injections.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
CONTENTS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Sterile
concentrate</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>240&nbsp;mg/24&nbsp;mL</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>IV use</span></p>

<p class=EMEABodyText><span lang=EN-GB>For single use only.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED
OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>8. EXPIRY DATE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Do not freeze.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Store in the original package in order
to protect from light.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAAddress><span lang=EN-GB>Bristol&#8209;Myers Squibb Pharma EEIG<br>
</span><span lang=EN-GB>Plaza 254<br>
Blanchardstown Corporate Park 2<br>
Dublin 15, D15 T867</span></p>

<p class=EMEAAddress><span lang=EN-GB>Ireland</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>EU/1/15/1014/003</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>13. BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>16. INFORMATION IN BRAILLE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black;background:lightgrey'>Justification
for not including Braille accepted</span><span lang=EN-GB style='color:black;
background:#CCCCCC'>.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>18. UNIQUE IDENTIFIER &#8209;
HUMAN READABLE DATA</span></p>

</div>

<p class=EMEABodyText><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>minimum PARTICULARS TO APPEAR ON small
IMMEDIATE PACKAGING units</span></p>

<p class=EMEATitlePAC><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitlePAC><span lang=EN-GB>VIAL LABEL</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT
AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO&nbsp;10&nbsp;mg/mL sterile
concentrate</span></p>

<p class=EMEABodyText><span lang=EN-GB>nivolumab</span></p>

<p class=EMEABodyText><span lang=EN-GB>IV use</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>2. METHOD OF ADMINISTRATION</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>Read the
package leaflet before use.</span></p>

<p class=EMEABodyText><span lang=EN-GB>For single use only.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>3. EXPIRY DATE</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>EXP</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>4. BATCH NUMBER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Lot</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>5. CONTENTS BY WEIGHT, BY VOLUME
OR BY UNIT</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>40&nbsp;mg/4&nbsp;mL</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:lightgrey'>100&nbsp;mg/10&nbsp;mL</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEATitlePAC><span lang=EN-GB>6. OTHER</span></p>

</div>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEATitle><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=EMEATitle><span lang=EN-GB style='color:black'>Package leaflet:
Information for the user</span></p>

<p class=EMEATitle><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB style='color:black'>OPDIVO&nbsp;10&nbsp;mg/mL
concentrate for solution for infusion</span></p>

<p class=EMEATitle><span lang=EN-GB style='color:black;font-weight:normal'>nivolumab</span></p>

<p class=EMEATitle><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>Read all of this leaflet carefully before you start using
this medicine because it contains important information for you.</span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Keep this leaflet. You may
need to read it again.</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>It is important that you keep the alert card
with you during treatment.</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you have any further
questions, ask your doctor.</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you get any side effects,
talk to your doctor. This includes any possible side effects not listed in this
leaflet. See section&nbsp;4.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>What is in this leaflet</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>1. What OPDIVO
is and what it is used for</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>2. What you
need to know before you use OPDIVO</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>3. How to
use OPDIVO</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>4. Possible
side effects</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>5. How to
store OPDIVO</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>6. Contents
of the pack and other information</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>1. What OPDIVO is and what it is used for</span></b></p>

<p class=EMEATitle align=left style='text-align:left'><span lang=EN-GB
style='color:black;font-weight:normal'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>OPDIVO is a medicine
used to treat:</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>advanced melanoma (a type of
skin cancer) in adults</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>melanoma after complete
resection in adults (treatment after surgery is called adjuvant therapy)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>advanced non&#8209;small
cell lung cancer (a type of lung cancer) in adults</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>advanced renal cell carcinoma (advanced kidney
cancer) in adults</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>classical Hodgkin lymphoma that has come back
after or has not responded to previous therapies, including an autologous stem&#8209;cell
transplant (a transplant of your own blood&#8209;producing cells) in adults</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>advanced cancer of the head
and neck in adults</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>advanced urothelial
carcinoma (bladder and urinary tract cancer) in adults</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>advanced oesophageal cancer (gullet cancer) in
adults</span><span lang=EN-GB style='color:black'>.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>It contains the
active substance nivolumab, which is a monoclonal antibody, a type of protein
designed to recognise and attach to a specific target substance in the body.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab attaches to a target protein
called programmed death&#8209;1 receptor (PD&#8209;1) that can switch off the
activity of T cells (a type of white blood cell that forms part of the immune
system, the bodys natural defences). By attaching to PD&#8209;1, nivolumab
blocks its action and prevents it from switching off your T cells. This helps
increase their activity against the melanoma, lung, kidney, lymphoid, head and
neck, bladder or oesophageal cancer cells.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO may be given in combination with </span><span
lang=EN-GB>other anti-cancer medicines</span><span lang=EN-GB>. It is important
that you also read the package leaflet for these other medicines. </span><span
lang=EN-GB>If you have any questions about these medicines, please ask your
doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>2. What you need to know before you use OPDIVO</span></b></p>

<p class=EMEATitle align=left style='text-align:left'><span lang=EN-GB
style='color:black;font-weight:normal'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>You should not be given OPDIVO</span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>if you are <b>allergic</b>
to nivolumab or any of the other ingredients of this medicine (listed in
section&nbsp;6 &quot;Contents of the pack and other information&quot;). <b>Talk
to your doctor</b> if you are not sure.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>Warnings and precautions</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Talk to your doctor
before using OPDIVO as it may cause:</span></p>

<p class=EMEABodyTextIndent style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB>Problems with your heart</span></b><span
lang=EN-GB> such as a change in the rhythm or rate of the heartbeat or an
abnormal heart rhythm.</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Problems with your lungs</span></b><span
lang=EN-GB style='color:black'> such as breathing difficulties or cough. These
may be signs of inflammation of the lungs (pneumonitis or interstitial lung
disease).</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Diarrhoea</span></b><span
lang=EN-GB style='color:black'> (watery, loose or soft stools) or any symptoms
of <b>inflammation of the intestines</b> (colitis), such as stomach pain and
mucus or blood in stool.</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Inflammation of the liver
(hepatitis).</span></b><span lang=EN-GB style='color:black'> Signs and symptoms
of hepatitis may include abnormal liver function tests, eye or skin yellowing
(jaundice), pain on the right side of your stomach area, or tiredness.</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Inflammation or problems
with your kidneys. </span></b><span lang=EN-GB style='color:black'>Signs and
symptoms may include abnormal kidney function tests, or decreased volume of
urine.</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Problems with your
hormone producing glands</span></b><span lang=EN-GB style='color:black'>
(including the pituitary, the thyroid, the parathyroid and adrenal glands) that
may affect how these glands work. Signs and symptoms that these glands are not
working properly may include fatigue (extreme tiredness), weight change or
headache, decreased blood levels of calcium and visual disturbances.</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Diabetes </span></b><span
lang=EN-GB style='color:black'>(symptoms include excessive thirst, the passing
of a greatly increased amount of urine, increase in appetite with a loss of
weight, feeling tired, drowsy, weak, depressed, irritable and generally unwell)
or <b>diabetic ketoacidosis </b>(acid in the blood produced from diabetes).</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Inflammation of the skin </span></b><span
lang=EN-GB style='color:black'>that can lead to severe skin reaction (known as
toxic epidermal necrolysis and Stevens&#8209;Johnson syndrome). Signs and symptoms
of severe skin reaction may include rash, itching</span><span lang=EN-GB>, <span
style='color:black'>and peeling of the skin (possibly fatal).</span></span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB>Inflammation of the muscles </span></b><span
lang=EN-GB style='color:black'>such as myocarditis (inflammation of the heart
muscle), myositis (inflammation of the muscles) and rhabdomyolysis (stiffness in
muscles and joints, muscle spasm).</span><b><span lang=EN-GB> </span></b><span
lang=EN-GB>Signs and symptoms may include muscle pain, stiffness, weakness, chest
pain, or severe fatigue.</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Solid organ transplant
rejection.</span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Graft&#8209;versus&#8209;host
disease.</span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB>Haemophagocytic lymphohistiocytosis</span></b><span
lang=EN-GB>. A rare disease in which our immune system makes too many of
otherwise normal infection fighting cells called histiocytes and lymphocytes.
Symptoms may include enlarged liver and/or spleen, skin rash, lymph node
enlargement, breathing problems, easy bruising, kidney abnormalities, and heart
problems.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Tell your doctor
immediately</span></b><span lang=EN-GB style='color:black'> if you have any of
these signs or symptoms or if they get worse. <b>Do not try to treat your
symptoms with other medicines on your own. </b>Your doctor may</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>give you other medicines in
order to prevent complications and reduce your symptoms,</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>withhold the next dose of
OPDIVO,</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>or stop your treatment with
OPDIVO altogether.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Please note that
these signs and symptoms are <b>sometimes delayed</b>, and may develop weeks or
months after your last dose. Before treatment, your doctor will check your
general health. You will also have <b>blood tests</b> during your treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>Check with your doctor or nurse before you are given OPDIVO
if:</span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>you have an <b>autoimmune
disease</b> (a condition where the body attacks its own cells);</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>you have <b>melanoma of the
eye</b>;</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>you were previously given
ipilimumab, another medicine for treating melanoma, and experienced <b>serious
side effects</b> because of that medicine;</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>you have been told that your
<b>cancer has spread to your brain;</b></span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>you have any history of <b>inflammation
of the lungs</b>;</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>you have been taken <b>medicines
to suppress your immune system.</b></span></p>

<p class=MsoNoSpacing style='margin-top:2.0pt'><b><span style='font-size:10.0pt;
font-family:"Arial",sans-serif'>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>Complications of stem cell transplant
that uses donor stem cells (allogeneic) after treatment with OPDIVO. </span></b><span
lang=EN-GB>These complications can be severe and can lead to death. Your healthcare
provider will monitor you for signs of complications if you have an allogeneic
stem cell transplant.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>Children and adolescents</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>OPDIVO should not be
used in children and adolescents below&nbsp;18&nbsp;years of age.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>Other medicines and OPDIVO</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Before you are
given OPDIVO, tell your doctor </span></b><span lang=EN-GB style='color:black'>if
you are taking any medicines that suppress your immune system, such as
corticosteroids, since these medicines may interfere with the effect of OPDIVO.
However, once you are treated with OPDIVO, your doctor may give you
corticosteroids to reduce any possible side effects that you may have during
your treatment and this will not impact the effect of the medicine.</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Tell your doctor </span></b><span
lang=EN-GB style='color:black'>if you are taking or have recently taken any
other medicines. <b>Do not take any other medicines </b>during your treatment
without talking to your doctor first.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>Pregnancy and breast&#8209;feeding</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Tell your doctor</span></b><span
lang=EN-GB style='color:black'> if you are pregnant or think you might be, if
you are planning to become pregnant, or if you are breast&#8209;feeding.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Do not use OPDIVO
if you are pregnant</span></b><span lang=EN-GB style='color:black'> unless your
doctor specifically tells you to. The effects of OPDIVO in pregnant women are
not known, but it is possible that the active substance, nivolumab, could harm
an unborn baby.</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>You must use <b>effective
contraception</b> while you are being treated with OPDIVO </span><span
lang=EN-GB>and for at least 5&nbsp;months following the last dose of OPDIVO</span><span
lang=EN-GB style='color:black'>, if you are a woman who could become pregnant.</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you become pregnant while
using OPDIVO <b>tell your doctor</b>.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>It is not known
whether OPDIVO gets into breast milk. A risk to the breast&#8209;fed infant
cannot be excluded. <b>Ask your doctor</b> if you can breast&#8209;feed during
or after treatment with OPDIVO.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>Driving and using machines</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>OPDIVO or OPDIVO in
combination with ipilimumab may have a minor influence on the ability to drive
and use machines; however, use caution when performing these activities until
you are sure that OPDIVO does not adversely affect you.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>OPDIVO contains sodium</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='color:black'>Tell your doctor</span></b><span
lang=EN-GB style='color:black'> if you are on a low&#8209;sodium (low&#8209;salt)
diet before you are given OPDIVO. This medicine contains&nbsp;2.5&nbsp;mg
sodium (main component of cooking/table salt) in each mL of concentrate.</span><span
lang=EN-GB> <span style='color:black'>OPDIVO contains 10&nbsp;mg sodium per 4&nbsp;ml
vial, 25&nbsp;mg sodium per 10&nbsp;ml vial or 60&nbsp;mg sodium per 24&nbsp;ml
vial, which is equivalent to 0.5%, 1.25% or 3% respectively, of the recommended
maximum daily dietary intake of sodium for an adult.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>You will also find key messages from
this package leaflet in the patient alert card you have been given by your
doctor. It is important that you keep this patient alert card and show it to
your partner or caregivers.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>3. How to use OPDIVO</span></b></p>

<p class=EMEATitle align=left style='text-align:left'><span lang=EN-GB
style='color:black;font-weight:normal'>&nbsp;</span></p>

<p class=EMEATitle align=left style='text-align:left'><span lang=EN-GB
style='color:black'>How much OPDIVO is given</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>When OPDIVO is given
on its own, the recommended dose is either 240&nbsp;mg given every 2&nbsp;weeks
or 480&nbsp;mg given every 4&nbsp;weeks depending on indication.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>When OPDIVO is given in combination with
ipilimumab for the treatment of skin cancer, the recommended dose of OPDIVO is&nbsp;1&nbsp;mg
of nivolumab per kilogram of your body weight for the first 4&nbsp;doses
(combination phase). Thereafter the recommended dose of OPDIVO is&nbsp;240&nbsp;mg
given every 2&nbsp;weeks or 480&nbsp;mg given every 4&nbsp;weeks (single&#8209;agent
phase). </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>When OPDIVO is given in combination with
ipilimumab for the treatment of advanced kidney cancer, the recommended dose of
OPDIVO is&nbsp;3&nbsp;mg of nivolumab per kilogram of your body weight for the
first 4&nbsp;doses (combination phase). Thereafter, the recommended dose of
OPDIVO is&nbsp;240&nbsp;mg given every 2&nbsp;weeks or 480&nbsp;mg given every
4&nbsp;weeks (single&#8209;agent phase).</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>When OPDIVO is given in combination with
ipilimumab and chemotherapy for the treatment of advanced </span><span
lang=EN-GB style='color:black'>non-small cell lung cancer</span><span
lang=EN-GB>, the recommended dose of OPDIVO is&nbsp;360 mg every 3&nbsp;weeks.</span></p>

<p class=EMEABodyText>After completion of 2&nbsp;cycles of chemotherapy, OPDIVO
is given in combination with ipilimumab, the recommended dose of OPDIVO is
360&nbsp;mg every 3&nbsp;weeks.</p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Depending on your
dose, the appropriate amount of OPDIVO will be diluted with sodium
chloride&nbsp;9&nbsp;mg/mL&nbsp;(0.9%) solution for injection or&nbsp;glucose
50&nbsp;mg/mL&nbsp;(5%) solution for injection before use. More than one vial
of OPDIVO may be necessary to obtain the required dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEATitle align=left style='text-align:left'><span lang=EN-GB
style='color:black'>How OPDIVO is given</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>You will receive
treatment with OPDIVO in a hospital or clinic, under the supervision of an
experienced doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>OPDIVO will be given
to you as an infusion (a drip) into a vein (intravenously) over a period
of&nbsp;30 or 60&nbsp;minutes, every&nbsp;2&nbsp;weeks or 4&nbsp;weeks,
depending on the dose you are receiving. Your doctor will continue giving you
OPDIVO for as long as you keep benefitting from it or until you no longer
tolerate the treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>When OPDIVO is given in combination with
ipilimumab, you will be given an infusion over a period of&nbsp;30&nbsp;minutes,
every&nbsp;3&nbsp;weeks for the first 4&nbsp;doses (combination phase).
Thereafter it will be given as an infusion over a period of&nbsp;30 or 60&nbsp;minutes,
every&nbsp;2&nbsp;weeks </span><span lang=EN-GB style='color:black'>or
4&nbsp;weeks, depending on the dose you are receiving </span><span lang=EN-GB>(single&#8209;agent
phase). </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>When OPDIVO is given in combination with
ipilimumab and chemotherapy for the treatment of advanced </span><span
lang=EN-GB style='color:black'>non-small cell lung cancer</span><span
lang=EN-GB>, you will be given an infusion over a period
of&nbsp;30&nbsp;minutes, every&nbsp;3&nbsp;weeks</span>.</p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEATitle align=left style='text-align:left'><span lang=EN-GB
style='color:black'>If you miss a dose of OPDIVO</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>It is very important
for you to keep all your appointments to receive OPDIVO. If you miss an appointment,
ask your doctor when to schedule your next dose.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEATitle align=left style='text-align:left'><span lang=EN-GB
style='color:black'>If you stop using OPDIVO</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Stopping your
treatment may stop the effect of the medicine. Do not stop treatment with
OPDIVO unless you have discussed this with your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>If you have any further
questions about your treatment or on the use of this medicine, ask your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>When OPDIVO is given in combination with
ipilimumab or in combination with ipilimumab and chemotherapy, you will first
be given OPDIVO followed by ipilimumab and then by chemotherapy.</span></p>

<p class=EMEABodyText><span lang=EN-GB>Please refer to the package leaflet of </span><span
lang=EN-GB>the other anti-cancer medicines </span><span lang=EN-GB>in order to
understand the use of these medicines. If you have questions about these
medicines, please ask your doctor.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>4. Possible side effects</span></b></p>

<p class=EMEATitle align=left style='text-align:left'><span lang=EN-GB
style='color:black;font-weight:normal'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Like all medicines, this
medicine can cause side effects, although not everybody gets them. Your doctor
will discuss these with you and will explain the risks and benefits of your
treatment.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Be aware of
important symptoms of inflammation.</span></b><span lang=EN-GB
style='color:black'> OPDIVO acts on your immune system and may cause
inflammation in parts of your body. Inflammation may cause serious damage to
your body and some inflammatory conditions may be life&#8209;threatening and
need treatment or withdrawal of OPDIVO.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>The
following side effects have been reported <b>with OPDIVO alone:</b></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Very
common (may affect more than&nbsp;1&nbsp;in&nbsp;10&nbsp;people)</span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Decrease in some white blood cells</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Diarrhoea (watery, loose or
soft stools), nausea</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Skin rash sometimes with
blisters, itching</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Feeling tired or weak</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Common
(may affect up to&nbsp;1&nbsp;in&nbsp;10&nbsp;people)</span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Infections of the upper
respiratory tract</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Allergic reaction, reactions
related to the infusion of the medicine</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Underactive thyroid gland (which
can cause tiredness or weight gain), overactive thyroid gland (which can cause
rapid heart rate, sweating and weight loss)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Decreased appetite</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Inflammation of the nerves (causing
numbness, weakness, tingling or burning pain of the arms and legs), headache,
dizziness</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>High blood pressure
(hypertension)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Inflammation of the lungs
(pneumonitis, characterised by coughing and difficulty breathing), shortness of
breath (dyspnoea), cough</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Inflammation of the
intestines (colitis), mouth ulcers and cold sores (stomatitis), vomiting,
stomach pain, constipation, dry mouth</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Skin colour change in
patches (vitiligo), dry skin, redness of the skin, unusual hair loss or
thinning</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Pain in the muscles, bones (musculoskeletal
pain) and joints (arthralgia)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Fever, oedema (swelling)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Uncommon
(may affect up to&nbsp;1&nbsp;in&nbsp;100&nbsp;people)</span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Serious lung infection
(pneumonia), bronchitis</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Increase in some white blood
cells</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Decreased secretion of
hormones produced by adrenal glands (glands situated above the kidneys),
underactive function (hypopituitarism) or inflammation (hypophysitis) of the
pituitary gland situated at the base of the brain, swelling of the thyroid
gland, diabetes </span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Dehydration, increased acid
levels in the blood</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Damage to nerves causing
numbness and weakness (polyneuropathy), </span><span lang=EN-GB>inflammation of
the nerves caused by the body attacking itself, causing numbness, weakness,
tingling or burning pain (autoimmune neuropathy)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Inflammation of the eye (which
causes pain and redness), </span><span lang=EN-GB>blurred<span
style='color:black'> vision, dry eyes</span></span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Fast heart rate, inflammation of the covering of
the heart and accumulation of fluid around the heart<span style='color:black'>
(pericardial disorders)</span></span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Fluid around the lungs</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Inflammation of the pancreas
(pancreatitis), </span><span lang=EN-GB>inflammation of the stomach (gastritis)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Inflammation of the liver
(hepatitis)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Severe condition of the skin
that causes red, often itchy spots, similar to the rash of measles, which starts
on the limbs and sometimes on the face and the rest of the body (erythema
multiforme), skin disease with thickened patches of red skin, often with
silvery scales (psoriasis), skin</span><span lang=EN-GB> condition of the face
where the nose and cheeks are unusually red (rosacea), hives (itchy, bumpy
rash)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Inflammation of <span style='color:black'>the </span>muscles
causing pain or stiffness <span style='color:black'>(polymyalgia rheumatica),</span><span
style='letter-spacing:.15pt'> inflammation of the joints (arthritis)</span></span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Inflammation of the kidney, kidney failure
(including abrupt loss of kidney function)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Pain, chest pain</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Rare
(may affect up to&nbsp;1&nbsp;in&nbsp;1000&nbsp;people)</span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>A disease causing the inflammation or
enlargement of a lymph node (Kikuchi lymphadenitis)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Life&#8209;threatening allergic reaction</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Acid in the blood produced
from diabetes (diabetic ketoacidosis)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>A temporary inflammation of the nerves that
causes pain, weakness, and paralysis in the extremities (Guillain&#8209;Barr
syndrome), loss of the protective sheath around nerves (demyelination), a condition
in which the muscles become weak and tire easily (myasthenic syndrome)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Inflammation of the brain</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Changes in the rhythm or
rate of the heartbeat, </span><span lang=EN-GB>abnormal heart rhythm,<span
style='color:black'> inflammation of the heart muscle</span></span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Inflammatory disease of
blood vessels</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Fluid in the lungs</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Ulcer of the small intestines</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>B</span><span lang=EN-GB>lockage
of bile ducts</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Severe and possibly fatal peeling of the skin
(toxic epidermal necrolysis or Stevens&#8209;Johnson syndrome)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Disease in which the immune system attacks the
glands that make moisture for the body, such as tears and saliva (Sjogrens
syndrome), aching muscles, muscle tenderness or weakness, not caused by
exercise (myopathy), inflammation of the muscles (myositis), stiffness in
muscles and joints, muscle spasm (rhabdomyolysis)</span></p>

<p class=EMEABodyText><a name="_BPDC_PR_INS_1043"></a><a
name="_BPDC_PR_INS_1042"></a><a name="_BPDC_PR_INS_1041"></a><a
name="_BPDC_PR_INS_1040"></a><a name="_BPDC_PR_INS_1039"></a><a
name="_BPDC_LN_INS_1037"></a><a name="_BPDC_PR_INS_1038"></a><a
name="_BPDC_PR_INS_1044"></a><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Other
side effects that have been reported with frequency not known (cannot be
estimated from the available data):</span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Temporary and reversible non-infectious
inflammation of the protective membranes surrounding the brain and spinal cord
(aseptic meningitis)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:10.0pt;font-family:Wingdings;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Solid
organ transplant rejection</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Chronic diseases associated with a build-up of
inflammatory cells in various organs and tissues, most commonly the lungs
(sarcoidosis)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Decreased function of the
parathyroid gland</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>A group of metabolic complications occurring
after cancer treatment characterised by high blood levels of potassium and
phosphate, and low blood levels of calcium (tumour lysis syndrome)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>An inflammatory disorder (most likely of
autoimmune origin) affecting the eyes, skin and the membranes of the ears,
brain and spinal cord (Vogt-Koyanagi-Harada syndrome) </span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>A condition where the immune system makes too
many infection-fighting cells called histiocytes and lymphocytes that may cause
various symptoms (called haemophagocytic lymphohistiocytosis)</span></p>

<p class=EMEABodyText style='margin-left:.25in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The following side effects have been
reported <b>with OPDIVO in combination</b> (the frequency and severity of side
effects may vary with the combination of anti-cancer medicines received)<b>:</b></span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Very
common (may affect more than&nbsp;1&nbsp;in&nbsp;10&nbsp;people)</span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1036"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Underactive
thyroid gland (which can cause tiredness or weight gain),overactive thyroid
gland (which can cause rapid heart rate, sweating and weight loss)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1035"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Decreased
appetite</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1034"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Headache</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Shortness of breath (dyspnoea)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1033"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Inflammation
of the intestines (colitis), diarrhoea (watery, loose or soft stools), vomiting,
nausea, stomach pain</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1032"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Skin
rash sometimes with blisters, itching</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1031"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Pain
in the joints (arthralgia), pain in the muscles and bones (musculoskeletal pain)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1030"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Feeling
tired or weak, fever</span></p>

<p class=EMEABodyTextIndent><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><a name="_BPDC_PR_INS_1029"></a><b><span
lang=EN-GB>Common (may affect up to&nbsp;1&nbsp;in&nbsp;10&nbsp;people)</span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Serious lung infection (pneumonia), infections
of the upper respiratory tract, </span><span lang=EN-GB>inflammation of the eye
(conjunctivitis)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1028"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Increase
in some white blood cells, decrease in neutrophils with fever</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1027"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Allergic
reaction, reactions related to the infusion of the medicine</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1026"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Decreased
secretion of hormones produced by adrenal glands (glands situated above the
kidneys), underactive function (hypopituitarism) or inflammation (hypophysitis)
of the pituitary gland situated at the base of the brain, swelling of the
thyroid gland, diabetes</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1025"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Dehydration,
decreased levels of albumin and phosphate in the blood</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1024"></a><a name="_BPDC_PR_INS_1023"></a><span lang=EN-GB
style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Inflammation of the nerves (causing numbness,
weakness, tingling or burning pain of the arms and legs), dizziness</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1022"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Inflammation
of the eye (which causes pain and redness), blurred vision, dry eye</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1021"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Fast
heart rate</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1020"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>High
blood pressure (hypertension)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1019"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Inflammation
of the lungs (pneumonitis, characterised by coughing and difficulty breathing),
fluid around the lungs, blood clots, cough</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1018"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Mouth
ulcers and cold sores (stomatitis), inflammation of the pancreas
(pancreatitis), constipation, dry mouth</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1017"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Inflammation
of the liver</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Skin colour change in patches (vitiligo), dry
skin, redness of the skin, unusual hair loss or thinning, hives (itchy rash)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1016"></a><a name="_BPDC_PR_INS_1015"></a><span lang=EN-GB
style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Inflammation of the joints (arthritis), muscle
spasm, muscle weakness</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Kidney failure (including abrupt loss of kidney
function)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1014"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Oedema
(swelling), pain, chest pain, chills</span></p>

<p class=EMEABodyText style='margin-left:.25in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Uncommon
(may affect up to&nbsp;1&nbsp;in&nbsp;100&nbsp;people)</span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1013"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Bronchitis</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1012"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Temporary
and reversible non&#8209;infectious inflammation of the protective membranes surrounding
the brain and spinal cord (aseptic meningitis)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Chronic diseases associated with a build&#8209;up
of inflammatory cells in various organs and tissues, most commonly the lungs
(sarcoidosis)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1011"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB
style='color:black'>Increased acid levels in the blood</span><span lang=EN-GB> </span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Acid in the blood produced from diabetes
(diabetic ketoacidosis)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Decreased function of the
parathyroid gland</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1010"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>A
temporary inflammation of the nerves that causes pain, weakness and paralysis
in the extremities (Guillain&#8209;Barr syndrome); damage to nerves causing
numbness and weakness (polyneuropathy); inflammation of the nerves; foot drop (peroneal
nerve palsy); inflammation of the nerves caused by the body attacking itself,
causing numbness, weakness, tingling or burning pain (autoimmune neuropathy);
muscle weakness and tiredness without atrophy (myasthenia gravis)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1009"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Inflammation
of the brain</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Changes in the rhythm or rate of the heartbeat,
abnormal heart rhythm, inflammation of the heart muscle, slow heart rate</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1008"></a><a name="_BPDC_PR_INS_1007"></a><span lang=EN-GB
style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Intestinal perforation, inflammation of the
stomach (gastritis), inflammation of the duodenum</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1006"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Skin
disease with thickened patches of red skin, often with silvery scales
(psoriasis), severe condition of the skin that causes red, often itchy spots,
similar to the rash of measles, which starts on the limbs and sometimes on the
face and the rest of the body (erythema multiforme)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1005"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Severe
and possibly fatal peeling of the skin (Stevens&#8209;Johnson syndrome)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Chronic disease of joints (spondyloarthropathy),
disease in which the immune system attacks the glands that make moisture for the
body, such as tears and saliva (Sjogrens syndrome), aching muscles, muscle
tenderness of weakness, not caused by exercise (myopathy), inflammation of the
muscles (myositis), stiffness in muscles and joints, muscle spasm (rhabdomyolysis),
inflammation of the muscles causing pain or stiffness (polymyalgia rheumatica)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1004"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Inflammation
of the kidney</span></p>

<p class=EMEABodyText><a name="_BPDC_PR_INS_1003"></a><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Rare
(may affect up to&nbsp;1&nbsp;in&nbsp;1000&nbsp;people)</span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_LN_INS_1001"></a><a name="_BPDC_PR_INS_1002"></a><span lang=EN-GB
style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Severe and possibly fatal peeling of the skin
(toxic epidermal necrolysis)</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Other
side effects that have been reported frequency not known (cannot be estimated
from the available data):</span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:10.0pt;font-family:Wingdings;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Solid
organ transplant rejection</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>A group of metabolic complications occurring
after cancer treatment characterised by high blood levels of potassium and
phosphate, and low blood levels of calcium (tumour lysis syndrome)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>An inflammatory disorder (most likely of
autoimmune origin) affecting the eyes, skin and the membranes of the ears,
brain and spinal cord (Vogt-Koyanagi-Harada syndrome) </span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Inflammation of the covering of the heart and
accumulation of fluid around the heart<span style='color:black'> (pericardial
disorders)</span></span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>A condition where the immune system makes too
many infection-fighting cells called histiocytes and lymphocytes that may cause
various symptoms (called haemophagocytic lymphohistiocytosis)</span></p>

<p class=EMEABodyText><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB>Tell your doctor immediately</span></b><span
lang=EN-GB> if you get any of the side effects listed above. Do not try to
treat your symptoms with other medicines on your own.</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Changes
in test results</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>OPDIVO alone or</span><span lang=EN-GB> in
combination may cause changes in the results of tests carried out by your
doctor. These include:</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Abnormal liver function tests (increased amounts
of the liver enzymes aspartate aminotransferase, alanine aminotransferase,
gamma-glutamyltransferase, or alkaline phosphatase in your blood, higher blood
levels of the waste product bilirubin)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Abnormal kidney function tests (increased
amounts of creatinine in your blood)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>High (hyperglycaemia) or low
(hypoglycaemia) sugar levels in the blood</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>A decreased number of red blood cells (which
carry oxygen), white blood cells (which are important in fighting infection) or
platelets (cells which help the blood to clot)</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>An increased level of the enzyme that breaks
down fats and of the enzyme that breaks down starch</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Increased or decreased amount of calcium or potassium</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Increased or decreased blood levels of magnesium
or sodium</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><a
name="_BPDC_PR_INS_1037"></a><span lang=EN-GB style='font-family:Wingdings'><span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-GB>Decrease
in body weight</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>Increased amount of thyroid stimulating hormone</span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>If you get any side effects, <b>talk to
your doctor</b>. This includes any possible side effects not listed in this
leaflet. You can also report side effects directly <span style='background:
lightgrey'>via the national reporting system listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a>. By reporting side effects
you can help provide more information on the safety of this medicine.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>5. How to store OPDIVO</span></b></p>

<p class=EMEATitle align=left style='text-align:left'><span lang=EN-GB
style='color:black;font-weight:normal'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Keep this medicine
out of the sight and reach of children.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Do not use this
medicine after the expiry date which is stated on the carton and the vial label
after EXP. The expiry date refers to the last day of that month.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Store in a
refrigerator (2C&nbsp;to&nbsp;8C).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Do not freeze.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Store in the
original package in order to protect from light.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The unopened vial
can be stored at controlled room temperature up to 25C with room light for up
to 48&nbsp;hours.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Do not store any
unused portion of the infusion solution for reuse. Any unused medicine or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>6. Contents of the pack and other information</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>What
OPDIVO contains </span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>The active substance is nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each mL of
concentrate for solution for infusion contains&nbsp;10&nbsp;mg of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Each vial contains
either&nbsp;40&nbsp;mg (in&nbsp;4&nbsp;mL), 100&nbsp;mg (in&nbsp;10&nbsp;mL)
or&nbsp;240&nbsp;mg (in&nbsp;24&nbsp;mL) of nivolumab.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>The other ingredients are
sodium citrate dihydrate, sodium chloride (see section&nbsp;2&nbsp;&quot;OPDIVO
contains sodium&quot;), mannitol&nbsp;(E421), pentetic acid,
polysorbate&nbsp;80&nbsp;</span><span lang=EN-GB>(E433)</span><span lang=EN-GB
style='color:black'>, sodium hydroxide, hydrochloric acid and water for
injections.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>What
OPDIVO looks like and contents of the pack</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>OPDIVO concentrate
for solution for infusion (sterile concentrate) is a clear to opalescent,
colourless to pale yellow liquid that may contain few light particles.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>It is available in
packs containing either&nbsp;1&nbsp;vial of&nbsp;4&nbsp;mL, 1&nbsp;vial
of&nbsp;10&nbsp;mL or&nbsp;1&nbsp;vial of&nbsp;24&nbsp;mL.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Not all pack sizes
may be marketed.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=EMEAAddress><span lang=EN-GB>Bristol&#8209;Myers Squibb Pharma EEIG<br>
</span><span lang=EN-GB>Plaza 254<br>
Blanchardstown Corporate Park 2<br>
Dublin 15, D15 T867</span></p>

<p class=EMEAAddress><span lang=EN-GB>Ireland</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=EMEABodyText><span lang=EN-GB>Swords Laboratories t/a Bristol&#8209;Myers
Squibb Cruiserath Biologics<br>
Cruiserath Road, Mulhuddart<br>
Dublin 15, D15 H6EF<br>
Ireland</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>For any information
about this medicine, please contact the local representative of the Marketing
Authorisation Holder.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='margin-left:.4pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Belgique/Belgi/Belgien</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>N.V. Bristol&#8209;Myers
  Squibb Belgium S.A.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tl/Tel: + 32 2
  352 76 11</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Lietuva</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb Kft.</span></p>
  <p class=EMEABodyText><span lang=EN-GB>Tel: +370 52 369140</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb Kft.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Te&#1083;.: + 359 2
  4942 480</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEABodyText><b><span lang=DE-CH style='color:black'>Luxembourg/Luxemburg</span></b></p>
  <p class=EMEABodyText><span lang=DE-CH style='color:black'>N.V. Bristol&#8209;Myers
  Squibb Belgium S.A.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tl/Tel: + 32 2
  352 76 11</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>&#268;esk
  republika</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb spol. s r.o.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tel: + 420 221 016
  111</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Magyarorszg</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol-Myers
  Squibb Kft.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tel.: + 36 1 808
  9433</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Danmark</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb Denmark</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tlf: + 45 45 93 05
  06</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Malta</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb S.r.l.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tel: + </span><span
  lang=EN-GB>356 23976333</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Deutschland</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb GmbH &amp; Co. KGaA</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tel: 0800 0752002
  (+49 (0)89 121 42&#8209;350)</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Nederland</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb B.V.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tel: + 31 (0)30
  300 2222</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.0pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.0pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Eesti</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb Kft.</span></p>
  <p class=EMEABodyText><span lang=EN-GB>Tel: +372 640 1030</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.0pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Norge</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb Norway Ltd.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tlf: + 47 67 55 53
  50</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:47.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:47.6pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb A.E.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&#932;&#951;&#955;:
  + 30 210 6074300</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:47.6pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>sterreich</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb GesmbH</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tel: + 43 1 60 14
  30</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:55.55pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:55.55pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Espaa</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb, S.A.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tel: + 34 91 456
  53 00</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:55.55pt'>
  <p class=EMEABodyText><b><span lang=PL style='color:black'>Polska</span></b></p>
  <p class=EMEABodyText><span lang=PL style='color:black'>Bristol&#8209;Myers
  Squibb Polska Sp. z o.o.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tel.: + 48 22 2606400</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>France</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb SARL</span></p>
  <p class=EMEATableLeft style='page-break-after:auto'><span lang=EN-GB>Tl: +
  33 (0)1 58 83 84 96</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Portugal</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb Farmacutica Portuguesa, S.A.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tel: + 351 21 440
  70 00</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Hrvatska</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb spol. s r.o.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='font-variant:small-caps'>Tel:
  +385 1 2078 508</span></p>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Romnia</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb Kft.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tel: + 40 (0)21
  272 16 00</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Ireland</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb Pharmaceuticals uc</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tel: + 353 (0)1
  483 3625</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Slovenija</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb spol. s r.o.</span></p>
  <p class=EMEABodyText><span lang=EN-GB>Tel: +386 1 2355 100</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.2pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>sland</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb AB </span><span lang=EN-GB style='color:black'>hj Vistor hf.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Smi: + 354 535
  7000</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:45.2pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Slovensk
  republika</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb spol. s r.o.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tel: + 421 2 20833
  600</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Italia</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb S.r.l.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tel: + 39 06 50 39
  61</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:44.6pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Suomi/Finland</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Oy Bristol&#8209;Myers
  Squibb (Finland) Ab</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Puh/Tel: + 358 9
  251 21 230</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:38.6pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:38.6pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb A.E.</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&#932;&#951;&#955;:
  + 357 800 92666</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:38.6pt'>
  <p class=EMEABodyText><b><span lang=DE-CH style='color:black'>Sverige</span></b></p>
  <p class=EMEABodyText><span lang=DE-CH style='color:black'>Bristol&#8209;Myers
  Squibb Aktiebolag</span></p>
  <p class=EMEABodyText><span lang=DE-CH style='color:black'>Tel: + 46 8 704 71
  00</span></p>
  <p class=EMEABodyText><span lang=DE-CH style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:60.95pt'>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:60.95pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Latvija</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb Kft.</span></p>
  <p class=EMEABodyText><span lang=EN-GB>Tel: +371 66164750</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=302 valign=top style='width:3.15in;padding:0in 0in 0in 0in;
  height:60.95pt'>
  <p class=EMEABodyText><b><span lang=EN-GB style='color:black'>United Kingdom</span></b></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Bristol&#8209;Myers
  Squibb Pharmaceuticals Ltd</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>Tel: + 44 (0800)
  731 1736</span></p>
  <p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>This leaflet was
last revised in</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Detailed information
on this medicine is available on the European Medicines Agency web </span><span
lang=EN-GB>site: <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'>---------------------------------------------------------------------------------------------------------------------------</span></u></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>The following
information is intended for healthcare professionals only:</span></b></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><u><span lang=EN-GB
style='color:black'>Preparation and administration of OPDIVO</span></u></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Preparation should
be performed by trained personnel in accordance with good practices rules, especially
with respect to asepsis.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>Calculating the dose</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>More than one vial
of OPDIVO concentrate may be needed to give the total dose for the patient.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Nivolumab
monotherapy:</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The prescribed dose
for the patient is 240&nbsp;mg or 480&nbsp;mg given regardless of body weight
depending on indication.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab </span><span lang=EN-GB
style='color:black'>in combination with ipilimumab:</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The <b>prescribed
dose</b> for the patient is given in mg/kg. Based on this prescribed dose,
calculate the total dose to be given.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>The <b>total nivolumab dose</b>
in mg&nbsp;=&nbsp;the patients weight in kg&nbsp;&nbsp;the prescribed dose in
mg/kg. </span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>The <b>volume of OPDIVO
concentrate</b> to prepare the dose (mL)&nbsp;=&nbsp;the total dose in mg,
divided by&nbsp;10 (the OPDIVO concentrate strength is&nbsp;10&nbsp;mg/mL). </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>Nivolumab </span><span lang=EN-GB
style='color:black'>in combination with ipilimumab and chemotherapy:</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The prescribed dose
for the patient is 360&nbsp;mg given regardless of body weight.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>Preparing the infusion</span></b></p>

<p class=EMEABodyText><b><span lang=EN-GB style='color:black'>Take care to
ensure aseptic handling</span></b><span lang=EN-GB style='color:black'> when
you prepare the infusion.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>OPDIVO can be used
for intravenous administration either:</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>without dilution,</span></b><span
lang=EN-GB style='color:black'> after transfer to an infusion container using
an appropriate sterile syringe;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>or</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>after diluting</span></b><span
lang=EN-GB style='color:black'> according to the following instructions: </span></p>

<p class=EMEABodyText style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>the final infusion concentration should range
between&nbsp;1&nbsp;and&nbsp;10&nbsp;mg/mL.</span></p>

<p class=EMEABodyText style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>the total volume of infusion must not exceed
160&nbsp;mL.&nbsp;For patients weighing less than 40&nbsp;kg, the total volume
of infusion must not exceed 4&nbsp;mL per kilogram of patient weight.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>OPDIVO concentrate may be
diluted with either: </span></p>

<p class=EMEABodyText style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>sodium chloride&nbsp;9&nbsp;mg/mL&nbsp;(0.9%)
solution for injection; or</span></p>

<p class=EMEABodyText style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB>50&nbsp;mg/mL&nbsp;(5%) glucose solution for
injection. </span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>STEP 1</span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Inspect the OPDIVO
concentrate for particulate matter or discoloration. Do not shake the vial.
OPDIVO concentrate is a clear to opalescent, colourless to pale yellow liquid.
Discard the vial if the solution is cloudy, is discoloured, or contains
particulate matter other than a few translucent&#8209;to&#8209;white particles.</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Withdraw the required volume
of OPDIVO concentrate using an appropriate sterile syringe. </span></p>

<p class=EMEABodyText><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB>STEP 2</span></b></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Transfer the concentrate
into a sterile, evacuated glass bottle or intravenous container (PVC or
polyolefin). </span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>If applicable, dilute with
the required volume of sodium chloride&nbsp;9&nbsp;mg/mL&nbsp;(0.9%) solution
for injection or&nbsp;50&nbsp;mg/mL&nbsp;(5%) glucose solution for injection.
For ease of preparation, the concentrate can be transferred directly into a pre&#8209;filled
bag containing the appropriate volume of sodium chloride&nbsp;9&nbsp;mg/mL
(0.9%) solution for injection or&nbsp;50&nbsp;mg/mL (5%) glucose solution for
injection.</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Gently mix the infusion by
manual rotation. Do not shake.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>Administration</span></b></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>OPDIVO infusion must
not be administered as an intravenous push or bolus injection.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Administer the
OPDIVO infusion <b>intravenously over a period of 30&nbsp;or 60&nbsp;minutes</b></span><span
lang=EN-GB> <b><span style='color:black'>depending on the dose</span></b><span
style='color:black'>.</span></span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>OPDIVO infusion
should not be infused at the same time in the same intravenous line with other
agents. Use a separate infusion line for the infusion.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Use an infusion set
and an in&#8209;line, sterile, non&#8209;pyrogenic, low protein binding filter
(pore size of&nbsp;0.2&nbsp;&#956;m&nbsp;to&nbsp;1.2&nbsp;&#956;m).</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>OPDIVO infusion is
compatible with:</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>PVC containers</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Polyolefin containers</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>Glass bottles</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>PVC infusion sets</span></p>

<p class=EMEABodyText style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Wingdings;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-GB style='color:black'>In&#8209;line filters with
polyethersulfone membranes with pore sizes of&nbsp;0.2&nbsp;m
to&nbsp;1.2&nbsp;m.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>After administration
of the nivolumab dose, flush the line with sodium
chloride&nbsp;9&nbsp;mg/mL&nbsp;(0.9%) solution for injection
or&nbsp;50&nbsp;mg/mL&nbsp;(5%) glucose solution for injection.</span></p>

<p class=EMEABodyText><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>Storage conditions and shelf life</span></b></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>Unopened
vial</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>OPDIVO must be <b>stored
in a refrigerator</b> (2C&nbsp;to&nbsp;8C). The vials must be kept in the
original package in order to protect from light. OPDIVO should not be frozen.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>The unopened vial
can be stored at controlled room temperature up to 25C with room light for up
to 48&nbsp;hours.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Do not use OPDIVO
after the expiry date which is stated on the carton and on the vial label after
EXP. The expiry date refers to the last day of that month.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><u><span lang=EN-GB>OPDIVO
infusion</span></u></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>Chemical and
physical in-use stability from the time of preparation has been demonstrated as
follows (times are inclusive of the administration period):</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=576
 style='width:432.35pt;margin-left:12.5pt;border-collapse:collapse;border:none'>
 <tr style='height:13.1pt'>
  <td width=219 rowspan=2 style='width:164.45pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.1pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Infusion preparation</span></b></p>
  </td>
  <td width=357 colspan=2 valign=top style='width:267.9pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:13.1pt'>
  <p class=EMEABodyText align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='color:black'>In-use stability</span></b></p>
  </td>
 </tr>
 <tr style='height:31.75pt'>
  <td width=149 valign=top style='width:111.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:31.75pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Storage at 2C to 8C protected from light</span></b></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:31.75pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>Storage at room temperature (&#8804;&nbsp;25C) and room
  light</span></b></p>
  </td>
 </tr>
 <tr style='height:31.45pt'>
  <td width=219 valign=top style='width:164.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:31.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Undiluted or diluted with sodium chloride 9&nbsp;mg/mL
  (0.9%) solution for injection</span></p>
  </td>
  <td width=149 style='width:111.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:31.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>30&nbsp;days</span></p>
  </td>
  <td width=208 style='width:155.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:31.45pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>24&nbsp;hours</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>(of total 30&nbsp;days storage)</span></p>
  </td>
 </tr>
 <tr style='height:28.05pt'>
  <td width=219 valign=top style='width:164.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Diluted with 50&nbsp;mg/mL (5%) glucose solution for
  injection</span></p>
  </td>
  <td width=149 style='width:111.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>24&nbsp;hours</span></p>
  </td>
  <td width=208 style='width:155.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.05pt'>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>8&nbsp;hours</span></p>
  <p class=EMEABodyText style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>(of total 24&nbsp;hours storage)</span></p>
  </td>
 </tr>
</table>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText><span lang=EN-GB>From a microbiological point of view the
prepared solution for infusion, regardless of the diluent, should be used
immediately. If not used immediately, </span><span lang=EN-GB style='color:
black'>in-use storage times and conditions prior to use are the responsibility
of the user and would normally not be longer than 24&nbsp;hours at 2</span><span
lang=EN-GB style='color:black'>C to 8C or 8&nbsp;hours (of the total 24&nbsp;hours
of storage) at room temperature (&#8804;&nbsp;25C), unless infusion
preparation has taken place in controlled and validated aseptic conditions.</span></p>

<p class=EMEABodyText><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEABodyText style='page-break-after:avoid'><b><span lang=EN-GB
style='color:black'>Disposal</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-GB style='color:black'>Do not store any unused portion of the infusion
solution for reuse. Any unused medicine or waste material should be disposed of
in accordance with local requirements.<a name="page_total_master3"></a><a
name="page_total"></a></span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

</div>

</body>

</html>
